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Abstract 
Macrophages (MΦ) are important to host defence and inflammation but plasticity in their 
gene expression profiles contributes to their functional heterogeneity. C5a is one of the most potent 
proinflammatory agents generated upon complement activation and binds to a specific receptor 
C5aR. Overproduction of C5a can contribute to numerous immune and inflammatory conditions. 
The objective of this thesis was to focus on human macrophage populations differentiated from 
primary human monocytes, and examine effects of C5a, C5aR agonists and antagonists, and TLR4-
C5aR crosstalk on inflammatory profiles of human monocytes and macrophages.  
Chapter One summarizes roles for C5a activation on human macrophages, briefly 
surveying C5a, C5aR and some important analogues of C5a that had been developed to study roles 
for C5a in vivo. This chapter discusses new insights into C5aR-related biological functions and 
diseases, macrophage polarization and the usefulness of mouse models for human biology in 
relation to how closely human and mouse macrophages reproduce functional responses. 
Chapter Two addresses macrophage polarization. Macrophage heterogeneity was 
previously achieved by differentiating monocytes with either GM-CSF or M-CSF (generating GM-
MΦ or M-MΦ), but was mostly studied on murine rather than human cells. This chapter describes a 
comparison of gene expression in populations of human macrophages (GM-MΦ versus M-MΦ), 
both in the basal state as well as in response to stimulation by LPS, using a combination of real-time 
PCR and cDNA microarray analysis, cellular migration, and functional responses. About 1000 
genes are differently regulated between unstimulated GM-MΦ versus M-MΦ. Although evidence is 
presented in this chapter that human GM-MΦ and M-MΦ have distinct pro- and anti-inflammatory 
responses in human monocyte-derived macrophages, their activation by LPS supported more of a 
continuum without clear functional distinctions between each population. 
Chapter Three investigates the effects of C5aR activation on GM-MΦ versus M-MΦ using 
cDNA microarray.  Previous reports only described gene expression in murine, rather than human, 
macrophages. Of ~40 genes substantially regulated by C5a in GM-MΦ and M-MΦ, 60% were 
common to both macrophage types. Furthermore, three different functional assays showed that C5a 
was equipotent on GM-MΦ and M-MΦ. These similarities for C5a-mediated functions could be due 
to GM-MΦ and M-MΦ having similar C5aR transcriptional and translational expression. A separate 
microarray experiment was conducted to overview the temporal gene expression profile induced by 
C5a on M-MΦ, enabling identification of rate-limiting genes as therapeutic targets in C5a-mediated 
inflammatory disorders. 
Chapter Four reports a comparative study of three known antagonists (3D53, W54011, 
JJ47) of C5a action via C5aR on M-MΦ. They were assessed for their relative advantages and 
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disadvantages as antagonists of C5aR. Traditionally, drug discovery has focused on optimizing 
ligand affinity for a specific receptor, enhancing functional potency, and improving drug-like 
properties for optimal pharmacokinetics and oral bioavailability. However, these optimization 
processes do not always improve in vivo efficacy. This chapter highlights some important 
considerations, often neglected in drug development – namely residence time, insurmountable or 
non-competitive antagonism for drug-receptor interactions. The non-competitive antagonist 3D53 
showed superior antagonist activity compared to competitive antagonists W54011 and JJ47 despite 
inferior oral bioavailability, and this was because 3D53 remained bound to C5aR on macrophages 
for over 16h whereas compounds W54011 and JJ47 were no longer bound to C5aR after 2h. As a 
result, 3D53 retained high potency (IC50 20nM) in the face of competition from increasing 
concentrations of C5a (0.1-300nM), whereas W54011 and JJ47 were ineffective antagonists against 
concentrations of C5a above 30nM. The benefits of longer residence time were also demonstrated 
in vivo in rats. Orally administered 3D53 was an effective anti-inflammatory agent for 16h, 
compared to less than 2h for W54011 and JJ47, in inhibiting C5aR-mediated paw oedema in male 
Wistar rats. 
Chapter Five reports crosstalk between TLR4 and C5aR in human macrophages. C5aR is 
shown to differentially modulate LPS-induced inflammatory responses in primary human 
monocytes versus macrophages. While C5a enhanced secretion of LPS-induced IL6 and TNF from 
human monocytes, C5a inhibited these responses in GM-MΦ and M-MΦ. LPS amplified C5a-
induced Gαi/c-Raf/MEK/ERK signalling in macrophages but not in monocytes. This synergy was 
independent of IL10, PI3K, p38, JNK, GM-CSF and M-CSF. C5a-mediated suppression of IL6 and 
TNF did not compromise but instead enhanced the clearance of Salmonella Typhimurium from 
macrophages. These findings implicated C5aR as a regulatory switch that modulates TLR4 
signalling via the Gαi/c-Raf/MEK/ERK signalling axis in human macrophages but not in human 
monocytes. 
Chapter Six summarises all key findings in chapters 2-5, which represent important new 
knowledge in the field of complement C5a-C5aR and their effects on primary human monocytes 
and macrophages. Advances made in this thesis are specifically highlighted, discussed in relation to 
their novelty and significance and differences from the literature, and possible future research 
directions that build on the findings in this thesis are also outlined in relation to the fields of 
immunology and pharmacology. 
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1.1 Abstract 
 
The complement system of around 30 plasma proteins is a central component of 
immunity, bridging innate and adaptive immune responses to infection and injury. If 
complement activation is prolonged or dysregulated, it can also turn become 
destructive to host cells and lead to numerous pathological conditions and diseases. 
Overproduction or underregulation of the potent proinflammatory and chemotactic 
protein, complement component C5a, has been implicated in numerous immune and 
inflammatory conditions. It is specifically recognized by the complement receptor 
C5aR, a G Protein Coupled Receptor (GPCR) on the surface of immune and other 
cells, and C5aR is a promising therapeutic target for complement modulation. Indeed 
GPCRs are the most prevalent signal-transducing cell surface proteins in 
pharmaceutical research. Of over 900 human GPCRs identified to date, more than one 
third are potential therapeutic targets for the treatment of diseases.  
Despite the importance of C5aR to drug discovery and inflammatory diseases 
and there are no antagonists of this protein in the marketplace. Although C5aR is 
widely expressed throughout the body, it is highly expressed in myeloid cells such as 
macrophages. This chapter summarizes the roles of C5a activation on human 
macrophages, briefly surveying C5a, C5aR and some important small molecule 
analogues of C5a that had been developed to study roles for C5a in vivo. 
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1.2 Introduction 
 
The immune system incorporates both cellular and molecular mechanisms to 
distinguish between host cells and foreign organisms or materials (1, 2). There are 
two main types of immunity: (a) innate immunity (unspecific) and (b) acquired 
immunity (specific). Innate immunity does not require previous exposure to, or 
memory of pathogens or tumours and among many components, includes physical 
barriers, mucous membranes, antimicrobial substances (e.g. lysozyme, peroxidase, 
histones and other inflammatory mediators), the complement system, phagocytes (e.g. 
neutrophils, macrophages) and natural killer (NK) cells. On the other hand, specific 
immunity can be acquired by infection or vaccination (3). Acquired immunity is 
usually classed into two subtypes: (a) the humoral response where B-lymphocytes (B-
cells) produce specific antibodies targeting foreign materials, and (b) cell-mediated 
responses where T-lymphocytes (T-cells) either help in maturing/priming other 
immune cells (B cells, dendritic cells (DC) and macrophages) or in destroying 
infected and/or tumour cells (Figure 1.1). 
 
Figure 1.1. Schematic representation of the cells involved in innate and adaptive 
immunity. Adapted from (3). 
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1.3 The complement system 
 
The complement system serves as an important effector of both innate and 
acquired immunity. Comprising over 30 soluble plasma, and insoluble membrane-
bound, proteins, the complement system acts in a wide variety of host defence, 
inflammatory, homeostatic and immune responses (4). Complement can be activated 
through at least three distinct pathways, (a) the classical pathway – initiated by 
antigen-antibody complexes; (b) the alternative pathway – initiated by bacteria and 
yeast cell walls; (c) the lectin pathway – initiated similarly to the classical pathway 
but in the presence complex polysaccharides and the absence of complement 
component 1q (C1q) (Figure 1.2). There is also mounting evidence that proteolytic 
enzymes (e.g. thrombin, trypsin) normally associated with other cascading networks 
are also be capable of activating complement (5-8).  
 
Figure 1.2. Schematic diagram of the three main pathways involved in 
complement activation.  
Classical, alternative and lectin pathways and factors involved in complement 
activation are shown. Two isoforms of C3 convertases are highlighted in the blue 
boxes and the two isoforms of C5 convertases are highlighted in the green box. C3a 
and C5a anaphylatoxins are highlighted in the brown and red boxes respectively (9). 
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The complement system contributes to opsonisation (tagging) and killing of 
microorganisms and foreign bodies, and the induction of adaptive immunity to protect 
the host from pathogens and infected or damaged cells. The activation of complement 
involves a series of initiation, amplification and proteolytic reactions to sequentially 
activate proteins and enzymes down the cascade (10, 11). The complement system is 
regulated at multiple levels, both temporally as well as spatially depending on which 
component is activated. For example, amplification of complement activation via the 
alternative pathway is regulated by the formation of the short-lived (t1/2 ~90 s) 
protease complex, C3 convertase (C3bBb) (10). There is also a second C3 convertase, 
(C4b2a) that forms when the classical or lectin pathway is activated (t1/2 ~10 min) 
(12). C3 convertases cleave the third complement component protein (C3) into its 
active form C3b, exposing its thioester bond to permit covalent attachment to nearby 
surfaces (13). The process must be tightly regulated to prevent non-specific attack of 
host cells, either by accelerating the decay of C3 convertases or by degrading existing 
C3b (to prevent formation of new C3 convertase) (14). C5 convertase is formed when 
free C3b binds to C3 convertase. C5 convertases can also exist in two isoforms, 
depending on the origin of C3 convertase. C5 convertases cleave C5 to produce C5b, 
and release the proinflammatory chemoattractant C5a that can interact with C5a 
receptors, which are highly expressed on immune cell surfaces. C5b then complexes 
with C6, C7, C8 and C9 to form the membrane attack complex (MAC) (15) 
responsible for initiating cell/pathogen lysis.  
There is a very delicate balance that must be maintained whenever the 
complement cascade is activated because of its destructive nature. Despite the 
stringent and multiple levels of self-regulatory mechanisms, excessive complement 
activation can occur because the rate of activation may exceed the capacity of host 
regulatory mechanisms (16). In many diseases, while complement activation may not 
be the primary initial disease-inducing culprit, tissues damage in certain conditions is 
clearly complement-driven. Some of the disorders known to be associated with 
prolonged or aberrant complement activation are briefly covered in (Table 1.1) (17).  
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Table 1.1. Disorders associated with complement activation (17). 
Classification Disorder 
Acute Adult respiratory distress syndrome 
Ischemia-reperfusion injury: Myocardial infarct 
Lung inflammation 
Hyperacute rejection (transplantation) 
Sepsis 
Cardiopulmonary bypass 
Burns, wound healing 
Asthma 
Restenosis 
Multiple organ dysfunction syndrome 
Trauma, hemorrhagic shock 
Guillain-Barré syndrome 
Chronic 
 
 
 
 
 
Paroxysmal nocturnal hemoglobinuria 
Glomerulonephritis 
Systemic lupus erythematosus 
Rheumatoid arthritis 
Infertility  
Alzheimer’s disease 
Organ rejection (transplantation) 
Fibrotic disorders 
Multiple sclerosis 
Biomaterials 
incompatibility 
Platelet storage 
Hemodialysis 
Cardiopulmonary bypass equipment 
 
1.4 Complement C5a receptors and signalling properties 
 
1.4.1 C5aR 
 
C5a acts through a specific receptor named C5a receptor (C5aR/C5AR1 or 
CD88). C5aR belongs to the seven membrane-spanning receptor superfamily and is 
functionally coupled to a pertussis toxin (PTX)-sensitive G-protein (18-20). The 
seven transmembrane receptors are also referred to as G protein-coupled receptors 
(GPCRs). Most GPCRs undergo conformational changes upon binding to their native 
agonist ligand, which activates an associated G-protein heterotrimer (a complex of α-, 
β- and γ-subunits) by exchanging its bound guanosine diphospate (GDP) for a 
guanosine triphosphate (GTP). The G-protein α-subunit (Gα), together with a bound 
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GTP dissociates from the dimer βγ-subunit and triggers a series of intracellular 
signals or target proteins directly depending on the subunit type (Figure 1.3).  
 
 
Figure 1.3. G-proteins contain three subunits (α , β  and γ), the Gα  subunit binds 
to a GDP molecule. 
When a G-protein binds an activated receptor, the GDP-binding subunit undergoes a 
subtle conformational change, and exchanges its GDP nucleotide by a GTP. GTP-
bound Gα subunits have different downstream effects depending which type of Gα is 
involved (21). 
 
Cellular stimulation of C5aR through pertussis toxin (PTX)-sensitive Gαi2, 
Gαi3, or PTX-insensitive Gα16, results in intracellular calcium mobilisation and 
activation of signalling pathways including phosphatidylinositol 3-kinase (PI3K), 
diacylglycerol (DAG), mitogen-activated protein kinase (MAPK), extracellular 
signal-regulated kinase (ERK) and other downstream signalling proteins (22-24). C5a 
can stimulate the synthesis and release of proinflammatory cytokines such as TNF, 
IL1β, IL6 and IL8 in human leukocytes (25, 26). C5aR expression is upregulated in 
mouse microvascular endothelial cells (MMEC) and rat alveolar epithelial cells 
(RAEC) by inflammatory mediators, such as lipopolysaccharide (LPS) or IL6 (27, 28). 
C5a has also been shown to exert strong synergistic effects with LPS for TNF, 
macrophage inflammatory protein-2 (MIP2), cytokine-induced neutrophil 
chemoattractant-1 (CINC1) and IL1B in RAEC (27).  
Human umbilical vein endothelial cells (HUVEC) constitutively express C5aR 
and, when stimulated with C5a at nanomolar (nM) concentrations, increase the 
mRNA expression of IL8, IL1B and RANTES in a time- and dose- dependent manner 
(29). C5a strongly decreases IL12 production in human monocytes treated with LPS 
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or interferon gamma (IFNG) (30). The evidence suggests that the C5a-C5aR 
signalling axis can produce cytokines and chemokines in many immune cell types. 
However, C5a-C5aR signalling can lead to completely opposite outcomes depending 
on the cell type. For example, C5a strongly suppresses LPS-induced TNF production 
in neutrophils but evidently shows the opposite effect in alveolar macrophages (31, 
32). Neutrophils increase cytosolic content of IκBα (nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor alpha) when stimulated with C5a, 
which inhibits NF-κB (nuclear factor kappa light chain enhancer of activated B cells) 
activation (32). On the other hand, NF-κB activation occurred within 15 min after 
C5a stimulation of monocytes and macrophages (31). The ability of C5a to 
simultaneously up- and down-regulate NF-κB dependent expression of genes such as 
TNF, IL6 and IL8, suggests that C5a-C5aR signaling is not a simple “on or off” 
switch model but is more complex and can be different in different cell types.  
 
1.4.2 C5L2, the second C5a receptor 
 
In 2000, Ohno et al. identified a second C5aR-like GPCR called C5L2 
(GPR77) (33). There is a 38% sequence homology between C5aR and C5L2 (34). 
C5L2 binds to C5a with similar affinity as C5aR, but binds to C5adesArg with higher 
avidity compared to C5aR (35, 36). However, C5L2 does not fit neatly with the 
perceived functions of C5a, generating controversy in the literature. C5L2 was 
initially thought to be a non-signalling receptor, as binding to C5a did not stimulate 
mobilisation of intracellular calcium, extracellular signal-related kinase (ERK) 
phosphorylation or receptor internalisation, in contrast to C5aR (33, 37, 38). It has 
been suggested that the inability of C5L2 to signal is due to a mutation in a highly 
conserved ‘DRY motif’ (Asp-Arg-Tyr) in many GPCRs, located at amino acid 
residues 137-139 near the third transmembrane domain. C5L2 has instead a ‘DLC 
motif’ (Asp-Leu-Cys) and when the leucine was substituted with an arginine residue, 
C5a could induce a small increase in intracelluluar calcium levels in 293T cells co-
expressing Gα16, suggesting that the central leucine is important for G protein 
uncoupling in C5L2 (36). Mice lacking C5L2 were found to have enhanced responses 
to both C5a and C5adesArg (38). A rat model of sepsis showed an increase in C5L2 
expression and blocking C5L2 with an anti-C5L2 antibody substantially increased the 
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concentration of the inflammatory cytokine IL6 (39). Interestingly, immune complex-
induced lung injury was attenuated in C5L2-/- mice (40), whereas another group 
described the opposite phenotype showing that C5L2-/- mice exhibited intensified 
immune complex-induced lung injury (38). The role of C5L2 in inflammatory 
responses is still highly controversial and at this time remains poorly understood. 
 
1.5 Complement component C5a 
 
Activation of the complement system also generates potent chemoattractants 
and markers for immune clearance that covalently attach to cell surfaces. For example, 
C3a, C4a and C5a are anaphylatoxins that are released during classical and lectin 
pathway activation, while C3a and C5a are also released during alternative pathway 
activation. Among these three polypeptides, C5a is the most potent anaphylatoxin 
followed by C3a then C4a (41, 42). Besides being the most potent, C5a has also been 
the most intensively studied of the anaphylatoxins (43). C5a is a polypeptide, which 
contains 74-79 amino acids depending on the species type (Figure 1.4). The NMR 
solution structure of hC5a was first solved in 1989, but ten residues at the C-terminus 
were highly disordered (44). A subsequent NMR structure with better resolutions 
reported by Zhang et al. showed that the human C5a structure is arranged into an anti-
parallel 4-helix bundle (1st helix4-12; 2nd helix18-26; 3rd helix32-39 and 4th helix46-63), 
being stabilized by three disulphide bonds (Cys21-Cys47, Cys22-Cys54 and Cys34-Cys55) 
and connected by three loop segments (1st loop13-17, 2nd loop27-33 and 3rd loop40-45) 
(45). The C-terminal residues69-74 form a helical turn conformation that brings Arg 74 
adjacent to Arg 62 (45). This C-terminal helical turn conformation (red) is critical for 
receptor activation (Figure 1.5). 
 
Figure 1.4. C5a peptide sequence alignment from various species.  
C5a(s) were aligned using ClustalW2 (46). Conserved residues are colored according 
to their physicochemical properties (http://www.ebi.ac.uk/tools/clustalw2). Adapted 
from (47). 
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C5a anaphylatoxin has many biological properties, including mast cell 
degranulation, recruitment of immune cells to sites of inflammation 
(chemoattractants), smooth muscle contraction, vasodilation and stimulation of 
proinflammatory cytokines such as tumour necrosis factor alpha (TNF), interleukin-6 
(IL6) and -1beta (IL1B) (48-52). The activity of C5a can be modulated by the enzyme, 
carboxypeptidase B. Serum carboxypeptidase B rapidly metabolises C5a to 
C5adesArg within seconds by removing the C-terminal arginine of C5a, which is 
important for binding to C5aR (53, 54). C5adesArg has a 10-1000 times reduced 
potency compared with C5a, depending on the function being measured and the cell 
type examined (55). The Kd of C5a and C5adesArg binding to C5aR is ~1 and 412-
660 nM respectively on bone marrow cells and monocytes (36, 56). It has now 
become apparent that uncontrolled or inappropriate production of C5a is specifically 
implicated in many inflammatory diseases as summarized in Table 1.2. The details 
and mechanisms underlying these diseases are investigated elsewhere and will not be 
discussed here. 
 
Figure 1.5. NMR solution structure of C5a at pH 5.2 (PDB ID code: 1KJS). 
Human C5a is a 74 glycoprotein consisting of four alpha helices (helix 1, cyan; helix 
2, orange; helix 3, pink and helix 4, blue) arranged in an anti-parallel orientation. The 
four-residue loop in the C-terminus (red) is critical for receptor activation (45).  
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Table 1.2. Pathologic conditions involving anaphylatoxin C5a.  
Classification Pathologic condition 
Cardiovascular Fibrosis in hypertension (57) 
Atherosclerosis in ApoE-/- mice (58) 
Preclinical atherosclerosis associated with systemic lupus 
erythematosus (59) 
Arterial injury in atherosclerosis-prone mice (60) 
Hemodialysis-associated thrombosis (61) 
Human coronary lesions (62) 
Complement and coagulation cascades (63) 
Arthritis Inflammation in autoimmune arthritis (64) 
Inflammatory arthritis (65) 
Rheumatoid arthritis (RA) (66) 
Autoimmune arthritis (67) 
Renal Kidney graft survival (68, 69) 
Tubulointerstitial injury (70) 
Liver Fulminant hepatic liver failure (71) 
Pregnancy Preterm delivery (72) 
Age-related 
muscular 
degeneration 
T-cell cytokine release in AMD (73) 
Nervous 
system 
Cerebral arteriovenous malformations (74) 
Incisional pain (75) 
Nociceptive sensitization (76) 
Mitochondrial functions of PC12 cells (77) 
Infection Experimental periodontitis (78) 
Bone loss in P. gingivalis infection (79) 
Necrotizing enterocolitis (80) 
S. aureus bacteraemia (81) 
Cerebral malaria (82) 
Gram-negative bacteraemia and endotoxic shock (83) 
NKT and NK function in sepsis (84) 
Respiratory 
disease 
Chronic obstructive pulmonary disease (85) 
Experimental allergic asthma (86, 87) 
Modified from (47). CNS, central nervous system; NK, natural killer cell; NKT, 
natural killer T cell. 
 
1.6 Ligands of C5aR 
 
Although the mission to discover complement therapeutics started over 30 years 
ago (88), there are still no small molecule drugs in the marketplace for targeting any 
complement protein. C5aR has been demonstrated to be an important and promising 
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therapeutic target for complement modulation (89). An antibody that blocks the 
proteolysis of C5 to C5a and C5b (an early precursor to membrane attack complex) 
has been clinically validated and approved by the U.S. Food and Drug Administration 
(FDA) for treating paroxysmal nocturnal hemoglobinuria (90). However, proteins can 
have limited utility as therapeutics due to the expense to produce, difficulties to 
formulate and can trigger unwanted immunogenic side effects. The failure of the anti-
C5 monoclonal antibody (mAb), pexelizumab, in some clinical studies for treating 
acute myocardial infarction was attributed to poor tissue penetration, leading to poor 
therapeutic efficacy. On the other hand, unlike proteins or antibodies, drug-like small 
molecules do not tend to possess these disadvantages for therapeutic invention.  
The idea of synthesizing the C-terminus of the human C5a as analogues to 
probe C5aR function started as early as in the 1970s. Peptide analogues of C5a 
containing residues 1-69, but lacking five residues of the C-terminal domain of native 
C5a, were discovered to bind to C5aR but failed to elicit activity at C5aR (91). 
Interestingly, the pentapeptide MQLGR (corresponding to C5a70-74) alone, or in 
combination with C5a1-69 was also inactive at C5aR (92). These results led to the 
hypothesis that C5a possesses an internal ‘recognition’ site in addition to the 
‘activation’ site contained in the C-terminal region of C5a (91). Since then, intensive 
efforts has been made to design and develop better analogues of C5a, both agonists 
and antagonists of C5aR (89).   
 
1.6.1 C5aR agonists 
 
Sequent extension of the pentapeptide ‘MQLGR’ to the octapeptide 
‘HKDMQLGR’ resulted in modest binding activity (93). Replacing the His residue 
with a Phe residue increased potency on C5aR (94). After conducting a series of SAR 
studies, the decapeptide EP-54 ‘YSFKPMPLdAR’ was later discovered by Sam 
Sanderson at the University of Nebraska with biological activity, but its agonist 
activity was still only in the µM concentration range (94). Although this decapeptide 
was a full agonist on human C5aR and had little or no activity on C5L2 (95), it also 
bound non-specifically to C3aR at µM concentrations (96). In contrast, EP-67 
‘YSFKDMP(Me)LdAR’ displayed weak agonist activity on C5aR and C3aR but had 
better activity on C5L2 (97-99). EP-54 and EP-67 were termed “response-selective” 
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as these peptide mimetics showed different responses at C5aR depending on the cell 
type (98), although these varying responses are probably due to receptor selectivity 
issues.  
Earlier structure activity studies led by researchers from Abbott Laboratories in 
the 1980s, produced analogues with higher affinity for human C5aR, while 
downsizing the peptide to six residues, N-Methyl-FKPdChaCha-dArg-OH, with nM 
activity against C5aR (100). Although this hexapeptide agonist was previously 
reported to bind with low affinity to C5L2 (101), but did not affect C5a binding to 
C5L2 even at high µM concentrations, more recent studies have shown otherwise 
(102). The selectivity of this peptide agonist for C5aR over C3aR was not 
investigated.  
First generation peptide agonists for C5aR were notorious for also binding to 
C3aR (96), despite the latter having only 37% sequence identity to C5aR (103). It is 
surprising that despite this notorious non-specific binding to C3aR, researchers 
developing C5a agonists have not investigated or disclosed whether or not their 
reported compounds were truly C5aR selective agonists. This has been a major hurdle 
in developing better C5aR agonists from uncertain starting points.  
 
1.6.2 C5aR antagonists 
 
Since the discovery of ‘N-Methyl-FKPdChaCha-dArg-OH’, further SAR 
studies have led to a family of hexapeptide analogues, ‘N-Methyl-FKPdCha(x)-dArg’, 
which can be agonists or antagonists depending on the properties of the fifth residue 
(x) (104). It was found that increasing the aromaticity at position (x) could lead to 
increased antagonist activity at C5aR (104). Interestingly, over a hundred peptide-
activated GPCRs recognize ligands with a turn structure and the conformation of this 
β/γ turn motif may be crucial to the mechanism of receptor activation (105, 106). 
Binding of C5a to C5aR involves three binding sites (9). Potential agonists and 
antagonists for C5aR have been designed based on this region (107).  
The compound known as “3D53”, a hexapeptide containing a cyclic 
pentapeptide AcF[OPdChaWR] was the first cyclic peptidomimetics C5aR antagonist 
and proved to be a potent and water-stable full antagonist of C5aR on human 
neutrophils (108) and most other human cell types expressing C5aR. 3D53 was 
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created by PhD student Allan Wong in the Centre for Drug Design and Development 
(3D Centre), University of Queensland in 1996. Figure 1.6 shows the molecular 
interaction between the Arg, dCha, Trp and AcPhe component of the 3D53 binding 
sites fitting into the binding pockets within the helices of human C5aR. 3D53 has an 
antagonist potency IC50 20 nM against human C5a (100 nM) (109). A variety of in 
vitro assays were used to determine the antagonist properties of 3D53, including 
inhibition assays of myeloperoxidase release from human polymorphonuclear cells 
(PMNs), C5a-mediated chemotaxis of PMNs, C5a-induced human umbilical artery 
contractions and E.coli-induced oxidative burst and phagocytosis (107, 110-112). 
3D53 was found to be a highly specific inhibitor of C5a mediated effects and had no 
cross reactivity with other GPCR ligands, such as formylmethionyl-leucyl-
phenylalanie (fMLP), leukotriene B4 (LTB4), and platelet-activating factor (PAF) 
(107). More interestingly, 3D53 does not bind to C5L2, which makes it an invaluable 
tool to use to study the effects of C5aR without background contamination with C5L2 
signals (101). Most importantly, 3D53 does not bind to C3aR (113). 
 
 
Figure 1.6. Modelled interaction between 3D53 (green) and human C5aR 
(orange).  
Molecular modelling showed ligand binding pockets (left: side view, right: top view) 
with Arg, Trp, dCha and AcPhe components of 3D53 fitting between helices of C5aR. 
Adapted from Monk et al (89). 
 
Eventually, 3D53 was licensed as PMX53 (Figure 1.7A) for clinical 
development by the now defunct Promics Ltd (subsequently passed on through a 
series of company takeovers to Peptech Pty Ltd, Arana Therapeutics Ltd, Cephalon 
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Inc. and then in 2011 to TEVA Pharmaceutical Industries Ltd, which is the world’s 
largest manufacturer of generic pharmaceuticals (114).  PMX53 was safe and well 
tolerated in Phase I clinical trials, and 3D53 has been the most intensely evaluated 
small molecule C5aR antagonist in human clinical trials. PMX53 was found to exert 
long lasting effects even though it had low oral bioavailability (114). What this means 
is that even a once daily dose was sufficient to maintain an effective therapeutic 
window in rats (115). A more stable derivative, PMX205 (Figure 1.7B), was later 
developed with a hydrocinnamic acid group in the N-terminus of PMX53 (116). 
PMX205 has also been investigated in animal models of Huntington’s disease (117), 
Alzheimer’s disease (118) and amyotrophic lateral sclerosis (ALS) (119).  
JPE-1375 (Figure 1.7C) was developed as a linear analogue of PMX53 by 
substituting the Arg residue with a Phe residue and adding a hydroorotic acid (Hoo) in 
place of the N-acetyl cap (120). Although JPE-1375 and PMX53 has similar reported 
potency on C5aR, JPE-1375 exhibited high microsomal stability (121). Despite 
promising results in renal allograft survival (122), AMD (123), experimental 
tubulointerstitial fibrosis (124) and atherosclerotic plaque stabilization (60), JPE-1375 
was discontinued early in development (125). 
    
 
Figure 1.7. C5aR peptidic antagonists. (A) PMX53, (B) PMX205 and (C) JPE-
1375. 
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Although these peptidic antagonists of C5aR were potent antagonists of C5aR, 
except for the cyclic peptide 3D53, they unfortunately also inherited some 
disadvantages of peptidic ligands for example, susceptibility to proteolytic cleavage in 
serum, low oral bioavailability as the result of hydrophilicity, and high molecular 
weights. To overcome problems associated with peptides, non-peptidic compounds 
have been sought with more drug-like properties such as higher oral bioavailability, 
cheaper synthesis, high stability in serum and resistance to enzymatic degradation.   
W54011 (Figure 1.8A) was developed by Mitsubishi Pharma, and was the 
result of an optimized series of substituted phenylguanidines and 
tetrahydronapthalene-based compounds (126). W54011 was reported to be a 
competitive non-peptidic C5aR antagonist. Although Sumichika et al. did not report 
the percent oral bioavailability of W54011, the authors claiming that this antagonist 
was potent and orally active in vivo (126). However, it is very hydrophobic and had 
problems with species specificity (active in human, cynomolgus monkey and gerbil 
but not as active in mouse, rat guinea pig, rabbit or dog neutrophils), which 
complicated pre-clinical studies (89).  
NDT9520492 (Figure 1.8B) was developed by Neurogen Corp and like 
W54011, NDT9520492 was also species-specific with antagonistic activity of IC50 
~300 nM at human and gerbil but not mouse or rat C5aR (127). NGD2000-1 
(chemical structure not disclosed), a derivative of NDT9520492 has been tested in 
phase II clinical trials for asthma and rheumatoid arthritis (89). Although NGD2000-1 
showed some promising results, it also targeted cytochrome P450 3A4 that halted all 
clinical developments (89). 
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Figure 1.8. C5aR non-peptidic anatagonists. (A) W54011, (B) NDT9520492 and 
aniline-substituted tetrahydroquinoline (C) JJ46 and (D) JJ47. 
 
A series of tetrahydroquinoline compounds were developed by Johnson & 
Johnson Pharmaceutical Research and Development with modest antagonist activity 
on C5aR at high µM concentrations (128). The introduction of functional groups on 
the anilines was a strategy intended to increase interactions between ligand and C5aR 
binding sites to improve potency (129). The potency of aniline-substituted 
tetrahydroquinoline compounds such as JJ46 (Figure 1.8C) resulted in 10-100 fold 
increased in potency to double-digit nanomolar concentrations against 1.5 nM human 
C5a in a calcium mobilization assay on human monocytic cell line U937. JJ47 
(Figure 1.8D) was the most potent antagonist of a series of aniline-substituted 
tetrahydroquinoline compounds developed by Johnson & Johnson Pharmaceutical 
Research and Development, with C5aR antagonist activity at single-digit nanomolar 
concentrations in a calcium mobilization assay with similar conditions. Docking of 
JJ47 in human C5aR homology model revealed that JJ47 binds into a putative ligand-
binding site where the diethylphenyl group may have hydrophobic interactions with 
residues Ile116 and Val286 of the receptor. These interactions may contribute to the 
increased in antagonistic activity in the aniline-substituted tetrahydroquinoline 
compounds. 
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W54011 and JJ47 are both by far the two most potent reported antagonists in 
literature with IC50 values of 3 (against 0.1 nM human C5a on human neutrophils) and 
7 nM (against 1.5 nM human C5a on U937 cells) respectively on human C5aR. 
However, W54011 did not progress and perform as well as 3D53 (IC50 values = 20-55 
nM against 0.1-100 nM human C5a on human neutrophils). To date, there has been no 
clinical development of JJ47. C5a has been implicated in numerous immune and 
inflammatory conditions but, to date, there is still no drug available for treating C5a-
C5aR-mediated diseases. As such, 3D53, W54011 and JJ47 have been chosen to 
uncover important fundamental reasons for the failure of small molecules in clinical 
trials (Chapter 4). 
 
1.7 New insights into C5aR-related biological functions and diseases 
 
The understanding of complement biology has undergone a significant 
metamorphosis since its original discovery as a heat-labile principle in serum that 
“complemented” antibodies in the killing of bacteria (130, 131). A system, which was 
traditionally described as a “complement” to humoral immunity, is now perceived as 
a central constituent of innate immunity and adaptive immune responses. 
Proinflammatory signalling and phagocytosis are essential for complement-mediated 
defence against infection (132). The “complementary” concept becomes inadequate in 
light of recent studies demonstrating functions of complement that are essential and 
“central” to the innate immune response, as well as functions that link innate with 
adaptive immunity (133). Complement must now be viewed as a system that 
orchestrates and connects various responses during immune and inflammatory 
reactions and not merely as a killer of bacteria (134). During activation and 
amplification, C5a is constantly generated and released into circulation, triggering 
proinflammatory signalling through C5aR. The expression of C5aR was initially 
thought to be restricted to myeloid blood cells, including neutrophils, monocytes, 
macrophages and eosinophils (135). It now appears that the receptors are widely 
distributed to multiple organs and tissues, including the liver, lungs, kidney, brain and 
the central nervous system (135-144). This is an indication that the effects of C5aR 
signaling may be involved in many other biological functions. Some unexpected and 
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recently discovered functions of the C5a-C5aR axis are briefly summarized in the 
next few sections.  
 
1.7.1 Interaction of RP S19 Oligomers with C5aR 
 
Monocytes and neutrophils make up ~70% of the total white blood cells in 
circulation. These cells are major phagocytic leukocytes that can migrate to sites of 
infection by sensing the anaphylatoxin C5a via C5aR. Endotoxic shock or septic 
shock is an acute diseased state characterized by systemic hypotension (145), 
pulmonary hypertension (146), depletion of circulating leukocytes and platelets as a 
result of severe infection and sepsis (147). Most cases of septic shock are caused by 
bacterial lipopolysaccharides (LPS) released from gram-negative bacteria (148), 
which in turn can also activate the complement system to generate C5a (149). Not 
surprisingly, an intravenous administration of C5a, or C5a peptidic agonists in 
animals also resulted in hypotension and neutropenia, similar to responses induced by 
LPS (150). The role of C5a in sepsis has already been extensively reviewed elsewhere 
(52), hence this will not be the focus of this section. Instead, an unsuspected ligand of 
C5aR, the RP S19 protein, will be briefly described here. 
Neutrophils can migrate more rapidly and induce vascular plasma leakage 
upon infiltration (151), whereas monocytes are superior in phagocytosis and antigen 
presentation but infiltrate tissues more slowly (152). Since these leukocytes migrate 
differently in response to inflammation, there is no surprise that they responded to the 
novel chemotactic factor, ribosomal protein S19 (RP S19) differently (153). RP S19, a 
component of the small subunit of the translation machinery (ribosome), can dimerize 
by a transglutaminase-catalyzed reaction (154), and is released into the circulation 
when infected or damaged cells undergo apoptosis. Although there is no molecular 
relationship between RP S19 and C5a, RP S19 can bind as a dimer to C5aR and 
induce chemotaxis (155). However, RP S19 does this with pro- and anti-apoptotic 
dual functions on neutrophils and monocytes respectively, thereby affecting the fate 
of different immune cells (156).  
The human C5a is a 74-residue glycosylated peptide consisting of four alpha 
helices arranged in an anti-parallel orientation (Figure 1.9). Apart from two short β-
sheets in the human RP S19 protein, the secondary structures are almost similar 
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between human C5a and RP S19 proteins (Figure 1.9) (157). Although there are no 
disulfide bond in RP S19, unlike C5a with 3 disulfide bonds, the overall tertiary 
structure of RP S19 appeared more loosely packed than C5a. Interestingly in human 
mast cells HMC-1, RP S19 triggers p38 MAPK activation instead of ERK1/2 
activation by C5a (158). It seems that this novel regulatory mechanism via C5aR in 
immunity is in place to prevent excessive tissue destruction by neutrophils, yet to 
attract monocytes to clear apoptotic cells that released dimerized RP S19 molecules. 
 
 
Figure 1.9. Comparative modelling between human C5a and RP S19 protein. 
Human C5a structure (PDB ID: 1CFA) and human RP S19 structure (homology 
model of Pyrococcus Abyssi, PDB ID: 2V7F). Adapted from (157) 
 
1.7.2 An unsuspected role for C5aR in cancer-related inflammation 
 
An association between chronic inflammation and cancer was initially 
suspected on the basis of two observations. First, C5a-induced chemotaxis has many 
similar features to cancer metastases. Second, there was epidemiological data 
correlating increased incidence of various malignancies in patients suffering from 
chronic inflammatory diseases (159). Numerous experimental studies have shown that 
chronic and indolent inflammation can increase the risk of malignant transformation, 
exacerbate tumour growth, enhance invasion of normal tissue and facilitate metastasis 
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(160, 161). Malignant tumour cells can suppress antitumour immune responses (162, 
163), by recruiting myeloid-derived suppressor cells (MDSCs), which in turn induced 
an antigen-specific CD8+ T cell tolerance response to evade tumour killing 
mechanisms (164, 165). Although complement activation plays various roles in 
mediating inflammatory responses, complement promoting the development and 
progression of malignant tumours was not substantiated for a very long time. Instead, 
complement activation was interpreted as host defence mechanisms for killing tumour 
cells (166-169), by analogy to the well-characterized role of complement in 
microorganism killing.      
Various components of the complement system can promote the growth of 
tumours in a mouse model of cervical carcinoma (170). Complement effectors such as 
anaphylatoxin C5a, can give rise to many proinflammatory mediators (171), these 
immunological events in turn create favourable microenvironments encouraging 
tumour growth (160, 172-174). Furthermore, C5aR was aberrantly expressed in 
various human cancers (175). Cellular cytoskeletal rearrangement and motility, as 
well as invasiveness of cancers cells, were greatly enhanced by C5a, and this 
enhancement by C5a were not observed in normal cells (175). Pharmacological 
blockade of C5aR with peptidic antagonist 3D53 (also commonly referred to as 
PMX53) in wild-type mice resulted in reduced tumour growth (170). The role of 
C5aR signaling in tumour development was also supported by reduced tumour growth 
in C5aR-/- mice (176). Furthermore, C5aR-deficient mice depleted of CD8+ T cells 
were free of tumour, leading to the conclusion that C5a promoted tumour growth by 
suppressing T-cell-mediated antitumour responses (170). 
The recent discovery that complement promotes the growth of malignant 
tumours (175) has shifted the paradigm in the field of cancer research, although such 
findings are also consistent with a growing appreciation for the role of inflammation 
in cancer progression. In light of this discovery, inhibiting the complement system 
seems to be a promising new approach to treating cancer. MDSCs in cancer patients 
were strongly believed to be the main culprit for the failure of antitumour 
immunization (165). Targeting C5aR in combination with antitumour immunization, 
may improve the efficacy of existing antitumour vaccines.   
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1.7.3 C5aR crosstalking with TLRs 
 
The complement system appears to have evolved as ancient defence machinery 
against microbial pathogens. Invading pathogens display unique pathogen-associated 
molecular patterns (PAMPs), which are detected by the host innate immune system 
via pattern recognition receptors (PRRs) (177, 178). The Toll-Like Receptors (TLRs) 
and complement are two key component systems of the innate immune response that 
can recognise PAMPs and facilitate microbial killing and clearance (131, 179). 
Although both systems have been historically investigated as separate entities, an 
emerging body of evidence indicates extensive crosstalk between TLR and 
complement signaling pathways in several in vitro as well as in vivo experimental 
human and mice models (180). Crosstalk between different signaling pathways in 
mammalian cells can result in unexpected and unique functional outcomes (181). 
Some pathogens have evolved to evade or exploit host microbial-killing by targeting 
C5aR and TLRs specifically. For example, virulence proteins secreted by 
Staphylococcus aureus bind to C5aR with potent antagonist activity, preventing 
recruitment of phagocytes to sites of infection (182). Porphyromonas gingivalis 
exploits the C5aR/TLR2 crosstalk by increasing cAMP production in macrophages, 
which suppresses macrophage immune function and enhances pathogen survival 
(183). Clearly, these pathogens have evolutionarily adapted to exploit 
complement/TLR crosstalk to their advantage.  
Of 10 known human TLRs, TLR4 responds to LPS from Gram-negative 
bacterial cell walls. TLR4 can signal through two different pathways dependent on, 
and modulated by, separate adaptor proteins MyD88 or Toll/IL-1R domain-containing 
adapter inducing IFN-β (TRIF) (184). LPS is not only known as a typical ligand for 
TLR4, it is also a complement activator (185-187). Synergistic crosstalk between 
TLR4 and C5aR was first documented in 1987, when human monocytes co-treated 
with LPS and C5a were reported to secrete elevated levels of IL-1β compared to 
either treatment alone (188). While C5aR and TLR4 signalling have been separately 
investigated in many studies, there is comparatively little reported about their 
interplay (180). Among recent reports on C5aR/TLR4 crosstalk, C5a has been found 
to downregulate TLR4-induced IL12 production via PI3K-dependent (189) and PI3K-
independent (190) pathways in mouse macrophages; to signal via the PI3K-Akt 
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pathway to enhance LPS-induced IL17F cytokine production (191), and to suppress 
LPS-induced IL17A and IL23 cytokine production in mouse macrophages (192). C5a-
induced suppression production and ERK1/2 phosphorylation.  
Part of Chapter 5 deals ahead with C5a acting via C5aR and differentially 
modulating LPS-induced inflammatory responses in primary human monocytes 
versus macrophages (193). While C5a enhanced secretion of LPS-induced IL6 and 
TNF from primary human monocytes, C5a inhibited these responses while increasing 
IL10 secretion in donor-matched human monocyte-derived macrophages 
differentiated by GM-CSF or M-CSF (193). C5a induced Gαi/c-Raf/MEK/ERK 
signaling was amplified in macrophages but not in monocytes by LPS. Furthermore, 
this C5a-mediated suppression of pro-inflammatory cytokines IL6 and TNF in 
macrophages did not compromise antimicrobial activity; C5a instead enhanced 
clearance of the gram-negative bacterial pathogen Salmonella enterica serovar 
Typhimurium from macrophages (193). These findings implicate C5aR as a 
regulatory switch that modulates TLR4 signaling via the Gαi/c-Raf/MEK/ERK 
signaling axis in human macrophages but not in human monocytes. The differential 
effects of C5a are consistent with amplifying monocyte proinflammatory responses to 
systemic danger signals, but attenuating macrophage cytokine responses (without 
compromising microbicidal activity) thereby restraining inflammatory responses to 
localized infections.  
However, most studies reporting C5a modulation of TLR4 signalling had been 
performed with murine (183, 189, 190) and few on human cells (193-195). There are 
important differences in LPS-induced TLR4 signaling between humans and mice 
(196-198), thus necessitating careful assessment of C5aR/TLR4 crosstalk in human 
cells. Some interpretations of human disease mechanisms have been made based on 
extrapolating observations from mouse studies which, although convenient, are often 
not appropriate (199). Future research is expected to elucidate additional regulatory 
links between complement and TLR signalings, particularly in human systems, and 
this is now considered to be pivotal for correctly understanding their precise roles in 
human health and human diseases.  
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1.7.4 Linking C5aR signalling to obesity and metabolic dysfunction  
 
Modern diets high in carbohydrates and saturated fats are the cause of current 
global epidemics in obesity, type II diabetes and cardiovascular disease. Obesity is a 
medical condition in which excess body fat has accumulated to the extent that it may 
have adverse effects on health. Individuals with metabolic dysfunction may inherit 
some of these conditions, such as abdominal obesity, glucose and insulin tolerance, 
elevated plasma triglycerides and cholesterol, and liver and cardiovascular 
abnormalities (200, 201). Obesity is causally linked to chronic low-grade 
inflammation, which contributes to the onset of metabolic disorders (202-205). 
However, the nature and importance of these links with inflammation remained 
unclear. Immune and metabolic systems are among the most fundamental 
requirements for survival. Historically, immunity and energy metabolism are 
considered to be two distinct disciplines. Energy homeostasis is now believed to be 
regulated and coordinated by signalling molecules and pathways that are common to 
those in inflammatory networks (206). Recently, specific modes of immunity and 
energy metabolism have been interrelated at the molecular, cellular, organ and 
organism levels (206-208). The energy balance and body composition are dependent 
on energy income and expenditure, which appears to be interrelated and regulated by 
food intake, fuel utilisation, thermogenesis and adipocyte metabolism (209, 210). Gut 
microbiota, immune networks, altered nutrient sensing and metabolism of fatty acids 
in adipose tissue can also contribute to the onset of obesity and metabolic dysfunction 
(211, 212).  
Activating the complement network triggers immune responses that use 
substantial amounts of energy to fight infection. Aberrant immune responses in 
chronic inflammatory states may exacerbate obesity and metabolic dysfunction (213). 
Elevated levels of C3 (a precursor to C5 and C5a) can be detected in patients 
suffering from type II diabetes and insulin resistance compared to healthy individuals 
(214, 215). Serum levels of C3 correlated with a progressive increase in body mass 
index (BMI) in subjects with severe, morbid or extreme obesity, and thus could be a 
potential biomarker for obesity (216). 
Interestingly, complement proteins C5a and C5aR have energy-conserving roles 
that are contraindicated in complement biology (217). Diet-induced obesity (DIO) 
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mice had increased C5aR mRNA expression in obese adipose tissue (218). C5aR 
deficiency in obese mice led to improved insulin sensitivity (218). PGE2 can have 
paracrine influences on adipocytes through the inhibition of lipolysis (219). 
Interestingly, stimulating murine adipocytes with PGE2 also led to increased gene and 
protein expression of C5aR (217). Antagonism of C5aR can dramatically attenuate 
obesity, visceral adiposity, adipose inflammation, glucose/insulin tolerance and 
cardiovascular dysfunction in rats induced by a high-carbohydrate high-fat diet (217). 
Thereby, this establishes an axis where C5a can exert paracrine control over 
adipocytes via adipose macrophages that secrete proinflammatory agents such as 
PGE2 (217), which are associated with phagocytosing excess lipids and possibly 
secreting antilipolytic factors to curtail the increase in free fatty acids during lipolysis 
in obesity (220).  
Taken together, the C5a-C5aR axis is now thought to contribute to macrophage 
accumulation and adipose tissue inflammation in obese subjects, thereby leading to 
the development of insulin resistance and aberrant metabolic functions in adipose 
tissues. These findings suggest that C5aR may represent a novel target to control the 
progression of metabolic dysfunction and weight gain in obese individuals.  
 
1.8 Mononuclear phagocytic system 
 
The mononuclear phagocytic system is derived from haematopoietic stem cells 
located in the bone marrow, a common myeloid progenitor cell that is the precursor of 
many different cell types, including neutrophils, erythrocytes, eosinophils, basophils, 
monocytes, macrophages, dendritic cells and mast cells (221). During monocyte 
development, myeloid progenitor cells CFU-GM (granuolocyte-macrophage colony-
forming units) generate monoblasts and sequentially give rise to pro-monocytes and 
finally monocytes. Monocytes are released from the bone marrow into the blood 
circulation as macrophages-precursor cells. As monocytes migrate out of the blood 
circulation, they can differentiate into macrophages either in the steady state or in 
response to inflammation (222). Long-lived tissue-specific macrophages can be found 
residing throughout the body including the bone (osteoclasts), alveoli, central nervous 
system (microglial cells), connective tissue (histiocytes), gastrointestinal tract, liver 
(Kupffer cells), spleen, adipose and peritoneum (222, 223). And depending on which 
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tissue the macrophages reside in and the stimulant exposure, they can have distinct 
appearances and different functional phenotypes. 
Macrophages are important immune effector cells that interplay between innate 
and adaptive immunity. In 1908, Élie Metchnikoff received the Nobel Prize in 
Medicine for his discovery of phagocytosis. Back in the early 1900s, macrophages 
were thought to primarily function as professional phagocytes and their other 
functions were overlooked for decades (224). By focusing on the immune functions of 
macrophages, immunologists have ignored their vital homeostatic roles, which are 
independent of their involvement in immune responses. The monocyte-macrophage 
axis plays essential roles in inflammation, antimicrobial defence and tissue wound 
healing but, like a double-edged sword, they are also the main culprits contributing to 
tissue destruction during some infections and inflammatory diseases (225). 
Macrophages have remarkable phagocytic capacities. On average, macrophages 
clear approximately 200 billion erythrocytes each day equating to almost 3 kg of iron 
and haemoglobin per year being recycled for the host to reuse (226). The host would 
not survive without this clearance process. Macrophages are also involved in the 
removal of cellular debris generated during tissue remodelling, and rapidly remove 
cells that have undergone apoptosis, infection or other recognisable damage. Some of 
these processes are carried out independent of immune signals and can result in little 
or no immune responses by unstimulated macrophages (227). However, if cells 
undergoing apoptosis as the consequence of some insults, infection or disease, then 
both defence and repair mechanisms are mobilized by the macrophages. Activated 
macrophages may undergo biochemical, morphological and functional changes and 
secrete an array of cytokines and chemokines, which in turn trigger inflammatory 
responses (228). Macrophage activation at sites of inflammation is typically transient 
with local tissue repair and remodelling in the process of restoring and establishing 
normal tissue function. However, at sites of resistant infectious agents (tuberculosis, 
herpes, HIV), or poorly biodegradable tissue irritants (foreign bodies), macrophages 
remained activated and fused together to form multinucleate giant cells (MGCs) that 
can persist for weeks or months surrounding the unresolved inflammatory site, 
forming the crown-like structure (CLS), a hallmark of chronic inflammation (229).   
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1.8.1 Macrophage infiltration into adipose tissue 
 
A key observation which supported the association between obesity and 
inflammation was the increased number of immune cells infiltration, in particular of 
macrophages into adipose tissue (230-232). Resident macrophages may constitute as 
much as 40% of the total cell population present in adipose tissue (230, 233, 234). 
Adipose tissues of obese human and obese animal models are infiltrated by a large 
number of macrophages and the severity of systemic inflammation and insulin 
resistance correlated to immune cells recruitment (205, 230). Weight loss in obese 
individuals reduced macrophage infiltration and proinflammatory profiles (232). 
Mirroring the Th1/Th2 nomenclature, polarized macrophages are often referred to as 
M1 (classically activated) or M2 (alternatively activated). Macrophages that 
accumulate in the adipose tissue of obese mice expressed markers of an M1 
phenotype, whereas adipose tissue macrophages (ATM) from lean mice expressed 
markers of an M2 phenotype (234). It has been proposed that M1 (also known as 
classically activated macrophages; CAMs) or M2 (also known as alternatively 
activated macrophages; AAMs) ATMs can be distinguished by the presence or the 
absence of CD11c surface marker (234), while others have proposed that the M1/M2 
designation for macrophages should be based on the ratio of IL-12 to IL-10, a ‘pro- 
versus anti- inflammatory’ cytokine productions model (235). M1 or CAM can be 
activated by LPS and IFN-γ to produce proinflammatory cytokines (TNF and IL6) 
and expressed inducible nitric oxide synthase (iNOS); to produce reactive oxygen 
species (ROS) and nitrogen intermediates (236). M2 or AAM on the other hand, can 
be activated by IL4 or IL13 and expressed arginase 1, CD206 (mannose receptor) and 
IL4R α-chain that are regulated by peroxisome proliferator-activated receptor gamma 
(PPARG) (237, 238). The majority of the M1 macrophages were found aggregating 
around ‘dead’ adipocytes to remove apoptotic cells from adipose tissue (239). 
Residual lipid droplets released by dead adipocytes were scavenged by the M1 
macrophage and formed CLS (Figure 1.10), a hallmark of chronic inflammation.  
Depletion of M1 marker genes such as TNF (240) and CCR2 (241) or the 
ablation of CD11c+ cells (242), resulted in normalized insulin sensitivity in insulin-
resistant subjects. M2 macrophages on the other hand, were thought to play a role in 
injured tissue repair and in suppressing the synthesis of proinflammatory cytokines by 
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producing antiinflammatory cytokine IL10 (236). Mice without peroxisome 
proliferator-activated receptor (PPAR)-γ and –β/δ expression resulted in insulin 
resistance and impaired M2 function (238, 243). Due to the nature of these 
macrophages, M1 macrophages were suggested to adapt the proinflammatory immune 
profile, increasing obesity-induced insulin resistance, whereas M2 macrophages were 
adapted to an anti-inflammatory immune profile promoting protective properties 
against it (244). 
 
 
Figure 1.10. Macrophages localize to crown-like structure (CLS) around 
individual adipocytes, which increase in frequency in obesity. Reference from 
(239). 
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1.8.2 Macrophage activation and polarization  
 
Functional polarization of macrophages into M1 and M2 cells is an 
operationally useful, simplified conceptual framework describing the plasticity of 
mononuclear phagocytes. However, macrophages have remarkable plasticity that 
allows them to efficiently respond to environmental signals and change their 
phenotype, and their physiology can be altered by both innate and adaptive immune 
responses (245), unlike lymphocyte, where phenotypic changes can be largely “fixed” 
by chromatin modifications after exposure to polarization cytokines (246, 247). M2-
polarized macrophages can be readily induced to express M1-associated genes by 
subsequent exposure to TLR ligands or IFN-γ (245, 248, 249). M2 designation further 
extended to include essentially all other types of macrophages (235). A growing body 
of evidence indicated that the M2 designation encompasses cells with differences in 
their physiology and biochemistry (250-252). As plasticity seems to be a general 
property of macrophages, the rigid assignment of M1 or M2 subset to in vivo 
inflammation and homeostasis does not make sense unless the overall immune 
response is dominated by one type of T cell response or by a single stimulus (226).  
Mosser and co-worker proposed that macrophage classification should be 
based on the fundamental macrophage functions; host defence, wound healing and 
immune regulation, instead of just an M1 or M2 designation (226). Shown in Figure 
1.11, is a classification of macrophages according to their functions as primary 
colours represented by a colour wheel, rather than a monochromatic linear scale 
designating M1 or M2 (226). This classification more accurately illustrates how 
macrophages can evolve to exhibit characteristics that are shared by more than one 
macrophage population, compared to the rigid designation of M1 versus M2. 
Furthermore, it classifies classically activated macrophages (CAMs) more closely 
related to other subsets than previously designated, covering the development of 
macrophages with shared characteristics rather than in isolation, resulting in a 
spectrum of macrophages. 
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Figure 1.11. Colour wheel of macrophage activation. Reference from (226). 
 
1.8.3 Understanding human macrophage biology from a mouse perspective 
 
Mice have been the experimental tools of choice for immunologists and the 
study of murine immune responses has yielded tremendous insights into the workings 
of the human immune system. Sequence comparison between the human and mice 
genomes showed only 300 or so genes are unique to individual species (253). Despite 
this conservation, it is now known that there are very significant differences between 
human and mice in development, activation and responses in both the innate and 
adaptive arms of host immune system. The antimicrobial peptides, defensins, one of 
the first lines of defence in higher organisms and often the only defence in lower 
animals (254), is one of the many differences between human and mouse innate 
immunity. Defensins can be found in abundance in neutrophils of human, rabbit and 
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even in rats, but are not found at all in mice (255, 256). Secondly, TLRs are important 
players in defence against invading pathogens (257), and recent discoveries and 
differences between both species have caused immunologists to re-think whether 
mice are truly suitable models to study human immunity in detail (258). 
 Mammalian TLR3 recognizes dsRNA and, upon binding, induces NF-κΒ 
activation and production of type I interferons (259). Alexopoulou et al. found that 
LPS can strongly react with TLR3 in murine (260, 261), but not in human cells (262, 
263). Interestingly, there are also important differences between humans and mice in 
TLR4 signaling induced by LPS (196-198). For the past three decades, nitric oxide 
(NO) has been recognized as an important player involved in tumours, autoimmune 
and chronic degenerative diseases, pathogenesis and control of infectious diseases 
(264). The expression of inducible NO synthase (iNOS) can be readily induced by 
IFN-γ and LPS in mouse macrophages (265). However, the same inflammatory agents 
failed to show consistent effects on human macrophages (266). Apparently, there was 
no NOS activity nor synthesis of tetrahydrobiopterin (BH4) in human macrophages 
when stimulated with IFN-γ or LPS (267), which was crucial for the stability and 
function of the iNOS enzyme in murine macrophages (268, 269). This led some 
investigators to wonder if human macrophages were capable of NO generation (267). 
During infection and other inflammatory conditions, elevated levels of NO can be 
detected in human subjects (270-273). Generation of NO was apparent in 
macrophages from patients with tuberculosis (274, 275), rheumatoid arthritis (276), or 
malaria (277), but not in peripheral blood mononuclear cells of healthy subjects (267, 
278). It was not until Hickman-Davis et al. discovered the ability of human alveolar 
macrophages to generate NO production by surfactant protein A (279). Sequentially, 
treatment with other inflammatory mediators, to name a few, IFN-αβ, IL-4 in 
combination with anti-CD23, chemokines, bacterial components, and the list goes on, 
have been reported to induce NO production in human macrophages (272, 280-282). 
The production of NO by human macrophages till to date has remained debateable 
(283, 284).  
 L-arginine metabolism in macrophages is regulated by the enzyme Arginase I 
(Arg1) to produce urea and ornithine or citrulline, and the enzyme iNOS to produce 
NO (285, 286). It has been suggested for mice that M2 can be characterized by the 
high expression of CD206, Arg1, MgII and IL-10 (222, 237). Interestingly, like iNOS, 
Arg1 expression was also not expressed by in vitro polarized human macrophages 
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stimulated with IFN-γ or IL-4 respectively, a contrast from their murine counterparts 
(287). Cell surface markers such as CD11b, CD18 (MAC-1), CD68, MAC-2 and 
F4/80 or EMR1 (human ortholog of murine F4/80) have been widely used by 
immunologists to distinguish macrophages from dendritic cells, especially in the field 
of immunometabolism where macrophages play key roles in the onset of metabolic 
disorders and obesity (288). However, Hamann et al. has disputed whether EMR1 
was not expressed in human macrophages but an eosinophil-specific receptor in 
human cells unlike its murine counterparts (289). Khazen et al. supported that EMR1-
F4/80 was the best macrophage marker not CD14 and CD68, but this conclusion was 
only drawn based on RAW264.7, a mouse macrophage not human (290). While F4/80 
is a specific marker for murine macrophages (291, 292), the absence of F4/80-EMR1 
on human macrophages merits further investigation.  
In summary, murine and human macrophages exhibit distinct differences in 
responses important for immunodefense and regulating inflammation (197, 283, 287, 
293, 294). It would seem that extrapolating data from mice to humans, although 
convenient, is often not appropriate (199). Indeed it is of great concern that 
researchers still today are using these inflammatory markers to determine macrophage 
phenotypes despite vigorous debate and controversy over the usefulness of mouse 
models for human biology. Perhaps, to understand macrophage biology, if not the 
whole immune system, investigations should primarily refocus on human cells, then 
translate novel interactions or regulatory mechanisms underlying such a function and 
further validate it in murine cells for further pre-clinical studies in mouse models, and 
not the other way around. Humans are not mice.  
 
1.8.4 Differentiating primary human monocytes with GM-CSF or M-CSF to 
generate human macrophages 
 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage 
colony-stimulating factor (M-CSF) were first defined by their abilities to generate in 
vitro colonies of mature myeloid cells from bone-marrow precursor cells and 
differentiation of these cells (granulocytic and macrophage by GM-CSF; and 
macrophages by M-CSF) (295, 296). The biological functions of these CSFs are quite 
distinct from one another, with different tissue distributions in steady state, different 
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structures, and different receptors. M-CSF receptor (CSF1R) is the tyrosine kinase c-
Fms (297, 298) and the GM-CSF receptor (CSF2R) comprises two subunits, α (ligand 
binding) and β (signaling) (299, 300). However, it became apparent that GM-CSF and 
M-CSF have other functions on account of their activities on mature myeloid cells 
(301-303). Since GM-CSF and M-CSF played such an important role in modulating 
myeloid cellular development and maintaining immune homeostasis, it is not 
surprising that drugs are currently being investigated in clinical trials in a number of 
inflammatory and autoinflammatory conditions (302, 304).  
More importantly, GM-CSF and M-CSF can be produced by various cells in 
response to infection, injury or inflammation, which are the major survival/mitogenic 
factors for the macrophage lineage with the capacity to activate monocytes and induce 
differentiation (222, 305, 306). M-CSF is passively produced in vitro by several cell 
types, especially macrophages, and circulates at detectable levels basally, whereas 
GM-CSF is usually undetectable but becomes elevated during immune/inflammatory 
responses in vivo to infection or in vitro in response to LPS or TNF (302, 307). GM-
CSF was first isolated from lungs (308) and monocytes differentiated with GM-CSF 
closely resemble alveolar macrophages (309, 310), or even immature dendritic cells 
(311, 312). M-CSF, also known as CSF1, was the first hemopoietic growth factors to 
be isolated (296) and monocytes differentiated with M-CSF closely resemble 
osteoclasts and peritoneal macrophages (313, 314) important for tissue 
remodelling/homeostasis (315). Therefore monocytes recruited to sites where CSF is 
dominant might differentiate into divergent phenotypes of macrophages. Monocytes 
exposed to either GM-CSF or M-CSF led to the differentiation of macrophages with 
some similarities in recognition patterns but showed significant variation in 
phenotypic appearances, cytokine productions, surface expressions, endocytosis and 
many more biological functions (305, 306, 309, 316-319). ). It is important to realise 
that there are a range of other differentiating agents in vivo that can also influence the 
outcome of M1- versus M2-like functional phenotypes. 
M1 and M2 macrophage phenotypes were described by analogy to Th1 and Th2 
lympocytes subsets. Macrophages differentiated in culture in the presence of GM-
CSF or M-CSF, were named proinflammatory M1 and anti-inflammatory M2 
phenotypes, respectively (317, 320). GM-CSF and M-CSF can influence macrophage 
phenotypic dependence on type I interferon signalling, at least in murine bone marrow 
cells (318). Although the functional heterogeneity of CSF-induced human monocyte-
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derived macrophages has been extensively studies (305, 316, 321, 322) and reviewed 
(222, 284), very few studies have actually compared the effects of GM-CSF and M-
CSF across species, human versus mouse. One study in particular, examined at the 
gene expression and only 17% of the genes in human monocytes differentiated by 
human GM-CSF versus M-CSF had a profile that was conserved in murine GM-CSF 
versus M-CSF differentiated murine monocytes (317). With such a high divergence 
across species, caution should therefore be exercised when interpreting the effects of 
CSF on human macrophage lineage cells from studies conducted on analogous murine 
cells. Since the classification of macrophages follows a continuum, the activation and 
polarization of macrophages should to be re-evaluated as a continuum (250) instead 
as separate distinction as previously reported (226). 
 
1.9 Thesis objectives  
 
G-protein coupled receptors (GPCRs) are the most prevalent signal-transducing 
cell surface proteins in pharmaceutical research. Of the over 900 human GPCRs 
identified to date (323, 324), more than one third of human GPCRs are potential 
therapeutic targets for the treatment of diseases (325). One such GPCR is the 
complement receptor (C5aR) for C5a. C5aR has been strongly implicated in many 
inflammatory diseases (17) and demonstrated to be an important and promising 
therapeutic target for complement modulation (89). Therefore it is desirable to 
modulate complement activation by using therapeutic interventions such as inhibitors 
or antibodies. Over the past two decades, C5aR antagonists have been reported but 
despite intensive efforts to progress an effective C5aR antagonist to market, this has 
not yet been achieved. Although C5aR is widely expressed throughout the body, it is 
expressed highly in myeloid cells, such as macrophages (89, 326). Macrophages play 
critical roles in host defence, inflammation and the maintenance of homeostasis. 
Macrophages have remarkable plasticity in their gene expression profiles and cell 
surface phenotypes, depending on which tissue the macrophages reside in and 
stimulant exposure.  
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1.9.1 Chapter two 
 
Since macrophage phenotypes were proposed to be a continuum (226), 
without a clear distinction between M1 and M2 subsets, we explored how differential 
or similar expression of genes affect  functions in primary monocytes differentiated in 
culture with GM-CSF (GM-MΦ) versus M-CSF (M-MΦ). The objective of this 
chapter is to characterize and validate GM-MΦ versus M-MΦ as suitable in vitro 
models to study proinflammatory and anti-inflammatory responses in human 
macrophages. 
 
1.9.2 Chapter three 
 
Effects of C5aR were previously reported in murine but not human cells (326), 
or macrophage cell-lines that had undergone mutations and did not behave the same 
as primary cells in vitro and in vivo (327). The objective of this chapter is to re-
evaluate the effects of human C5a and gain knowledge on C5aR-mediated responses 
in primary human macrophages, which will be invaluable to the development of drugs 
against C5aR-mediated diseases. 
 
1.9.3 Chapter four 
 
The only FDA approved treatment that targets C5a-C5aR interaction is a 
humanized antibody which actually binds C5, thereby preventing the formation of 
C5a but also the formation of the membrane attack complex that effects pathogen 
lysis. C5a has been implicated in numerous immune and inflammatory conditions but 
to date, there is no drug available for treating C5a-C5aR-mediated diseases. The 
objectives of this chapter are to conduct a comparative study on three previously 
reported antagonists of human C5aR (W54011, JJ47 and 3D53), to investigate 
possible differences in their properties that might account for problems in clinical 
development of small molecule antagonists in clinical trials, and to choose one 
antagonist for further studies (Chapter 5) on synergistic effects of C5a on 
lipopolysaccharide action on macrophages and monocytes. 
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1.9.4 Chapter five 
 
Monocytes and macrophages are important innate immune cells equipped with 
danger sensing receptors, including complement and Toll-like receptors. However, 
most studies reporting C5a modulation of TLR4 signalling had been performed with 
murine rather than human cells. Some interpretations of human disease mechanisms 
have been made based on extrapolating observations from mouse studies. However, 
there are important differences in LPS-induced TLR4 signaling between humans and 
mice, thus necessitating careful reassessment of C5aR/TLR4 crosstalk in human cells. 
The objective of this chapter is to compare the modulation of human C5a on LPS-
induced inflammatory responses in primary human monocytes versus macrophages.  
 
1.9.5 Chapter six 
 
This chapter summarizes key findings reported in chapters 2-5, which represent 
new knowledge for researchers in the field of complement C5aR and its effects on 
primary human monocytes and macrophages, and indicates possible future research 
directions related to immunology and pharmacology. 
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2.1  Abstract 
  
Macrophages have remarkably plasticity in their gene expression profiles and 
cell surface phenotypes, depending on which tissue the macrophages reside in and 
stimulant exposure. These variations give rise to different populations of cells with 
distinct functions. Granulocyte-macrophage colony-stimulating factor (GM-CSF) or 
macrophage colony-stimulating factor (M-CSF) is used in cell culture to differentiate 
primary human monocytes to macrophages (Human Monocyte-Derived 
Macrophages) into two different populations (GM-MΦ and M-MΦ). Although they 
do not have distinct responses when activated by LPS, they represent a continuum 
model with GM-MΦ being more pro-inflammatory than M-MΦ (higher levels of 
proinflammatory cytokines such as IL6, TNF, MCP1), and M-MΦ being more anti-
inflammatory than GM-MΦ (higher levels of anti-inflammatory cytokine IL10). GM-
MΦ and M-MΦ exhibit significant differences in gene expression with more than 
1000 genes differentially expressed under basal conditions. The IPA software has 
identified large differences between GM-MΦ and M-MΦ in bio-functions such as 
cellular movement, haematological development and inflammatory response. Genes 
such as LEP, CCL2, IL10, CSF1, OLR1, IL1RN, GPR120, MMP10, PPBP and 
CXCL5 were selected from the list of gene hits and were validated by real-time PCR. 
The largest functional differences between GM-MΦ and M-MΦ have been further 
investigated and validated as well. GM-MΦ is not only more proinflammatory in 
nature, but also more robust to LPS stimulation and can migrate to site of 
inflammation four times more rapidly than M-MΦ. This chapter has characterized and 
validated GM-MΦ and M-MΦ as suitable in vitro models to study proinflammatory 
and anti-inflammatory responses specific for human monocyte-derived macrophages. 
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2.2 Introduction 
 
Monocytes and macrophages are important immune effector cells interplaying 
between innate and adaptive immunity. Monocytes are released from the bone 
marrow into the blood circulation as macrophage precursor cells. Monocytes can 
differentiate into macrophages when they migrate from the circulation into the tissue 
in the steady state or in response to inflammation. Macrophages can be found residing 
throughout the body tissues and, depending on which tissue the macrophages reside in 
and the stimulants they become exposed to, they can have distinct appearances and 
cell surface phenotypes (1). The monocyte-macrophage axis plays essential roles in 
immune functions such as inflammation, antimicrobial immune defence and tissue 
wound healing but, like a double-edged sword, these cells are also the main culprits in 
tissue destruction during certain infections and inflammatory diseases (2).  
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage 
colony-stimulating factor (M-CSF) were originally defined as hemopoietic growth 
factors (3). However, these cytokines are also major survival/mitogenic factors for the 
macrophage lineage, with the capacity to activate and induce monocytic 
differentiation to macrophage (1). GM-CSF and M-CSF are quite distinct with 
different tissue distributions in the steady state, different structures and different 
receptors, with the M-CSF receptor (CSF1R) being the tyrosine kinase c-Fms and the 
GM-CSF receptor (CSF2R) comprising α (ligand binding domain) and β (signalling 
domain) subunits (4, 5). M-CSF is passively produced in vitro by several cell types, 
especially macrophages, and circulates at detectable levels basally, whereas GM-CSF 
is usually undetectable but becomes elevated during immune/inflammatory responses 
in vivo to infection or in vitro in response to LPS or TNF (6, 7).  
GM-CSF was first isolated from lungs (8) and monocytes differentiated with 
GM-CSF closely resemble alveolar macrophages (9). M-CSF, also known as CSF1, 
was the first of the hemopoietic growth factors to be isolated and was found to be 
important for the development, proliferation and differentiation of osteoclasts and 
peritoneal macrophages (10, 11) and tissue remodelling/homeostasis (12). Therefore, 
monocytes recruited to sites would differentiate into divergent phenotypes of 
macrophages depending on the CSF present. M1 and M2 macrophage phenotypes 
were described by analogy to Th1 and Th2 lymphocyte subsets; macrophages 
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differentiated in culture in the presence of GM-CSF or M-CSF were named 
proinflammatory M1 and anti-inflammatory M2 phenotypes, respectively (13, 14). 
The functional heterogeneity of CSF-induced human monocyte-derived macrophages 
has been reviewed elsewhere (15). GM-CSF and M-CSF can influence macrophage 
phenotypic dependence on type I interferon signalling, at least in murine bone marrow 
cells (16). However, only around 17% of the genes in a comparison of human 
monocytes differentiated by human GM-CSF versus M-CSF had a profile that was 
conserved in murine bone marrow cells differentiated by GM-CSF versus M-CSF 
(14). With such a high divergence across species, caution should therefore be 
exercised when interpreting the effects of a CSF on human macrophage lineage cells 
from studies conducted on analogous murine cells.  
 
2.3  Aims 
 
This chapter will describe and validate monocyte-derived macrophages 
differentiated with either GM-CSF (GM-MΦ) or M-CSF (M-MΦ), as models for 
proinflammatory ‘M1-like’ and antiinflammatory ‘M2-like’ primary human 
macrophages, to gain insights into the contributions of these macrophages to 
inflammation. Therefore the specific aims of this chapter were: 
1. To identify cell-type specific differences in gene expression profiles of GM-
MΦ and M-MΦ by cDNA microarray analysis. 
2. To validate the differentially expression of genes by quantitative realtime-PCR 
analysis. 
3. To identify conserved and divergent downstream biological functions for GM-
MΦ versus M-MΦ. 
4. To examine the contributions and properties of these macrophages basally or 
in responses to inflammatory stimuli, such as LPS, in a selection of 
appropriate functional studies.  
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2.4 Materials and Methods 
 
2.4.1 Reagents 
 
Recombinant human GM-CSF and M-CSF were purchased from PeproTech. 
LPS from Salmonella enterica (serotype Minnesota RE 595) was purchased from 
Sigma-Aldrich. All cell culture reagents were purchased from Invitrogen and all 
analytical grade chemical reagents were obtained from Sigma-Aldrich, unless 
otherwise stated.  
 
2.4.2 Isolation of human monocytes and macrophages 
 
PBMCs were isolated from buffy coats of anonymous donors (Australian Red 
Cross Blood Service, Kelvin Grove, Queensland, Australia) by density centrifugation 
using Ficoll-Paque Plus (GE Healthcare) manufacturer’s instructions. Contaminating 
erythrocytes were removed by repeated washing with ice-cold sterile water. CD14+ 
MACS® microbeads were used to positively select monocytes from isolated PBMCs 
according to manufacturer’s instructions (Miltenyi Biotec). CD14+ monocytes were 
seeded at 1 x 106 cells/mL in IMDM supplemented with 10% FBS, 100 U/mL 
penicillin, 100 µg/mL streptomycin and 2 mM GlutaMAX at 37 °C in presence of 5% 
CO2. To generate human monocyte-derived macophages (HMDM), CD14+ 
monocytes were cultured in the presence of either 10 ng/mL GM-CSF (GM-MΦ) or 
M-CSF (M-MΦ) for at least 6 days.  
 
2.4.3 RNA extraction and reverse transcription 
 
Total RNA was extracted from cells using an RNeasy Mini Plus kit (Qiagen) 
and following manufacturer’s instruction. RNA concentrations were determined by 
measuring absorbance at λ = 260/280 nm on a Nanodrop spectrophotometer. Total 
RNA (2-10 µg) extracted from cells and random oligo dT primer (1 µg) were initially 
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incubated at 70°C for 10 min and then cooled on ice for at least 1 min before being 
reverse transcripted with Superscript III (Invitrogen) at 50°C for 50 min, then 70°C 
for 10 min. cDNA samples were stored at -20°C until further use.  
 
2.4.4 Real-time quantitative polymerase chain reaction (real-time qPCR) 
 
Primers were designed using the free web-based software Primer-BLAST 
National Center for Biotechnology Information (NCBI). cDNA (50 ng) was prepared 
together with SYBR® Green PCR master mix (Applied Biosystems™) and relevant 
primers to perform real time-PCR on the ABI PRISM® 7500 Real Time PCR System 
(Applied Biosystems™). Conditions were used according to the manufacturer’s 
instructions. Relative gene expression was normalised against 18S rRNA expression 
and then converted to fold change against control samples. All samples were analysed 
in duplicates. Primer sequences used are: CD68, 5’-TTTGGGTGAGGCGGTTCAG-3’ 
and 3’-CCAGTGCTCTCTGCCAGTA-5’; EMR1, 5’- 
CCACCTGCACCTCTGCGTGTG-3’ and 3’-GGCGCAGCCCATCTTGTTGTC-5’; 
LEP, 5’-ATGTCCAAGCTGTGCCCATCCAA-3’ and 3’- 
TTGGAGGAGACTGACTGCGTGTGT-5’; CCL2, 5’-
AGCTCGCACTCTCGCCTCCAG-3’ and 3’- 
GGCATTGATTGCATCTGGCTGAGC-5’; IL10, 5’- 
TGGAGGAGGTGATGCCCCAAGC-3’ and 3’- 
AAATCGATGACAGCGCCGTAGC-5’; CSF1, 5’- 
CTCCAGCCAAGGCCATGAGA-3’ and 3’-CAGCAAGACCAGGATGACACTG-
5’; OLR1, 5’-CCCTTGCTCGGAAGCTGAAT-3’ and 3’- 
GCTTGCTGGATGAAGTCCTGAA-5’; IL1RN, 5’- 
GGTACTGCCCGGGTGCTACTTT-3’ and 3’- 
GGTCGGCAGATCGTCTCTAAAGC-5’; GPR120, 5’- 
GAGATCTCGTGGGATGTCTCT-3’ and 3’-CCTTGATGCCTTTGTGATCTGT-5’; 
MMP10, 5’-CCAGGACACAGTTTGGCTCATGCC-3’ and 3’- 
AATTGGTGCCTGATGCATCTTCTGT-5’; PPBP, 5’- 
TGGCGAAAGGCAAAGAGGAA-3’ and 3’-TGGGATGAATTCCAGAGGTTGT-
5’; CXCL5, 5’-AGACCACGCAAGGAGTTCAT-3’ and 3’- 
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CTTCAGGGAGGCTACCACTTC-5’; IL6, 5’-GCCCACCGGGAACGAAAGAGA-
3’ and 3’-GACCGAAGGCGCTTGTGGAGAAG-5’; IL8, 5’- 
ACCACCGGAAGGAACCATCTCACT-3’ and 3’- 
CTTGGCAAAACTGCACCTTCACAC-5’; TNF, 5’- 
CCCAGGGACCTCTCTCTAATC-3’ and 3’-ATGGGCTACAGGCTTGTCACT-5’. 
 
2.4.5 Hybridization and analysis of human array-based gene expression 
 
Quality controls were performed on the RNA to check the integrity, purity and 
concentration of samples. Synthesis of biotin-labelled cRNA, hybridisation to 50-mer 
probes on the HumanHT-12 v4.0 Expression BeadChip (Illumina®) and detection of 
hybridised target cRNA were performed by Australian Genome Research Facility 
(AGRF) according to the Illumina® whole-genome gene expression beadchips 
manufacturer’s instruction. GeneSpring GX software version 11.5 (Agilent 
Technologies) and web-based IPA software (Qiagen) was used for the analysis of 
differences in gene expression between GM-MΦ and M-MΦ. Statistically significant 
differences between samples with more than 2-fold change were assessed using 
student t-test. 
 
2.4.6 Enzyme-linked immunosorbent assay (ELISA) 
 
Cells were seeded at 1 x 106 cells/mL and serum-deprived overnight in the 
incubator prior to treatment. Cell culture supernatants were collected and cytokines 
level were determined using specific ELISA sets from BD Pharmingen, according to 
the manufacturer’s instructions. 
 
2.4.7 In vitro migration assay (modified Boyden chamber) 
 
Migration of human macrophages was measured in a modified Boyden 
chamber migration assay using Transwell inserts with a 5 µm porous membrane 
(Corning). Cells were loaded into the migration chamber in serum free medium. To 
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initial cell migration, serum free medium was placed in the lower chamber. At the end 
of the time course study, cells were removed from the upper side of the membranes, 
and nuclei of migratory cells on the lower side of the membrane were stained with 
DAPI. And counted under a fluorescence microscope using a x10 objective. 
 
2.4.8 Actin visualization by fluorescence microscopy 
 
HMDMs were seeded (5 x 105 cells/mL) overnight on glass coverslips. Cells 
were serum deprived for at least 6 h prior to treatment as described in figure legend. 
After treatment, cells were fixed with 4% formaldehyde and permeabilized with 0.5% 
Triton-X 100 for 15 min. Cells were stained with FITC-phalloidin (400 nM) (Sigma) 
and nuclei were stained with Prolong® Gold DAPI (Invitrogen). Images were 
acquired using a x40 objective. 
 
2.4.9 Statistical analysis 
 
Data were plotted and analysed using GraphPad Prism version 5.0c for Mac OS 
X (GraphPad Software). Statistically significant differences were assessed using 
student’s t-test for paired comparison. All values of independent parameters are 
shown as mean ± SEM of at least three independent experiments, unless otherwise 
stated. Significance was set at *p < 0.05, **p < 0.01 and ***p < 0.001. 
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2.5 Results 
 
2.5.1 GM-CSF or M-CSF is necessary for macrophage differentiation and 
survival 
 
Freshly isolated CD14+ human monocytes were obtained from buffy coats of 
healthy blood donors provided by Australian Red Cross Blood Service. Blood 
monocytes were seeded at 1 x 106 cells/mL in 10% FBS/IMDM medium alone or in 
the presence of 10 ng/mL GM-CSF or M-CSF in vitro. In the absence of either GM-
CSF or M-CSF, more than 90% of the cell population died after 7 days in culture 
(Figure 2.1).  
CSFs were necessary for monocytes survival and differentiation into 
macrophages. By appearance, monocytes appeared to be less adherent to the plastic 
surface of culture plates, followed by GM-MΦ (monocytes differentiated with GM-
CSF) and M-MΦ (monocytes differentiated with M-CSF) being most adherent. The 
morphology of the two populations of macrophages was distinct after 6 days; GM-
MΦ were round shaped, whereas M-MΦ were more elongated in shape. Macrophages 
were harvested at the end of the 6 days differentiation by scraping. The expected cell 
yields by this differentiating protocol varied from 50 to 80%. This difference in cell 
yields was limited to donor-to-donor variation rather than differences between CSF 
used in differentiation. High variations were often observed across donors, rather than 
within the same donor. 
The mRNA levels of specific macrophage markers, such as CD68 and EMR1, 
were used to monitor the differentiation process. As expected, CD68 was increased 
after 4 days of differentiation (Figure 2.2A), and EMR1 after 6 days (Figure 2.2B), in 
the presence of either GM-CSF or M-CSF. The mRNA expression levels of CD68 
and EMR1 between GM-MΦ and M-MΦ were not significantly different at the end of 
the 7 days differentiation protocol with either GM-CSF or M-CSF (Figure 2.2C, D). 
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Figure 2.1. GM-CSF and M-CSF are required for monocytes survival and differentiation.  
Human CD14+ monocytes were seeded at 1 x 106 cells/mL 10% FBS/IMDM in the absence or presence of either differentiating agents (10 
ng/mL GM-CSF or M-CSF) for 6 days. The morphologies of cells were monitored by light microscope using a x20 objective on day 0, 2, 4 and 
6. 
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Figure 2.2. Macrophage markers CD68 and EMR1 expression levels in GM-MΦ 
and M-MΦ. 
Human CD14+ monocytes were differentiated to HMDMs with either GM-CSF (10 
ng/mL) (GM-MΦ, black) or M-CSF (10 ng/mL) (M-MΦ, white) in 10% FBS/IMDM 
over a 6 day time course. Macrophage marker (A,C) CD68 and (B,D) EMR1 gene 
expression were monitored during differentiation, in the presence of GM-CSF (black) 
or in the presence of M-CSF (white) on Days 0, 2, 4 and 6. Genes were detected by 
quantitative realtime-PCR, normalised against 18S rRNA expression and converted to 
fold change relative to Day 0. Error bars are means ± SEM of three independent 
experiments (n=3). *p < 0.05, **p < 0.01 and ***p < 0.001 by student t-test.  
 
 
2.5.2 Temporal study of monocyte-derived macrophage response to LPS 
stimulation 
 
To characterise the phenotypic differences between the two subtypes of (GM-
MΦ and M-MΦ), we examined their responses to LPS (5 ng/mL) for 24 h in 10% 
FBS/IMDM medium on day 0, 2, 4 and 6 during the differentiation process, in the 
presence of either GM-CSF (10 ng/mL) or M-CSF (10 ng/mL).  
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During the course of differentiation, proinflammatory cytokines such as IL6, 
TNF and MCP1/CCL2 were generally highly produced in GM-MΦ compared to M-
MΦ (Figure 2.3A-C). This trend was observed even at day 1, with IL6 and MCP1 
being produced in monocytes after exposure to GM-CSF (10 g/mL) for a day 
compared to monocytes without CSF exposure. By day 2, monocytes in the presence 
of M-CSF adopted the anti-inflammatory profile of M2-like macrophages by 
secreting less proinflammatory cytokines compared to monocytes in the presence of 
GM-CSF. Interestingly, both subtypes of macrophages passively secreted MCP1, but 
MCP1 is inducible by LPS in GM-MΦ but not in M-MΦ (Figure 2.3C). IL6, TNF 
and IL10 on the other hand were not passively secreted but LPS-induced only in GM-
MΦ and M-MΦ (Figure 2.3A, B, D).  
Although GM-MΦ and M-MΦ did not have distinct responses when activated 
by LPS, they represented a continuum model where GM-MΦ being more pro-
inflammatory than M-MΦ and M-MΦ being more anti-inflammatory than GM-MΦ. 
The data supported the hypothesis that macrophages can be highly heterogeneous in 
terms of their polarization, and can respond spontaneously according to the 
microenvironment and external stimuli, and hence these macrophages have high 
“plasticity”. The responsiveness of GM-MΦ and M-MΦ to LPS was compared and 
validated in these two subtypes of macrophages. 
In summary, the data suggested that human monocytes differentiated with 
GM-CSF leads to the formation of proinflammatory macrophages (M1-likeness), and 
M-CSF leads to the formation of anti-inflammatory macrophages (M2-likeness).  
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Figure 2.3. Temporal study of IL6, TNF, MCP1 and IL10 cytokine production in 
LPS activated GM-MΦ and M-MΦ.  
Human CD14+ monocytes (grey) were differentiated to HMDMs with either GM-
CSF (10 ng/mL) (GM-MΦ, black) or M-CSF (10 ng/mL) (M-MΦ, white) in 10% 
FBS/IMDM over a 6 day time course. These cells were also treated with LPS (5 
ng/mL) for 24 h in 10% FBS/IMDM on Day 0, 2, 4 and 6 to monitor LPS-induced (A) 
IL6, (B) TNF, (C) MCP1 and (D) IL10 in HMDMs. ELISA was used to detect 
cytokines secreted in culture media. Error bars are means ± SEM of three independent 
experiments (n=3). *p < 0.05, **p < 0.01 and ***p < 0.001 by student t-test. 
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2.5.3 Transcriptional difference between GM-MΦ and M-MΦ by cDNA 
microarray analysis 
 
The previous section described and characterized GM-MΦ and M-MΦ after 
activated by LPS. In this section, differentially expressed genes between GM-MΦ and 
M-MΦ at their resting state were analysed globally by cDNA microarray experiments. 
Four batches of pair-wise donor-matched cells were submitted to AGRF for reading 
on an Illumina microarray platform. Labelled cRNA were detected by hybridising to 
50-mer probes on the HumanHT-12 v4 BeadChip (Illumina®) comprising of 47,231 
probes derived from NCBI RefSeq Release 38 (November 7, 2009); of which 28,688 
probes corresponded to well-established coding transcripts, 11,121 probes 
corresponded to provisional coding transcripts, 1,752 probes corresponded to well-
established non-coding transcripts and 2,209 probes corresponded to provisional non-
coding transcripts. The raw data obtained was quantified, normalised and filtered 
using the GeneSpring software v11.5. The statistical significant threshold limit was 
set at p < 0.05 and employed the Benjamini-Hochberg method to control the false 
discovery rate (17). The cut-off value for fold change was set at two-fold. In order for 
an outcome to be considered as positive, the hit must pass these two conditions. 
Using these criteria, the comparison of GM-MΦ and M-MΦ identified more 
than 1000 hits, of which 568 were upregulated in GM-MΦ against M-MΦ (Appendix 
I), and 592 were downregulated in GM-MΦ against M-MΦ (Appendix II). Due to 
the extension list of genes differentially expressed between GM-MΦ and M-MΦ, for 
simplicity, genes that were ≥ 5 fold altered were shortlisted and represented in the 
heat map; with red representing genes upregulated in GM-MΦ and green representing 
genes downregulated in M-MΦ (Figure 2.4). 
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Figure 2.4. Heat map representation of genes differentially expressed in GM-MΦ 
and M-MΦ that were ≥ 5 fold changed. 
CD14+ monocytes were seeded at 1x106 cels/mL and differentiated to HMDMs in 
the presence of 10 ng/mL GM-CSF (GM-MΦ) or 10 ng/mL M-CSF (M-MΦ) for 6 
days. cDNA microarray was performed on mRNA extracted from four individual 
donors at the end of 6 days differentiation, using the Illumina HumanHT-12 v4 
BeadChip array. Colour bar shows log2 fold change in gene expression. Heat map 
representation of normalized signal intensity values for genes that were at least altered 
by ≥ 5-fold. Red colour represents upregulated genes and green colour represents 
downregulated genes in GM-MΦ versus M-MΦ.  Chosen genes indicated by black 
arrows are validated by real-time PCR. Full list of genes altered ≥ 2-fold change, refer 
to (Appendix I and II). 
 
A subset of genes was selected from the heat map and validated by real-time 
PCR (Table 2.1). All ten genes selected for the PCR experiments correlated to the 
microarray experiment in terms of the direction of fold changes. However, the 
magnitude of fold change was mostly higher in PCR than microarray with the 
exception of LEP, MMP10 and CXCL5. It is apparent that the greater the fold changes, 
the higher the variation that is observed. This is not surprising as resolution is higher 
and more sensitive in real-time PCR than in microarray, but most importantly, both 
experiments adopted different methods to normalize the raw data. Normalization 
algorithms were used in microarray whereas expression values in PCR were 
normalized against housekeeping genes, in this case 18S rRNA expression.   
 
Table 2.1. Correlation between microarray and real-time PCR gene expression 
Gene 
Fold change (GM-MΦ vs M-MΦ) 
Microarray Real-time PCR 
LEP -34.1 -14.9 
CCL2 -5.8 -6.2 
IL10 -5.5 -7.8 
CSF1 5.5 5.2 
OLR1 6.5 6.7 
IL1RN 7.7 20.6 
GPR120 8.3 10.5 
MMP10 49.3 19.7 
PPBP 60.2 149.0 
CXCL5 69.1 34.3 
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2.5.4 Pathway analysis of differentially expressed genes between GM-MΦ 
and M-MΦ 
 
The list of differentially expressed genes between GM-MΦ and M-MΦ 
exposed to LPS were uploaded to online software, Ingenuity Pathway Analysis (IPA). 
The IPA software was used to analyse the microarray data and detect expression 
patterns of genes linked to specific biological functions and signalling pathways. The 
top 4 populated bio-functional categories that were highly modulated by the 
differentially expressed genes between GM-MΦ and M-MΦ were (i) cellular 
movement, (ii) haematological system development and functions, (iii) immune cell 
trafficking and (iv) inflammatory responses (Figure 2.5).  
 
Figure 2.5. Heatmap representative of an overview for biological functions and 
processes differentially expressed between GM-MΦ and M-MΦ.  
Visualization of biological functions is represented by the heatmap; z-score ≥ 2 is 
predicted to increase (orange) and ≤ 2 is predicted to decrease (blue).  
 
The primary aim for this chapter was to compare different populations of 
human macrophages produced from primary human monocytes using different 
differentiating agents, GM-CSF versus M-CSF. It was expected that GM-CSF 
differentiated macrophages would adopt a more proinflammatory profile of gene 
expression, while M-CSF-differentiated macrophages would be more anti-
inflammatory. Interestingly, the majority of the differentially expressed genes did fall 
into the haematological system development and functions category. In Figure 2.3, 
GM-MΦ was found to be more robust in LPS signalling than M-MΦ in producing 
proinflammatory cytokines IL6, TNF and MCP1/CCL2, while M-MΦ produced more 
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anti-inflammatory IL10. Since the inflammatory response category was ranked among 
the top 4 functional categories affected in these macrophages, it is evident that GM-
MΦ and M-MΦ would adopt different immune profiles when activated. The bio-
functional categories, cellular movement and inflammatory responses, will be 
investigated further in the next two sections. 
 
2.5.5 Cellular movement and actin cytoskeleton in GM-MΦ and M-MΦ  
 
Macrophages can migrate actively through the walls of blood vessels into 
surrounding tissues under inflammatory or non-inflammatory conditions. The basal 
cellular migration ability of GM-MΦ and M-MΦ were tested in a Boyden chamber in 
serum free IMDM medium. There was no difference in the number of migrated cells 
after 3 h. However, M-MΦ took 4 times longer (GM-MΦ, 6 h; M-MΦ, 24 h) to 
migrate 200 cells to the lower side of the membrane than GM-MΦ (Figure 2.6).  
 
Figure 2.6. GM-MΦ migrates faster than M-MΦ in the Boyden chamber.  
GM-MΦ and M-MΦ (1 x 105 cells/100 µL) were added to the upper chamber of the 
Transwell in serum free medium and allowed to migrate through the 5µm porous 
membrane into the lower chamber. Migrated cells on the lower side of the membrane 
were stained with DAPI and counted under a fluorescence microscope using a x10 
objective. Error bars are means ± SEM of three independent experiments (n=3). ***p 
< 0.001 by student t-test. 
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These observations support the hypothesis that M1-like or proinflammatory 
macrophages are more robust in cellular movement and can readily infiltrate inflamed 
tissues when signal is triggered, whereas M2-like or anti-inflammatory macrophages 
are less motile and reside within tissues to maintain tissue resolution and homeostasis 
(18).  
Cell migration is a complex process that involves the formation of new focal 
contacts and disruption of existing focal contacts (19). Actin polymerization is 
necessary in cellular movement and to form lamellipodia (20). Lamellipodia are 
cytoskeletal protein actin projections on the surface of the cell. GM-MΦ and M-MΦ 
were stained with phalloidin to detect for polymerized actin. Untreated GM-MΦ has 
more polymerized actin in the cytosol compared to untreated M-MΦ (Figure 2.7). 
The formation of lamellipodia was also evident in untreated GM-MΦ but absent in 
M-MΦ. Rho belongs to a superfamily of small GTPases that can regulate the 
polymerization of actin to produce lamellipodia. Indeed, the lamellipodia formation 
seen in GM-MΦ is Rho-dependent because GM-MΦ treated with selective Rho-
associated protein kinase inhibitor Y-27632 blocked lamellipodia formation. Rho 
activator Calpeptin-treated GM-MΦ and M-MΦ led to lamellipodia formation. These 
results suggest that the presence of lamellipodia on macrophages is mediated by Rho 
GTPase activation. The presence of lamellipodia, probably due to higher Rho activity, 
in GM-MΦ but not M-MΦ may explain why GM-MΦ are able to migrate faster than 
M-MΦ. 
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Figure 2.7. GM-MΦ has more basal actin polymerization than M-MΦ.   
GM-MΦ and M-MΦ were pre-treated with either Rho inhibitor Y-27632 (30 µM) or 
Rho activator Calpeptin (1 unit/mL) for 20 min. After fixation, treated and untreated 
human macrophages (GM-MΦ and M-MΦ) were stained with 400 nM FITC-
phalloidin (green) and nuclei were visualized with DAPI (blue) using a x40 objective. 
 
2.5.6 GM-MΦ and M-MΦ have similar GPCR signalling profile except for 
Gα12/13 signalling 
 
The Gα12/13 family is best known for their involvement in the processes of cell 
proliferation and morphology, such as actin stress fibre and focal adhesion formation. 
Interactions with Rho guanine nucleotide exchange factors (RhoGEFs) are thought to 
mediate many of these processes (21). Interestingly, there was no significance 
difference in upstream GPCR-mediated signalling between GM-MΦ and M-MΦ. 
However, Gα12/13 signalling appears to be significantly different between GM-MΦ and 
M-MΦ (Figure 2.8).  
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Figure 2.8. Expression analysis of G-protein coupling receptor signalling 
pathway-linked genes between GM-MΦ and M-MΦ.  
The x-axis displays selected canonical pathways and the y-axis displays the 
significance by –log(p-value). P values are calculated using the right-tailed Fisher’s 
Exact test. The threshold lines denotes the cutoff value for significance, which 
represent p = 0.05 
 
Activation of Rho, or the regulation of events mediated by Rho, is often taken 
as evidence of Gα12/13 signalling. The differences in Rho activation between GM-MΦ 
and M-MΦ, as observed by lamellipodia shown in Figure 2.7, is also reflected in the 
microarray results when compared for genes related to Gα12/13 signalling pathway in 
Figure 2.8.  
 
2.5.7 Inflammatory responses in GM-MΦ and M-MΦ 
 
Pain, heat, redness, swelling and loss of function are the classical signs of 
acute inflammation. Inflammation is a complex array of biological responses of 
tissues to harmful stimuli, such as pathogens, irritants, or damaged cells. Due to the 
complex nature of inflammatory responses, the focus of this section on inflammatory 
responses will be only on selected cytokine production by macrophages (GM-MΦ and 
M-MΦ) (Figure 2.9). 
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Figure 2.9. Expression analysis of human cytokine signalling and production 
pathway-linked genes between GM-MΦ and M-MΦ.  
The x-axis displays selected canonical pathways and the y-axis displays the 
significance by –log(p-value). P values are calculated using the right-tailed Fisher’s 
Exact test. The threshold lines denotes the cutoff value for significance, which 
represent p = 0.05 
 
IL10-, TREM1-, IL6-, IL8-, IL17- and TNFR2-signalling pathway-linked 
genes are significantly different between GM-MΦ and M-MΦ. However, most of 
these cytokines are not produced by macrophages basally, unless triggered by a 
stimulant such as LPS. IL17 cytokines are primarily produced by Th17 helper cells 
and are involved in autoimmune diseases (28). Given that IL17-signalling was three 
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fold more abundant in M-MΦ than in GM-MΦ, suggested that M-MΦ may have 
major contributions to organ-specific autoimmune conditions driven by Th17 cells. 
Cells of the monocyte-macrophage lineage have been recognized to be heterogeneous 
(1) and there is considerable interest in their polarization and functional diversity. 
Since macrophage phenotypes were proposed to be a continuum rather than distinctly 
separate for M1 and M2 types (18), would GM-MΦ and M-MΦ have distinct 
responses when activated by LPS or would their responses to LPS be similar? 
 
2.5.8 Monocyte-derived macrophages cytokine and gene responses to LPS 
stimulation 
 
GM-MΦ and M-MΦ were seeded at 1 x 106 cells/mL in 12-well plate format 
and left in 5% CO2 incubator at 37 °C overnight for cells to adhere. Cells were serum 
deprived for at least 8 h prior to treatment. Cells were treated with LPS (5 ng/mL) for 
24 h. Untreated and LPS-treated cell culture supernatants were collected and analysed 
for cytokine productions by ELISA. Cells were also lysed and collected for mRNA 
extraction. GM-MΦ responded more robustly to LPS-induced proinflammatory 
cytokine productions such as IL6, IL8 and TNF (Figure 2.10A-C), compared to M-
MΦ. Conversely, LPS-induced IL10 production was higher in M-MΦ than GM-MΦ 
(Figure 2.10D). The robustness of GM-MΦ in responding to LPS stimulation 
compared to M-MΦ was also reflected at mRNA levels. LPS induced higher 
expression levels of IL6, IL8 and TNF in GM-MΦ (Figure 2.10E-G) and higher IL10 
expression levels in M-MΦ (Figure 2.10H). 
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Figure 2.10. LPS-induced IL6, IL8, TNF and IL10 proteins and gene expressions.  
GM-MΦ (black) and M-MΦ (white) were subjected to LPS (5 ng/mL) stimulation for 
24 h. LPS-treated and untreated cell culture supernatants were collected to detect 
cytokine production and total mRNA were isolated from cell lysates at the end of LPS 
treatment. Genes were detected by real-time PCR, normalised against 18S rRNA 
expression and converted to fold change relative to control. Error bars are means ± 
SEM of three independent experiments (n=3). *p < 0.05, **p < 0.01 and ***p < 0.001 
by student t-test. 
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2.6  Discussion 
 
GM-CSF and M-CSF, previously known as hemopoietic growth factors, are 
now better known as mediators involved in regulating the macrophage lineage leading 
to macrophage heterogeneity. In the field of immunology, macrophages are now 
routinely categorized in subpopulations according to their gene expression profiles 
induced by various cytokines and pathogen-derived ligands. Although correlations 
between murine and human macrophages differentiated with CSFs are as low as 17%, 
it is appealing that information about macrophage mechanisms and signalling 
pathways were extrapolated from murine counterparts to understand human 
macrophage immunity. Although genetic differences between GM-CSF differentiated 
and M-CSF differentiated human monocyte-derived macrophages have been reported 
in a few studies (14, 22), others have focused mainly on polarization profiles (23) or 
dependence on interferon signalling (16). This chapter instead describes the functional 
heterogeneity of GM-MΦ and M-MΦ in the basal state and in response to LPS and, 
most importantly, validate these cell populations as in vitro models for gaining 
insights to human macrophage biology.   
Cellular migration and inflammatory responses have been identified as the most 
important biological functions by microarray and pathway analysis, and to be 
different between human GM-MΦ and M-MΦ. Macrophages are motile and able to 
migrate actively through the walls of blood vessels into surrounding tissues. The 
exchange between M1/M2 macrophage populations locally within the tissues can 
change over time and is associated with pathology (18). Two well-studied examples 
of pathology as the result of macrophage phenotypic switching are cancer and 
obesity-induced inflammation. Rho GTPases are important regulators of the actin 
cytoskeleton and thereby control cellular adhesion and migration. Although GM-CSF 
stimulation led to increased Rac2 expression, while M-CSF increased RhoA 
expression during myeloid differentiation (24), the actual cellular migration is not 
addressed in this study. GM-MΦ has the propensity to migrate more rapidly 
compared to M-MΦ, in fact 4 times faster in this study. When visualized under the 
microscope, GM-MΦ appeared to have more lamellipodia formation compared to M-
MΦ. The lamellipodia formation is sensitive to Rho GTPase inhibitor, thereby 
suggesting that the level of Rho activity between GM-MΦ and M-MΦ is different.  
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Macrophages have a ‘plastic’ gene expression phenotype that can change 
rapidly depending on the microenvironment signals and even lead to a switching of 
phenotype from M1 to M2 and vice versa (25, 26). In fact, even the presence of serum 
has been demonstrated to alter macrophage polarization (27). Interestingly, after the 6 
days differentiation protocol in the presence of 10% serum, the magnitude of IL6, 
TNF and IL10 cytokine production was increased by the presence of serum and CSFs, 
but the correlation between GM-MΦ and M-MΦ was not affected when comparing 
their responses to LPS (Figure 2.3 versus Figure 2.10). Besides influences of serum 
in macrophage polarization, the duration of CSF exposure can directly influence gene 
expressions (14). This reinforced the view that, when studying macrophage biology 
and in particular macrophage polarization, the culturing conditions and durations need 
to be taken into account. 
 
2.7 Conclusions 
 
In conclusion, GM-MΦ and M-MΦ exhibit significant differences in gene 
expression under basal conditions and these differences lead to different signalling 
outcomes for these cells when challenged with the bacteria-mimicking stimulant LPS. 
Data generated from cDNA microarray and PCR experiments correlated with each 
other. The largest functional differences between GM-MΦ and M-MΦ have been 
further investigated and validated as well. GM-MΦ is not only more proinflammatory 
in nature, but also more robust to LPS stimulation and can migrate to site of 
inflammation more rapidly than M-MΦ. This chapter has characterized and validated 
GM-MΦ and M-MΦ as suitable in vitro models to study proinflammatory and anti-
inflammatory responses specific for human monocyte-derived macrophages. 
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3.1 Abstract 
 
In Chapter 2, GM-MΦ and M-MΦ were found to be quite different from each 
other. These differences were recorded to be the largest in the microarray experiment 
as calculated by distant matrix algorithms in this chapter. Therefore it was expected 
that GM-MΦ and M-MΦ, with large genomic differences would respond to C5a 
differently. C5a exerted similar effects on GM-MΦ and M-MΦ in the calcium release, 
ERK phosphorylation and macrophage migration assays. The EC50 values of C5a in 
these three functional assays between GM-MΦ and M-MΦ were comparable. The 
transcriptional profile stimulated by C5a included several genes whose products are 
proinflammatory such as chemokines and cytokines (CCL3, CCL3L1, CCL3L3, 
CXCL2, IL8, PTGS2 and TNF). C5a also stimulated the expression of a number of 
transcription factors (ATF3, EGR1, EGR2, EGR3, FOS, FOSB and JUNB) that 
amplified immune responses and were also likely to be involved in a positive 
feedback loop resulting in the stimulation of expression of themselves and other 
proinflammatory genes. FOSB and FOS genes were highly upregulated in human 
macrophages (GM-MΦ and M-MΦ) when stimulated with C5a. At the same time, 
C5a can limit immune responses and likely participates in a negative feedback loop to 
preserve homeostasis and dampen down damage by activating ZFP36, SOCS3, 
NFKBIZ, DUSP1 and DUSP6 genes. A list of 33 genes that were commonly 
stimulated by C5a on GM-MΦ and M-MΦ was uploaded for Ingenuity Pathway 
Analysis (IPA) and top ranking diseases and functions between GM-MΦ and M-MΦ 
overlapped with major pathways involved in neurological disease, cancer, cell death 
and survival. A separate microarray experiment was conducted to create an overview 
of the temporal profile of C5a induced genes and it was found that all genes 
differentially regulated by C5a could be further categorised into clusters according to 
their temporal profile, with cluster 1, 2 and 3 featuring genes that were upregulated by 
C5a at 0.5, 6 and 18 h respectively and cluster 4 featuring genes that were 
downregulated by C5a at 6 h. By identifying the clusters of genes activated by C5a, 
potential rate-limiting gene candidates may be identified for potential clinical 
intervention in C5a-mediated inflammatory disorders. 
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3.2  Introduction 
 
C5a is one of the most potent inflammatory mediators generated upon 
complement activation through C5 cleavage and usually accompanied by the 
formation of the membrane attack complex (1). C5a has been show to stimulate 
proinflammatory cytokines such as tumour necrosis factor alpha (TNF), interleukin-6 
(IL6) and -1beta (IL1B) in various cell types (2-6). These inflammatory mediators 
were produced as the result of increased transcriptional activity induced by C5a, 
which suggested that transcriptional regulation was important in C5a signalling.  
Only one study has been reported in the literature to date on the use of cDNA 
microarray analysis to assess gene expression induced by C5a and this was performed 
with human umbilical vein endothelial cells (HUVECs) (7). C5a particularly induced 
gene expression of cell adhesion molecules (E-selectin, ICAM-1, VCAM-1), 
cytokines/chemokines (VEGFC, IL6) (7). In HUVECs, C5a activated a similar set of 
genes to those induced by either TNF or LPS (7).  
The chief receptor for C5a (C5aR) is widely distributed in the human body (8), 
but especially highly expressed in leukocytes, particularly neutrophils, monocytes and 
macrophages (ArrayExpress: E-MTAB-513). A high throughput transcriptional 
profile of RNA from individual human tissues, as well as a mixture of 16 different 
human tissues, has been reported (Illumina Body Map) by ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress) (9). Although C5aR signalling pathways have 
been previously defined in human neutrophils in 1994 (10), the transcriptional 
regulation of inflammatory genes by C5a in human leukocytes remains to be 
determined to date. In particular, the C5a-induced gene expression profile in human 
macrophages has not been reported and was of interest to us in the context of Chapter 
2, to build on our knowledge of inflammatory gene expression differences between 
M1-like and M2-like macrophages (GM-MΦ and M-MΦ). 
Plasticity is a hallmark of macrophages. When activated by innate recognition 
or signals from lymphocyte subsets, macrophages can undergo adaptive responses 
playing critical roles in immunity by selectively participating in the initiation of host 
defence, inflammation and the maintenance of homeostasis (11). This phenomenon of 
macrophages has been extensively reviewed by others and therefore will not be 
discussed here (12, 13). Exposing freshly isolated CD14+ human blood monocytes to 
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different differentiating agents (GM-CSF or M-CSF) for 6 days, gave rise to 
macrophages with large genomic differences, which then translated to differences in 
cellular movement, haematological development and inflammatory responses 
between GM-MΦ and M-MΦ (Chapter 2).  Based on the variable levels of C5aR 
expression in across different human tissue samples, it was considered that 
macrophages would be a good cell model to investigate C5a-induced gene expression. 
Thus, it was decided that a cDNA study of C5a-induced gene expression in GM-MΦ 
and M-MΦ would likely provide valuable insights to C5a-mediated inflammation in 
inflammatory cells known to be associated with immunity and chronic inflammatory 
diseases. 
 
3.3 Aims 
 
In Chapter 2, the differently stimulated culturing of primary human 
monocytes to obtain macrophage-like cells, GM-MΦ and M-MΦ, has been 
established as producing suitable in vitro models for primary human proinflammatory 
and anti-inflammatory macrophages, respectively. Therefore, in this chapter, a 
comparative study on the effects of human C5a on GM-MΦ versus M-MΦ will be 
reported with the objective of identifying similarities and differences in responses of 
these different cell types to recombinant human C5a. The specific aims of this chapter 
were: 
1. To determine the potency of C5a on GM-MΦ and M-MΦ in several 
functional assays, namely, intracellular Ca2+ mobilization, ERK 
phosphorylation and cell migration. 
2. To identify cell-type specific differences in gene expression profiles of GM-
MΦ and M-MΦ in response to C5a stimulation by microarray analysis. 
3. To identify conserved and divergent downstream biological processes 
induced by C5a between GM-MΦ and M-MΦ. 
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3.4 Methods 
 
3.4.1 Reagents 
 
Recombinant human GM-CSF and M-CSF were purchased from PeproTech. 
Recombinant human C5a was purchased from Sino Biological Inc. All cell culture 
reagents were purchased from Invitrogen and all analytical grade chemical reagents 
were obtained from Sigma-Aldrich, unless otherwise stated.  
 
3.4.2 Isolation of human monocytes and macrophages 
 
PBMCs were isolated from buffy coats of anonymous donors (Australian Red 
Cross Blood Service, Kelvin Grove, Queensland, Australia) by density centrifugation 
using Ficoll-Paque Plus (GE Healthcare) manufacturer’s instructions. Contaminating 
erythrocytes were removed by repeated ice-cold sterile water. CD14+ MACS® 
microbeads were used to positively select monocytes from isolated PBMCs according 
to manufacturer’s instructions (Miltenyi Biotec). CD14+ monocytes were seeded at 1 
x 106 cells/mL in IMDM supplemented with 10% FBS, 100 U/mL penicillin, 100 
µg/mL streptomycin and 2 mM GlutaMAX at 37 °C in presence of 5% CO2. To 
generate human monocyte-derived macophages (HMDM), CD14+ monocytes were 
cultured in the presence of either 10 ng/mL GM-CSF (GM-MΦ) or M-CSF (M-MΦ) 
for at least 6 days.  
 
3.4.3 Intracellular calcium mobilization assay 
 
HMDMs were seeded at 0.5 x 106 cells/mL (100 µL) in black-wall, clear-
bottom 96-well plates (Corning) and incubated at 37 °C in the presence of 5% CO2 
overnight for cells to adhere. Cells were washed once with assay buffer (Hank’s 
buffered salt solution (HBSS), 20 mM HEPES, 2.5 mM probenecid, pH 7.4). 100 µL 
of dye-loading buffer (12 mL of assay buffer, 1% FBS, 25 µL of Fluo-3AM 
(Invitrogen) (final concentration = 4 µM), 25 µL 20% pluronic acid) was added to 
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each well and incubated for 1 h at 37°C. Excess loading dye was washed away with 
assay buffer before adding 50 µL of tested compound. Fluorescence intensity was 
recorded with on FLIPR Tetra (Molecular Devices) with excitation and emission 
wavelengths of 485 nm and 520 nm respectively. Calcimycin ionophore A23187 (25 
µM) (Sigma) is used as a dye loading positive control. 
 
3.4.4 Receptor saturation binding assay 
 
Binding equilibrium was measured by titrating various concentration of [125I]-
C5a (2200 Ci/mmol, Perkin Elmer) with 1 x106 cells/mL in Tris buffer (50 mM Tris, 
3 mM MgCl2, 0.1 mM CaCl2, 0.5% (w/v) bovine serum albumin, pH 7.4) for 60 min 
in a 96-well Nunc round bottom plate at room temperature. Unbound [125I]-C5a was 
removed by filtration through glass microfiber filter GF/B (Whatman) which had been 
soaked in 0.6% polyethyleneimine to reduce non-specific binding. The filter was 
washed 3 times with cold buffer (50 mM Tris) pH 7.4 and bound [125I]-C5a was 
assessed by scintillation counting on Microbeta counter. Specific [125I]-C5a binding 
was defined as the difference between total binding and non-specific binding as 
determined in the presence of 1 µM unlabeled C5a. Bmax and Kd values were 
calculated by nonlinear regression analysis using GraphPad Prism. 
 
3.4.5 Quantification of ERK1/2 phosphorylation by AlphaScreen Surefire 
 
Cells were seeded at 4000 cells/well in white 384-ProxiPlate (PerkinElmer) 
overnight. On the following day, media was removed from the cells and were serum-
deprived for 2 h to reduce basal ERK1/2 activity, prior to stimulation with C5a over a 
stated time course. Cells were lysed with Alphascreen SureFire lysis buffer, with 
shaking for 10 min at room temperature and assayed for phosphor-ERK1/2 
(phosphor-Thr202/Tyr204) according to Alphascreen SureFire assays (PerkinElmer) 
manufacturer’s instructions. At completion of the assay, signal in the wells was 
measured using Pherastar (BMG Labtech). 
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3.4.6 In vitro migration assay (modified Boyden chamber) 
 
Migration of human macrophages was measured in a modified Boyden 
chamber migration assay using Transwell inserts with a 5 µm porous membrane 
(Corning). Cells were loaded into the migration chamber in serum free medium. To 
initial cell migration, serum free medium was placed in the lower chamber. At the end 
of the time course study, cells were removed from the upper side of the membranes, 
and nuclei of migratory cells on the lower side of the membrane were stained with 
DAPI. And counted under a fluorescence microscope using a x10 objective. 
 
3.4.7 Enzyme-linked immunosorbent assay (ELISA) 
 
Cells were seeded at 1 x 106 cells/mL and serum-deprived overnight in the 
incubator prior to treatment. Cell culture supernatants were collected and cytokines 
level were determined using specific ELISA sets from BD Pharmingen, according to 
the manufacturer’s instructions. 
 
3.4.8 RNA extraction and reverse transcription 
 
Total RNA was extracted from cells using an RNeasy Mini Plus kit (Qiagen) 
and following manufacturer’s instruction. RNA concentrations were determined by 
measuring absorbance at λ = 260/280 nm on a spectrophotometer. Total RNA (2-10 
µg) extracted from cells and random oligo dT primer (1 µg) were initially incubated 
at 70°C for 10 min and then cooled on ice for at least 1 min before being reverse 
transcripted with Superscript III (Invitrogen) at 50°C for 50 min, then 70°C for 10 
min. cDNA samples were stored at -20°C until further use.  
 
3.4.9 Real-time quantitative polymerase chain reaction (real-time PCR) 
 
Primers were designed using the free web-based software Primer-BLAST 
National Center for Biotechnology Information (NCBI). cDNA (50 ng) was prepared 
together with SYBR® Green PCR master mix (Applied Biosystems™) and gene-
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specific primers to perform real-time PCR on the ABI PRISM® 7500 Real Time PCR 
System (Applied Biosystems™). Conditions were used according to the 
manufacturer’s instructions. Relative gene expression was normalised against 18S 
rRNA expression and then converted to fold change against control samples. All 
samples were analysed in duplicates. Primer sequences used are: C5AR1, 5’-
GCCCAGGAGACCAGAACATGAACTC-3’ and 3’- 
TCCACAGGGGTGTTGAGGTCCA-5’; CCL3, 5’- 
CCCACATTCCGTCACCTGCTCAG-3’ and 3’- 
AGCAGCAAGTGATGCAGAGAACTG-5’; TNF, 5’- 
TCTGGCCCAGGCAGTCAGATC-3’ and 3’-CACTGGAGCTGCCCCTCAGC-5’; 
IL8, 5’-ACCACCGGAAGGAACCATCTCACT-3’ and 3’- 
CTTGGCAAAACTGCACCTTCACAC-5’; PTGS2, 5’- 
TGGCAGGGTTGCTGGTGGTA-3’ and 3’-TCTGCCTGCTCTGGTCAATGGA-5’; 
IL1B, 5’-CCTCTTCGAGGCACAAGGCACAA-3’ and 3’- 
TGGCTGCTTCAGACACTTGAGCAAT-5’; EGR1, 5’- 
CGAGCACCTGACCGCAGAGTCT-3’ and 3’-GGGGGCAGTCGAGTGGTTTGG-
5’; FOSB, 5’-GACCCTCAGCCCTGGCCTTT-3’ and 3’-
CAGCCCCTCACTGCCTTCCT-5’; TLR7, 5’-GAACGCCCTGGCCACAGACA-3’ 
and 3’-ACAGCCAGGCCTCTCCTTGGT-5’; TLR8, 5’- 
AGCTGCGCTACCACCTTGAAGA-3’ and 3’- 
GGCCAATCCCGGATCCCAATCC-5’; FABP5, 5’- 
GCACCCACCATGGCCACAGT-3’ and 3’-CGCAAAGCTATTCCCACTCCTAGC-
5’; LEP, 5’-GTAGGAATCGCAGCGCCAACG-3’ and 3’- 
TCCGCACAGGGTTCCCCAATG-5’; ATF3, 5’-CGAGCGGAGCCTGGAGCAAA-
3’ and 3’-GGGGACAGGCAGGGGACGAT-5’; DUSP5, 5’- 
ATGACCAGGGTGGCCCAGTTGAA-3’ and 3’- 
CGGGAGACATTCAGCAGGGCTGTG-5’; DUSP6, 5’- 
CGACGAGAGCAGCAGCGACT-3’ and 3’- 
TGAAGCCACCTTCCAGGTAGAACG-5’; CD83, 5’- 
TCACTTGTTTTGCACGGCTACAGA-3’ and 3’- 
TGGGGAGGTAACTGGGAGAAAAGC-5’; CD276, 5’- 
ACAGCTGCCTGGTGCGCAAC-3’ and 3’-TGGACCTCCACGGCTCCTGT-5’; 
CTSL1, 5’-TCCGAGCCGGGTGGACACAGT-3’ and 3’- 
 107 
AGCTGAGGCAATTCCCAGGCAAAA-5’; TIMP3, 5’- 
AGCTGGAGCCTGGGGGACTG-3’ and 3’-GGCCCGGATCACGATGTCGG-5’; 
MMP19, 5’-AGGTGGCGCCCGTGGACTA-3’ and 3’- 
GGGCCAGGACTCTCCCTCAGA-5’. 
 
3.4.10 Hybridization and analysis of human array-based gene expression 
 
Quality controls were performed on the RNA to check the integrity, purity and 
concentration of samples. Synthesis of biotin-labelled cRNA, hybridisation to 50-mer 
probes on the HumanHT-12 v4.0 Expression BeadChip (Illumina®) and detection of 
hybridised target cRNA were performed by Australian Genome Research Facility 
(AGRF) according to the Illumina® whole-genome gene expression beadchips 
manufacturer’s instruction. GeneSpring GX software version 11.5 (Agilent 
Technologies) and web-based Ingenuity Pathway Analysis (IPA) software (Ingenuity 
Systems, Inc.) was used for the analysis of differences in C5a-mediated gene 
expression between GM-MΦ and M-MΦ. Statistically significant differences between 
samples with more than 2-fold change were assessed using student t-test. 
 
3.4.11 Statistical analysis 
 
Data were plotted and analysed using GraphPad Prism version 5.0c for Mac OS 
X (GraphPad Software). Statistically significant differences were assessed using 
student’s t-test for paired comparison. All values of independent parameters are 
shown as mean ± SEM of at least three independent experiments, unless otherwise 
stated. Significance was set at *p < 0.05, **p < 0.01 and ***p < 0.001. 
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3.5 Results 
 
C5a is generated by the cleavage of C5 during complement activation and it is 
known to have powerful proinflammatory actions and attracts immune cells to sites of 
infection or tissue damage. Serum levels of C5a can reach as high as 100 nM in 
patients with sepsis (14). The local concentration of C5a is expected to be higher at 
the site of inflammation, but this has not been determined. Human C5a (100 nM) 
induces significant apoptosis in freshly isolated thymocytes (15). Other lymphoid 
cells such as B and T cells had similar apoptotic responses when treated with such a 
concentration of C5a (16). As it is the objective to investigate the acute responses of 
C5a under normal healthy physiological conditions, it is therefore crucial that HMDM 
are not over-stimulated or over-stressed as in a chronic or diseased state. The calcium 
mobilization, ERK phosphorylation and macrophage migration assays will be 
conducted to determine the optimum concentration of human C5a for stimulating 
HMDMs (GM-MΦ: macrophages differentiated with GM-CSF; and M-MΦ: 
macrophages differentiated with M-CSF). This optimized concentration of C5a 
(~EC80 values) will be used to treat GM-MΦ and M-MΦ and analysed for the 
microarray experiment.  
 
3.5.1 C5a has similar agonist potency on GM-MΦ and M-MΦ 
 
C5a can induce intracellular calcium mobilization in a variety of cells upon 
C5aR activation (17). C5a had similar potency on the C5aRs of GM-MΦ and M-MΦ 
as determined by Ca2+ mobilization assay (Figure 3.1). Interestingly, GM-MΦ and 
M-MΦ not only achieved similar EC50 values, but the maximal responses induced by 
C5a (300 nM) were also similar in these two subtypes of macrophages (Figure 3.1B). 
Higher maximal responses are usually indicative of higher receptor expressions. This 
is also an indication that the number of C5aR receptors expressed on both GM-MΦ 
and M-MΦ cell surface may be similar.  
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Cells pEC50 ± SEM EC50 (nM) n 
GM-MΦ 8.6 ± 0.1 2.3 3 
M-MΦ 8.9 ± 0.1 1.3 3 
Figure 3.1. C5a-induced intracellular calcium mobilization in HMDM. 
(A) Ca2+ mobilization in GM-MΦ or M-MΦ was induced by various concentrations 
of recombinant human C5a. Cells treated with calcimycin (25 µM) were used as a 
dye-loading control. (B) Maximal Ca2+ mobilization induced by C5a (300 nM) in 
GM-MΦ (black) and M-MΦ (white) were plotted against calcimycin control. Error 
bars are means ± SEM of three independent experiments (n=3). ***p < 0.001 by 
student t-test. 
 
Besides calcium mobilization, C5a can also induce ERK phosphorylation (10). 
Similar to previous calcium release results in Figure 3.1, C5a has similar potency on 
the C5aR of GM-MΦ and M-MΦ (Figure 3.2). Although GM-MΦ adopted a more 
proinflammatory profile than M-MΦ, as characterized in Chapter 2, C5a exerts 
similar effects on both GM-MΦ and M-MΦ based on data collected from calcium 
release and ERK activation assays, measuring different biological readouts. 
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Cells pEC50 ± SEM EC50 (nM) n 
GM-MΦ 8.4 ± 0.4 4.2 3 
M-MΦ 8.6 ± 0.3 2.8 3 
Figure 3.2. C5a-induced ERK1/2 phosphorylation in HMDM. 
ERK phosphorylation in GM-MΦ and M-MΦ was induced by various concentrations 
of recombinant human C5a. Cells were treated for 5 min and lyzed to stop C5a-
induced reaction. Phosphorylated ERK1/2 was measured by AlphaScreen® SureFire® 
assays. Error bars are means ± SEM of three independent experiments (n=3). 
 
3.5.2 GM-MΦ and M-MΦ have similar C5aR expression levels 
 
Total mRNA was isolated from GM-MΦ and M-MΦ to measure C5AR gene 
expression by real-time PCR. The raw data collected was normalized against 18S 
ribosomal RNA as relative gene expression. There were no significant difference in 
C5AR expression levels between GM-MΦ and M-MΦ (Figure 3.3). Although there 
were no differences in C5aR expression at the transcriptional levels between GM-MΦ 
and M-MΦ, the same trend may not be reflected at the translational levels. A key 
assumption, and often the biggest flaw commonly made by researchers, was that the 
levels of mRNA expression correlates with levels of protein expression. This 
assumption is certainly far from being perfect, and has often been conveniently 
overlooked (18, 19). The mean correlations between protein and corresponding RNA 
levels were about 0.2 - 0.3. In other words, very little correlation exists between gene 
and protein expression. 
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Figure 3.3. GM-MΦ and M-MΦ have similar C5AR gene expression. 
Total mRNA extracted from GM-MΦ (black) and M-MΦ (white) were used to 
measure C5AR gene expression by real-time PCR. Raw values were then normalised 
against 18S rRNA expressions. Error bars are means ± SEM of three independent 
experiments (n=3). 
 
Total protein expression of interest can be easily determined by performing 
western blots. However, GPCRs have been shown to have enhanced functions in 
optimized conditions without changing total receptor protein expression levels (20, 
21), therefore total protein expression level may not be that useful when ascertaining 
GPCR functions. The amount of functional receptors must be measured by ligand 
binding because the total receptor yield does not account for receptors that are either 
in an inactive form or located intracellularly with no access to external ligand binding.  
To measure the levels of functionally active C5aR, a saturation-binding assay 
was used to determine the expression of functional C5aR on the cell surface using 
radioactive 125I-C5a. As expected, GM-MΦ and M-MΦ have similar Bmax values 
(total density of receptors) (Figure 3.4). 
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Cells Bmax (fmol/mg) Kd (pM) 
GM-MΦ 12.0 117.5 
M-MΦ 11.2 87.5 
 
Figure 3.4. GM-MΦ and M-MΦ have similar cell surface C5aR expressions. 
Receptor saturation assay was performed using 1 x 106 cells/mL (A) GM-MΦ and (B) 
M-MΦ and incubated with various concentration of 125I-C5a in the absence or in the 
presence of C5a (1 µM) to determine total and non-specific C5aR binding. (C and D) 
Specific binding values were calculated by subtracting non-specific binding values 
from total binding values. Counts were converted to fmol/mg and represented by the 
scatchard plot. Bmax and Kd values were calculated using nonlinear regression after 
converting cpm values to fmol/mg values. Error bars are means ± SEM of three 
independent experiments (n=3). 
 
3.5.3 C5a-mediated chemotaxis in GM-MΦ and M-MΦ  
 
Metabolic dysfunction is associated with increased immune cells (especially 
macrophages, mast cells and T cells) infiltrating into adipose tissue (22, 23). 
Macrophages constitute as much as 40% of the cell population in the adipose tissue of 
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obese humans and animals (24). Although macrophages are highly plastic in their 
responses and largely influenced by their local environment, no one has actually 
reported whether the chemotactic index between macrophage subtypes are different or 
not. Since C5a is one of the most potent endogenous agents known to induce 
chemotaxis of immune cells, especially macrophages, the chemotactic responses 
between GM-MΦ and M-MΦ were compared in a migration assay herein. The cell 
migration assay measured the ability of macrophages to migrate across a physical 
barrier (5 µm porous membrane) over time. Cells that have migrated from the upper 
chamber across to the lower chamber of the Transwell will be quantified under a 
microscope. The greater the number of cells counted, the higher the chemotactic 
potential. The basal cellular migration ability of GM-MΦ and M-MΦ were tested and 
there were little or no difference between the number of GM-MΦ and M-MΦ cells 
that migrated across the Tanswell membrane after 3 h in Chapter 2. However, after 6 
h, the number of GM-MΦ compared to M-MΦ substantially increased.  
Therefore, the time point 3 h was chosen to investigate the effects of C5a on 
macrophage migration in GM-MΦ and M-MΦ in this chapter. Low concentrations of 
C5a (0.1 nM) did not induce chemotaxis in M-MΦ (Figure 3.5B) but the same 
concentration of C5a in GM-MΦ induced 2-fold more cells to migrate relative to 
control (Figure 3.5A). This trend was also observed at a much higher concentration 
of C5a (EC90 = 3 nM). Despite the magnitude of response seen in GM-MΦ compared 
to M-MΦ, C5a appeared to exert equipotent chemotactic effects on both subtypes 
with similar EC50 values at sub nanomolar concentrations (Figure 3.5C, D). 
In summary, C5a had equipotent effects on both GM-MΦ and M-MΦ in all 
three functional assays investigated in this study; the calcium mobilization assay, 
ERK phosphorylation assay and cell migration assay. These results were unexpected, 
as one would hypothesize or expect that inflammatory responses mediated by C5a 
would be exacerbated in GM-MΦ; macrophages with a proinflammatory background 
compared to M-MΦ; macrophages with an anti-inflammatory background. Results 
from these functional assays supported the theory that macrophages are more likely to 
be influenced depending on their microenvironment rather than their previous 
polarization background. 
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Cells pEC50 ± SEM EC50 (nM) n 
GM-MΦ 9.5 ± 0.2 0.3 3 
M-MΦ 9.4 ± 0.2 0.4 3 
 
Figure 3.5. C5a is equipotent in mediating chemotaxis on GM-MΦ and M-MΦ. 
 (A) GM-MΦ: black and (B) M-MΦ: white; were serum-deprived overnight prior to 
addition to the upper chamber of the Transwell and then allowed to migrate through 
the 0.5µm porous membrane into the lower chamber containing serum free media 
with various concentrations of C5a (0.1-30 nM) for 3 h. Migrated cells on the lower 
side of the membrane were stained with DAPI and counted under a fluorescence 
microscope using a x10 objective. (C) Chemotactic index is expressed as % against 
C5a maximal response. (D) The EC50 values were calculated using the Prism software. 
Error bars are means ± SEM of three independent experiments (n=3). **p < 0.01 and 
***p < 0.001 by student t-test. 
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3.5.4 C5a-induced gene expressions on GM-MΦ and M-MΦ 
 
C5a appeared to be equipotent on GM-MΦ and M-MΦ in all three functional 
assays; calcium release, ERK phosphorylation and macrophage migration. The EC80 
value of C5a on GM-MΦ and M-MΦ in the calcium release and ERK 
phosphorylation assay was calculated to be ~ 30 nM, whereas this value was 10-fold 
more potent in the migration assay. The migration assay was performed with longer 
exposure of the cells to C5a (3 h), compared to the calcium release and ERK 
phosphorylation assays (5 min). This could be the reason for differences in potency 
between assays; hence in the PCR and later with microarray, C5a will be used at 30 
nM for inducing gene expression.  
 The levels of CCL3, TNF, IL8, PTGS2, IL1B and EGR1 mRNA expression 
were significantly amplified after exposing GM-MΦ and M-MΦ to C5a for 0.5 h, and 
all 6 genes were more highly expressed in GM-MΦ than M-MΦ (Figure 3.6). 
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Figure 3.6. A panel of genes induced by 30 nM C5a after 0.5 h.  
GM-MΦ (black) and M-MΦ (white) were serum deprived overnight before treating 
with 30 nM C5a for 0.5 h. The expression of (A) CCL3, (B) TNF, (C) IL8, (D) PTGS2, 
(E) IL1B and (F) EGR1 genes was detected by quantitative real-time PCR. The 
relative expression of genes was normalized against 18S rRNA. Error bars are means 
± SEM of three independent experiments (n=3). *p < 0.05, **p < 0.01 and ***p < 
0.001 by student t-test. 
 
3.5.5 Quality control of genes hits: sample variations versus C5a treatments 
 
cDNA microarray analysis of C5a-treated human umbilical vein endothelial 
cells (HUVEC) (7), or C5aR-antagonist-treated tissues from disease murine models of 
secondary cataract (25) and neuropathic pain (26) have been previously performed. It 
was very surprising that such an analysis had not been reported in primary human 
macrophages, or at the very least on other macrophages. Microarray technology has 
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become a widely used tool for the rapid generation of gene expression and functional 
genomics data, however it is crucial that the conditions and treatments are optimized 
before performing the microarray experiment to gather good quality data and 
reproducible information. Given that the magnitude of gene responses induced by 30 
nM C5a for 0.5 h on both GM-MΦ and M-MΦ was considerable (Figure 3.6), the 
signal to noise ratio was considered to be sensitive enough to be able to detect 
changes in gene expression in the notoriously low sensitivity microarray platform.  
While primary cells usually give much better gene expression profiles than 
laboratory cultured immortalized cells, a drawback is that genetic variations between 
donor samples can be significant, leading to distortion and inflated error rates and 
associated reproducibility issues. Increasing the population size can help to overcome 
variably between donors but a large population pool (n ≤ 20), increases technical 
difficulty and is too expensive for most academic research. As such, four instead of 
three (n=4) different donor-matched human monocyte-derived macrophages 
populations were differentiated by GM-CSF (GM-MΦ) and M-CSF (M-MΦ) for 
analysis by microarray. A total of 24 samples were submitted to Australian Genome 
Research Facility (AGRF) for reading on an Illumina microarray platform and 
processing as described in Chapter 2. The experimental design carried out for the 
microarray experiment was illustrated in Table 3.1. Since the focus of this chapter 
was on C5a, non C5a-treated samples (*) will not be discussed here. The raw data 
obtained was quantified, normalised and filtered using the GeneSpring software v11.5. 
 
Table 3.1. The experimental design carried out for the microarray experiment. 
 
Donor 1 Donor 2 
GM-MΦ A Untreated B * C C5a G Untreated H * I C5a 
M-MΦ D Untreated E * F C5a J Untreated K * L C5a 
 
Donor 3 Donor 4 
GM-MΦ M Untreated N * O C5a S Untreated T * U C5a 
M-MΦ P Untreated Q * R C5a V Untreated W * X C5a 
GM-MΦ or M-MΦ was seeded at 2 x 106 cells per well in a 6-well plate format and 
then serum deprived overnight when cells were adherent. The next day, cells were 
stimulated with 30 nM C5a for 0.5 h and then lysed cells to extract total mRNA. 
*Treatments not part of this thesis. 
 
All samples were subjected to hierarchical clustering using pairwise distance 
matrix analysis by BioConductor software (27, 28). This is a very simple and quick 
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method to visualize and measure how similar or different all the samples are from one 
another, with clusters being most convergent at the bottom and divergent at the top. 
Samples that were most divergent were grouped according to the subtype of 
macrophages (GM-MΦ versus M-MΦ), and their differences were documented in 
Chapter 2, followed by donor-to-donor variations, and lastly by treatments (Figure 
3.7). Although this distribution was not unexpected, it again reinforced the fact that 
the differences between donors can be greater than the differences between treatments 
versus control.  
 
Figure 3.7. Hierarchical clustering of samples used for the microarray analysis. 
The dendrogram represents 24 samples being clustered using the pairwise distance 
matrix algorithms by BioConductor (28) and ranked with samples most closely 
related at the bottom and most divergent at the highest. 
 
In the dendrogram, sample X (Donor 4: M-MΦ treated with 30 nM C5a) 
appeared to be an outlier (Figure 3.7), which was very surprising because all samples 
had undergone preliminary in-house quality control checks before submission for 
microarray gene expression. The calculated 28S:18S ratio for sample X was 1.5 
which suggested that mRNA were intact and not degraded (Figure 3.8). This value 
was consistent cross all samples (~1.5-1.7). The concentration of mRNA was also 
within the manufacture’s recommendation. Given that the mRNA conditions were 
ideal and properly processed, the reason for this outlier was unlikely due to poor 
sample preparation. The dendrogram was drawn based on normalized data (Figure 
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3.9B), which was the recommended practice under the assumption that all samples 
were handled the same.  
 
Name 
Start 
Size 
[NT] 
End 
Size 
[NT] 
Area 
% of total 
Area 
18S 1499 1891 56.9 21.5 
28S 2868 4093 85 32.1 
 
Overall Results 
    
RNA Area: 265.0   
RNA Conc: 123 ng/µL   
rRNA ratio [28S/18S]: 1.5   
 
Figure 3.8. mRNA quality and sample assessment report for sample X. 
The mRNA quality for sample X was assessed by electrophoresis of total RNA 
followed by staining with ethidium bromide. The calculated 28S:18S rRNA ratio was 
1.5.  
 
However, this was not the case as a comparison between the raw (Figure 
3.9A) and the normalized (Figure 3.9B) density plot of intensity showed that the 
intensity peak of sample X was at least 3-fold lower than the rest of the samples. 
Using the venn diagram plot, the intersection consisting of 36 genes were commonly 
regulated by C5a between 4 donors versus 3 donors (without sample X) (Figure 3.10). 
This result further confirmed that the sample X being flagged as an outlier originated 
from differences in signal intensity rather than differences in expression. As such, all 
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4 donors will be included in the analysis to achieve better statistic significance 
compared to 3 donors. 
 
 
Figure 3.9. Comparison of density plot of intensity between (A) raw and (B) 
normalized data. 
Gene expression data measured by HumanHT-12v4 Beadchip are preprocessed using 
image analyzer to extract expression values from images and scaling algorithms to 
make expression values comparable across chips.  
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Figure 3.10. Venn diagram comparison between genes hits obtained using 4 
donors versus 3 donors treated with 30 nM C5a for 0.5 h in M-MΦ. 
Circles represented the ANOVA analysis of C5a-regulated genes obtained by 4 
donors (blue) versus 3 donors (omit sample X) (yellow). Numbers inside each 
compartment represented the number of transcripts that were significant (≥ 2-fold 
change, p < 0.05) for that effect. The interacting region represents genes consistently 
upregulated by both 4 donors and 3 donors analysis.   
 
3.5.6 Microarray experiment 1: Genes regulated by C5a on GM-MΦ versus 
M-MΦ  
 
Labelled cRNA were detected by hybridising to 50-mer probes on the 
HumanHT-12 v4 BeadChip (Illumina, Inc. San Diego, USA). Out of 47,231 probes, 
28,688 probes were detected for well-established coding transcripts, 11,121 probes 
were detected for provisional coding transcripts, 1,752 probes were detected for well-
established non-coding transcripts and 2,209 probes were detected for provisional 
non-coding transcripts. The raw data obtained was quantified, normalised and filtered 
using the GeneSpring software v11.5. The statistical significance threshold limit was 
set at P < 0.05 and the Benjamini-Hochberg method was employed to control the 
false discovery rate (29). The cut-off value for fold changes was set at 2-fold. In order 
for an outcome to be considered as a positive hit, it must pass these two conditions. 
Gene hits with well-established coding transcripts were considered while the rest of 
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the hits were excluded from this analysis. Genes with duplicated or triplicated hits had 
their respective fold changes averaged.  
There were a total of 53 genes in GM-MΦ and 40 genes in M-MΦ upregulated 
after subjecting the cells to 30 nM C5a for 0.5 h. The list of genes uniquely regulated 
by C5a in either GM-MΦ (20 genes) or M-MΦ (7 genes) is summarized in Table 3.2, 
and the list of genes commonly regulated (33 genes) by C5a in both GM-MΦ and M-
MΦ is summarized in Table 3.3. 
 
Table 3.2. Genes upregulated by 30 nM C5a in either GM-MΦ or M-MΦ after 
0.5 h were expressed as fold changes. 
Gene GM-MΦ# Accession  Gene M-MΦ
# Accession 
CCDC138 2.1 NM_144978.1  CCL14 3.6 NM_032962.2 
CCL8 3.1 NM_005623.2  DEFB104A 2.1 NM_080389.1 
CD69 2.7 NM_001781.1  HMGN3 2.8 NM_004242.2 
CRCP 2.2 NM_001040648.1  MCL1 2.2 NM_021960.3 
DISC1 2.2 NM_018662.2  NFASC 2.0 NM_001005387.1 
DUSP2 3.9 NM_004418.2  PRUNE2 2.3 NM_138818.2 
EBI2 2.3 NM_004951.3  PSORS1C1 2.3 NM_014068.1 
ETNK1 2.4 NM_001039481.1     
IGFBPL1 2.5 NM_001007563.1     
IL1A 4.6 NM_000575.3     
JUN 2.3 NM_002228.3     
PPM1K 2.1 NM_152542.2     
SERPINB2 2.5 NM_002575.1     
SLC25A25 2.6 NM_052901.2     
SNORA41 2.5 NR_002590.1     
TAGAP 3.0 NM_054114.3     
TNFSF9 2.2 NM_003811.2     
TRK1 2.5 NR_001449.1     
TSC22D3 2.2 NM_198057.2     
ZNF571 2.4 NM_016536.3     
#Fold change annotated in GM-MΦ and M-MΦ columns indicates the difference in 
gene expression between untreated and C5a-treated macrophages. 
 
Given that the EC50 values of C5a on GM-MΦ and M-MΦ in the functional 
assays conducted such as ERK phosphorylation, calcium release and macrophage 
migration were so similar, it was not surprising that the magnitude of genes 
commonly mediated by C5a were similar as well (Table 3.3).  
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Table 3.3. Genes commonly upregulated by 30 nM C5a in GM-MΦ and M-MΦ 
after 0.5 h were expressed as fold changes. 
Gene GM-MΦ# M-MΦ# Accession 
ATF3 2.8 2.6 NM_001040619.1 
AXUD1 2.6 2.4 NM_033027.2 
BTG2 5.3 3.9 NM_006763.2 
CCL3 3.2 2.9 NM_002983.1 
CCL3L1 3.5 3.5 NM_021006.4 
CCL3L3 3.1 2.7 NM_001001437.3 
CXCL2 3.5 2.4 NM_002089.3 
CYP4B1 3.7 2.2 NM_000779.2 
DUSP1 8.4 5.7 NM_004417.2 
DUSP6 3.9 3.1 NM_001946.2 
EGR1 13.2 13.3 NM_001964.2 
EGR2 3.5 3.7 NM_000399.2 
EGR3 4.9 5.5 NM_004430.2 
FOS 14.4 24.5 NM_005252.2 
FOSB 395.7 201.0 NM_006732.1 
IER2 4.3 3.2 NM_004907.2 
IER3 3.2 2.1 NM_003897.3 
IL8 3.7 2.5 NM_000584.2 
JUNB 3.5 2.6 NM_002229.2 
KLF2 5.6 3.8 NM_016270.2 
KLF4 3.5 3.8 NM_004235.3 
KLF6 2.2 3.3 NM_001008490.1 
MAFF 2.9 2.5 NM_012323.2 
NFKBIZ 3.9 2.9 NM_001005474.1 
NR4A2 5.3 6.9 NM_006186.2 
PHLDA1 3.3 2.5 NM_007350.3 
PMAIP1 2.2 3.2 NM_021127.1 
PTGS2 4.3 3.4 NM_000963.1 
RGS1 4.6 6.3 NM_002922.3 
RGS2 2.1 2.2 NM_002923.1 
SOCS3 3.1 3.9 NM_003955.3 
TNF 4.5 3.6 NM_000594.2 
ZFP36 4.4 4.5 NM_003407.2 
#Fold change annotated in GM-MΦ and M-MΦ columns indicates the difference in 
gene expression between untreated and C5a-treated macrophages. 
 
Interestingly, out of all the genes upregulated by C5a in both GM-MΦ and M-
MΦ, 33 of them were commonly upregulated (Figure 3.11), which translated into 
62% - 83% of the genes identically mediated between GM-MΦ and M-MΦ. To 
analyze the functional effects of the genes differentially regulated by C5a in GM-MΦ 
or in M-MΦ, the entire list of genes (Table 3.2 and Table 3.3) was uploaded into IPA 
in order to generate network, functional and pathway analyses. 
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Figure 3.11. Venn diagram comparison of genes upregulated by 30 nM C5a for 
0.5 h on GM-MΦ versus M-MΦ. 
Circles represented the ANOVA analysis of C5a-regulated genes by GM-MΦ (blue) 
versus M-MΦ (yellow). Numbers inside each compartment represented the number of 
transcripts that were significant (≥ 2-fold change, p < 0.05) for that effect. The 
interacting region represents genes consistently upregulated by both population of 
human macrophages.  
 
The pathway analysis converted the list of C5a-upregulated genes and each 
annotated gene was mapped to its corresponding gene object into a set of relevant 
networks based on the Ingenuity Pathways Knowledge Base (IPKB). The networks 
were generated from the focus molecules (list of differentially regulated genes 
uploaded into IPA) and then focus molecules with the most interactions to other focus 
molecules were then connected together to form a network. Non-focus molecules 
from IPKB were then added to form a network based upon molecular function 
consisting of 35 molecules. These genetic networks were then sorted based on the 
score, which reflects the probability that a collection of genes equal to or greater than 
the number in a network that could be achieved by chance alone. 
The network with the highest score for C5a-treated macrophages was 30 for 
GM-MΦ (Table 3.4) and 34 for M-MΦ (Table 3.5), which composed of 14 genes and 
15 genes respectively. The top ranking diseases and functions commonly between 
GM-MΦ and M-MΦ overlapped with major pathways involved in neurological 
disease, cancer, cell death and survival and the gene network corresponding to those 
pathways were depicted in Figure 3.12.  
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Table 3.4. Top 5 network functions and associated diseases that were 
upregulated by C5a in GM-MΦ as analyzed by IPA 
Top Diseases 
and Functions Score 
Focus 
Molecules Molecules in Network
# 
Neurological 
Disease, 
Cancer, Cell 
Death and 
Survival 
 
30 14 
Adaptor protein 1, ATF3, CaMKII, Caspase 3/7, 
Cg, Creb, DUSP1, DUSP2, DUSP6, EGR1, 
EGR3, Eotaxin, ERK1/2, FOSB, FSH, GC-GCR 
dimer, Hdac, IER2, JINK1/2, JUN, JUNB, 
KLF6, LDL, Lh, MAP2K1/2, Mek, PDGF BB, 
PHLDA1, PI3K (family), PMAIP1, PTPase, 
SERPINB2, SWI-SNF, TCF, thyroid hormone 
receptor 
Inflammatory 
Response, 
Cellular 
Movement, 
Hematological 
System 
Development 
and Function 
 
20 10 
Akt, Calcineurin protein(s), CCL3, CCL8, 
CCL3L1/CCL3L3, CXCL2, cyclooxygenase, 
elastase, Fc gamma receptor, Fcer1, Gm-csf, 
Growth hormone, HLA-DR, IER3, Ifn, Ifn 
gamma, Ige, Ikb, IKK (complex), IL1, IL17a 
dimer, IL1A, lymphotoxin-alpha1-beta2, NFkB 
(family), NfkB-RelA, NfkB1-RelA, NFKBIZ, 
Nr1h, Oas, SAA, SOCS3, Tlr, Tnf receptor, 
TNFSF9, TSC22D3 
Cellular 
Movement, 
Cell Cycle, 
Gene 
Expression 
 
20 10 
AGTPBP1, ATF4, ATP5I, beta-estradiol, BMP2, 
BTBD10, CCDC138, CDK5, CREB1, CREB5, 
CSRNP1, CYP4B1, DDIT3, DLEU1, ELK3, 
ETNK1, FGF4, FOSL1, HTATIP2, JUNB, 
JUND, MAFB, miR-17-5p (and other miRNAs 
w/seed AAAGUGC), miR-450b-3p (and other 
miRNAs w/seed UGGGAUC), NUCB2, PPM1K, 
SERPINB2, SLC25A25, TAGAP, TBP, TGM2, 
TMSB10/TMSB4X, tretinoin, UBC, ZNF571 
Cell-To-Cell 
Signaling and 
Interaction, 
Cellular 
Growth and 
Proliferation, 
Cellular 
Development 
 
14 8 
ADCY, ADRB, BCR (complex), BTG2, calpain, 
Cbp/p300, CD69, Cyclin E, ERK, estrogen 
receptor, IFN Beta, IgG, Igm, IL8, IL12 
(complex), IL12 (family), Immunoglobulin, 
Interferon alpha, JUN/JUNB/JUND, KLF4, 
MAFF, MEF2, MHC CLASS I (family), NADPH 
oxidase, Nfat (family), P38 MAPK, Pro-
inflammatory Cytokine, PTGS2, Rap1, RGS2, 
sphingomyelinase, STAT5a/b, TMSB4, TSH, 
ZFP36 
Cell Signaling, 
Molecular 
Transport, 
Vitamin and 
Mineral 
Metabolism 
 
10 6 
aldosterone, amino acids, CaMKII, CCR4, CDK5, 
chemokine, CHRM3, CHRM4, Ck2, CRCP, 
DDIT3, DISC1, Endothelin, EPO, ethanol, 
GNRH1, GNRH, Gpcr, GPR183, Gsk3, Histone 
h3, Histone h4, IGFBPL1, Mapk, MC4R, miR-
1231-3p (and other miRNAs w/seed GCCCUGU), 
MOS, NPS, Pka, PLC, PTH, RGS1, SFTPA1, 
STAT, TNF 
#Focus molecules were represented in the network as bolded genes.  
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Table 3.5. Top 5 network functions and associated diseases that were 
upregulated by C5a in M-MΦ as analyzed by IPA 
Top Diseases 
and Functions Score 
Focus 
Molecules Molecules in Network
# 
Neurological 
Disease, 
Cancer, Cell 
Death and 
Survival 
 
34 15 
Adaptor protein 1, Ap1, ATF3, CaMKII, Caspase 
3/7, Cg, Creb, DUSP1, DUSP6, EGR1, EGR3, 
ERK1/2, FOSB, FSH, Hdac, IER2, 
Immunoglobulin, JUNB, KLF4, KLF6, LDL, Lh, 
MAP2K1/2, MCL1, Mek, MIR101, Pdgf 
(complex), PDGF BB, PHLDA1, PMAIP1, 
PTGS2, PTPase, RGS2, TCF, Vegf 
Inflammatory 
Response, 
Cellular 
Movement, 
Hematological 
System 
Development 
and Function 
 
21 10 
Akt, CCL3, CCL14, CCL3L1/CCL3L3, 
CXCL2, DEFB104A/DEFB104B, elastase, Fc 
gamma receptor, Fcer1, Gm-csf, Growth 
hormone, HLA-DR, IER3, Ifn, IFN Beta,Ifn 
gamma, Ige, IgG, IL1, IL8, IL12 (complex), 
Interferon alpha, KLF2, NFkB (family), NfkB-
RelA, NfkB1-RelA, Notch, Nr1h, Oas, PI3K 
(family), Pro-inflammatory Cytokine, SAA, 
SOCS3, Tlr, ZFP36 
Cancer, 
Cellular 
Development, 
Cellular 
Growth and 
Proliferation 
 
11 6 
ADCY, ANKS1A, ATF4, ATF7, BMP2, CAPN2, 
CDK5, CSRNP1, CYP4B1, DAB2, DDIT3, 
FAM50A, FOSL1, GRM5, JUNB, JUND, 
KCNIP3, KDM2A, KRT15, MC1R, miR-1207-5p 
(and other miRNAs w/seed GGCAGGG), 
NBPF10 (includes others), NFASC, NMI, PKP2, 
PRUNE2, PSORS1C1, RAP1GAP, SLC19A1, 
SUPT6H, TMSB10/TMSB4X, TPR, tretinoin, 
TRPV4, UBC 
Cell 
Morphology, 
Cell-To-Cell 
Signaling and 
Interaction, 
Inflammatory 
Response 
 
9 5 
26s Proteasome, amino acids, caspase, CDK5, 
chemokine, Ck2, Focal adhesion kinase, GNRH1, 
Gsk3, HISTONE, Histone h3, HMGN3, Hsp70, 
IL12 (family), Mapk, Mmp, MMP23B, MOS, 
Neurotrophin, NFkB (complex), NFKBIZ, 
NR4A2, PDGF-AA, PI3K (complex), Pka, PLC, 
Ras homolog, RGS1, RNA polymerase II, SNCG, 
STAT, TEC/BTK/ITK/TXK/BMX, TFIIA, TNF, 
Ubiquitin 
Cell Cycle, 
Cellular 
Development, 
Embryonic 
Development 
 
6 4 
AMPK, BCR (complex), BTG2, Calcineurin 
protein(s), Cbp/p300, CD3, Collagen type I, 
Cyclin E, cyclooxygenase, EGR2, ERK, estrogen 
receptor, FOS, Histone h4, Hsp27, IKK 
(complex), Integrin, Jnk, JUN/JUNB/JUND, 
MAFF, NADPH oxidase, Nfat (family), Nos, P38 
MAPK, Pkc(s), Rac, Rap1, Ras, Rb, Rock, Sapk, 
STAT5a/b, TCR, Tgf beta, TSH 
#Focus molecules were represented in the network as bolded genes.  
 
The functional pathway mapping analysis also suggested that C5a activation 
in human macrophages is also involved in a variety of cellular and pathological 
conditions (score ≥ 10), such as inflammatory responses, cellular movement, cellular 
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development, haematological system development and function, cellular growth and 
proliferation based on matching C5a-induced gene expression to pathways. 
 
Figure 3.12. Functionally related gene network with highest score constructed 
from genes commonly upregulated by 30 nM C5a on GM-MΦ and M-MΦ. 
Genes commonly upregulated by 30 nM C5a on GM-MΦ and M-MΦ were uploaded 
into Ingenuity Pathway Analysis (IPA) software. Nodes displayed in red represented 
genes upregulated by C5a and the magnitude of expression was reflected by the 
intensity of the colour with darker red indicating higher levels of expression.  
 
The magnitude of expression was reflected by the intensity of the colour, with 
darker red indicating higher levels of expression. Most of the C5a-upregulated genes 
detected by microarray were not more than 25-fold changed except for the expression 
of FOSB gene, which was 396 and 201 fold altered by C5a in GM-MΦ and M-MΦ 
respectively. cDNA microarray provides an unprecedented capacity for whole 
genome profiling. However, the quality of gene expression data obtained from 
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microarray can vary greatly with platforms and procedures used (30). Although the 
list of genes differentially expressed between control and treated samples detected in 
the microarray experiment was already validated by quantitative real-time PCR 
previously in Chapter 2, the magnitude of fold change in the FOSB gene appeared to 
be oddly high, unlike the FOS gene (~15- to 25-fold change) which was the closest 
related gene. As suspected, the expression of FOSB was found to be out of the 
sensitivity range when validated by real-time PCR (Figure 3.13). Although the fold 
change values for FOSB gene were inaccurate, the differences between GM-MΦ and 
M-MΦ were consistent showing higher expression in GM-MΦ against M-MΦ across 
two platforms.  
 
Figure 3.13. Correlation between microarray and quantitative real-time PCR 
FOSB gene expression upregulated by 30 nM C5a on GM-MΦ and M-MΦ. 
The expression of FOSB gene induced by 30 nM C5a for 30 min in GM-MΦ (black) 
and M-MΦ (white) were detected by microarray and quantitative real-time PCR. 
Error bars are means ± SEM of three-four independent experiments (n=4, microarray; 
n=3, PCR). *p < 0.05 and **p < 0.01 by student t-test. 
 
The transcriptional program stimulated by C5a included several genes whose 
products are proinflammatory such as chemokines and cytokines (CCL3, CCL3L1, 
CCL3L3, CXCL2, IL8, PTGS2 and TNF). C5a also stimulated the expression of a 
number of transcription factors (ATF3, EGR1, EGR2, EGR3, FOS, FOSB and JUNB) 
that amplified immune responses and were also likely to have a positive feedback 
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loop resulting in the stimulation of expression of themselves and other 
proinflammatory genes. FOSB and FOS genes were highly upregulated in human 
macrophages (GM-MΦ and M-MΦ) when stimulated with C5a. The FOS gene family 
consists of 4 members, namely FOS, FOSB, FOSL1 and FOSL2. Besides 
inflammation, FOS proteins had also been implicated as a regulator of cell 
proliferation, differentiation and transformation by dimerising with proteins of the 
JUN family to form the transcription factor complex activating protein-1 (AP-1) (31). 
C5a activation in human macrophages upregulated genes such as ZFP36 can interfere 
with TNF production by destabilizing its mRNA (32), and also cytokine signaling 
suppressors (SOCS3, NFKBIZ, DUSP1 and DUSP6) (33, 34). These genes were 
simultaneously activated by C5a to prevent excessive damage that could be 
deleterious by dampening down proinflammatory responses and restore homeostasis.  
In contrast to the number of genes upregulated by C5a, the number of genes 
downregulated by C5a was very modest in GM-MΦ with only 1 gene (CLEC1B, -2.2 
fold change), and in M-MΦ with 5 genes (SNORD99, -3.6 fold change; BTRC, -2.3 
fold change; SNORA33, -2.2 fold change; CDC14C, -2.1 fold change and PTPRU, -2 
fold change). Therefore, a separate microarray experiment was conducted to overview 
the temporal profile of C5a-induced gene expression in macrophages extending the 
observation beyond 0.5 h stimulation. 
 
3.5.7 Microarray experiment 2: Temporal profile of genes mediated by C5a 
on M-MΦ 
 
The temporal study with different time points (0, 0.5, 6 and 18 h) was 
conducted in M-MΦ only, not in GM-MΦ (since majority of the upregulated genes 
were commonly expressed between GM-MΦ and M-MΦ) from three different healthy 
blood donors. Moreover, macrophages can undergo dynamic changes during different 
phases of the immune response. For example, in physiological conditions, 
proinflammatory macrophages mediate tissue damage and initiate inflammatory 
responses but at the later stage when the initiate inflammatory wave subsides, the 
antiinflammatory macrophages will begin wound healing and initiate haemostasis (12, 
35). These temporal changes on macrophages have been observed in several other 
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pathological conditions and diseases (36-38). As such, it was suspected that C5a 
would exert a greater effect on M-MΦ than GM-MΦ at later time points. 
There were a total of 147 genes significantly regulated by 30 nM C5a on M-
MΦ (Figure 3.14). As expected, at 0.5 h time point post C5a stimulation, all genes 
induced were upregulated in M-MΦ. At 6 h time point, a number of genes that were 
not responsive to C5a stimulation at earlier time point (0.5 h) were either 
downregulated or upregulated. Majority of the genes that were upregulated by C5a at 
0.5 h, returned to baseline expression by 6 h time point. These differentially regulated 
genes can be further categorised into clusters according to their temporal profile, with 
cluster 1, 2 and 3 featuring genes that were upregulated by 30 nM C5a at 0.5, 6 and 18 
h respectively and cluster 4 featuring genes that were downregulated by 30 nM C5a at 
6 h (Figure 3.15).  
 
 
Figure 3.14. Temporal profile of 147 genes differentially regulated by 30 nM on 
M-MΦ. 
Genes were represented by colors according to their temporal profile (yellow: 
upreguated genes after 0.5 h, orange: upregulated genes after 6 h and blue: 
downregulated after 6 h). All genes represented in the profile plot were at least 2-fold 
change and p < 0.05 by ANOVA. 
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Figure 3.15. Four clusters of genes were categorised based on their responses to 
30 nM C5a treatments and the duration the event occurred. 
Cluster 1, 2 and 3 featured genes that were upregulated ≥ 2-fold change at 0.5 h 
(yellow), 6 h (orange) and 18 h (pale yellow) respectively. Cluster 4 featured genes 
that were downregulated ≥ 2-fold change at 6 h. All genes are p < 0.05 by ANOVA. 
 
3.5.7.1 Inflammatory genes regulated by C5a 
 
C5a plays an essential role in inflammation and innate immunity against 
infectious disease and Table 3.6 lists inflammation-related genes regulated by C5a. 
C5a induces acute inflammatory responses in a variety of disease models (39, 40). 
Important inflammatory mediators such as IL1B (6 fold, 0.5 h), PTGS2 (3.3-fold, 0.5 
h) and TNF (2.6 fold, 0.5 h) were upregulated as the result of C5a stimulation. C5a 
anaphylatoxin is a potent chemotaxin and upregulated chemokines such as CCL8 (2.5 
fold, 0.5 h), CCL3 (2.9-fold, 0.5 h), CCL3L1 (2.6-fold, 0.5 h), CCL4L2 (2.5-fold, 0.5 
h), CCL3L3 (2.4-fold, 0.5 h), CCL7 (6.1-fold, 6 h), CCL2 (2.2-fold, 0.5 h and 2.4-fold, 
6 h) while CXCR4 was downregulated (-2.4-fold, 6 h) in the microarray experiment. 
IL1B mRNA expression peaks at 0.5 h and was quickly reduced to basal expression 
level when IL1RN was upregulated (2-fold, 6 h), which seems to suggest a direct 
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feedback mechanism in M-MΦ to prevent hyper-stimulation by C5a via IL1B 
expression.  
 
Table 3.6. Inflammatory genes upregulated (black) or downregulated (red) by 30 
nM C5a. 
Gene Name 0.5h 6h 18h 
Interleukin 1, beta 6.0  1.4  (-1.3) 
Prostaglandin-endoperoxide synthase 2 3.3  1.2  1.0  
Heparin-binding EGF-like growth factor 2.5  (-1.1) (-1.4) 
Chemokine (C-C motif) ligand 8 2.5  1.3  (-1.1) 
Chemokine (C-C motif) ligand 3 2.9  1.0  (-1.4) 
Tumor necrosis factor 2.6  1.4  (-1.0) 
Chemokine (C-C motif) ligand 3-like 1 2.6  (-1.1) (-1.1) 
Chemokine (C-C motif) ligand 4-like 2 2.5  1.2  (-1.4) 
Zinc finger protein 36 2.4  (-1.2) (-1.2) 
Chemokine (C-C motif) ligand 3-like 3 2.4  (-1.0) (-1.3) 
Chemokine (C-C motif) ligand 7 1.3  6.1  (-1.0) 
Interleukin 1 receptor antagonist 1.1  2.0  (-0.2) 
Tumor necrosis factor superfamily, member 21 (-1.2) 2.6  (-1.0) 
Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 1.0  2.4  1.1  
Chemokine (C-C motif) ligand 2 2.2  2.4  1.2  
Heparanse (-1.1) (-4.7) (-1.4) 
Toll-like receptor 7 (-1.1) (-2.9) (-1.2) 
Leptin (-1.2) (-2.2) (-1.5) 
Arachidonate 15-lipoxygenase, type B 1.0  (-2.6) (-1.7) 
Transient receptor potential cation channel,  
subfamily M, member 2 1.1  (-2.5) (-1.1) 
Chemokine (C-X-C motif) receptor 4 (-1.4) (-2.4) (-1.5) 
Hydrogen voltage-gated channel 1 (-1.2) (-2.4) (-1.1) 
Toll-like receptor 8 (-1.1) (-2.2) (-1.0) 
 
3.5.7.2 Metabolism- or biosynthesis-related genes regulated by C5a 
 
The immune system requires a steady intake of nutrients to maintain proper 
functions. The relationship between nutrition and immunity is complex. From this 
microarray analysis, more than 15 metabolism- or biosynthesis-related genes were 
significantly regulated as the result of C5a stimulation (Table 3.7). C5a has not been 
shown to play a direct role in metabolic homeostasis before. Interestingly, fatty acid 
transporters (FABP5 and FABP5L2) and amino acid transporters (SLC7A1 and 
SLC7A5) were found to be more than 2-fold upregulated in M-MΦ stimulated with 
C5a and this may be an important observation in relation to possible effects of C5a on 
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adiposity. On the other hand, sugar transporter (SLC45A4) and iron transporter 
(SLC40A1) genes were more than 2-fold downregulated. CTSL1 and CTPS are 
important enzymes for intracellular protein catabolism and biosynthesis of 
phospholipids and nucleic acids respectively. CTSL1 and CTPS mRNA levels were 
upregulated (more than 2-fold) by C5a stimulation in HMDM, while the genes 
encoding for enzymes responsible for lipid metabolism (PPAP2B, ALOX15B and 
LYPLAL1) and protein metabolism (DPEP2) were downregulated (more than 2-fold). 
 
Table 3.7. Metabolism- or biosynthesis-related genes upregulated (black) or 
downregulated (red) by 30 nM C5a. 
Gene Name 0.5h 6h 18h 
Solute carrier family 7, member 1 (-1.1) 2.5  (-1.1) 
Solute carrier family 7, member 5 1.1  2.3  (-1.1) 
Fatty acid binding protein 5-like 2 1.2  2.1  (-1.3) 
Fatty acid binding protein 5 1.1  2.2  (-1.2) 
Cathepsin L1 1.0  2.2  1.1  
CTP synthase 1.0  2.0  1.1  
Leptin (-1.2) (-2.2) (-1.5) 
Chromosome 5 open reading frame 13 1.0  (-2.7) (-1.1) 
Arachidonate 15-lipoxygenase, type B 1.0  (-2.6) (-1.7) 
Phosphatidic acid phosphatase type 2B (-1.2) (-2.7) (-1.4) 
Solute carrier family 45, member 4 (-1.1) (-2.5) (-1.2) 
Transient receptor potential cation channel,  
subfamily M, member 2 1.1  (-2.5) (-1.1) 
Solute carrier family 40, member 1 (-1.0) (-2.2) (-1.2) 
Lysophospholipase-like 1 (-1.1) (-2.1) (-1.1) 
Dipeptidase 2 (-1.2) (-2.0) (-1.3) 
Thymidylate synthetase (-1.1) (-1.1) 2.2  
 
3.5.7.3 Signal transduction or transcription related genes regulated by C5a 
 
Genes associated with signal transductions and transcriptions are listed in 
Table 3.8. Epidermal growth factor response genes, EGR3 (7.3-fold), EGR1 (4.3-
fold) and EGR2 (4.2-fold) were upregulated in M-MΦ after stimulating with C5a for 
0.5 h. The inducible zinc finger transcription factors EGR1, EGR2 and EGR3, 
participate in the transcriptional regulation of genes in controlling biological rhythm, 
by activating the transcription of target genes whose products are required for 
mitogenesis and differentiation (41, 42). Stress response gene, ATF3, was also 
upregulated (5.3-fold) in M-MΦ stimulated with C5a. These early C5a-induced 
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responses were quickly suppressed back to basal expression levels after 6 h. EGR1 
and ATF3 are immediate early response genes that are associated with many 
inflammatory conditions and can be activated after C5a stimulation (41, 43).  
 
Table 3.8. Signal transduction- or transcription-related genes upregulated 
(black) or downregulated (red) by 30 nM C5a. 
Gene Name 0.5h 6h 18h 
Early growth response 3 7.3  1.1  (-1.0) 
Pleckstrin homology-like domain, family A, member 1 5.7  2.2  (-1.4) 
FBJ murine osteosarcoma viral oncogene homolog B 5.9  (-1.3) (-1.3) 
Activating transcription factor 3 5.3  (-1.3) (-1.5) 
Early growth response 1 4.3  1.0  (-1.5) 
Early growth response 2 4.2  (-1.1) (-1.9) 
Dual specificity phosphatase 5 3.0  1.4  (-1.1) 
Dual specificity phosphatase 6 2.4  1.9  1.1  
BTG family, member 2 2.8  (-1.2) (-1.5) 
Zinc finger protein 36 2.4  (-1.2) (-1.2) 
Kruppel-like factor 6 2.2  (-1.1) (-1.1) 
Polymerase I and transcript release factor (-1.1) 2.4  (-1.2) 
Megakaryocyte-associated tyrosine kinase 1.2  2.2  1.1  
Filamin B, beta (-1.2) 2.6  (-1.4) 
Transmembrane protein 158 1.0  2.4  (-1.3) 
MARCKS-like 1 1.0  2.4  1.1  
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 1.0  2.0  (-1.2) 
P8 protein (-1.1) (-2.4) (-1.3) 
D site of albumin promotor binding protein (-1.0) (-2.4) 1.3  
SLIT-ROBO Rho GTPase activating protein 3 (-1.0) (-2.4) (-1.3) 
Pellino homolog 2 (-1.2) (-2.2) (-1.1) 
AT rich interactive domain 3A 1.1  (-2.1) (-1.1) 
Zinc finger protein 467 1.0  (-2.1) (-1.2) 
Zinc finger protein 581 1.0  (-2.1) (-1.2) 
Ubiquitin-like with PHD and ring finger domains 1 (-1.0) 1.2  2.5  
 
3.5.7.4 Cell cycle-related genes regulated by C5a 
 
Agonists such as TNF, LPS and C5a can activate pro-apoptotic and anti-
apoptotic genes in endothelial cells (7, 44, 45). C5a induces proliferation, migration 
and vessel formation in endothelial cells (46). More than 20 cell cycle-related genes 
was found to be mediated by C5a (Table 3.9). DUSP5 (3-fold, 0.5 h) and DUSP6 
(2.4-fold, 0.5 h) were upregulated in M-MΦ by C5a stimulation. The DUSP family 
negatively regulate members of the mitogen-activated protein (MAP) kinase 
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superfamily (MAPK/ERK, SAPK/JNK, p38), which are associated with cellular 
proliferation and differentiation. 
 
Table 3.9. Cell cycle-related genes upregulated (black) or downregulated (red) 
by 30 nM C5a. 
Gene Name 0.5h 6h 18h 
Pleckstrin homology-like domain, family A, member 1 5.7  2.2  (-1.4) 
FBJ murine osteosarcoma viral oncogene homolog B 5.9  (-1.3) (-1.3) 
Early growth response 1 4.3  1.0  (-1.5) 
Dual specificity phosphatase 5 3.0  1.4  (-1.1) 
AXIN1 up-regulated 1 3.1  1.1  (-1.1) 
Dual specificity phosphatase 6 2.4  1.9  1.1  
Tumor necrosis factor 2.6  1.4  (-1.0) 
CD83 molecule 2.4  1.0  (-1.4) 
Myeloid-associated differentiation marker 2.5  1.7  (-1.2) 
Kruppel-like factor 4 2.4  (-1.5) (-1.2) 
Myeloid cell leukemia sequence 1 2.3  1.0  (-1.2) 
GDNF family receptor alpha 2 1.0  4.0  (-1.1) 
CD276 molecule 1.1  2.5  (-1.2) 
Tumor necrosis factor superfamily, member 21 (-1.2) 2.6  (-1.0) 
Lamin A/C 1.4  2.5  1.0  
Cathepsin L1 1.0  2.2  1.1  
CTP synthase 1.0  2.0  1.1  
Matrix metallopeptidase 19 1.5  2.2  1.5  
Bcl2 modifying factor (-1.3) (-3.1) (-1.5) 
Chromosome 5 open reading frame 13 1.0  (-2.7) (-1.1) 
HtrA serine peptidase 4 (-1.2) (-2.6) (-1.7) 
Yippee-like 3 1.2  (-2.6) (-1.0) 
AT rich interactive domain 3A 1.1  (-2.1) (-1.1) 
B-cell CLL/lymphoma 11A (-1.2) (-2.2) (-1.5) 
Fas apoptotic inhibitory molecule 3 (-1.2) (-1.6) (-2.0) 
 
FOSB was also upregulated (5.9 fold, 0.5 h) in M-MΦ when stimulated with 
C5a. Interestingly, CD83 was upregulated (2.4-fold) in C5a-stimulated HMDM. 
CD83 is one of the best-known and characterised maturation markers for human 
dendritic cells (DCs). The CD83 protein is preformed intracellularly in monocytes, 
macrophages and dendritic cells and is stably expressed on activated dendritic cells 
(47). C5a can induce monocyte recruitment and differentiation into dendritic cells by 
TNF and prostaglandin E2-dependent mechanisms (48). It is however not known if 
C5a differentiates macrophages to dendritic cells. CD276 is a costimulatory B7 
molecule that signals through CD28 and may participate in the priming of T cells (49). 
Unstimulated antigen presenting cells are largely B7 negative. CD276 is upregulated 
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when DCs macrophages, B cells and Langerhans’ cells are activated. CD276 was 
upregulated (2.5-fold) in M-MΦ after stimulating with C5a for 6 h. 
3.5.7.5 Adhesion- or migration-related genes regulated by C5a 
 
Chemotaxis plays a major role in macrophage accumulation at the site of an 
infection or tissue damage. C5a can manifest chemotactic activity in macrophages, 
and some adhesion- or migration-related genes regulated by C5a in M-MΦ are listed 
in Table 3.10. FAM129B (3.7-fold), TIMP3 (2.2-fold) and MMP19 (2.2-fold) were 
upregulated in M-MΦ when stimulated with C5a.  
 
Table 3.10. Adhesion- or migration-related genes upregulated (black) or 
downregulated (red) by 30 nM C5a. 
Gene Name 0.5h 6h 18h 
Family with sequence similarity 129, member B 1.1  3.7  (-1.0) 
TIMP metallopeptidase inhibitor 3 1.2  2.2  (-1.5) 
Neuropilin 1 (-1.2) 2.3  1.1  
Matrix metallopeptidase 19 1.5  2.2  1.5  
Purinergic receptor P2Y, G-protein coupled, 8 (-1.1) (-2.9) (-1.5) 
Plasminogen activator, urokinase 1.0  (-2.4) (-1.2) 
Adhesion molecule, interacts with CXADR antigen 1 (-1.1) (-2.1) (-1.6) 
Polycystic kidney disease 2-like 1 (-1.1) (-2.1) (-2.1) 
 
Although FAM129B did not regulate cell growth and division, the deletion of 
FAM129B in melanoma cells significantly impaired B-raf/MEK/Erk-dependent 
invasion into extracellular matrix. MMP19 encodes for the metalloproteinase-19 
enzyme that was found to be involved in the breakdown of extracellular matrix, 
whereas TIMP3 encodes for the tissue inhibitor of metalloproteinase-3. It appeared 
that C5a might direct cellular movement to the target site by regulating the expression 
of MMP19 and TIMP3 in M-MΦ. 
 
3.5.7.6 Validation by real-time PCR 
 
Of all 147 genes (Appendix III), 18 genes (IL1B, TNF, CCL3, PTGS2, TLR7, 
TLR8, FABP5, LEP, FOSB, ATF3, EGR1, DUSP5, DUSP6, CD83, CD276, CTSL1, 
TIMP3 and MMP19) were selected for validation by real-time PCR. These genes 
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represented genes activated by C5a and are strongly implicated in inflammation, 
metabolism, signalling and chemotaxis in M-MΦ (Figure 3.16).  
 
 
Figure 3.16. C5a can affect genes involved in inflammation, metabolism, 
signaling, chemotaxis and cell cycle on M-MΦ. 
 
The directions of fold change were consistent in 17 out of 18 genes, with LEP 
gene being the only exception, validated with PCR against the result in the microarray 
(Figure 3.17).  
Although the magnitude of fold change for selected genes were mostly higher 
in real-time PCR experiments compared to that of microarray, this is not surprising as 
resolution is higher and more sensitive in real-time PCR. C5a has been long known to 
exert potent proinflammatory effects on immune cells. Here, genes that were 
drastically regulated by a single exposure of 30 nM C5a within the first 6 h returned 
to basal state after 18 h. It is expected that C5a can attribute very different profiles 
depending on whether it is an acute versus chronic exposure to C5a. Human 
macrophages (GM-MΦ and M-MΦ) will undergo a single exposure of C5a at 30 nM 
for 30 min in order to investigate the acute responses of C5a on primary human 
macrophages. 
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Figure 3.17. Correlation between microarray and real-time PCR expression. 
The set of column obtained by microarray (black) and real-time PCR (white), with 
three columns representing the duration of 30 nM C5a treatment in M-MΦ (1st 
column, 0.5 h; 2nd column, 6 h; 3rd column, 18 h). The dotted lines across the graph 
represented the 2-fold change threshold. Error bars represent mean ± SEM of three 
donors (n=3). 
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3.6 Discussion 
 
The complement system can be activated via three separate pathways to 
promote inflammatory responses, eliminate invading pathogens and enhance immune 
responses. Under physiological conditions, the concentrations of C5a are relatively 
low, promoting beneficial effects on the priming of neutrophils and monocytes as well 
as activating endothelial cells to support efficient innate immune responses against 
infection (6). However, C5a is like a double-edge sword in also causing immune 
paralysis of phagocytic cells due to excessive complement activation resulting in an 
overproduction of C5a (50). High levels of C5a can be detected in the serum of 
patients suffering with sepsis and can reach as high as 100 nM (14). Although the 
local concentration of C5a has not been determined, it is expected to be higher at the 
sites of infection and inflammation. Human C5a above 100 nM concentration has 
been show to induce apoptosis in freshly isolated thymocytes (15). Other lymphoid 
cells such as B and T cells had similar apoptotic responses when treated with such a 
concentration of C5a (16). With this in mind, C5a treatment concentrations for human 
primary macrophages (GM-MΦ and M-MΦ) had been optimized to be 30 nM, to 
investigate how C5a would physiologically exert its biological effects on these 
macrophages without activating death signals. 
C5a was previously reported to stimulate the synthesis and release of 
proinflammatory cytokines such as TNF and IL1β from human leukocytes, not 
specifically human macrophages (51). A common mistake in studying mRNA 
expression is that gene expression is informative in the prediction of protein 
expression, but this is more often than not the case (18, 52) and it is certainly not the 
case in this study here on human macrophages differentiated with GM-CSF or M-CSF 
from human CD14+ monocytes. C5a was found to readily upregulate IL1B and TNF 
mRNA expression in both human macrophages (GM-MΦ and M-MΦ) measured by 
microarray and PCR. However, their corresponding proteins were not detectable in 
the culture media of C5a-treated macrophages (data not shown). This observation is 
consistent with work reported by others (53, 54). C5a provided a transcriptional 
(gene) but not translational (protein), signal for IL1β and TNF in human peripheral 
blood mononuclear cells (54). So not surprisingly, majority of the genes regulated by 
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C5a in human macrophages were involved in the gene transcriptional network 
(Figure 3.12).  
Transcriptional regulation plays an important role in both differentiation and 
homeostasis (55, 56). Two of the major classes of regulatory elements are involved in 
transcriptional regulation by extracellular signals, the AP-1/TRE (57) and the 
ATF/CRE (58). The Fos gene family consists of 4 members namely, FOS, FOSB, 
FOSL1 and FOSL2. These genes encoded for the leucine zipper proteins that can 
dimerize with proteins of the JUN family (c-Jun, JunB and JunD) to form the 
transcription factor complex AP-1 or phorbol 12-O-tetradecanoate 13-actate (TPA) 
responsive element (TRE). The ATF/CRE element (TGACGTCA) was defined as the 
activating transcription factor (ATF) binding site or the cAMP responsive element 
(CRE). The ATF/CRE site is recognised by ATF or CRE binding protein (CREB) 
(59). ATF3 gene encodes a member of the activating transcription factor/cAMP 
responsive element binding protein (ATF/CREB) family, which is usually induced by 
physiological stresses. The Fos/Jun and ATF/CREB families were first thought to 
have distinct sets of transcription factors that share the same leucine zipper motif, and 
have different DNA binding specificities. This theory was later proven to be wrong 
(60). Members of the ATF/CREB family can form selective cross-family 
heterodimers with members of the Fos/Jun family to have distinguishable binding 
specificities in response environmental stimuli. This diversity increases the 
complexity in transcriptional regulation, which C5a can evidently manipulate to 
maintain balance between inflammatory responses and homeostasis. Interestingly, 
human umbilical vein endothelial cells could also activate EGR1 and ATF3 when 
stimulated with C5a but only after 2 h (7), as opposed to 0.5 h in human macrophages 
discovered in this study. Perhaps it is the different chronological pattern of gene 
activation observed in different cell types upon C5a stimulation that is key to the 
differential outcome of C5a-mediated effects across different cell types.  
The toll-like receptors and complement related proteins are the key innate 
defence systems in the body and the two systems were previously thought to function 
as separate entities. However recently, Hajishengallis et al reviewed the complement 
system and noted that TLR crosstalk reinforces innate immunity or regulates 
excessive inflammation, through synergistic or antagonistic interactions (61). This 
crosstalk is still not well investigated and there are many questions about the possible 
interplay between complement activation and TLR activation. Surprisingly, TLR7 and 
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TLR8 genes were downregulated in M-MΦ when stimulated with C5a. Chapter 5 has 
described the differential crosstalk observed between C5aR and TLR4 on human 
monocytes versus macrophages. It might be worth investigating if this TLR4/C5aR 
crosstalk could be extended further to TLR7 or TLR8. Understanding this interplay 
and its relationship to innate and adaptive immunity may uncover important new 
aspects of immunological stimulation and control as well as lead to validation of new 
targets for therapeutic regulation. 
 
3.7  Conclusions 
 
Macrophages have a ‘plastic’ gene expression phenotype that can change 
rapidly depending on the microenvironment and even lead to a switching of 
phenotype from M1 to M2 and vice versa (62). This is supported in Chapter 2 where 
GM-MΦ and M-MΦ were found to be quite different in their genotypes from each 
other. Their genotypic differences were shown to be greater than C5a treatment in the 
microarray experiment as calculated by distant matrix algorithms (Figure 3.7) and it 
is reasonable to expect that these two macrophage subtypes with large genomic 
differences (Chapter 2) would respond differently when stimulated by C5a (Chapter 
3). However, in this chapter it was found that genes stimulated by C5a were found to 
be at least 62% identical between GM-MΦ and M-MΦ.  
C5a was also found to exert similar effects on GM-MΦ and M-MΦ in different 
functional assays - calcium release, ERK phosphorylation and macrophage migration. 
More importantly, this study has provided important clues to the temporal role of 
C5a-induced gene expression in primary human macrophages. By identifying the 
cluster of genes activated by C5a, potential rate-limiting gene candidates may be 
identified for potential clinical intervention in C5a-mediated inflammatory disorders. 
Some of the genes found in this chapter to be highly responsive to C5a stimulation in 
human macrophages were used to compare three reported C5a ligands for their 
underlying antagonist mechanisms in Chapter 4.  
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4.1  Abstract 
 
Activation of complement produces a cascading network of plasma and 
membrane proteins that functions to rapidly identify, tag, lyse and quickly eliminate 
foreign and infectious organisms, as well as damaged cells, from the host, thereby 
contributing to immune defence. When the foreign stimulus cannot be removed 
quickly, the acute immune response is prolonged (sometimes for years) and 
complement proteins, such as C5a and its receptors, may be excessively expressed. 
Uncontrolled complement activation can cause many inflammatory and autoimmune 
disorders, leading to chronic inflammatory diseases and cancer. Potential therapeutics 
have been developed to target several complement proteins, but the only FDA 
approved treatment that targets C5a-C5aR interaction is a humanized antibody which 
actually binds C5 thereby preventing the formation of C5a as well as formation of the 
membrane attack complex that effects pathogen lysis. In this present study, three 
previously reported antagonists of human C5aR (W54011, JJ47 and 3D53) have been 
compared, with the goal of choosing one for further studies (Chapter 5) on synergistic 
effects of C5a on lipopolysaccharide action on macrophages and monocytes. All three 
antagonists were confirmed here as being potent antagonists (IC50 < 50 nM against 
0.1 nM human C5a). However, IC50 for a competitive (‘surmountable’) antagonist is 
dependent on the concentration of the competing agonist, so both W54011 and JJ47 
became antagonists at only µM concentrations when the concentration of C5a 
increased above 30 nM concentrations. By contrast, 3D53 is a non-competitive 
(“insurmountable”) antagonist that maintains its potency at low nM concentrations 
against 0.1 to 300 nM C5a. 3D53 had a much longer duration of action (t1/2 = 22 h) on 
human macrophages than W54011 (t1/2 = 1.2) or and JJ47 ( t1/2 = 0.6 h). 3D53 was not 
only superior to W54011 and JJ47 in an assay measuring intracellular calcium release, 
but also in a cell migration (chemotaxis) assay, where antagonist-treated macrophages 
were exposed to C5a for 16 h. Furthermore, orally administered 3D53 was an 
effective anti-inflammatory agent for up to 16h, compared to ≤ 2h for W54011 and 
JJ47, in inhibiting C5aR-mediated paw oedema in male Wistar rats, even though 
3D53 reportedly has low oral bioavailability and is rapidly cleared from blood while 
W54011 and JJ47 are reportedly much more orally bioavailable. The results highlight 
the fact that receptor affinity, antagonist potency, drug-likeness and oral 
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bioavailability of a ligand for its receptor are insufficient to define the effectiveness 
and duration of biological action. Rather, the lifetime of the binary receptor-ligand 
complex can be even more important in dictating drug efficacy in the cellular and 
organismal context. Based on the findings herein, 3D53 was selected for further study 
in Chapter 5. 
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4.2 Introduction 
 
Complement component C5a, is a potent chemotactic factor for neutrophils and 
other leukocytes (1). C5a exerts these activities by binding to a G-protein coupled 
C5a receptor (C5aR) (2), with a second receptor C5L2 of uncertain function also 
known (3), although this has largely been reported to be non-signalling and may play 
a secondary control role on levels of C5aR being accessible to ligands. C5aR 
expression has been traditionally thought to be limited primarily to myeloid blood 
cells, including neutrophils, monocytes, macrophages and eosinophils but recent 
evidence suggests it is more widely distributed to organs, including the liver, kidney 
and the central nervous system than previously thought (4-7). The effects of C5a-
C5aR interaction may also be involved in other biological functions besides immunity 
and inflammation. C5aR signalling has recently been linked to the development of 
obesity and metabolic dysfunction in rats (8) and may be important in cancer 
development (9-11). Clearly, C5a is not just another agent regulating inflammation 
and chemtaxis, although these are perhaps the best-documented functions to date.  
Complement operates in a non-specific manner, attacking both foreign as well 
as host cells if the latter are tagged for destruction. Complement activation is usually 
tightly regulated by host self-regulatory mechanisms during normal physiology 
condition. However, excessive complement activation can occur when the extent of 
activation exceeds the capacity of host mechanisms to regulate it, leading to an 
overproduction of C5a in circulation and, eventually, to many inflammatory and 
autoimmune disorders (12). As such, it is desirable to modulate complement 
activation by using therapeutic interventions such as inhibitors or antibodies. 
Antibodies that block the proteolysis of C5 to C5a and C5b (an early precursor to 
membrane attack complex) has been clinically validated and approved by the U.S. 
Food and Drug Administration (FDA) for treating paroxysmal nocturnal 
hemoglobinuria (13). However, protein as effective inhibitors are expensive to 
produce, difficult to formulate and can potentially trigger unwanted immunogenic 
side effects. The failure of anti-C5 mAb pexelizumab in clinical studies for treating 
acute myocardial infarction was found to be due to poor tissue penetration, leading to 
poor therapeutic efficacy. On the other hand, unlike proteins or antibodies, drug-like 
small molecules do not possess these disadvantages in therapeutic invention. 
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Although the mission towards complement therapeutics started over 30 years ago (14), 
there are still no small molecule drugs in the marketplace for targeting complement. 
C5aR has been demonstrated to be an important and promising therapeutic target for 
complement modulation (2). Efforts in developing C5aR antagonists have resulted in 
the discovery of different types of ligands, including antibodies, peptides, 
peptidomimetics and non-peptidic small molecules (2).  
Over the past two decades, a few potent small molecule C5aR antagonists have 
been reported with activity in various animal models and in humans (15). Despite 
such intensive efforts to develop an effective C5aR antagonist to market, this has not 
yet been achieved with pre-clinical and early stage clinical trials being thwarted by 
unexpected problems. Traditionally, drug discovery has focused on optimizing ligand 
affinity for a specific receptor, enhancing functional potency and selectivity, and 
improving drug-like properties for optimal pharmacokinetics and oral bioavailability. 
However, these optimization processes have not always led to optimal in vivo efficacy 
(16). Consequently, advancing drugs based on their simple in vitro potencies and 
affinities may not be sufficient high chances of clinical success and more 
sophisticated thinking needs to be brought to traditional drug design and development 
approaches to advancing compounds to market.  
This chapter highlights an important consideration, often overlooked or not 
given enough importance, in drug development – namely residence time for drug-
receptor interactions. Here, three potent C5aR antagonists described in literature were 
chosen for a comparative study to re-evaluate their intrinsic properties as antagonists 
on C5aR. The compounds were 3D53 (17), W54011 (18) and JJ47 (19).  
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The original cyclic peptide scaffold 3D53 was designed in our group from 
linear peptides, such as compound C089 (20), which was derived from the C-terminus 
of C5a through many years of peptide research at Abbott and then Merck. After many 
structure-activity relationship (SAR) studies, 3D53 was created by PhD student Allan 
Wong in the Centre for Drug Design and Development (3D Centre), University of 
Queensland in 1996. It was the first cyclic peptidomimetics C5aR antagonist and 
proved to be a potent and water-stable full antagonist of C5aR on human neutrophils 
(21). Eventually, 3D53 was licensed as PMX53 for clinical development by the now 
defunct Promics Ltd (subsequently passed on through a series of company takeovers 
to Peptech Pty Ltd, Arana Therapeutics Ltd, Cephalon Inc. and then in 2011 by 
TEVA Pharmaceutical Industries Ltd, which is the world’s largest manufacturer of 
generic pharmaceuticals (22).  PMX53 was safe and well tolerated in Phase I clinical 
trials, and 3D53 has been the most intensely evaluated small molecule C5aR 
antagonist in human clinical trials. 
W54011 was developed by Mitsubishi Pharma, and was the result of an 
optimized series of substituted phenylguanidines and tetrahydronapthalene-based 
compounds (18). W54011 was reported to be a competitive non-peptidic C5aR 
antagonist. Although Sumichika et al. did not report the percent oral bioavailability of 
W54011, the authors claimed that this antagonist was potent and orally active in vivo 
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(18). However, it is very hydrophobic and had problems with species specificity 
(active in human, cynomolgus monkey and gerbil but not as active in mouse, rat 
guinea pig, rabbit or dog neutrophils), which complicated pre-clinical studies (2).  
JJ47 was the most potent antagonist of a series of aniline-substituted 
tetrahydroquinoline compounds developed by Johnson & Johnson Pharmaceutical 
Research and Development, with C5aR antagonist activity at single-digit nanomolar 
concentrations in a calcium mobilization assay (19). Since W54011 and JJ47 are non-
peptidic antagonists of C5aR, they were not expected to have the disadvantages of 
peptidic ligands, for example, susceptibility to proteolytic cleavage in serum, low oral 
bioavailability as the result of hydrophillicity, and high molecular weights. Based on 
reported IC50 values, 3D53 appeared to be the least potent C5aR antagonist among the 
three antagonists, as well as with the least drug-like properties (Table 4.1). 
Furthermore, the former two compounds obey the rule-of-five (23, 24) prediction for 
oral bioavailability (hydrogen bond donors (HBD) ≤ 5, hydrogen bond acceptors 
(HBA) ≤ 10, LogP < 5, MW < 500), whereas 3D53 does not (Table 4.2). 
 
Table 4.1. Reported activity of 3D53, W54011 and JJ47 on human C5aR. 
Compound Antagonist IC50 (nM)+ 
Human C5a 
concentration 
(nM) 
Cell-types 
used 
Oral 
bioavailability 
(%) in rats 
3D53 55 
(18) 
20 (25) 
0.1 
100 
Human 
neutrophils 1 
(22) 
W54011 3 (18) 0.1 Human neutrophils N.D.
* 
JJ47 7 (19) 1.5 U937 21# (19) 
+Values are determined by calcium release versus stated hC5a concentration. 
*Presumably high, values not disclosed by the authors. #Pharmacokinetic study was 
derived from a represented compound of the same series. 
 
 
Table 4.2. Comparison of rule-of-five parameters of 3D53, W54011 and JJ47 
 3D53 W54011 JJ47 
HBD 12 0 2 
HBA 10 4 4 
CLogP 3.2 7.4 6.6 
MW 896.1 456.6 458.7 
Values that are bolded do not obey the rule-of-five prediction for oral bioavailability.  
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By these criteria, 3D53 would be expected to be least drug-like, least effective 
in vitro, and least effective given orally to animals. In summary, 3D53 is least drug-
like of these antagonists. 
 
4.3 Aims 
 
The overall objective of this chapter was to select the most appropriate C5aR 
antagonist for studies in Chapter 5. Three reported antagonists (3D53, W54011 and 
JJ47) with quite different chemical structures, comparable antagonist potency at low 
nanomolar concentrations, and oral activity in animals have been re-examined here 
for functional potency, drug-like potential and oral efficacy. The specific aims for this 
chapter were: 
1. To re-assess the reported antagonism by 3D53, W54011 and JJ47 using C5a-
induced calcium release in human macrophages. 
2. To investigate and compare the mechanisms of antagonism for the three 
antagonists. 
3. To compare properties of these antagonists using different in vitro assays. 
4. To compare these antagonists in C5a-induced inflammation in an animal 
model, thereby potentially relating in vitro observations to in vivo outcomes.     
 
4.4 Methods 
 
4.4.1 Reagents 
 
Recombinant human M-CSF was purchased from PeproTech (USA). 
Recombinant human C5a was purchased from Sino Biological Inc (China). C5aR 
antagonists (3D53 (26), W54011 (18) and JJ47 (19)) and C5a peptide agonist Ac-Phe-
Lys-Pro-D-Cha-Cha-D-Arg-OH (modified with an acetyl-capped on the N-terminus) 
(27) were synthesized and characterized (analytical HPLC, mass spectroscopy and 
nuclear magnetic resonance spectroscopy) in-house as described (18, 19, 26). All cell 
culture reagents were purchased from Invitrogen (Australia) and all analytical grade 
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chemical reagents were obtained from Sigma-Aldrich (Australia), unless otherwise 
stated.  
 
4.4.2 Animals 
 
The in vivo work was undertaken, on my behalf, by Mr Adam Cotterell 
(Institute for Molecular Bioscience, University of Queensland). Male Wistar rats (6-8 
wk, 250 ± 50 g) were bred at the Animal Resources Centre (Canning Vale, WA, 
Australia) and housed post-shipment at the Australian Institute for Bioengineering 
and Nanotechnology (University of Queensland, Brisbane, QLD, Australia). Animals 
were maintained in a 12-h light-dark cycle according to the standard of holding 
facility with food and water provided. Male Wistar rats were given 3D53 (5 mg/kg, 
n=3/group) or W54011/JJ47 (30 mg/kg, n=2/group) (p.o. via gavage in olive oil, 500 
µL) prior to C5aR peptide agonist (C5aR-PA) administration. Control animals 
received only olive oil (500 µL p.o.). After specific time-points, C5aR-PA was 
administered into the right hind paw pad (350 µg in saline, 100 µL, i.pl). The left hind 
paw acted as a control, receiving saline only (100 µL). Paw thickness and widths were 
measured at 1 h post-injection using digital callipers (World Precision Instruments, 
Sarasota, FL, USA) and swelling was expressed as area (mm2; thickness x width) and 
plotted as percentage change from baseline of each individual paw. The animal ethics 
committee of The University of Queensland approved all experiments performed in 
this study. 
 
4.4.3 Isolation of human monocytes and macrophages 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats 
of anonymous donors (Australian Red Cross Blood Service, Kelvin Grove, 
Queensland, Australia) by density centrifugation using Ficoll-Paque Plus (GE 
Healthcare) manufacturer’s instructions. Contaminating erythrocytes were removed 
by repeated ice-cold sterile water. CD14+ MACS® microbeads were used to 
positively select monocytes from isolated PBMCs according to manufacturer’s 
instructions (Miltenyi Biotec). CD14+ monocytes were seeded at 1 x 106 cells/mL in 
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IMDM supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin 
and 2 mM GlutaMAX at 37 °C in presence of 5% CO2. To generate human 
monocyte-derived macrophages (HMDM), CD14+ monocytes were cultured in the 
presence 10 ng/mL M-CSF for at least 6 days. 
 
4.4.4 Isolation of rat bone marrow cells and macrophages  
 
Bone marrow cells (BMC) were aseptically eluted from excised rat femurs by 
injecting vigorously with RPMI medium through the bone marrow cavity. 
Contaminating erythrocytes were removed by repeated ice-cold sterile water. BMC 
were seeded at 1 x 106 cells/mL in RPMI supplemented with 10% FBS, 100 U/mL 
penicillin, 100 µg/mL streptomycin and 2 mM GlutaMAX at 37 °C in presence of 5% 
CO2. To generate rat bone marrow-derived macrophages (BMM), BMC were cultured 
in the presence 10 ng/mL M-CSF for at least 6 days. 
 
4.4.5 Intracellular calcium mobilization assay 
 
HMDM were seeded at 0.5 x 106 cells/mL (100 µL) in black-wall, clear-
bottom 96-well plates (Corning) and incubated at 37 °C in the presence of 5% CO2 
overnight for cells to adhere. Cells were washed once with assay buffer (Hank’s 
buffered salt solution (HBSS), 20 mM HEPES, 2.5 mM probenecid, pH 7.4). 100 µL 
of dye-loading buffer (12 mL of assay buffer, 1% FBS, 25 µL of Fluo-3AM 
(Invitrogen) (final concentration = 4 µM), 25 µL 20% pluronic acid) was added to 
each well and incubated for 1 h at 37°C. Excess loading dye was washed away with 
assay buffer before adding 50 µL of tested compound. Fluorescence intensity was 
recorded with on FLIPR Tetra (Molecular Devices) with excitation and emission 
wavelengths of 485 nm and 520 nm respectively. Calcimycin ionophore A23187 (25 
µM) (Sigma) is used as a dye loading positive control. 
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4.4.6 Quantification of ERK1/2 phosphorylation by AlphaScreen Surefire 
 
Cells were seeded at 4000 cells/well in white 384-ProxiPlate (PerkinElmer) 
overnight. On the following day, media was removed from the cells and were serum-
deprived for 2 h to reduce basal ERK1/2 activity, prior to stimulation with C5a over a 
stated time course. Cells were lysed with Alphascreen SureFire lysis buffer, with 
shaking for 10 min at room temperature and assayed for phosphor-ERK1/2 
(phosphor-Thr202/Tyr204) according to Alphascreen SureFire assays (PerkinElmer) 
manufacturer’s instructions. At completion of the assay, signal in the wells was 
measured using Pherastar (BMG Labtech). 
 
4.4.7 In vitro migration assay (modified Boyden chamber) 
 
Migration of human macrophages was measured in a modified Boyden 
chamber migration assay using Transwell inserts with a 5 µm porous membrane 
(Corning). Cells were loaded into the migration chamber in serum free medium. To 
initial cell migration, serum free medium was placed in the lower chamber. At the end 
of the time course study, cells were removed from the upper side of the membranes, 
and nuclei of migratory cells on the lower side of the membrane were stained with 
DAPI. And counted under a fluorescence microscope using a x10 objective. 
    
4.4.8 RNA extraction and reverse transcription 
 
Total RNA was extracted from cells using an RNeasy Mini Plus kit (Qiagen) 
and following manufacturer’s instruction. RNA concentrations were determined by 
measuring absorbance at λ = 260/280 nm on a spectrophotometer. Total RNA (2-10 
µg) extracted from cells and random oligo dT primer (1 µg) were initially incubated 
at 70°C for 10 min and then cooled on ice for at least 1 min before being reverse 
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transcripted with Superscript III (Invitrogen) at 50°C for 50 min, then 70°C for 10 
min. cDNA samples were stored at -20°C until further use.  
 
4.4.9 Real-time quantitative polymerase chain reaction (real-time qPCR) 
 
Gene-specific primers were designed using the free web-based software 
Primer-BLAST National Center for Biotechnology Information (NCBI). Quantitative 
real-time PCR was performed using an ABI Prism 7900 real-time PCR system 
(Applied Biosystems), cDNA (50 ng), SYBR® Green PCR master mix (Applied 
Biosystems) and gene-specific primers. Conditions were used according to the 
manufacturer’s instructions. Relative gene expression was normalised against 18S 
rRNA expression and then converted to fold change against control samples. All 
samples were analysed in duplicates. Primer sequences used are: ATF3, 5’-
CGAGCGGAGCCTGGAGCAAA-3’ and 3’-GGGGACAGGCAGGGGACGAT-5’; 
TNF, 5’-TCTGGCCCAGGCAGTCAGATC-3’ and 3’-
CACTGGAGCTGCCCCTCAGC-5’; IL1B, 5’-
CCTCTTCGAGGCACAAGGCACAA-3’ and 3’-
TGGCTGCTTCAGACACTTGAGCAAT-5’; CCL3, 5’-
CCCACATTCCGTCACCTGCTCAG-3’ and 3’-
AGCAGCAAGTGATGCAGAGAACTG-5’; PTGS2, 5’- 
TGGCAGGGTTGCTGGTGGTA-3’ and 3’-TCTGCCTGCTCTGGTCAATGGA-5’; 
18S, 5’-ACCACGGGTGACGGGGAATC-3’ and 3’- 
CCGGGTCGGGAGTGGGTAAT-5’. 
 
4.4.10 Statistical analysis 
 
Data were plotted and analysed using GraphPad Prism version 5.0c for Mac OS 
X (GraphPad Software). Statistically significant differences were assessed using 
student’s t-test for paired comparison. All values of independent parameters are 
shown as mean ± SEM of at least three independent experiments, unless otherwise 
stated. Significance was set at *p < 0.05, **p < 0.01 and ***p < 0.001. 
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4.5 Results 
 
4.5.1 3D53, a potent and non-competitive C5aR antagonist 
 
3D53, W54011 and JJ47 were reported to be potent human C5aR ligands with 
low nanomolar antagonism activity (18, 19, 25). However, antagonism was measured 
under different assay conditions, making it is difficult to draw comparisons from 
previously reported data. For example, 3D53 and W54011 were evaluated with 
human neutrophils, whereas JJ47 was evaluated with human monocytic cell line U937. 
The reported IC50 values were also derived from experiments using different 
concentrations of human C5a, whereas this parameter is usually dependent on the 
concentration of agonist being measured against.  
A comparative study between 3D53, W54011 and JJ47 was therefore 
conducted here, so that these antagonists could be directly compared and ranked for 
antagonist properties. Since these compounds are structurally different, the 
mechanism of the antagonism for 3D53, W54011 and JJ47 against human C5a was 
also investigated in a C5a-induced intracellular calcium release assay using human 
macrophages. The concentration-response curves for Ca2+ mobilization induced by 
C5a were determined in the presence of increasing concentrations of the three 
antagonists (Figure 4.1). A reduction of the maximal C5a responses was observed as 
concentrations of 3D53 increased, but there was no sideways rightward displacement 
of the curve typical of a ‘competitive’ antagonist, suggesting that 3D53 is an 
insurmountable C5aR antagonist (Figure 4.1A). However, W54011 and JJ47 both 
shifted rightward the concentration-response curves for C5a-induced calcium release 
in human macrophages, without depressing the maximal responses, indicating that 
both were competitive antagonists (Figure 4.1B, C). Furthermore, the Schild plot or 
pA2 analysis revealed that the slope of the regression was not 1.0 for 3D53 (Figure 
4.1D), which by definition is classified to be non-competitive (28). On the other hand, 
the slope of regression for W54011 (Figure 4.1E) and JJ47 (Figure 4.1F) was ~1, 
consistent with W54011 and JJ47 being competitive antagonists with antagonist IC50 
dependent on the concentration of C5a being measured against. Although these 
observations were consistent with previously reported data for 3D53 (25) and 
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W54011 (18) on neutrophils, the mechanism of antagonism for JJ47 was previously 
unknown, nor were Schild plots reported previously. 
 
 
Figure 4.1. Mechanism of C5aR antagonism for 3D53, W54011 and JJ47 against 
human C5a. 
Concentration dependent responses of C5a with treatment of antagonist (A) 3D53, (B) 
W54011 and (C) JJ47 at various concentration (0 nM, ; 3 nM, ¢; 10 nM, p; 30 
nM, ¿; 100 nM, Â; 300 nM, q; 1000 nM, ê) with C5a (300 nM) as 100% response 
in human macrophages. Schild plots for antagonists (D) 3D53, (E) W54011 and (F) 
JJ47 against human recombinant C5a. Calculated pA2 values for 3D53, W54011 and 
JJ47 are 8.3, 8.6 and 8.3 respectively. Error bars are means ± SEM of three 
independent experiments (n=3). 
 
Since IC50 values for the insurmountable antagonist 3D53 were independent of 
the concentration of agonist, in this case the C5a concentration, 3D53 still maintained 
its antagonistic potency at low nanomolar concentrations even in the presence of 
concentrations of C5a as high 300 nM (Figure 4.2A). On the other hand, W54011 lost 
its nM antagonist activity at 100 nM C5a (Figure 4.2B), with the even less potent 
JJ47 losing its nM antagonist potency at just 10 nM C5a (Figure 4.2C). Although 
these antagonists were previously reported to be potent activity at low nM 
concentrations, clearly these reported IC50 values are only of this magnitude at very 
low concentrations of C5a. W54011 and JJ47 are not truly potent antagonists under 
changing physiological conditions, where local concentrations of C5a are expected to 
be higher than 0.1 nM during inflammation (29, 30). 
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C5a 3D53 W54011 JJ47 
(nM) pIC50 ± SEM IC50 (nM) pIC50 ± SEM IC50 (nM) pIC50 ± SEM IC50 (nM) 
300 7.8 ± 0.1 17 5.8 ± 0.9 1456 6.0 ± 0.9 1071 
100 7.9 ± 0.1 14 6.5 ± 0.4 350 6.2 ± 0.4 632 
30 7.8 ± 0.2 15 7.3 ± 0.2 55 6.3 ± 0.4 509 
10 8.0 ± 0.3 11 7.6 ± 0.2 24 6.9 ± 0.2 122 
3 8.5 ± 0.5 3 8.1 ± 0.3 9 8.0 ± 0.2 10 
1 8.5 ± 1.0 3 8.4 ± 0.6 4 8.8 ± 0.7 2 
Figure 4.2. Antagonist potencies (IC50) and dependence on C5a concentration. 
Inhibitory responses of antagonist (A) 3D53, (B) W54011 and (C) JJ47 against 
various concentration of C5a (300 nM, ; 100 nM, ¢; 30 nM, p; 10 nM, ¿; 3 nM, 
q; 1 nM, ê) with C5a (300 nM) inducing 100% relative response in human 
macrophages. Calculated pIC50 ± SEM and IC50 values of the three C5aR antagonists 
were summarized in the table against concentration of C5a. Error bars are means ± 
SEM of three independent experiments (n=3). 
 
4.5.2 3D53 has a longer residence time than W54011 and JJ47 
 
Residence time in biochemistry is usually determined by measuring ‘on’ and 
‘off’ rates for affinity, but this is more difficult to measure on cell surfaces. An 
indication of residence was instead determined for the three C5aR antagonists by 
incubating human macrophages in a saturating concentration of each antagonist (1 
µM) for one hour, the cells washed to remove unbound ligands, and the treated cells 
were challenged with C5a at EC50 concentration (3 nM), as determined in chapter 3, 
and observed at the stated times. If the ligand was still associated with the receptor, 
C5a did not trigger intracellular calcium release and there was no fluorescence 
response. It appeared that competitive antagonists W54011 and JJ47 had very short 
half-lives for duration of antagonist action, 1.2 h and 0.6 h respectively (Figure 4.3A). 
On the other hand, 3D53 had a much longer duration of action, t1/2 = 18.2 h (Figure 
4.3B).  
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C5aR Antagonist Half-life t1/2 ± SEM (h) 
3D53 18.2 ± 4.1 
W54011 1.2 ± 0.3 
JJ47 0.6 ± 0.2 
 
Figure 4.3. 3D53 has a longer residence time on human C5aR compared to 
W54011 and JJ47.  
Cells were pre-treated with 1 µM C5aR antagonist () 3D53, (p) W54011 and () 
JJ47 for 1 h. Excess unbound antagonists were removed by washing. (A, B) 
Antagonist residence time on C5aR was determined by subjecting treated cells to 3 
nM C5a during the stated duration post antagonist-treatment. Calculated half-life for 
3D53, W54011 and JJ47 are 18.2 h, 1.2 h and 0.6 h respectively. Error bars are means 
± SEM of three independent experiments (n=3). 
 
4.5.3 C5a-induced chemotaxis is efficiently blocked by 3D53 but not 
W54011 and JJ47  
 
Insurmountable antagonism implies that the off-rate of the antagonist from the 
receptor-binding site is so slow that a true equilibrium between the agonist and 
antagonist on the receptor cannot be attained in the short timeframe of the calcium 
release assay. Therefore, a more stringent assay was performed to report on the 
surmountability of the antagonists. The chemotaxis migration assay, in which cells 
migrate along an agonist concentration gradient due to agonist-receptor interaction, is 
a more stringent test than the calcium release assay. This is because antagonist-treated 
macrophages are now exposed to C5a for 16 h continuously instead of for 5 min at 
different intervals. Antagonists with a fast off-rate will be inefficient in this assay 
because, once the antagonist has dissociated, C5a immediately activates the cells and 
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induce migration. Human macrophages were stimulated with C5a at EC80 
concentration (3 nM) to induce cell migration (as described in Chapter 3). 
While 3D53 was able to block C5a-induced migration, W54011 and JJ47 were 
not even at 1 µM concentrations (Figure 4.4). C5a is one of the most potent 
endogenous agents known to induce chemotaxis of immune cells. Since the 
antagonists W54011 and JJ47 failed to block chemotaxis, a primary function of C5a, 
of macrophages, one may wonder if these antagonists can be functional in an in vivo 
setting. 
 
 
Figure 4.4. Comparative antagonism of human macrophage migration (induced 
by 3 nM rhC5a) by 0.1 µM and 1 µM 3D53, W54011 and JJ47. 
Human macrophages were serum-deprived overnight prior to addition to the upper 
chamber of the Transwell and then allowed to migrate through the 0.5µm porous 
membrane into the lower chamber containing serum free media with or without 3 nM 
C5a for 16 h. For antagonism of C5aR, cells were treated with 3D53 (0.1 or 1 µM), 
W54011 (0.1 or 1 µM) or JJ47 (0.1 or 1 µM) for 1 h. Unbound antagonists were 
washed away prior to stimulation with 3 nM human recombinant C5a. Migrated cells 
on the lower side of the membrane were stained with DAPI and counted under a 
fluorescence microscope using a x10 objective. Chemotactic index is expressed as 
fold change against control.  Error bars are means ± SEM of three independent 
experiments (n=3). ***p < 0.001 by student t-test. 
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4.5.4 C5aR-PA is a selective peptidic agonist of C5aR at low micromolar 
concentration 
 
The activities of C5a can be modulated by the enzyme carboxypeptidase, 
which rapidly metabolizes C5a to C5adesArg in serum within seconds by removing 
the C-terminal arginine that is important for binding to C5aR (31). C5adesArg has a 
10-1000 times reduced potency compared to C5a depending the function being 
measured (32). It is technically not feasible to establish a C5aR-induced inflammatory 
rat model using recombinant C5a protein due to this degradation, not to mention too 
costly. Interestingly, only 8 residues of the C-terminus of C5a are responsible for its 
agonist activity on C5aR, although the remainder of C5a is crucial for high affinity 
binding and thus agonist potency (33). A previously reported C5aR agonist peptide, 
Phe-Lys-Pro-DCha-Cha-DArg-OH, was developed based on the C-terminus of C5a 
(34). Peptides are generally not stable because proteolytic enzymes recognize their 
random or strand like conformations in water (35), but by incorporating D-residues, 
N-methyl substitutents or acetylating the N-terminus increases stability to proteolytic 
degradation (36, 37). Ac-FKP-dChaCha-dR-OH (referred to now as C5aR-PA), is an 
agonist of C5aR and was used here as a cheaper and more feasible tool to induce 
C5aR-mediated paw oedema in rats, and for comparing the effectiveness of 3D53, 
W54011 and JJ47 as antagonists of C5aR-induced paw oedema in rats. 
C5aR-PA was previously reported to be selective for C5aR over C5L2 (27), 
but it was unclear whether it non-specifically bound to C5aR. First generation peptide 
agonists for C5aR were notorious for also binding to C3aR (38), despite the latter 
having only 37% sequence identity to C5aR (39). The desensitization calcium assay 
was setup to investigate the selectivity of C5aR-PA for C5aR, over other GPCRs 
capable of also inducing calcium release upon activation. The first addition of rhC5a 
at 1 µM was sufficient to desensitize all C5aR present on human macrophages 
(Figure 4.5A). These cells were then no longer responsive to additional C5a, as 
shown by the absence of a second spike in the fluorescence corresponding to a 
calcium signal. However, a second spike was present when these C5aR-desensitized 
cells were exposed to 1 µM C3a, suggesting that other GPCRs can still be readily 
activated upon stimulation if the second compound is not specific for C5aR (Figure 
4.5B).  
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Agonist pEC50 ± SEM EC50 (nM) 
C5a 8.7 ± 0.1 2.2 
C5aR-PA 7.1 ± 0.1 82.9 
 
Figure 4.5. C5aR-PA is a selective C5aR peptide agonist at low µM concentration. 
Desensitization assays were performed with 1 µM C5a at t0 to desensitize C5aR on 
human macrophages. (A) Cells were challenged with 1 µM C5a at t920 to confirm 
C5aR desensitization. (B) Cells were challenged with 1 µM C3a at t920 to confirm that 
the cells is still capable of inducing calcium release when other receptors are activated. 
(C) Cells were challenged with 1 µM C5aR-PA at t920 to confirm ligand selectivity to 
C5aR. (D) Calcium release in macrophages was induced by various concentration of 
(¢) C5aR-PA or () C5a. (E) For antagonism of C5aR, cells were pretreated with 
3D53, W54011 and JJ47 (1 µM, 30 min) prior to 300 nM C5aR-PA stimulation. Cells 
treated with calcimycin (25 µM) were used as a dye-loading control. Error bars are 
means ± SEM of four independent experiment (n=4). ***p < 0.001 by student t-test. 
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This was an important control because there was a possibility that the cells 
could have been depleted of cytosolic calcium released from the ER as the result, 
these cells are no longer able to trigger calcium release upon activation of other 
GPCRs. The desensitization assay revealed that the C5aR-PA was selective for C5aR 
at 1 µM concentration (Figure 4.5C), but not above 10 µM as shown by a second 
calcium signal spike (Figure 4.5D). It is possible that C5aR-PA may therefore bind 
non-specifically to C3aR and other GPCRs at concentrations above 1 µM on human 
macrophages. C5aR-PA treatment above 1 µM on human macrophages should thus be 
avoided to trigger C5aR specific responses. C5aR-PA was also ~40-fold less active 
than C5a in the calcium release assay on human macrophages (Figure 4.5E). C5aR-
PA is more stable in serum, which means that it is also more biologically active and 
will be inducing a stronger and sustainable C5aR-mediated response in vivo compared 
to its native C5a protein. C5aR-PA mimics the C-terminus of the native C5a protein, 
which is responsible for the binding and activation of C5aR signalling. Given that 
3D53, W54011 and JJ47 were able to block C5aR-PA-induced calcium release in 
human macrophages (Figure 4.5F), these antagonists likely bind similarly to C5aR-
PA. Although there is no structural evidence in the literature describing where and 
how these antagonists bind, the results here shed some insights on which pockets 
within the C5aR helical-transmembrane domain these antagonists might interact. 
 
4.5.5 C5aR-induced ERK phosphorylation in human and rat macrophages 
 
After validating C5aR-PA as a suitable agonist substitute for the native C5a 
protein, as a tool to examine C5aR mediated responses in human macrophages, this 
section was aimed at determining whether C5aR-PA was mimicking the effect of C5a 
in inducing C5aR-mediated responses in rats, as shown earlier in vitro for human 
macrophages.  
To monitor C5aR activation, C5aR-PA and human C5a (up to 300 nM) were 
first examined on rat macrophages differentiated from rat bone marrow cells. 
However, neither agonist was able to induce calcium release (data not shown). 
Another pathway related to GPCR signalling, ERK phosphorylation, was therefore 
monitored since human C5a able to induce ERK phosphorylation in rat macrophages 
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(Figure 4.6). Although human C5a was ~15-fold less potent on rat C5aR compared to 
human C5aR on macrophages in the ERK phosphorylation assay.  
 
 
Species of 
Macrophages pEC50 ± SEM EC50 (nM) 
Human 8.6 ± 0.3 2.8 
Rat 7.3 ± 0.4 41.8 
 
Figure 4.6. C5a-induced ERK phosphorylation in human and rat macrophages. 
ERK1/2 phosphorylation in Human-MΦ (¢) and Rat-MΦ () was induced by 
various concentrations of recombinant human C5a. Cells were treated for 5 min and 
lyzed to stop C5a-induced reaction. Phosphorylated ERK1/2 was measured by 
AlphaScreen® SureFire® assays. Error bars are means ± SEM of three independent 
experiments (n=3). 
 
4.5.6 Antagonism of C5a- and C5aR-PA- induced gene expressions in 
human and rat macrophages 
 
A panel of genes (ATF3, TNF, IL1B, CCL3 and PTGS2) was next chosen to 
monitor C5aR-induced mRNA expression upon activation by C5a and C5aR-PA. C5a 
substantially amplified these 5 genes after 30 min exposure, as evidenced in 
microarray studies in chapter 3. Both human and rat macrophages were treated with 
C5a and C5aR-PA (at EC90 concentration) to induce C5aR-mediated gene expression. 
EC90 values of C5a and C5aR-PA were calculated from the concentration-dependent 
 170 
curves for calcium release (Figure 4.5D) and ERK phosphorylation (Figure 4.6) 
assays for human or rat macrophages. All three antagonists efficiently blocked C5a-
induced ATF3, TNF, IL1B and PTGS2 gene expressions at 1 h post-antagonism 
(Figure 4.7A-C,E), and W54011 and JJ47 to a lesser extent blocked C5a-induced 
CCL3 gene expressions (Figure 4.7D). However, at 16 h post-antagonism, while 
3D53 still antagonized C5a-mediated gene expressions, W54011 and JJ47 did not 
(Figure 4.7F-J). This is consistent with the antagonists W54011 and JJ47 having 
much shorter durations of action due to much shorter residence times on C5aR, being 
completely displaced from the receptor well within 16 h.  
As expected, the magnitude of gene expression induced by 10 nM C5a 
(Figure 4.7) and 300 nM C5aR-PA (Figure 4.8) appeared to be very similar, thereby 
reaffirming the accuracy and reproducibility of the EC90 values translated from the 
calcium release assay to PCR. Mirroring the results obtained from the three 
antagonists against C5a, all three antagonists also efficiently blocked C5aR-PA-
induced gene expressions ATF3, TNF, IL1B and CCL3 (Figure 4.8A-D), and again 
W54011 and JJ47 to a lesser extent blocked C5aR-PA-induced PTGS2 gene 
expression (Figure 4.8E). Both W54011 and JJ47 were ineffective at blocking C5aR-
PA-induced gene expression after 16 h post-antagonism, whereas 3D53 maintained its 
antagonist effect even at this time point (Figure 4.8F-J). The effectiveness of 3D53, 
W54011 and JJ47 in blocking C5a-induced and C5aR-PA-induced gene expression 
thus correlated well with their respective residence times inferred by the results of 
Figure 4.3 reported for human macrophages. 
The magnitude of response for gene expression induced by human C5a and 
C5aR-PA on rat macrophages was surprisingly more modest (Figure 4.9A-E), even 
though these macrophages were treated at EC90 concentrations as determined in the 
ERK phosphorylation assay (Figure 4.6). Since C5aR-PA did not manage to induce a 
large response in rat macrophages, antagonism of 3D53 and W54011 and JJ47 were 
measured against 100 nM C5a. At 1 h post-antagonism, all three antagonists blocked 
gene expression induced by human C5a on rat macrophages (Figure 4.9F-J). Most 
importantly, all three antagonists were able to recognize C5aR expressed on the cell 
surface of the rat macrophages and blocked responses mediated by human C5a. 
Therefore, it was feasible to compare 3D53, W54011 and JJ47 in vivo using rats as 
the choice of animal model.  
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Figure 4.7. Comparative antagonism of C5a-induced gene expressions in human 
macrophage by 3D53, W54011 and JJ47 at 1h versus 16 h post-treatment. 
Human macrophages were treated with 10 nM C5a and cells are lysed after 30 min to 
stop the reaction. For antagonism of C5aR, cells were pretreated with 1 µM 3D53, 
W54011 or JJ47 for 1 h. Excess unbound antagonists were removed by washing and 
subjected to C5a treatment after (A-E) 1 h or (F-J) 16 h post-treatment with 
antagonist. The expressions of (A,F) ATF3, (B,G) TNF, (C,H) IL1B, (D,I) CCL3 and 
(E,J) PTGS2 were detected by quantitative real-time PCR, normalized against 18S 
rRNA and converted to fold change relative to control (untreated). Error bars are 
means ± SEM of three independent experiments (n=3). **p < 0.01 and ***p < 0.001 
by student t-test. 
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Figure 4.8. Comparative antagonism of C5aR-PA-induced gene expressions in 
human macrophage by 3D53, W54011 and JJ47 at 1h versus 16 h post-treatment. 
Human macrophages were treated with 300 nM C5aR-PA and cells are lysed after 30 
min to stop the reaction. For antagonism of C5aR, cells were pretreated with 1 µM 
3D53, W54011 or JJ47 for 1 h. Excess unbound antagonists were removed by 
washing and subjected to C5aR-PA treatment after (A-E) 1 h or (F-J) 16 h post-
treatment with antagonist. The expressions of (A,F) ATF3, (B,G) TNF, (C,H) IL1B, 
(D,I) CCL3 and (E,J) PTGS2 were detected by quantitative real-time PCR, 
normalized against 18S rRNA and converted to fold change relative to control 
(untreated). Error bars are means ± SEM of three independent experiments (n=3). *p 
< 0.05, **p < 0.01 and ***p < 0.001 by student t-test. 
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Figure 4.9. Comparing C5aR-PA- and C5a- induced gene expressions in rat 
macrophage and antagonism of C5a responses by 3D53, W54011 and JJ47 at 1h 
post-treatment. 
Rat macrophages were treated with (A-E) 0.1 µM C5a or (F-J) 0.3 µM C5aR-PA and 
cells are lysed after 30 min to stop the reaction. For antagonism of C5aR, cells were 
pretreated with 1 µM 3D53, W54011 or JJ47 for 1 h. Excess unbound antagonists 
were removed by washing and subjected to C5a treatment after (A-E) 1 h post-
treatment with antagonist. The expressions of (A,F) ATF3, (B,G) TNF, (C,H) IL1B, 
(D,I) CCL3 and (E,J) PTGS2 were detected by quantitative real-time PCR, 
normalized against 18S rRNA and converted to fold change relative to control 
(untreated). Error bars are means ± SEM of four independent experiments (n=4). *p < 
0.05, **p < 0.01 and ***p < 0.001 by student t-test. 
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4.5.7 Comparing 3D53, W54011 and JJ47 in C5aR-PA-induced rat paw 
oedema  
 
The experiments in this section were carried out by research assistant Mr 
Adam Cotterell (University of Queensland), who performed all the Wistar rat 
experiments here under my direction and at my request.  
Since C5aR-PA did not induce large enough responses in the PCR 
experiments on rat macrophages but C5a did, a pilot study was conducted to 
determine whether C5aR-PA was able to induce an inflammatory response in male 
Wistar rats. The left hind paw was given 100 µL saline as baseline control to the right 
hind paw which was given 350 µg C5aR-PA in 100 µL saline. Both hind paw 
thickness are recorded over 4 h duration. The maximal swelling induced by 350 µg 
C5aR-PA was recorded at 1 h and started to subside after 4 h post-injection (Figure 
4.10A). Higher amount of C5aR-PA (1 mg and 2 mg) did not further increase the 
magnitude of paw swelling, therefore the optimized amount of C5aR-PA injected per 
paw was 350 µg. To antagonize C5aR-PA-induced paw swelling, 5 mg/kg and 10 
mg/kg 3D53 were given orally with 500 µL olive 1 h prior to C5aR-PA injection. 
Treatment with 3D53 at 5 mg/kg reduced paw swelling by ~30% (Figure 4.10B), 
with no greater effect at 10 mg/kg, and the reduction in swelling was sustained after 2 
h post-injection of agonist.  
On the other hand, W54011 at 5 mg/kg did not block C5aR-PA-induced paw 
swelling (Figure 4.10C). Even at 10 mg/kg, W54011 did not appear to have an effect 
until 1h post-injection but the antagonist effect was quickly lost by 2 h post-injection 
(Figure 4.10C). W54011 has been reported to block C5a-induced gerbil neutropenia 
with concentrations ranging 3-30 mg/kg (18). Since W54011 at 10 mg/kg did not 
appear to have much effect, the dose was increased to 30 mg/kg for the next study. No 
in vivo data for JJ47 was available, so rats were treated at the same dose as W54011 
(30 mg/kg). Thus the comparison in vivo experiment involved Wistar rats given 3D53 
at 5 mg/kg/p.o. (Figure 4.10C), W54011 and JJ47 at 30 mg/kg/p.o. (Figure 4.10D,E), 
all 1 h prior to intraplantar injection into rear paws with the inflammogen, 350µg 
C5aR-PA. 
At 30 min post-injection, W54011 was more effective than 3D53 and JJ47 
with 35% reduction in paw swelling (Figure 4.10E). However, W54011 lost its 
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antagonist activity after 2 h. Even though 3D53 was only given at 5 mg/kg, compared 
to W54011 and JJ47 at 30 mg/kg, the antagonist effect on paw swelling was 
maximally sustained from 2-16 hours (Figure 4.10D). Interestingly, JJ47 only caused 
15% reduction in paw swelling at 30 min (Figure 4.10F), its antagonist effect (albeit 
weak) lasting for 2 h, or 4 times longer than W54011. Clearly, 3D53 was a far 
superior antagonist of C5aR-mediated paw inflammation than the other two 
compounds. 
 
 
Figure 4.10. Evaluating antagonism of 3D53, W54011 and JJ47 on C5aR-PA-
induced paw oedema in male Wistar rats (courtesy of Mr Adam Cotterell, 
University of Queensland). 
Optimization for C5aR-PA-induced paw oedema in male Wistar rats were performed 
by (A) intraplantar (i.pl.) administration of C5aR-PA (0.35-2 mg per paw in 100 µL 
of saline control). Paw swelling (% area change from baseline) was recorded over 4 h 
duration. Both (B) 3D53 and (C) W54011 (5 and 10 mg/kg, p.o. in 500 µL olive oil 
per rat) given orally 1 h prior 350 µg C5aR-PA injection (n=2 per group). To 
determine the in vivo residence time of (D) 3D53 (5 mg/kg, p.o., n=3 per group), (E) 
W54011 (30 mg/kg, p.o., n=2 per group) and (F) JJ47 (30 mg/kg, p.o., n=2 per group) 
were given orally 1 h prior 350 µg C5aR-PA injection at the specific time-points post-
antagonism. Error bars are means ± SEM normalized to maximal swelling of saline 
control. *p < 0.05, **p < 0.01 and ***p < 0.001 by student t-test. 
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4.6 Discussion 
 
Complement activation ultimately leads to the generation of the potent 
chemoattractant C5a, which interacts with the receptors C5aR and C5L2, activating 
important signaling pathways that are crucial for pathogenic defence and maintaining 
immune homeostasis. However, when C5a is excessively generated as the result of an 
overly active immune system, one strategy to control its effects without 
compromising formation of C5b and the pathogen-removing membrane attack 
complex, is to bind a masking ligand (antagonist) to C5aR (or possibly C5L2). One 
approved therapeutic for modulating complement is an anti-C5 antibody, but this 
prevents formation of C5b as well as C5a and thus compromises formation of C5b-
derived membrane attack complex (MAC). Besides disabling the most important 
function of the complement system, formation of MAC, biologics are extremely 
expensive with poor bioavailability and poor tissue penetration, rendering it 
impossible for treating chronic inflammatory diseases, which requires repeated dosing.  
Intensive efforts have been made to develop C5aR antagonist for over two decades 
but the success rate of a candidate drug moving to the pre-clinical development phase 
has been disappointingly low. Three previously reported antagonists of C5aR, 3D53, 
W54011 and JJ47 have been re-evaluated here. Although all antagonists were 
reported to have low nanomolar antagonist properties against C5a under a defined set 
of conditions, results in this chapter have shown the danger of making such as 
conclusion and uncovered important reasons for the failure of W54011 and JJ47 in 
clinical trials. 
First, a key point often overlooked is that IC50 is a concentration-dependent 
term. Thus reports of IC50 for antagonists can only be compared against the same 
concentration of agonist on the same cell type under identical experimental conditions. 
Thus, the differences shown in this chapter for the three antagonist compared are 
important. The cyclic peptide 3D53 was an insurmountable antagonist of C5aR on 
human macrophages, and its IC50 was virtually independent of the concentration of 
C5a (0.1nM to 300 nM); whereas W54011 and JJ47 were competitive and 
surmountable antagonists of C5aR on human macrophages, and their IC50 values 
varied by three orders of magnitude in the C5a concentration range 0.1 nM to 300 nM 
(Figure 4.1, 4.2). Serum levels of C5a can reach as high as 100 nM in patients with 
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sepsis (29). The local concentration of C5a however, is expected to be even higher at 
sites of inflammation, but this is yet to be determined. These results raise the question 
as to whether W54011 and JJ47, and other surmountable antagonists can be effective 
therapeutic agents to treat C5a-mediated diseases. 
A second key point concerns residence time on the receptor. Human 
macrophages were treated with each of the antagonists, and then subsets of these cell 
populations were treated with rhC5a at different times to compare the duration of 
action of each of the antagonists. A striking difference was observed in duration of 
antagonist action, with 3D53 action being an order of magnitude longer than for 
W54011 and JJ47 (ca. t1/2 20h vs 2h). This difference is a reflection of a much longer 
residence time on the receptor C5aR for 3D53, which does not bind at all to C5L2 
(27). The interpretation of this data is that 3D53 would require once a day 
administration, whereas W54011 and JJ47 would be required on a 1-2 hourly basis, 
not to mention in larger quantities because they would be rendered ineffective as the 
serum or local tissue concentration of C5a increases. Clearly, a non-competitive 
antagonist has advantages over competitive antagonists. The important properties 
conferred by longer residence time are not widely appreciated and often overlooked in 
drug design and development. Residence time is beginning to make some impact on 
some drug discovery programs, the recently reported being a prime example of why 
longer residence time is preferred as there were already twenty kinase inhibitors in 
advanced clinical trials or in man (40). Increasing residence time for drugs can 
overcome less optimal pharmacokinetic profiles that really only report on plasma 
levels of circulating drugs.  
The third important point concern a very misleading pharmacokinetic 
measurement F% or oral bioavailability, which is currently considered the most 
important property in drug design and development. When a drug is administered 
intravenously, bioavailability is 100%. Since drugs that are administered orally or via 
other routes have to cross membrane barriers before exerting effects in systemic 
circulation, their oral bioavailability is usually much lower. F% is the fraction of an 
orally administered drug that reaches systemic circulation against an intravenously 
administered drug. A high F% means that a lower dose is necessary to achieve a 
desired therapeutic effect and therefore potentially reduces the risks of side effects or 
off-target effects and toxicity. Drugs with poor F% on the other hand can result in low 
oral efficacy, higher dose required and higher variability between individuals, leading 
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to unpredictable drug responses. The current method used to determine oral 
bioavailability is liquid chromatography-mass spectrometry (LC-MS). The concept is 
the theory that blood levels of a drug correlate with efficacy, but this can be 
fundamentally incorrect if the drug targets cell surface receptors like GPCRs. For 
example, the reported F% value for 3D53 is 1% (22), while the reported F% values 
for W54011 and JJ47 are as high as 21% (18, 19). If these values are truly an estimate 
of the amount of drug exerting its effect on its targeted receptor, 3D53 will be an 
inferior antagonist compared to W54011 and JJ47 based on F%. However, in vivo 
studies and data from clinical trials reported so far have proven otherwise.  
Blood collected from treated animals is centrifuged, and only the plasma is kept 
for analysis. Since it is chemically not possible to separate and isolate drugs bound to 
all targeted cell receptors, blood cells and unwanted serum proteins are discarded 
before loading to the LC-MS in order to reduce background noise. As shown earlier, 
3D53 has a very slow relative off-rate (t1/2 = 18.2 h) compared to W54011 (t1/2 = 1.2 
h) and JJ47 (t1/2 = 0.6 h). It is expected that the majority of 3D53 is bound for a long 
time to C5aR expressed throughout the body, including in organs and tissues. Since 
the current protocol only determines oral bioavailability based on drugs present in 
plasma, this is a major flaw for drugs that have a fast on-rate (fast clearance from 
blood) and a slow off-rate. Thus the reported F% for 3D53 is clearly an underestimate 
for the actual amount of bioavailable drug, and ignores the efficiency of oral 3D53 in 
quickly targeting C5aR. A fast clearance rate from plasma combined with and a low 
F%, are commonly interpreted as resulting in low efficacy, a conclusion that is clearly 
wrong as shown here for 3D53. The affinity of a ligand for its receptor does not, per 
se, define the effectiveness and duration of biological action. Rather, it is the lifetime 
of the binary receptor-ligand complex that in part dictates the effect in the cellular and 
organismal context. If the drug is circulating in the blood, unbound to its targeted 
receptor, it is not exerting its effect and this needs to be considered more carefully in 
drug optimization studies. 
W54011 has been previously reported to inhibit C5a-induced calcium release in 
human, cynomolgus monkey and gerbils neutrophils, but not in mice, rats, guinea pigs, 
rabbits and dogs neutrophils (18). However, in this study, W54011 clearly had 
antagonist effect against C5a-mediated gene expression in rat macrophages (Figure 
4.9) as well as in vivo in the Wistar rat models of C5aR-PA-induced paw oedema 
(Figure 4.10E). W54011 has also been shown to be a C5aR antagonist in mouse 
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dendritic cells (41). These results suggest that the interpretation made by Sumichika et. 
al., that W54011 has only a narrow cross-species reactivity may not be true, at least 
not for rats and mice. The correct interpretation from their results should be that 
human C5a only triggers calcium mobilization in human, cynomolgus monkey and 
gerbils neutrophils, but not in mouse, rats, guinea pigs, rabbits or dogs neutrophils. In 
this study, human C5a failed to stimulate calcium release, but did stimulated ERK 
phosphorylation and amplified C5a-related gene expression, in Wistar rat 
macrophages.  
 Peptide analogues of the C5a anaphylatoxin were based on 8 residues at the C-
terminus of human C5a but only had modest binding activity (33). Peptide agonist 
YSFKPMPLdAR was later discovered by Sam Sanderson at the University of 
Nebraska with improved biological activity, but still in the high µM range (42). 
Although this decapeptide was a full agonist on C5aR (43), it also bound non-
specifically to C3aR at µM concentrations (38). Structure activity studies led by 
researchers from Abbott Laboratories over a decade in the 1980s, produced analogues 
with better affinity to C5aR, while downsizing the peptide to six residues, N-Methyl-
FKPdChaCha-dArg-OH, with nM activity against C5aR (44). Although this 
hexapeptide agonist was previously reported to bind with low affinity to C5L2 (45), 
but did not affect C5a binding to C5L2 even at high µM concentrations, separate 
studies have now shown otherwise (27). By swapping the N-methyl to an acetyl cap, 
C5aR-PA mimicked the native C5a protein more closely as determined by NMR 
spectroscopy (unpublished data by Dr Martin Stoermer). Acetylating peptides can 
result in increased metabolic stability and improved in vivo efficacy (36, 37, 46).   
Human C5aR is 64.9% identical in amino acid sequence to rat C5aR (Figure 
4.11A). Despite the high similarity between human and rat C5aRs, there are a handful 
of non-conserved residues within the putative transmembrane region of C5aRs where 
C5a or ligands are expected to bind. A follow-up study on W54011 investigated why 
this antagonist exerted its antagonism across limited species and found that the 
underlying reason was due to the Trp (W) residue in the transmembrane domain V 
(47). Results from this study and others (41), have demonstrated that W54011 in fact 
can exert its antagonistic effects in mice and rat models, thereby refuting claims for a 
species-specific effect of W54011.  
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Figure 4.11. Amino acid sequence comparison of human and rat C5aR and C5a. 
Sequence alignment between human and rat (A) C5aRs and (B) C5a anaphylatoxins 
were performed using online software ClustalW2. Consensus symbols (*) indicates 
fully conserved residue, (:) indicates residues with strongly similar properties, (.) 
indicates residues with weakly similar properties. Residues with no symbols are not 
similar. Putative transmembrane domains are indicated by solid black lines (48). 
Residues previously reported responsible for agonistic activity of C5a are indicated by 
black open box (33). Genbank ID for human and rat C5aRs are gi:4502509 and 
gi:16758418; for C5a are gi:227968182 and gi:913781 respectively. Sequence 
similarity score between human and rat C5aRs: 64.9% and C5a: 63.5%.  
 
Although C5aR-PA had full agonist activity on human macrophages, it 
appeared to be a partial agonist on rat macrophages. C5aR-PA did not induce calcium 
release in rat macrophages, but did induce paw oedema in rat models. Scola et. al., 
have previously identified that human recombinant C5a did not bind very well to rat 
C5aR but rat recombinant C5a on the other hand, bind efficiently to human C5aR as 
well as rat C5aR (27). Since C5aR-PA was designed based on human C5aR, it is 
expected to exert similar effects as human C5a. Even though human and rat C5a are 
63.5% identical, the eight residues at C-terminal that are responsible for C5a agonist 
responses are conserved except for one residue (Figure 4.11B). Since human C5a can 
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activate gene expressions and ERK phosphorylation, but not calcium release, in rat 
macrophages, could this residue (a single change from Gln to Leu) be important for 
activating calcium release? If so, would not it be also possible to develop a C5aR 
biased ligands that could block certain C5a-mediated signalling pathways while 
leaving other pathways functional and responsive to C5a? 
 
4.7 Conclusions 
 
This chapter is a comparative study of three reported antagonists of C5aR, with 
the goal of selecting one of three known antagonists of C5a action to probe C5a 
function in monocytes and macrophages in Chapter 5.  This chapter has demonstrated 
that the residence time of an antagonist measured in vitro in cells translates into, and 
is vitally important for, in vivo efficacy. Drug discovery has been traditionally 
focused on optimizing for receptor affinity, drug potency, receptor selectivity and 
drug-like properties to maximise oral bioavailability and pharmacokinetics for a given 
compound series. However, these properties do not necessarily maximise in vivo 
efficacy (16), and this chapter has highlighted this point. At the molecular level, drug 
action is usually effected when the drug is bound to its molecular target, in this case a 
GPCR. In principle, the longer that the receptor-antagonist complex is maintained 
intact, the longer the intended antagonist effect that is produced. This fundamental 
property of a ligand, residence time on the receptor, is not a new concept but perhaps 
has not been appreciated to the extent it needs to be.  
Both the pharmaceutical drug industry and academic researchers in the field of 
drug discovery face tremendous challenges in taking new and better drugs to the 
market. However, perhaps the biggest problem faced is a less realised one, have we 
lost sight of the importance of basic biology? Time is of the essence in drug 
development, but this is also especially true in drug efficacy where residence time of a 
drug on its specific receptor can also be critical in determining the duration of drug 
action  
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5.1 Abstract 
 
Monocytes and macrophages are important innate immune cells equipped with 
danger sensing receptors, including complement and Toll-like receptors. Complement 
protein C5a, acting via C5aR, is shown here to differentially modulate LPS-induced 
inflammatory responses in primary human monocytes versus macrophages. While 
C5a enhanced secretion of LPS-induced IL6 and TNF from primary human 
monocytes, C5a inhibited these responses while increasing IL10 secretion in donor-
matched human monocyte-derived macrophages differentiated by GM-CSF or M-CSF. 
C5a induced Gαi/c-Raf/MEK/ERK signaling was amplified in macrophages but not in 
monocytes by LPS. Accordingly, the Gαi inhibitor PTX and MEK inhibitor U0126 
blocked the inhibition by C5a of LPS-induced IL6 and TNF production from 
macrophages. This synergy was independent of IL10, PI3K, p38, JNK and the 
differentiating agent. Since C5a did not inhibit IL6 production from macrophages 
induced by other TLR agonists that are selective for TRIF (poly I:C) or MyD88 
(imiquimod), C5a selectively regulates LPS-mediated responses. Furthermore, this 
C5a-mediated suppression of pro-inflammatory cytokines IL6 and TNF in 
macrophages did not compromise antimicrobial activity; C5a instead enhanced 
clearance of the gram-negative bacterial pathogen Salmonella enterica serovar 
Typhimurium from macrophages. These findings implicate C5aR as a regulatory 
switch that modulates TLR4 signaling via the Gαi/c-Raf/MEK/ERK signaling axis in 
human macrophages but not in human monocytes. The differential effects of C5a are 
consistent with amplifying monocyte proinflammatory responses to systemic danger 
signals, but attenuating macrophage cytokine responses (without compromising 
microbicidal activity) thereby restraining inflammatory responses to localized 
infections.   
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5.2 Introduction 
 
Complement is an important cascading network of over 30 soluble plasma, and 
insoluble membrane-bound, proteins that cooperate in innate immunity in the 
recognition, opsonization, destruction, and removal of pathogens and infected or 
damaged cells. Complement activation by classical, alternative, lectin pathways and 
other routes is tightly controlled, producing the lytic membrane attack complex 
(MAC), as well as opsonins such as C3b and proinflammatory anaphylatoxins C3a, 
C4a and C5a. Elevated plasma levels of C5a or its receptor are associated with 
inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases, 
respiratory distress syndrome, ischemia-reperfusion injury and sepsis (1). C5a binds 
to and signals through the receptor C5aR (CD88), a class A rhodopsin-like G protein-
coupled receptor (2), and to a second receptor C5L2 which does not couple G proteins, 
may be non-signalling but may also modulate C5aR (3, 4). C5aR couples to the 
pertussis toxin-sensitive Gαi, and in some cells like monocytes to the pertussis toxin-
insensitive Gα16, and recruits β-arrestins-1,2 to the plasma membrane (1, 5). C5a 
activates downstream several signalling pathways, including Akt, MAPK/ERK kinase 
(MEK), phosphatidylinositol 3-kinase (PI3K), phosphokinase A (PKA), 
phospholipase C (PLC) and NF-κB (1). 
 The Toll-like receptors (TLRs) are an important family of type I 
transmembrane proteins that respond to infectious organisms and danger signals by 
initiating inflammatory responses, activating microbial killing and clearance 
mechanisms, and priming the adaptive immune response (6). Of ten known human 
TLRs, TLR4 responds to lipopolysaccharide (LPS) from Gram-negative bacterial cell 
walls. TLR4 can signal through two different pathways dependent upon, and 
modulated by, separate adaptor proteins MyD88 or TRIF (7). MyD88 activates 
IRAKs (IL1R-associated kinases) and TRAF6 (TNF-receptor-associated factor 6), as 
well as transcription factors NF-κB, AP-1 and IRF5 further downstream. TRIF signals 
the induction of type I IFNs by recruiting TRAF3 and RIP1 to activate transcription 
factor IRF3, NF-κB and AP-1. Both MyD88 and TRIF activate AP-1 via downstream 
MAPK activation (8), although NF-κB and MAPK activation by TRIF occurs later 
than for MyD88 (9). 
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 Crosstalk between different signalling pathways in mammalian cells can result 
in unexpected and unique functional outcomes (10). Some pathogens have evolved to 
evade or exploit host microbial-killing by targeting C5aR and TLRs specifically. For 
example, virulence proteins secreted by Staphylococcus aureus bind to C5aR with 
potent antagonist activity, preventing recruitment of phagocytes to sites of infection 
(11). Porphyromonas gingivalis exploits the C5aR/TLR2 crosstalk by increasing 
cAMP production in macrophages, which suppresses macrophage immune function 
and enhances pathogen survival (12). Clearly, these pathogens have evolutionarily 
adapted to exploit complement/TLR crosstalk to their advantage. While C5aR and 
TLR4 signalling have been separately investigated in many studies, there is 
comparatively little reported about their interplay (13). Among recent reports on 
C5aR/TLR4 crosstalk, C5a has been found to downregulate TLR4-induced IL12 
production via PI3K-dependent (14) and PI3K-independent (15) pathways in mouse 
macrophages; to signal via the PI3K-Akt pathway to enhance LPS-induced IL17F 
cytokine production (16), and to suppress LPS-induced IL17A and IL23 cytokine 
production in mouse macrophages (17). C5a-induced suppression of LPS-inducible 
IL17A/IL23 axis was reported to occur via enhanced IL10 production and ERK1/2 
phosphorylation. However, most studies reporting C5a modulation of TLR4 
signalling had been performed with murine rather than human cells (18, 19). Some 
interpretations of human disease mechanisms have been made based on extrapolating 
observations from mouse studies. However, there are important differences in LPS-
induced TLR4 signaling between humans and mice (20-22), thus necessitating careful 
assessment of C5aR/TLR4 crosstalk in human cells.  
 Monocytes and macrophages are important cellular mediators of innate 
immunity and are targets for C5a and LPS. Some features of LPS signalling are also 
distinctly different between human monocytes and macrophages (23). Monocytes act 
as danger sensors in the circulation and typically generate a more rapid, heightened 
inflammatory response than macrophages to danger signals. For example, LPS alone 
can trigger inflammasome activation in monocytes, whereas an additional activation 
signal such as ATP is required in macrophages (24). The present study compares 
effects of C5a on LPS responses in primary human monocytes versus donor-matched 
macrophages derived through differentiating monocytes with either GM-CSF or M-
CSF. Surprisingly, we found that C5a differentially modulated LPS responses 
depending upon the cell type, that C5a activated the Gαi/c-Raf/MEK/ERK axis to 
 191 
selectively downregulate pro-inflammatory cytokine production from macrophages 
but not monocytes, and that effects on macrophages do not compromise but instead 
stimulate pathogen killing. Thus, it is proposed that C5a has distinctly different 
regulatory effects on myeloid cell functions during localized versus systemic 
inflammatory responses.  
In the present study, crosstalk between C5aR and TLR4 was investigated in 
human monocytes and human monocyte-derived macrophages (HMDM) using the 
respective ligands C5a and LPS. 
 
5.3 Aims 
 
While C5aR and TLR4 signalling had been separately investigated in many 
studies (10), there was comparatively little reported about their interplay. Since there 
had been some conflicting reports about the interplay between LPS and C5a in mouse 
vs human cell studies (20-23), we sought to clarify this interplay for human cells. 
Therefore, we sought to discover whether complement protein C5a, acting via C5aR, 
differentially modulated lipopolysaccharide (LPS)-induced inflammatory responses in 
primary human monocytes versus human macrophages. The specific aims of this 
chapter were: 
1. To determine if LPS-induced responses are differentially modulated by C5a in 
human monocytes versus macrophages 
2. To identify which signalling pathways are involved in the C5aR/TLR4 
crosstalk in monocytes versus macrophages  
3. To find out where signalling cascades intersect in monocytes and macrophages 
to mediate C5aR/TLR4 crosstalk 
 
The results discussed in this chapter have also been accepted in the Journal of 
Immunology (Appendix IV).  
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5.4 Materials and Methods 
 
5.4.1 Reagents 
 
Recombinant human GM-CSF, M-CSF and IL10 were purchased from 
PeproTech. LPS from Salmonella enterica (serotype Minnesota RE 595), U0126 
monothanolate, wortmannin and pertussis toxin (PTX) were purchased from Sigma-
Aldrich. Imiquimod R837 (IMQ) and polyinosinic-polycytidylic acid (poly(I:C)) were 
purchased from InvivoGen. Human C5a was purchased from Sino Biological Inc. 
Goat neutralizing antibody against human IL10 (AB-217-NA) was purchased from 
R&D Systems. C5aR antagonist (3D53 also licensed as PMX53) (1, 25) was 
synthesized and characterized (analytical HPLC, mass spectroscopy and NMR 
spectroscopy) in-house as described (26). Antibodies against phosphorylated c-Raf 
and total c-Raf were purchased from Cell Signaling Technology. All cell culture 
reagents were purchased from Invitrogen and all analytical grade chemical reagents 
were obtained from Sigma-Aldrich, unless otherwise stated. 
 
5.4.2 Isolation of human monocytes and macrophages 
 
PBMCs were isolated from buffy coats of anonymous donors (Australian Red 
Cross Blood Service, Kelvin Grove, Queensland, Australia) by density centrifugation 
using Ficoll-Paque Plus (GE Healthcare) manufacturer’s instructions. Contaminating 
erythrocytes were removed by repeated ice-cold sterile water. CD14+ MACS® 
microbeads were used to positively select monocytes from isolated PBMCs according 
to the manufacturer’s instructions (Miltenyi Biotec). CD14+ monocytes were seeded 
at 1 x 106 cells/mL in IMDM supplemented with 10% FBS, 100 U/mL penicillin, 100 
µg/mL streptomycin and 2 mM GlutaMAX at 37°C in presence of 5% CO2. To 
generate human monocyte-derived macophages (HMDM), CD14+ monocytes were 
cultured in the presence of either 10 ng/mL GM-CSF (GM-MΦ) or M-CSF (M-MΦ) 
for at least 6 days.  
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5.4.3 Quantitative cytokine ELISA 
 
Cells were seeded at 1 x 106 cells/mL and serum-deprived overnight in the 
incubator prior to treatment. LPS and C5a treatments were pre-mixed prior to 24 h 
stimulation. Cell culture supernatants were collected and cytokines level were 
determined using specific ELISA sets from BD Pharmingen, according to the 
manufacturer’s instructions. 
 
5.4.4 Isolation of mRNA and RT-PCR 
 
Total RNA was extracted from cells using an RNeasy Mini Plus kit (Qiagen), 
according to the manufacturer’s instructions. Total cellular RNA (2-10 µg) was 
reverse transcribed to cDNA using oligo dT primer (1 µg) and Superscript III 
(Invitrogen), according to the manufacturer’s instructions. cDNA samples were stored 
at -20°C until further use.  
 
5.4.5 Gene expression analysis by real-time PCR 
 
Gene-specific primers were designed using the free web-based software 
Primer-BLAST (National Center for Biotechnology Information). Quantitative real 
time-PCR was performed using an ABI PRISM® 7900 Real Time PCR System 
(Applied Biosystems™), cDNA (50 ng), SYBR® Green PCR master mix (Applied 
Biosystems™) and gene-specific primers. Relative gene expression was normalised 
against 18S rRNA expression and then converted to fold change against control 
samples. All samples were analysed in duplicate. Primer sequences used are: CD68, 
5’-TTTGGGTGAGGCGGTTCAG-3’ and 3’-CCAGTGCTCTCTGCCAGTA-5’; 18S, 
5’-ACCACGGGTGACGGGGAATC-3’ and 3’-CCGGGTCGGGAGTGGGTAAT-5’.  
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5.4.6 Quantification of MEK1, ERK1/2, p38 and JNK phosphorylation by 
AlphaScreen Surefire 
 
Cells were seeded at 4000 cells/well in white 384-ProxiPlate (PerkinElmer) 
overnight. On the following day, media was removed from the cells and were serum-
deprived for 2 h to reduce basal ERK1/2 activity, prior to stimulation with C5a over a 
stated time course. Cells were lysed with Alphascreen SureFire lysis buffer, with 
shaking for 10 min at room temperature and assayed for phosphor-MEK1 (phosphor-
Ser218/Ser222), phosphor-ERK1/2 (phosphor-Thr202/Tyr204), phosphor-p38 
(phosphor-Thr180/Tyr182) and phosphor-JNK (phosphor-Thr183/Tyr185) according 
to Alphascreen SureFire assays (PerkinElmer) manufacturer’s instructions. At 
completion of the assay, signal in the wells was measured using Pherastar (BMG 
Labtech). 
 
5.4.7 Western blot analysis 
 
Samples were homogenized in 50 mM Tris (pH 7.4), 1.7 mM SDS and 
protease inhibitor cocktail (Roche Applied Science). Equal amounts of total cell 
lysates (10 µg) were loaded and subjected to denaturing SDS-PAGE, transferred to 
PVDF membranes, and proteins were detected using antibodies against 
phosphorylated and total C-Raf protein (Cell Signalling Technology). Bands were 
visualized by an ECL method and quantified by densitometry measurements of 
phospho c-Raf normalized with total c-Raf against control. 
 
5.4.8 Bacterial clearance assay 
 
Intracellular survival of Salmonella enterica serovar Typhimurium (S. 
Typhimurium) strain SL1344 within HMDMs was monitored in gentamicin exclusion 
assays (27). M-MΦ were seeded at 200,000 cells/well in penicillin-streptomycin (P/S) 
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free media containing M-CSF (10 ng/mL). On the following day, cells were infected 
with S. Typhimurium at a multiplicity of infection (MOI) of 100. One hour post-
infection, cells were washed with gentamicin (200 µg/mL) in P/S-free media and 
further incubated (1 h) to kill extracellular bacteria in the same media. Additional 
incubations beyond this 2 h time point were carried out in media containing 20 µg/mL 
gentamicin. At specific time points, cells were washed twice and lysed with 0.01% 
Triton X-100 in PBS, after which lysates were cultured overnight on LB agar. Colony 
counts were performed to assess intracellular bacterial loads. The MOI was also 
confirmed by plating out inoculum on LB agar plates and performing colony counts. 
Treatments with C5a (30 nM) were conducted by co-treatment with bacteria upon 
infection. For antagonism assays, cells were pretreated with the C5a inhibitor 3D53 (1 
µM) 30 min prior to infection. 3D53 was also added back following the washing with 
gentamicin-containing media.  
 
5.4.9 Statistical analysis 
 
Data were plotted and analysed using GraphPad Prism version 5.0c for Mac OS 
X (GraphPad Software). Statistically significant differences were assessed using 
student’s t-test for paired comparison. All values of independent parameters are 
shown as mean ± SEM of at least three independent experiments, unless otherwise 
stated. Significance was set at *p < 0.05, **p < 0.01 and ***p < 0.001. 
 
 
  
 196 
5.5 Results 
 
5.5.1 C5a acting via C5aR differentially modulates LPS-signalling in 
human CD14+ monocytes versus macrophages. 
 
In light of recent discoveries linking crosstalk between Toll-like receptors and 
the complement system as possible control points for regulation of host defence (13), 
this study compared C5aR/TLR4 crosstalk between human monocytes and 
macrophages, given their different roles in responding to inflammatory stimuli. C5a 
decreased LPS-induced secreted levels of IL6 and TNF in both GM-MΦ and M-MΦ, 
but increased the levels of the same proinflammatory cytokines in monocytes (Figure. 
5.1A, B). On the other hand, C5a enhanced LPS-induced IL10 production from 
macrophages, but had no effect on this response in monocytes (Figure. 5.1C). This 
suggests that the regulatory effects of C5aR on TLR4 depend upon cellular context, 
for example differentiation status. Although C5aR mediates C5a-dependent responses, 
a second C5a receptor, C5L2, has also been reported to exhibit anti-inflammatory 
functions (3, 28). However, the biological roles of C5L2 in inflammation are highly 
controversial. Our group has previously developed 3D53, a potent, insurmountable 
and selective antagonist of C5aR that does not bind C5L2 (29, 30). 3D53 blocked the 
immunomodulatory effects of C5a on TLR4 signalling in both macrophages and 
monocytes (Figure. 5.1D-F), thus demonstrating that the observed responses of C5a 
were mediated via C5aR, rather than C5L2. 
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Figure 5.1. C5a acting via C5aR-dose-dependently modulates LPS-induced IL6, 
TNF and IL10 cytokine production in human monocytes and macrophages (GM-
MΦ and M-MΦ) via C5aR. 
 (A-C) Human CD14+ monocytes (grey) and HMDMs (GM-MΦ, black; M-MΦ, 
white) were serum-deprived for at least 8 h before treatment with LPS (5 ng/mL) in 
the absence or presence of various concentration of C5a (0.03-300 nM) for 24 h. (D-
F) For antagonism of C5aR, cells were pre-treated with 3D53 (1 µ , 30 min) prior to 
C5a and LPS stimulation. ELISA was used to detect levels of secreted (A, D) IL6, (B, 
E) TNF and (C, F) IL10 in culture media. Error bars are means ± SEM of three 
independent experiments (n=3). *p < 0.05, **p < 0.01 and ***p < 0.001 by student t-
test. 
 
5.5.2 Temporal study of C5aR/TLR4 crosstalk in HMDMs 
 
To further characterise the phenotypic switch in C5a responsiveness during 
monocyte to macrophage differentiation, time course experiments were performed. As 
expected, mRNA levels of the macrophage marker CD68 were increased after 4 days 
of differentiation in the presence of either GM-CSF or M-CSF (Figure. 5.2A). 
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Figure 5.2. C5AR and TLR4 mRNA levels are increased during differentiation of 
CD14+ monocytes to macrophages with GM-CSF or M-CSF. 
(A) CD68, (B) C5AR and (C) TLR4 gene expression were monitored during 
differentiation of CD14+ monocytes, in the presence of GM-CSF (black) or in the 
presence of M-CSF (white) on Days 0, 2, 4 and 6. (D) C5AR and (E) TLR4 gene 
mRNA levels were also measured when treated with either C5a (30 nM) or LPS (5 
ng/mL) overnight. Genes were detected by real-time PCR, normalised against 18S 
rRNA expression and converted to fold change relative to Day 0. Error bars are means 
± SEM of three independent experiments (n=3) against control (Day 0). *p < 0.05, 
**p < 0.01 and ***p < 0.001 by student t-test. 
 
The mRNA expression levels of C5AR and TLR4 are increased during 
monocyte to macrophage differentiation (Figure 5.2B, C). Levels of C5AR and TLR4 
mRNA were not affected by C5a treatment, but LPS decreased C5AR expression by 
~30% (Figure 5.2D, E), consistent with a previous study (31). The suppressive effect 
of C5a on LPS-induced cytokine production was apparent by day 4 for TNF, and by 
 199 
day 6 for IL6 (Figure. 5.3B, C). Increased IL10 production was also observed by day 
4 (Figure. 5.3D).  
 
 
Figure 5.3. Temporal study of C5aR/TLR4 crosstalk in monocytes and 
macrophages. 
Human CD14+ monocytes were differentiated to HMDMs with either GM-CSF (10 
ng/mL) (GM-MΦ, black) or M-CSF (10 ng/mL) (M-MΦ, white) in 10% FBS/IMDM 
over a 6 d time course. Macrophage marker These cells were also treated with LPS (5 
ng/mL) ± C5a (30 nM) for 24 h in 10% FBS/IMDM on Day 0, 2, 4 and 6 to monitor 
suppression by C5a of LPS-induced IL6 and TNF in HMDMs. ELISA was used to 
detect (A) IL6, (B) TNF and (C) IL10 secreted in culture media. Error bars are means 
± SEM of three independent experiments (n=3). *p < 0.05, **p < 0.01 and ***p < 
0.001 by student t-test. 
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5.5.3 C5a suppresses LPS-induced IL6 and TNF via Gαi- and MEK-
dependent signalling. 
 
C5a-dependent C5aR signalling involves coupling to Gαi proteins (5, 32). 
PTX, which specifically interferes with Gαi protein signalling, was used to investigate 
whether the blockade of Gαi signalling could reverse inhibition of TLR4 responses by 
C5a. As expected, all modulatory effects of C5a on LPS-induced cytokine production 
from monocytes and macrophages were sensitive to PTX (Figure. 5.4A-C). These 
results confirmed involvement of C5aR- and not C5L2-signalling in this crosstalk, as 
C5aR but not C5L2 employs Gαi signalling (1, 3). We also pharmacologically 
targeted downstream signalling of C5aR signalling and found that the MEK inhibitor 
U0126, a selective inhibitor of the ERK pathway (33), prevented immunomodulation 
by C5a of LPS-induced IL6 and TNF production in macrophages, but not monocytes 
(Figure. 5.4A, B). Interestingly, although the literature suggested that ERK1/2 is 
involved in TLR-induced IL10 production from human macrophages (15, 34), it was 
found here that C5a enhanced LPS-mediated IL10 production in an ERK1/2-
independent, but Gαi-dependent, manner (Figure. 5.4C). Similarly, LPS-induced IL-
10 production from monocytes, as well as GM-MΦ and M-MΦ, was ERK-
independent (Figure. 5.4C). 
In monocytes, the enhancement of LPS-induced IL6 production by C5a was 
altered by the presence of MAPK p38- and PLCβ- inhibitors, SB203580 and U73122 
respectively, whilst the enhancement of LPS-induced TNF production was affected by 
PKA inhibitor PKI-14-22 (Figure. 5.5A, D). This effect was not observed in 
macrophages (Figure. 5.5B-C, E-F). Collectively, these data suggest that C5a-
dependent ERK1/2 phosphorylation selectively suppresses LPS-induced IL6 and TNF 
production in macrophages. 
 201 
 
Figure 5.4. C5a suppression of LPS-induced IL6 and TNF in macrophages is 
sensitive to PTX and MEKi (U0126) treatment. 
To inhibit Gαi-dependent interactions, cells were pre-treated with PTX (200 ng/mL, 
overnight); or for MEK1/2 inhibition, U0126 (1 µM, 30 min), prior to LPS (5 ng/mL) 
± C5a (30 nM) stimulation of monocytes (grey) and HMDMs (GM-MΦ, black; M-
MΦ, white). ELISA was used to detect (A) IL6, (B) TNF and (C) IL10 secreted 
cytokine relative to the LPS response (100%) at 24 h post-stimulation. Error bars are 
means ± SEM of three independent experiments (n=3). *p < 0.05, **p < 0.01 and 
***p < 0.001 by student t-test.   
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Figure 5.5. Signalling pathway analysis of C5aR/TLR4 crosstalk in monocytes 
and macrophages. 
Human CD14+ monocytes (grey) and HMDMs (GM-MC5aR/TLR4 crosstalk in 
monocytes and macrophages.nM) ± LPS (5 ng/mL) for 24 h in 10% FBS/IMDM. To 
inhibit (i) Gαi-dependent interactions, cells were pre-treated overnight with PTX (200 
ng/mL); (ii) p38-dependent interactions, cells were pretreated for 30 min with 
SB203580 (600 nM), (iii) PLC-dependent interactions, cells were pretreated for 30 
min with U73122 (1 µM) and (iv) PKA-dependent interactions, cells were pretreated 
for 30 min with PKI 14-22 (100 nM), prior to LPS (5 ng/mL) ± C5a (30 nM) 
stimulation of human monocytes (grey) and HMDMs (GM-MΦ, black; M-MΦ, 
white) for 24 h. ELISA was used to detect (A-C) IL6 and (D-F) TNF cytokine with 
LPS as 100% response. Error bars are means ± SEM of three independent 
experiments (n=3). **p < 0.01 and ***p < 0.001 by student t-test. 
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5.5.4 C5a and LPS synergize for Raf/MEK/ERK phosphorylation in 
macrophages 
 
The data for PTX and U0126 inhibitors showed that C5a modulated 
suppression of LPS-mediated inflammatory responses was dependent on Gαi-
coupling and MAPK ERK1/2 phosphorylation. Therefore additional checkpoints in 
the signalling pathway between Gαi signalling and upstream of ERK phosphorylation 
(Gαi/Raf/MEK/ERK) signalling cascade were investigated to further map the 
crosstalk signalling mechanisms between C5aR and TLR4.  
Interestingly, C5a phosphorylated c-Raf only in macrophages (both GM-MΦ 
and M-MΦ) but not in monocytes (Figure. 5.6A). Co-treatment of GM-MΦ or M-MΦ 
with LPS and C5a synergistically promoted c-Raf phosphorylation. This synergy was 
not observed in monocytes. LPS triggered MEK1 phosphorylation in macrophages 
(Figure. 5.6B). Although C5a and LPS each induced MEK1 phosphorylation in 
monocytes and macrophages, the synergistic effect of LPS and C5a co-treatment was 
only observed in macrophages. Consistent with this, co-treatment of GM-MΦ or M-
MΦ with LPS and C5a synergistically promoted ERK1/2 phosphorylation, whereas 
this synergy was not observed for monocytes (Figure. 5.6C).  
 
5.5.5 C5a and LPS synergise in phosphorylation of ERK1/2 but not p38 or 
JNK in macrophages   spacing 
 
Since C5a plus LPS potentiate ERK1/2 in macrophages, the temporal profile 
of ERK1/2 activation together with other MAPK (p38 and JNK) in response to C5a 
versus C5a plus LPS were investigated next. C5a induced a transient peak in ERK1/2 
phosphorylation within 5 min in monocytes (Figure. 5.7A) and macrophages (Figure. 
5.7B, C), but as previously observed (Figure. 5.6C), LPS amplified this response 
only in macrophages. LPS at 5 ng/mL concentration did not stimulate ERK1/2 
phosphorylation in HMDM, however, at a higher concentration (1 µg/mL), ERK1/2 
phosphorylation was detected after 20 min (Figure. 5.7D). 
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Figure 5.6. C5a induced Raf/MEK/ERK phosphorylation is amplified in 
macrophages but not in monocytes by LPS. 
To quantify c-Raf, MEK1 and ERK1/2 phosphorylation, monocytes (grey) GM-MΦ 
(black) and M-MΦ (white) were treated with LPS (5 ng/mL) ± C5a (30 nM) for 5 min, 
after which cells were lysed. (A) C-Raf phosphorylation was detected by western blot 
and probed with antibodies against phospho c-Raf and total c-Raf. Bands were 
visualized by an ECL method and quantified by densitometry measurements of 
phospho c-Raf normalized with total c-Raf against control. Levels of phosphorylated 
(B) MEK1 and (C) ERK1/2 were measured by AlphaScreen® SureFire® assays. 
Error bars are means ± SEM of three independent experiments (n=3). **p < 0.01 and 
***p < 0.001 by student t-test. 
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Figure 5.7. C5a-induced ERK1/2 phosphorylation is amplified in macrophages 
but not monocytes by LPS. 
To quantify (A-C) ERK1/2, cells (monocytes, GM-Mon is amplified in macrophages 
but nong/mL) ± C5a (30 nM) over 10 min, (D) over 30 min, after which cells were 
lysed. Phosphorylated ERK1/2 was measured by AlphaScreen® SureFire® assays. 
Treatments by C5a, LPS or both were represented by broken lines, dotted lines and 
solid lines, respectively. Error bars are means ± SEM of three independent 
experiments (n=3). **p < 0.01 and ***p < 0.001 by student t-test. 
 
C5a appeared to have little or no effect on p38 (Figure. 5.8A-C) and JNK 
phosphorylation (Figure. 5.8D-F), and did not amplify LPS-mediated activation of 
these signalling responses in monocytes and macrophages. Although LPS at 5 ng/mL 
concentration did not stimulate ERK1/2 phosphorylation in HMDM, LPS did induce 
p38 and JNK phosphorylation, at the same concentration. 
Although there was no synergistic effect for p38 phosphorylation in 
monocytes, the C5a-mediated amplification of LPS-induced IL6 production (Figure. 
5.5A), but not TNF production (Figure. 5.5B), from these cells was affected by the 
p38 inhibitor SB203580. Furthermore, SB203580 did not block the suppression by 
C5a of LPS-induced IL6 and TNF production in macrophages (Figure. 5.5B-C, E-F).  
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Figure 5.8 LPS-induced p38 and JNK phosphorylation is not affected by C5a in 
macrophages and monocytes. 
To quantify (A-C) p38 and (D-F) JNK phosphorylation, cells (monocytes, GM-MΦ 
and M-MΦ) were treated with LPS (5 ng/mL) ± C5a (30 nM) over 10 min, after 
which cells were lysed. Phosphorylated p38 and JNK were measured by 
AlphaScreen® SureFire® assays. Treatments by C5a, LPS or both were represented 
by broken lines, dotted lines and solid lines, respectively. Error bars are means ± SEM 
of three independent experiments (n=3). **p < 0.01 and ***p < 0.001 by student t-test. 
 
5.5.6 C5a-mediated suppression of LPS-induced IL6 and TNF is IL10- and 
PI3K-independent. 
 
C5a has been previously reported to enhance LPS-induced IL10 cytokine 
production from macrophages (15), and has also been reported to suppress IL17A and 
IL23 by enhancing IL10 production (17). Consistent with such a mechanism, C5a 
upregulated LPS-induced IL10 production from macrophages, but did not alter this 
response in monocytes (Figure. 5.1C). However, the ability of the MEK inhibitor to 
block C5a-mediated suppression of IL6 and TNF production, without affecting 
enhancement of IL10 production in macrophages, implied that the inhibitory effects 
on IL6 and TNF were IL10-independent (Figure. 5.4C). Although, LPS-induced IL6 
and TNF production was suppressed with increasing concentrations of IL10 (Figure. 
5.9A, B) which is consistent with literature indicating that IL10 attenuates IL6 and 
TNF production from activated macrophages (34, 35), a neutralizing antibody against 
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human IL10 (10 µg/mL) completely blocked the effect of exogenously added IL10 (2 
ng/mL) in macrophages (Figure. 5.9C, D) and its addition prior to LPS stimulation, 
resulted in increased TNF production in M-MΦ.  
 
 
Figure 5.9. Anti-inflammatory IL10 cytokine suppressed LPS-induced IL6 and 
TNF production. 
(A,B) M-Mi-inflammatory IL10 cytokine supprng/mL) with various concentration of 
recombinant human IL10 (0.05-10 ng/mL) for 24 h. (C-D) To block IL10 activity, 
neutralizing anti-IL10 (10 n IL10 (0.05-10 F production.n in exogenng/mL) ± IL10 (2 
ng/mL) 24 h exposure. (A,C) IL6 production and (B,D) TNF were detected by ELISA. 
Error bars are means ± SEM of three independent experiments (n=3). *p < 0.05 and 
**p < 0.01 by student t-test against positive control (LPS alone) or otherwise 
indicated. 
 
However, C5a still suppressed IL6 and TNF production in the presence of the 
neutralizing antibody against human IL10 (Figure 5.10A, B), thus demonstrating that 
the immunomodulation by C5a was independent of IL10. Therefore, C5a-enhanced 
LPS-induced IL10 production does not account for the inhibition of inducible IL6 and 
TNF production by C5a.  
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Figure 5.10. C5a suppression of LPS-induced IL6 and TNF macrophages is 
IL10-independent. 
To determine dependency of IL10, GM-MΦ (black) and M-MΦ (white) were 
pretreated with neutralizing antibody against hIL10 (10 µg/mL, 30 min) prior to LPS 
(5 ng/mL) ± C5a (30 nM) stimulation, after which (A) IL6 and (B) TNF production 
were monitored at 24 h post-stimulation. Error bars are means ± SEM of three 
independent experiments (n=3). *p < 0.05, **p < 0.01 and ***p < 0.001 by student t-
test. 
 
Apart from IL10, the immunomodulation by C5a was also found to be 
independent of LPS-induced PI3K signalling in GM-MΦ (Figure. 5.11A, B) and in 
M-MΦ (Figure. 5.11C, D). The presence of the pan PI3K inhibitor wortmannin at the 
highest concentration (100 nM) did not abolish C5a-mediated suppression of LPS-
inducible IL6 and TNF release, although wortmannin on its own appears to enhance 
LPS-induced IL6 and TNF production from macrophages at 100 nM concentration.  
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Figure 5.11. C5a suppression of LPS-induced IL6 and TNF macrophages is 
PI3K-independent. 
To determine dependency of PI3K signalling, wortmannin (1-100 nM, pre-treated for 
1 h) prior to LPS (5 ng/mL) ± C5a (30 nM) stimulation, after which (A,C) IL6 and 
(B,D) TNF production were monitored at 24 h post-stimulation. Error bars are means 
± SEM of three independent experiments (n=3). *p < 0.05, **p < 0.01 and ***p < 
0.001 by student t-test. 
 
5.5.7 C5a attenuation of LPS-induced IL6 is selectively TLR4-mediated in 
macrophages 
 
TLR4 signalling involves two major pathways, the Mal/MyD88- and the 
TRAM/TRIF-dependent pathways (7). To determine whether C5a affected responses 
through multiple TLRs in primary human macrophages, poly(I:C) (TLR3 agonist 
signalling via TRIF) and IMQ (TLR7 agonist signalling via MyD88) were used. In 
contrast to TLR4 activation by LPS, C5a amplified poly(I:C)-induced (TRIF-
dependent) IL6 production from GM-MΦ (Figure. 5.12B), whereas it did not induce 
detectable levels of this cytokine in monocytes and M-MΦ (Figure. 5.12A, C).  
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Figure 5.12. Suppression by C5a of inducible IL6 production from macrophages 
is selective for LPS responses. 
Human CD14+ monocytes (grey) and HMDMs (GM-MΦ, black; M-MΦ, white) were 
treated with (i) LPS (TLR4 agonist, 5 ng/mL) ± C5a (30 nM) stimulation, (ii) 
Poly(I:C) (TLR3 agonist, 10 µg/mL) ± C5a (30 nM) stimulation or (iii) Imiquimod 
(IMQ) (TLR7 agonist, 10 iquimodod3 agonisnM) stimulation for 24 h in 10% 
FBS/IMDM. ELISA was used to detect (A-C) IL6 and (D-F) IL10 secreted in culture 
media. Error bars are means ± SEM of three independent experiments (n=3). *p < 
0.05, **p < 0.01 and ***p < 0.001 by student t-test. 
 
In the case of IMQ-induced (MyD88-dependent) IL6 production, C5a 
enhanced this response in human monocytes, as well as in both human macrophage 
populations. C5a also increased poly(I:C)-induced and IMQ-induced IL10 production 
in monocytes and M-MΦ (Figure. 5.12D, F), but did not modulate this response in 
GM-MΦ (Figure. 5.12E). These results suggest that suppression of inducible IL6 
production by C5a in GM-MΦ and M-MΦ was selective for TLR4 signalling. 
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5.5.8 C5a enhances clearance of Salmonella Typhimurium from HMDM 
 
There is evidence in support of C5aR/TLR crosstalk being exploited by some 
pathogens for host subversion (12, 35). Therefore, the impact of C5a on the ability of 
HMDM to clear S. Typhimurium was examined in collaboration with a colleague, Ms 
Juliana Arrafin (IMB). As expected, C5a alone did not have any bactericidal effect on 
S. Typhimurium (Figure. 5.13A). Instead, C5a promoted the clearance of this 
bacterial pathogen from M-MΦ, an effect that was reversed by the C5aR antagonist 
3D53 (Figure. 5.13B).  
 
Figure 5.13. C5a decreases S. Typhimurium survival in M-MΦ. 
(A) Growth of S. Typhimurium was monitored ± C5a (100 nM) over 7 h. (B) M-Ma 
(100 nMC5a (100 nMred Typhimurium (MOI 100) ± C5a (30 nM). For antagonism of 
C5aR, M-MΦ were pre-treated with 3D53 (1 µM) for 30 min prior to C5a stimulation. 
Intra-macrophage survival was assayed at 2 h and 8 h post-infection. Graph shows a 
representative of three independent experiments. Error bars are means ± SEM of 
experimental triplicates.  **p < 0.01 and ***p < 0.001 by student t-test. Courtesy of 
Juliana Arrafin (IMB). 
 
In cytotoxicity assays monitoring LDH release, infection assay supernatants 
harvested 8h post-infection showed no differences in macrophage viability 
irrespective of treatment (DMSO, SLI344, hC5a, 3D53, or combinations), thereby 
indicating that reduced bacterial loads upon C5a treatment were not a result of 
increased macrophage death. Thus, C5a enhances human macrophage antimicrobial 
responses, while reducing production of key pro-inflammatory cytokines from these 
cells. 
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5.6 Discussion 
 
Most pathogens trigger both complement and TLR activation, and crosstalk 
between these two systems could potentially impact on inflammatory and anti-
microbial responses in vivo in infectious disease. However, studies on C5aR/TLR 
crosstalk have typically focused on monocytes or macrophages separately. No 
previously reported study has directly compared the impact of crosstalk on the 
functional responses of primary human monocytes versus donor-matched human 
macrophages. The present study has found that the myeloid differentiation state is an 
important variable in determining the impact of C5aR/TLR4 crosstalk on 
inflammatory responses of human monocytes and macrophages. New findings here 
suggest that C5a modulates TLR4 signalling in macrophages to favour pathogen 
clearance, while simultaneously limiting excessive inflammatory responses. This 
control may be important during localized infections, whereas C5a detection by 
monocytes likely acts as an alarm signal that triggers or amplifies inflammatory 
responses during systemic infections.  
 The mechanisms of C5aR/TLR4 crosstalk are complex and evidently species- 
and cell type-dependent. In human monocytes, C5aR signalling has been reported to 
both downregulate (36) and upregulate (37) TLR-induced IL12 production. Although 
those studies were performed on similar IFNγ-primed human blood monocytes, the 
second signal used to stimulate the cells was different. C5a suppressed LPS-induced 
IL12 production, but upregulated S. aureus Cowan I-induced IL12 production. 
Although not addressed in either study, the variations reported are likely due to 
different TLRs being activated and differentially affected by C5aR signalling. The 
current study emphasizes that C5a suppression of IL6 production is specific to 
LPS/TLR4 signalling in human macrophages, since IL6 production is actually 
boosted by C5aR crosstalk with other TLRs, such as TLR3 and TLR7. Similarly, in 
mouse macrophages, C5a was reported to selectively crosstalk with TLR4, but not 
TLR3, in suppressing IL27 (p28) production (38). C5a is thus not only a potent 
chemotactic agent, attracting immune cells to site of infection or injury, but it also 
differentially modulates host immune responses, possibly tailoring them to match a 
particular type of infection.  
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 The differentiating agents GM-CSF and M-CSF have differential effects on 
macrophage lineage populations, which contribute to their functional heterogeneity 
(39). GM-MΦ are often considered as ‘M1-like’ macrophages, while M-MΦ are 
classed as ‘M2-like’ macrophages, according to their cytokine and gene expression 
profiles (40, 41). Whilst LPS-induced inflammatory cytokine production was clearly 
enhanced in GM-MΦ compared to M-MΦ in the present study, C5a exerted a similar 
suppressive effect on inflammatory responses in both human macrophage populations. 
Thus, the phenotypic switch in C5a responsiveness during monocyte to macrophage 
differentiation occurred irrespective of the differentiating agent. In the future, it will 
be of interest to determine whether other macrophage polarizing factors (e.g. IL-4, 
IgG) influence the ability of C5a to suppress TLR4-inducible inflammatory mediator 
production. Although the basal levels of C5AR and TLR4 increased during the course 
of differentiating monocytes to macrophages, the differences in the expression levels 
are unlikely to be the cause for the phenotypic switch in the crosstalk. Firstly, C5a 
treatments did not alter C5AR expression levels. Secondly, C5a had opposing effects 
on inducible cytokine production when the macrophages were challenged with 
Poly(I:C) or Imiquimod, instead of LPS.  
 The effects of C5a on TLR4 responses were PTX-sensitive in both monocytes 
and macrophages, suggesting a Gαi-sensitive mechanism. C3a can also bind to a 
PTX-sensitive receptor, C3aR that can recruit Goi-coupling when activated. Others 
have shown that C3a acting on IFNγ-primed macrophages from C5aR-/- mice (14), as 
well as other Gαi-specific ligands acting on IFNγ-primed human monocytes (42), can 
negatively regulate LPS-induced IL12 production. Also, PI3K signalling has been 
implicated in C5a regulation of LPS signalling. The pan PI3K inhibitor wortmannin 
was reported by la Sala et al to block the suppression by C5a of IL12p70 production 
(42), but this was not the case in the study performed by Hawlisch et al (14). In our 
study, wortmannin treatment had no impact on C5a-mediated suppression of LPS-
induced IL6 and TNF production in human macrophages. This suggests that the 
crosstalk is not only tightly regulated at multiple checkpoints in the signalling cascade, 
but that it is also highly dependent on the activation status of the cells. 
 As shown previously in human neutrophils (32,43), C5a can activate the 
Raf/MEK/ERK signalling cascade either directly via Gαi activation or indirectly via 
Gβϒ/PLCβ/PKC pathways. Here, it was found that C5a-mediated suppression of 
LPS-induced IL6 and TNF was independent of PLCβ-signalling (Supp. Fig. 2). 
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Although C5a rapidly phosphorylated ERK1/2 in both monocytes and macrophages 
(Fig X), consistent with the literature (14, 15), only in macrophages did C5a increase 
c-Raf phosphorylation in the presence of LPS, leading to further downstream increase 
in phosphorylation of MEK and ERK. Since, LPS and C5a did not synergize to alter 
other MAPKs (p38 and JNK) in monocytes and macrophages, the differences in 
monocytes and macrophages are attributed to the activation of Gαi/c-Raf/MEK/ERK 
pathway by C5a with LPS in macrophages versus monocytes. 
 Low concentrations of LPS failed to stimulate ERK phosphorylation. However, 
only high concentrations of LPS triggered delayed ERK1/2 activation (20 min post-
stimulation) by comparison with the C5a response, which occured within 5 min. The 
MAP3K tumour progression locus 2 (TPL2) is essential for activation of ERK1/2 by 
multiple TLRs, including TLR4, in macrophages (44). Consistent with this, it was 
observed that LPS triggered MEK1 phosphorylation in macrophages independently of 
activation of another MAP3K, c-Raf. ERK activation can produce different results, 
depending upon the stimulus and cell types, especially if comparing primary cells 
versus laboratory cultured cell lines (45). C5a enhanced ERK1/2 activation in rat 
neutrophils, and this was associated with an increase in IL6 production (46). This 
contrasts with our present findings for human macrophages. Complement-mediated 
ERK1/2 activation also inhibited IL12 production in human monocytes and mouse 
macrophages (14, 42), whereas the opposite was observed in mouse dendritic cells 
(DC) (47). Such reported variations in effects of C5a on LPS responses reinforce the 
view that observations of complement-mediated effects on TLR signalling are likely 
to not only be cell- and species-specific, but also to vary with the inflammatory 
readout being monitored.  
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5.7 Conclusions 
 
In summary, this study has identified C5aR as a regulatory switch that 
modulates LPS/TLR4 signalling via the Gαi/c-Raf/MEK/ERK signalling axis in 
primary human macrophages, but not in monocytes. Extrapolating data from mouse to 
human, although convenient, is often not appropriate (48). Regulatory mechanisms 
involved in C5aR/TLR4 crosstalk that were previously reported in mouse studies may 
not be necessarily be conserved in humans. Differential effects of C5a on monocytes 
versus macrophages have been demonstrated here, and are consistent with the need to 
either amplify monocyte proinflammatory responses during systemic danger 
recognition but to attenuate macrophage proinflammatory cytokine responses (without 
compromising microbicidal activity) during localized infections. These differences 
between immune cell responses and control mechanisms might conceivably be 
targeted for therapeutic benefit. For example, many therapies, including 
chemotherapy, radiation, cancer vaccines and small-molecule drugs, already utilise 
immune cell-specific treatment strategies (49), but the rational basis for targeting 
specific cell types frequently lacks a level of understanding necessary to optimise 
such treatments. Studies such as this one have the potential to unlock secrets relating 
to interacting human immunoreceptors and control mechanisms that are not obvious 
in studies targeting one particular receptor on a specific human immune cell type, let 
alone on immune cells from other mammalian species. 
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6.1  Thesis summary 
 
Macrophages are immune cells produced by the differentiation of monocytes in 
tissues. Macrophages were first discovered in the early 1900s and were thought to 
assume a defensive role in innate immunity by their remarkable phagocytic capacities 
to engulf and destroy invading microbes. However, in the 1970s macrophages were 
also found to regulate adaptive immunity via the activation and proliferation of 
lymphocytes (1). Since then, the roles of macrophages have extended beyond being 
just primarily as phagocytes (2). The roles of macrophages are now known to be 
important in many aspects of physiology, not just immunity. Therefore, it is not 
surprising that macrophages and complement can also cooperate closely in mounting 
immune responses. The anaphylatoxin C5a is an extremely potent proinflammatory 
peptide produced during activation of the complement protein network by infection, 
injury or metabolic disturbance. The principal receptor for C5a (C5aR) has been 
strongly implicated in many inflammatory diseases and C5aR antagonists have shown 
promise as therapeutic agents for modulating C5a-associated inflammatory conditions, 
at least in animal models. No C5aR antagonist has yet progressed in human trials to a 
marketable drug (3). Significant challenges need to be overcome in order to bring a 
drug to market, not the least of which is obtaining a better understanding of how C5a 
is involved in normal and aberrant physiology. Therefore, in part this research 
program sought to investigate properties of human C5a on human monocytes and 
their differentiated forms, macrophages, to further profile the role of C5a and its 
receptor C5aR in immunity. 
Chapter One summarizes the current status of complement C5a and C5aR 
research in relation to inflammation and macrophages. This chapter not only serves as 
a general overview on the current status of the field, it also identifies important 
information gaps and obstacles that are currently faced by researchers in the field. For 
example, one of the biggest assumptions made by many researchers has been that 
mechanisms underlying C5aR signalling in murine cells can be extrapolated to human 
diseases, even though there are crucial differences in signalling mechanisms between 
human and murine cells (4). Unfortunately, C5aR activation has often been studied 
using murine rather than human cells. For example, the only cDNA microarray 
analysis of gene expression induced by C5a-treated human cells was performed on 
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non-immune cells (5), even though the majority of effects mediated by C5a have to 
date been associated with immune cells, macrophages in particular (6). Another 
problem is that human macrophages have remarkable plasticity in functional and 
phenotypic responses upon activation, which makes the analysis of human 
macrophages responses to C5a quite complex. Depending on the activation stage of 
the macrophages, the same stimulant can trigger different outcomes (7). Moreover, 
MAPK signalling by primary and cultured cells are different (8). The combination of 
these kinds of differences has made understanding human immunology and 
inflammatory diseases mediated by macrophages extraordinarily complex.  
Although the primary objective of this thesis was not focused on the complexity 
of human macrophages, some assessment of the effect of the monocyte-macrophages 
lineage was made in Chapter Two, where different populations of macrophages were 
studied following differentiation of primary human monocytes with GM-CSF or M-
CSF to macrophages (MΦ). GM-CSF and M-CSF have been used before as 
differentiating agents for murine bone marrow cells to generate different populations 
of murine macrophages, termed M1 and M2 respectively according to genomic 
analysis (9) and extracellular secretory proteomics (10). In this thesis chapter, the 
focus was on gene expression profiling human macrophages (GM-MΦ versus M-MΦ) 
in response to LPS, the major component of the outer membrane of Gram-negative 
bacteria. We were interested in comparing effects of stimulating gene expression in 
these different cell populations to better understand macrophage plasticity in 
immunity. Rather than exhibiting distinct gene expression profiles, the different 
human macrophage populations represented more of a continuum model rather than 
distinctive genotypes/phenotypes (M1 or M2). These observations challenge current 
dogma that human macrophages exhibit either distinctly pro- or anti-inflammatory 
phenotypes depending on the differentiation state, instead suggesting much less 
functional diversity than previously thought.  
In collaboration with Mr. Daniel Hohenhaus and Associate Professor Matthew 
Sweet the GPCR repertoire of primary human macrophages (GM-MΦ versus M-MΦ) 
was profiled using TaqMan Low Density Array (TLDA), with the finding that only 15 
of 380 GPCRs were differentially expressed between these cell populations in the 
basal state (11). This small difference was similarly identified in the cDNA 
microarray profiling reported in Chapter 2, implying that even though the primary 
cells have huge genetic variations from different batches of human macrophages, 
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these variations did not compromise the analysis of GM-MΦ versus M-MΦ, as 
demonstrated on two different platforms (cDNA microarray and TLDA). Importantly, 
these studies also revealed that LPS signalling could influence GPCR expression in 
human macrophages, suggesting that novel mechanisms involved in Toll-Like 
receptors (TLRs) and GPCRs signalling exist that are important for human 
macrophages response. 
As mentioned earlier, the only previously reported cDNA microarray analysis 
of gene expression induced by C5a-treated human cells was performed on non-
immune cells (5). Therefore, Chapter Three assessed the responses of human 
macrophages (GM-MΦ versus M-MΦ) to human C5a. C5a had similar potency on 
both populations of macrophages (GM-MΦ and M-MΦ) in three different functional 
assays (calcium release, ERK phosphorylation and macrophage migration), despite 
the large genomic differences found between GM-MΦ and M-MΦ in their basal state 
in Chapter 2. C5a also induced similar genomic changes on GM-MΦ and M-MΦ as 
analysed globally by microarray. The majority of genes induced by human C5a 
belongs to proinflammatory cytokines and chemokines (CCL3, CCL3L1, CXCL2, IL8, 
PTGS2 and TNF), and a number of transcription factors (ATF3, EGR1, EGR2, EGR3, 
FOS, FOSB and JUNB). A total of 33 genes commonly induced by human C5a after 
30 min on GM-MΦ and M-MΦ were analysed by Ingenuity Pathway Analysis and the 
majority of the associated overlapping signalling pathways were involved in 
neurological disease, cancer, cell death and survival. Since all of the C5a-induced 
genes on human macrophages were upregulated, it was important to understand what 
C5a also did to human macrophages after 30 min. A separate microarray experiment 
was conducted to overview the temporal gene expression profile of the effects of C5a 
on human macrophages. Interestingly, C5a induced a set of genes related to 
metabolism and biosynthesis after 6 h, suggesting that C5a has important roles not 
only in regulating immunity and inflammation, but also in cellular metabolism as well.  
Chapter Four reports a comparative study of the effects of three potent C5aR 
antagonists described in the literature (3D53, W54011, JJ47), and re-evaluated their 
relative antagonist potential on human C5aR on human macrophages and in a simple 
rat model of inflammation (paw oedema induced by C5aR agonist). Traditionally, 
drug discovery focuses on optimizing ligand affinity for a specific receptor, 
enhancing functional potency and selectivity, and improving drug-like properties for 
optimal pharmacokinetics and oral bioavailability. These optimization processes have 
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not always led to optimal in vivo efficacy. The reported oral bioavailability for 3D53 
is much lower than for W54011 and JJ47. However, a single oral dose of 3D53 
inhibited C5aR-mediated paw oedema in male Wistar rats for at least 16 hours, 
whereas this effect lasted less than 2 hours for orally administered W54011 or JJ47. 
This difference was traced here to a much longer residence time (very slow off rate) 
on human C5aR for 3D53 than for W54011 and JJ47. This property was also reflected 
in vitro in that 3D53 is a non-competitive, insurmountable, antagonist of human C5aR, 
and retains its high potency (IC50 ~20 nM), independent of the C5a concentration (0.1 
nM to 300 nM), whereas W54011 and JJ47 are both competitive antagonists that are 
only potent (IC50 < 20 nM) antagonists against low C5a concentrations (0.1 nM) but 
become ineffective against C5a concentrations above 30 nM. Chapter 4 highlighted 
the fact that receptor affinity, antagonist potency, drug-likeness and oral 
bioavailability of a ligand for its receptor are sometimes insufficient for defining the 
effectiveness and duration of biological action of a drug candidate. Rather, the 
residence time of ligand on the receptor is much more important in dictating the drug 
efficacy in both cellular and organismal contexts. Too often, researchers seek IC50 
values for putative antagonists without considering the mechanism of antagonism, 
thus IC50 values which are dependent on concentration of the competing agonist may 
be meaningless in vivo where physiological conditions are constantly changing 
depending on the severity of disease, unlike the controlled conditions of in vitro 
assays. A further demonstration of the value of long receptor residence time was 
highlighted by an in vivo study in Chapter 4. 
Abbott Laboratories developed a relatively potent C5aR agonist in the 1980s 
(12), namely Phe-Lys-Pro-DCha-Cha-DArg-OH, which was reported to be selective 
for C5aR over C5L2 (13). This peptide was used in this chapter to induce a C5aR-
mediated paw oedema in male Wistar rats, which was challenged by each of the three 
antagonists compared above. Mirroring the effects on macrophages in vitro, 3D53 
was able to inhibit induction of this paw oedma for at least 16 h after a single oral 
dose (5 mg/kg), whereas orally delivered W54011 (30 mg/kg) and JJ47 (30 mg/kg) 
were effective for less than 2 h in suppressing the onset of the rat paw oedema. 
Interestingly, 3D53 at 5 mg/kg p.o. was unable to fully block (~ 40%) the paw 
oedema induced by the C5aR peptidic agonist and a higher dose (10 mg/kg, p.o.) did 
not increase inhibition. This suggested that the inflammatory response induced by the 
peptidic agonist might not only be mediated through C5aR activation. Evidence of its 
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non-selectivity was further provided via a calcium de-sensitization assay, in which 
macrophages primed by C5a to desensitise C5aR still responded after 5 minutes to 
other non-C5a agonists. The C5aR-mediated in vivo model is only as good as the 
agonist triggering the C5aR response. Clearly the Abbott agonist is not as receptor 
selective as previously thought and, since C5a itself is too expensive and unstable in 
vivo to use, there is scope for developing a more selective small molecule agonist for 
C5aR. When a more selective C5aR agonist is available, this paw oedema experiment 
should be repeated to further prove that 3D53 is effective in specifically abolishing 
C5aR-mediated inflammation in vivo. 
Chapter Five reports the novel observation that human C5a, acting via C5aR, 
modulates responses of human macrophages but not human monocytes to LPS (14). 
C5a suppressed the LPS-induced production of proinflammatory cytokines IL6 and 
TNF in macrophages, while promoting more efficient killing of Salmonella 
Typhimurium. The suppressive effect of human C5a of LPS-induced IL6 and TNF 
production on human macrophages acted independent of the differentiating agents, 
GM-CSF and M-CSF. Rather, C5a induced Gαi/c-Raf/MEK/ERK signalling was 
amplified in human macrophages but not in human monocytes by LPS. However, 
there were marked differences between the signalling mechanisms activated by C5a 
and LPS, via receptor C5aR/TLR4 crosstalk on human macrophages, compared to a 
previous report for murine macrophages (15). This crosstalk to suppress 
proinflammatory cytokines was not dependent on IL10 or PI3K for human 
macrophages, contrary to previously reported findings for mouse macrophages. This 
emphasises the danger in extrapolating signalling mechanisms in murine macrophages 
to human macrophages. C5a can also bind to a second receptor, C5L2 (16). The 
involvement of C5L2 in the C5aR/TLR4 crosstalk was ruled out here through the use 
of a C5aR-selective antagonist that does not bind to C5L2 (17), the blockade of C5aR 
signalling abolishing C5a-mediated effects on LPS signalling. However, it was 
recently reported that activation of C5aR in human macrophages led to heteromer 
formation with C5L2 to regulate C5aR signalling, a process that was enhanced by 
C5a, but not by C5adesArg (18). Besides C5a, C5adesArg was also shown to suppress 
LPS-induced IL6 and TNF in a dose-dependent manner on human macrophages (18). 
This finding is inconsistent with our preliminary results, as C5adesArg did not have 
an effect on LPS-induced IL6 and TNF production on human macrophages (Figure 
6.1). Nevertheless, given the differential effect of C5a on LPS signalling between 
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human monocytes and human macrophages, it would be useful to determine whether 
this C5aR/C5L2 heteromer formation occurs in human monocytes. 
 
 
Figure 6.1. C5adesArg did not suppress LPS-induced IL6 and TNF production.  
M-MΦ were serum deprived for at least 8 h before treatment with LPS (5 ng/mL) in 
the absence or presence of C5adesArg (300 nM) for 24 h. ELISA was used to detect 
levels of secreted (A) IL6 and (B) TNF in culture media. Error bars are means ± SEM 
of two independent experiments (n=2). n.s (not significant) by student t-test. 
 
C5a and macrophages are also involved in other important physiological 
processes (19). Although not a major part of this thesis, I did conduct additional 
experiments briefly summarized here on the role of C5a and macrophages in 
metabolism and obesity. Activating complement proteins in blood triggers immune 
responses and requires energy to fight infection. Further experiments were performed 
in collaboration with Drs. Junxian Lim and Abishek Iyer, to identify new energy 
conserving roles for complement protein C5a and C5aR on diet-induced obesity on 
male Wistar rats (Appendix V). These roles challenged the field of complement 
biology and suggest that complement signalling through these proteins and receptors 
plays previously unknown roles in regulating metabolism and energy homeostasis. 
Rats fed on high-energy diet for 16 weeks had higher complement activation in blood 
serum. Many of the metabolic disorders associated with the high-energy diet on rats 
were attenuated by daily oral administration of selective small molecular antagonists 
of C5aR (3D53). Interestingly, C5a enhanced PGE2 production in murine 
macrophages RAW264.7, and also PGE2, on the other hand, increased both gene and 
protein expressions of C5aR on murine mature adipocytes 3T3-L1 (Figure 6.2). 
These results suggested that C5a acted directly on immune cells, which in turn 
exerted paracrine control over adipocytes via macrophages in the adipose tissues. 
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Figure 6.2. C5aR antagonist modulates inflammatory responses in RAW264.7 
macrophages. 
(A) Enhancement in PGE2 secretion on macrophages RAW264.7 by human C5a (100 
nM) can be inhibited by pre-treatment with C5aR antagonist (10 µM 3D53). (B) 
PGE2 (2 µg/mL) upregulates protein and mRNA levels of C5aR in 3T3-L1 
adipocytes. Expression of mRNA was normalised against 18S rRNA and fold change 
was calculated relative to untreated control. Error bars are mean ± SEM of three 
independent experiments (n=3). **p < 0.01 by student t-test.  
 
Although C3adesArg (also known as acylation stimulating protein, ASP) was 
previously reported to activate adipocytes via C5L2, for triglyceride synthesis and 
fatty acid uptake in 3T3-L1 adipocytes (20), the same role for C5a activating 
adipocytes has not previously been reported. The development of adipogenesis 
requires uptake of excess nutrients, such as glucose and fatty acids, and indeed C5a 
was found to be able to stimulate uptake of BODIPY-fatty acid (FA) and 2-
deoxyglucose (2-DG) (Figure 6.3) by 3T3-L1 adipocytes. Pre-treatment with the 
C5aR specific antagonist 3D53 inhibited C5a-induced uptake of FA and 2-DG 
suggesting that such responses were specific to C5aR and not via C5L2 signalling 
(21). Consistent with this finding, another group of researchers reported the same 
observation, supporting the role of C5aR in obesity and adipose tissue inflammation 
although their diet-induced obesity was studied in mice instead of rats (22).  
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Figure 6.3. Antagonists of C5aR and C3aR can modulate lipid homeostasis in 
3T3-L1 adipocytes. 
Like insulin (50 nM), C5aR antagonist (10 µM 3D53) can inhibit C5a-induced (100 
nM) uptake of (A) BODIPY-fatty acid (FA) and (B) 2-deoxyglucose (2-DG) in 3T3-
L1 adipocytes. Error bars are mean ± SEM of three independent experiments (n=3). 
*p < 0.05 and **p < 0.01  by student t-test.  
 
In conclusion, the thesis has highlighted some important considerations when 
investigating human macrophages and monocytes for immunoregulatory effects. It is 
clear that the differentiation status of such immune cells in vitro can give misleading 
information in regards to genotype and functional phenotype, when compared either 
(a) in vitro between human cell populations, (b) in vitro with murine cell populations, 
or (c) in vivo with responses in animal (and presumably human) models of healthy 
versus diseased physiology. Moreover, the effects of C5a mediated responses can also 
be interpreted differently between macrophages of different species, of different 
differentiation status, and in response to different stimuli. The development of more 
effective C5aR antagonists has been handicapped by some of these differences and 
may be overcome in the future by giving more consideration to (a) murine versus 
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human species differences, (b) differences in responses in primary cells compared 
with cultured cell lines, (c) cell types relevant to a specific diseased state, (d) 
molecular mechanisms of antagonism that can affect duration and efficacy of 
treatment, and (e) the nature of the cell type, degree of receptor expression, 
stimulatory effects on receptor expression and crosstalk with other receptors. The 
characterisation of two populations of human macrophages GM-MΦ and M-MΦ in 
this thesis and responses mediated by human C5a have so far resulted in publications 
in (i) the Journal of Immunology (Appendix IV) and (ii) Immunobiology (Appendix 
V) (11, 14), while the work on metabolism and C5a has been published in FASEB J 
(Appendix VI) (21). 
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Appendices 
  
Appendix I 
 
All genes up-regulated ≥ 2 fold change in GM-MΦ versus M-MΦ 
  
Appendix I
Gene FC p (Corr) Accession Gene FC p (Corr) Accession
TACSTD2 98.2 7.8E-05 NM_002353.1 UBE2C 8.8 1.3E-03 NM_181803.1
CEACAM8 90.1 6.1E-06 NM_001816.2 HRASLS3 8.5 2.6E-02 NM_007069.2
CXCL5 87.3 1.5E-04 NM_002994.3 IGFBP2 8.4 5.6E-03 NM_000597.2
CXCL5 69.1 7.8E-05 NM_002994.3 MUCL1 8.3 3.6E-03 NM_058173.2
PPBP 60.2 1.7E-05 NM_002704.2 C1RL 8.3 1.2E-04 NM_016546.1
S100P 57.8 4.0E-05 NM_005980.2 GPR120 8.3 1.6E-03 NM_181745.2
CCL24 55.2 9.9E-04 NM_002991.2 NR3C1 8.2 6.0E-04 NM_001018077.1
MMP10 49.3 9.8E-05 NM_002425.1 NCAPG 8.2 6.2E-03 NM_022346.3
MARCO 38.6 3.8E-06 NM_006770.3 DLGAP5 8.1 3.3E-04 NM_014750.3
IL1F8 33.1 5.1E-05 NM_014438.3 ADAMTSL4 8.1 6.1E-06 NM_025008.3
FCER2 31.5 3.8E-06 NM_002002.3 ECSCR 8.1 1.0E-05 NM_001077693.2
RETN 30.2 5.6E-06 NM_020415.2 SYNC1 7.9 4.0E-04 NM_030786.1
IL17RB 29.2 1.5E-03 NM_018725.3 DLGAP5 7.9 9.5E-04 NM_014750.3
KIFC3 27.6 2.5E-04 NM_005550.2 VCAN 7.7 2.8E-02 NM_004385.2
CA12 27.4 2.4E-05 NM_001218.3 C11ORF82 7.7 7.8E-05 NM_145018.2
CCL23 25.6 3.2E-05 NM_005064.3 IL1RN 7.7 5.6E-03 NM_173843.1
FGD5 23.4 7.6E-06 NM_152536.2 BIRC5 7.7 1.2E-03 NM_001168.2
ALDH1A2 23.3 6.0E-05 NM_170697.1 MTE 7.6 1.5E-04 NM_175621.2
PPARG 22.9 8.9E-04 NM_015869.4 PKIA 7.5 2.2E-04 NM_181839.1
CES1 21.4 2.5E-04 NM_001266.4 NDP 7.4 1.8E-02 NM_000266.1
CES4 20.8 2.4E-04 NR_003276.1 MRC1L1 7.3 7.2E-05 NM_001009567.1
STAC 20.7 3.8E-06 NM_003149.1 KRT79 7.3 2.5E-04 NM_175834.2
C19ORF59 20.1 2.2E-05 NM_174918.2 C20ORF123 7.1 1.9E-02 XM_938433.2
CHDH 19.7 2.4E-03 NM_018397.3 HMMR 7.1 1.5E-03 NM_012484.1
ALDH1A2 19.3 1.3E-04 NM_170696.1 SERPINA1 7.0 7.2E-05 NM_001002236.1
PCOLCE2 19.0 7.6E-04 NM_013363.2 ALOX5 7.0 5.4E-04 XM_001127464.1
MOBKL2B 18.4 3.8E-06 NM_024761.3 LOC731954 6.8 3.8E-04 XR_015662.2
FAM23B 18.4 7.6E-06 NM_001013629.1 CSF1 6.7 7.2E-06 NM_172212.1
COL22A1 17.5 1.1E-02 NM_152888.1 RNASE2 6.7 1.6E-04 NM_002934.2
GLDN 17.2 6.7E-06 NM_181789.2 HBEGF 6.6 5.0E-04 NM_001945.1
MT1H 15.2 7.5E-05 NM_005951.2 CENPM 6.6 4.6E-03 NM_001002876.1
CCL23 14.9 5.1E-05 NM_145898.1 OLR1 6.5 4.8E-03 NM_002543.3
ADAMTSL4 13.4 5.2E-05 NM_025008.3 RGNEF 6.4 7.6E-04 NM_001080479.1
TREM1 12.7 6.1E-06 NM_018643.2 C1QA 6.4 2.3E-04 NM_015991.1
LOC645638 12.7 4.0E-05 XR_040455.1 CDC45L 6.3 1.7E-02 NM_003504.3
IL1F8 12.7 1.5E-04 NM_173178.1 MS4A14 6.3 5.5E-04 NM_001079692.1
OR8G5 12.7 1.6E-03 NM_001005198.1 ARAP3 6.2 2.7E-04 NM_022481.5
SPINK1 11.7 4.8E-03 NM_003122.2 NEDD9 6.1 2.1E-04 NM_006403.2
MT1G 11.6 4.0E-05 NM_005950.1 ASPM 6.1 1.3E-03 NM_018136.3
AGRP 11.3 2.7E-04 NM_007316.1 CA12 6.0 2.5E-03 NM_001218.3
HSD11B1 11.1 2.5E-05 NM_181755.1 TK1 6.0 6.5E-03 NM_003258.2
HSD11B1 10.7 2.4E-05 NM_005525.2 RAP1GAP 5.9 4.2E-03 NM_002885.1
UBE2C 10.5 1.7E-03 NM_181800.1 CTSG 5.9 1.1E-03 NM_001911.2
CPE 10.5 1.4E-02 NM_001873.1 NEK2 5.9 8.6E-04 NM_002497.2
CES1 10.5 4.2E-04 NM_001025195.1 CHI3L2 5.9 5.1E-03 NM_004000.2
CFH 10.2 6.1E-05 NM_001014975.1 ZBTB7C 5.8 1.5E-03 NM_001039360.1
HSD11B1 9.8 2.5E-05 NM_181755.1 VSIG4 5.8 3.5E-04 NM_007268.2
EMR3 9.7 7.2E-05 NM_032571.2 TTC39B 5.8 1.2E-02 NM_152574.1
CFH 9.6 3.8E-05 NM_001014975.1 LDLRAP1 5.8 9.3E-05 NM_015627.2
APM-1 9.4 1.2E-03 XM_113971.4 FANCE 5.8 4.8E-06 NM_021922.2
HES2 9.4 1.2E-03 NM_019089.3 CCL18 5.6 1.6E-03 NM_002988.2
KIAA0101 9.3 1.0E-02 NM_014736.4 CSF1 5.5 6.7E-06 NM_172212.1
CSF1 9.2 7.2E-06 NM_000757.3 CDC2 5.4 1.1E-02 NM_001786.2
TOP2A 9.0 4.1E-03 NM_001067.2 TCEA3 5.4 1.2E-02 NM_003196.1
KIF20A 9.0 8.4E-04 NM_005733.1 FAIM2 5.3 3.8E-02 NM_012306.2
ZDHHC19 8.9 8.5E-05 NM_001039617.1 CTSW 5.2 2.1E-03 NM_001335.3
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Gene FC p (Corr) Accession Gene FC p (Corr) Accession
PITX1 5.2 3.8E-05 NM_002653.3 FOLR3 4.0 2.1E-03 NM_000804.2
CDC2 5.2 6.5E-03 NM_001786.2 CAMP 4.0 1.8E-03 NM_004345.3
APOBEC3B 5.1 8.0E-03 NM_004900.3 VNN2 3.9 3.0E-02 NM_078488.1
LOC644680 5.1 6.5E-03 XM_932300.1 APOL4 3.9 7.6E-04 NM_030643.3
TEX14 5.1 2.5E-02 NM_031272.3 C20ORF127 3.9 1.7E-03 NM_080757.1
IL7R 5.0 1.6E-03 NM_002185.2 WWTR1 3.9 5.6E-03 NM_015472.3
KIF11 5.0 1.8E-03 NM_004523.2 MAPRE3 3.9 6.0E-04 NM_012326.2
ANKRD29 5.0 3.4E-03 NM_173505.2 FAM113B 3.9 2.2E-03 NM_138371.1
CDC20 4.9 3.0E-03 NM_001255.2 SH2B2 3.9 2.9E-04 NM_020979.2
TCF7L2 4.9 2.2E-04 NM_030756.2 TM7SF4 3.9 2.1E-04 NM_030788.2
ITGB3 4.9 7.6E-03 NM_000212.2 LOC653481 3.9 8.2E-03 XM_927594.1
HMMR 4.8 1.2E-03 NM_012485.1 C6ORF105 3.8 1.8E-03 NM_032744.1
IL1F5 4.8 1.9E-02 NM_173170.1 RHBDD2 3.8 4.5E-04 NM_001040456.1
AURKB 4.8 5.1E-03 NM_004217.2 HS.126245 3.8 4.5E-04 CR743148
C12ORF59 4.7 1.8E-03 NM_153022.1 MRC1 3.8 7.6E-04 NM_002438.2
S1PR4 4.7 1.5E-04 NM_003775.2 HPGD 3.8 2.0E-03 NM_000860.3
IL1A 4.7 3.5E-02 NM_000575.3 ZBTB8A 3.8 4.9E-04 NM_001040441.1
ANLN 4.6 3.7E-03 NM_018685.2 SOBP 3.8 1.8E-03 NM_018013.3
KIFC1 4.6 3.8E-03 NM_002263.2 CTNNAL1 3.8 1.5E-03 NM_003798.2
ABCG2 4.6 2.9E-02 NM_004827.2 VASP 3.7 1.5E-04 NM_003370.3
CTNNAL1 4.6 2.2E-03 NM_003798.1 GPD1 3.7 7.6E-03 NM_005276.2
RRM2 4.6 2.0E-02 NM_001034.1 C15ORF21 3.7 9.3E-05 NM_001005267.1
SPIN4 4.6 1.1E-03 NM_001012968.2 TMCC3 3.7 2.9E-04 NM_020698.1
TYMS 4.6 2.2E-02 NM_001071.1 AQP3 3.7 8.0E-04 NM_004925.3
SVIL 4.5 7.6E-04 NM_003174.3 DDO 3.7 7.6E-04 NM_004032.2
SERPINA1 4.5 5.1E-05 NM_001002235.1 IL3RA 3.7 1.7E-02 NM_002183.2
AQP12A 4.5 4.0E-05 NM_198998.1 CLEC12A 3.7 3.3E-04 NM_201623.2
LOC730081 4.4 4.2E-03 XR_041261.1 SERPINA1 3.7 9.3E-05 NM_001002236.1
MT1A 4.4 2.9E-04 NM_005946.2 IL1F10 3.7 9.6E-03 NM_173161.1
MT2A 4.4 2.0E-04 NM_005953.2 SPN 3.6 4.2E-04 NM_003123.3
CES1 4.4 1.8E-03 XM_945034.1 KAL1 3.6 2.6E-02 NM_000216.2
CLEC12A 4.4 2.1E-04 NM_138337.4 KBTBD11 3.6 3.8E-04 NM_014867.1
S100A13 4.3 6.0E-05 NM_001024211.1 PKIA 3.6 5.3E-03 NM_006823.2
GINS2 4.3 8.0E-03 NM_016095.1 NRGN 3.6 6.5E-03 NM_006176.1
IL1RN 4.3 4.2E-03 NM_173843.1 IL1RN 3.6 8.9E-03 NM_173842.1
BUB1 4.3 7.4E-03 NM_004336.2 RHBDD2 3.6 6.4E-04 NM_001040456.1
MPZL2 4.3 1.0E-02 NM_005797.2 DEFB1 3.6 9.3E-03 NM_005218.3
SPINT1 4.2 3.1E-03 NM_003710.3 CLEC12A 3.6 1.5E-04 NM_138337.4
IL7R 4.2 1.6E-03 XM_937367.1 CCND2 3.6 1.1E-02 NM_001759.2
CKAP2L 4.2 1.0E-02 NM_152515.2 APCDD1L 3.5 9.9E-03 NM_153360.1
RGNEF 4.2 2.2E-03 XM_932949.2 LAPTM4B 3.5 5.5E-03 NM_018407.4
GPX3 4.2 1.6E-03 NM_002084.3 CD1B 3.5 3.7E-02 NM_001764.2
CPM 4.2 1.6E-03 NM_001874.3 MS4A14 3.5 1.1E-03 NM_032597.3
MT1E 4.1 3.0E-03 NM_175617.3 LOC728744 3.5 2.0E-02 XM_001128342.1
NDC80 4.1 3.7E-03 NM_006101.1 PAQR5 3.5 4.1E-03 NM_017705.2
ALOX5AP 4.1 1.0E-05 NM_001629.2 SNAI3 3.5 5.9E-05 NM_178310.1
LGALS3BP 4.1 1.5E-03 NM_005567.2 GCHFR 3.5 3.8E-04 NM_005258.2
CCNA2 4.1 2.9E-03 NM_001237.2 ITGA6 3.5 4.0E-03 NM_000210.2
MTMR11 4.1 1.1E-03 NM_181873.2 GALNT12 3.5 2.9E-03 NM_024642.3
HS.116870 4.1 8.3E-04 BG776012 LOC400174 3.5 1.1E-03 XR_016147.1
CCNB2 4.1 1.5E-03 NM_004701.2 ITGA6 3.4 2.4E-03 NM_000210.2
LOC650261 4.1 1.2E-02 XM_939353.1 CDT1 3.4 2.3E-02 NM_030928.2
FCHO1 4.0 1.1E-03 NM_015122.1 ALAS1 3.4 6.0E-05 NM_000688.4
PRSS21 4.0 4.4E-03 NM_144956.1 PRC1 3.4 8.7E-03 NM_199413.1
CCND2 4.0 9.2E-03 NM_001759.2 CENPN 3.4 8.5E-05 NM_018455.3
FLJ21986 4.0 1.0E-02 NM_024913.3 CLEC1A 3.4 2.1E-02 NM_016511.2
Aug-99 4.0 1.8E-03 NM_019106.4 FCGR1B 3.4 2.8E-03 NM_001004340.1
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ARAP3 3.4 1.8E-03 NM_022481.5 P2RX1 2.9 3.6E-03 NM_002558.2
TMEM173 3.3 5.2E-04 NM_198282.1 HS.4892 2.9 1.2E-02 AF131834
CALCOCO1 3.3 3.8E-04 NM_020898.1 CLEC6A 2.9 5.1E-03 NM_001007033.1
PROS1 3.3 5.8E-04 NM_000313.1 CLEC1B 2.9 8.5E-03 NM_016509.3
ANKRD29 3.3 2.7E-02 NM_173505.2 UGP2 2.9 5.2E-05 NM_006759.3
MYOZ1 3.3 1.2E-03 NM_021245.2 KCNE1 2.9 2.9E-03 NM_000219.2
SORT1 3.3 1.7E-04 NM_002959.4 ECHDC2 2.9 3.7E-02 NM_018281.2
GPRIN3 3.3 8.0E-04 NM_198281.2 NMB 2.9 5.2E-04 NM_021077.3
CENPA 3.3 1.5E-02 NM_001042426.1 ADAMTSL4 2.9 7.3E-03 NM_019032.4
TREML3 3.3 1.2E-02 XM_929970.2 Aug-99 2.9 1.7E-03 NM_019106.4
MT1F 3.3 9.2E-03 NM_005949.2 MFGE8 2.9 1.5E-02 NM_005928.1
SLC44A2 3.3 1.7E-04 NM_020428.2 FCGR1C 2.8 2.4E-03 NM_001128589.1
KIF2C 3.3 9.9E-04 NM_006845.2 SEMA4B 2.8 1.6E-03 NM_198925.1
FCGR1A 3.3 1.6E-03 NM_000566.2 HRK 2.8 1.7E-02 NM_003806.1
CDKN3 3.3 3.6E-04 NM_005192.2 NLRP2 2.8 4.9E-02 NM_017852.1
S100A16 3.2 4.4E-03 NM_080388.1 CENPM 2.8 1.0E-02 NM_001002876.1
PPARD 3.2 8.5E-05 NM_006238.2 HIST2H2AB 2.8 1.4E-03 NM_175065.2
PODXL 3.2 1.5E-02 NM_001018111.1 LOC646674 2.8 3.7E-03 XR_042303.1
NLRP12 3.2 2.0E-02 NM_144687.1 GSN 2.8 1.7E-04 NM_198252.2
TMEM44 3.2 2.4E-03 NM_138399.3 CLEC5A 2.8 5.1E-03 NM_013252.2
CTAGE5 3.2 6.1E-04 NM_203355.1 LOC647357 2.8 1.3E-03 XR_001274.1
MCM10 3.2 3.4E-02 NM_018518.3 C17ORF87 2.8 1.6E-03 NM_207103.2
LOC729652 3.2 1.8E-02 XR_040489.1 TSPAN32 2.8 9.9E-03 NM_005705.4
C7ORF58 3.2 2.5E-03 NM_001105533.1 PPIC 2.8 2.2E-02 NM_000943.4
CDCP1 3.2 1.2E-02 NM_178181.1 TSPAN32 2.8 1.1E-03 NM_005705.4
LOC100131391 3.2 1.5E-03 XM_001726689.1 ABCB9 2.8 1.1E-03 NM_019624.2
CHST11 3.1 7.1E-03 NM_018413.3 LOC401002 2.8 1.8E-03 XR_018284.1
LOC641972 3.1 1.6E-03 XM_935742.1 F5 2.8 3.6E-03 NM_000130.4
PPP1R13B 3.1 1.4E-02 NM_015316.2 JUP 2.7 1.3E-03 NM_021991.1
CDCP1 3.1 2.7E-03 NM_178181.1 FAM89A 2.7 1.6E-02 NM_198552.1
TGFA 3.1 1.7E-03 NM_003236.1 UGP2 2.7 4.5E-04 NM_006759.3
FBXO15 3.1 1.6E-03 NM_152676.1 TMEM44 2.7 2.3E-02 NM_138399.3
GJB2 3.1 3.1E-03 NM_004004.4 TMPO 2.7 1.5E-03 NM_003276.1
FBP1 3.1 9.6E-05 NM_000507.2 TPX2 2.7 9.8E-03 NM_012112.4
SPOCD1 3.1 4.8E-03 NM_144569.4 STMN1 2.7 2.6E-02 NM_005563.3
PROCR 3.1 1.1E-02 NM_006404.3 LOC649276 2.7 6.3E-03 XM_938336.1
OR8G1 3.1 2.2E-02 NM_001002905.1 LOC645726 2.7 3.0E-03 XR_018230.2
CEP55 3.0 1.1E-02 NM_018131.3 PKMYT1 2.7 9.0E-03 NM_182687.1
PROK1 3.0 2.3E-04 NM_032414.2 SSBP3 2.7 5.1E-03 NM_018070.3
LOC647108 3.0 1.4E-02 XM_934378.1 FGFRL1 2.7 3.9E-04 NM_021923.3
MGAT3 3.0 4.5E-02 NM_002409.4 SLC39A3 2.7 4.0E-05 NM_213568.1
EMR3 3.0 1.3E-03 NM_032571.3 BUB1B 2.7 3.3E-04 NM_001211.4
MAP1LC3A 3.0 2.0E-03 NM_181509.1 IL1RAP 2.7 3.7E-03 NM_134470.2
CBS 3.0 5.1E-03 NM_000071.1 LOC441019 2.7 4.5E-03 XM_498969.2
MT1H 3.0 2.1E-02 NM_005951.1 ACOX1 2.7 3.9E-03 NM_004035.4
MGC26733 3.0 3.8E-04 NM_144992.3 NUSAP1 2.7 4.1E-03 NM_018454.5
ABCB9 3.0 2.4E-03 NM_019624.2 SYNC 2.6 9.7E-03 NM_030786.2
C11ORF21 3.0 1.6E-02 NM_001142946.1 ABAT 2.6 1.4E-02 NM_000663.3
FCGR1B 2.9 2.5E-03 NM_001017986.1 ACVRL1 2.6 2.9E-03 NM_000020.1
COL8A2 2.9 4.0E-05 NM_005202.1 QSOX1 2.6 2.3E-04 NM_002826.4
SPN 2.9 2.7E-04 NM_001030288.1 CDCP1 2.6 7.7E-03 NM_178181.1
SSPN 2.9 1.3E-03 NM_005086.3 CPM 2.6 4.4E-02 NM_001005502.1
HES2 2.9 3.5E-03 NM_019089.3 KIF11 2.6 1.1E-02 NM_004523.2
AOC3 2.9 2.2E-02 NM_003734.2 BHLHB3 2.6 2.7E-04 NM_030762.1
CACNG1 2.9 1.3E-03 NM_000727.2 MCF2L2 2.6 3.9E-02 NM_015078.2
GPT 2.9 5.6E-03 NM_005309.1 PCGF2 2.6 4.4E-03 NM_007144.2
LMNB1 2.9 9.2E-03 NM_005573.2 LOC389049 2.6 4.2E-03 XR_017334.2
Appendix I
Gene FC p (Corr) Accession Gene FC p (Corr) Accession
CDC42EP3 2.6 3.7E-02 NM_006449.3 CD276 2.4 1.7E-03 NM_025240.2
SH2D3C 2.6 7.9E-03 NM_170600.1 HS.563550 2.4 1.9E-02 BQ184411
FAM64A 2.6 6.7E-03 NM_019013.1 HPCAL1 2.4 4.7E-03 NM_134421.1
ABCG1 2.6 1.8E-02 NM_016818.2 E2F2 2.4 2.9E-02 NM_004091.2
QPCT 2.6 1.2E-03 NM_012413.3 ACTA2 2.4 1.3E-02 NM_001613.1
COL8A2 2.6 3.2E-04 NM_005202.1 OIP5 2.4 3.1E-02 NM_007280.1
SAV1 2.6 8.9E-04 NM_021818.2 HS.561747 2.4 1.5E-04 BU935198
TCN1 2.6 2.5E-02 NM_001062.3 S100A13 2.4 4.4E-03 NM_005979.2
AMICA1 2.6 7.6E-03 NM_153206.1 LPCAT2 2.4 2.7E-04 NM_017839.3
LOC100132510 2.6 3.6E-04 XM_001725190.1 POLD1 2.4 5.5E-04 NM_002691.1
LOC653204 2.6 1.9E-03 XM_926469.1 RAB17 2.4 3.2E-02 NM_022449.1
OIP5 2.6 1.2E-02 NM_007280.1 DNASE2B 2.4 2.9E-03 NM_021233.2
VDR 2.6 4.7E-03 NM_000376.2 LOC729057 2.4 2.7E-03 XR_042044.1
CFH 2.6 1.7E-03 NM_001014975.1 PELI3 2.4 7.8E-03 NM_145065.1
LOC441241 2.6 8.4E-04 XM_935516.1 LOC730546 2.4 9.5E-03 XM_001126287.1
ALAS1 2.5 2.1E-04 NM_199166.1 DENND5A 2.4 4.0E-03 NM_015213.2
RASL11A 2.5 5.7E-03 NM_206827.1 USP30 2.4 1.2E-03 NM_032663.2
PRKAR1A 2.5 4.3E-04 NM_212471.1 TGM2 2.3 9.2E-03 NM_004613.2
CRABP2 2.5 3.1E-02 NM_001878.2 ABHD14A 2.3 1.4E-02 NM_015407.3
PPIC 2.5 3.8E-02 NM_000943.4 CLEC11A 2.3 2.2E-03 NM_002975.2
HS.173957 2.5 3.0E-03 AW967735 C14ORF106 2.3 2.2E-03 NM_018353.3
C14ORF72 2.5 5.9E-03 XM_944937.2 LOC1001290342.3 1.2E-03 XM_001720357.1
LOC387841 2.5 4.4E-03 XM_932678.1 BACE1 2.3 4.2E-03 NM_138972.2
SPC24 2.5 6.6E-03 NM_182513.1 C17ORF47 2.3 2.5E-02 NM_001038704.1
ALOX5 2.5 1.7E-02 NM_000698.2 C5ORF4 2.3 7.9E-03 NM_032385.3
SIGLEC11 2.5 2.5E-02 NM_052884.1 C17ORF87 2.3 1.1E-02 NM_207103.1
KIAA0922 2.5 2.5E-03 NM_015196.2 LOC729259 2.3 2.2E-03 XR_037945.1
FAM19A3 2.5 1.4E-02 NM_182759.2 C5ORF27 2.3 2.7E-03 XR_040299.1
NDUFV3 2.5 1.0E-03 NM_001001503.1 NUAK2 2.3 1.5E-03 NM_030952.1
FAM89A 2.5 2.2E-03 NM_198552.1 MGC33556 2.3 2.0E-02 NM_001004307.1
SPINT1 2.5 3.1E-03 NM_003710.3 PEX14 2.3 1.9E-03 NM_004565.2
C1QB 2.5 4.2E-02 NM_000491.3 NFIX 2.3 2.6E-02 NM_002501.2
UHRF1 2.5 3.2E-02 NM_001048201.1 ZNF609 2.3 5.9E-03 NM_015042.1
SLC22A16 2.5 3.7E-03 NM_033125.2 LIPN 2.3 1.0E-02 NM_001102469.1
TNFSF13 2.5 1.5E-02 NM_172088.1 FCGR2B 2.3 3.5E-03 NM_004001.3
PDE1B 2.5 3.5E-02 NM_000924.2 ABAT 2.3 8.0E-04 NM_000663.3
NEXN 2.5 2.1E-03 NM_144573.3 HS.187499 2.3 1.9E-02 BC063871
EPR1 2.5 3.1E-02 NR_002219.1 FAM89A 2.3 8.8E-03 NM_198552.1
TMPO 2.5 3.2E-04 NM_003276.1 FLJ40453 2.3 4.7E-02 NM_001007542.1
PDE3B 2.4 4.8E-03 NM_000922.2 BCL2A1 2.3 6.6E-03 NM_004049.2
CDCA3 2.4 1.7E-02 NM_031299.3 SMAD7 2.3 4.2E-03 NM_005904.2
C9ORF127 2.4 1.5E-03 NM_016446.2 TSPAN18 2.3 8.5E-03 NM_130783.3
CDS1 2.4 1.5E-03 NM_001263.2 RAPGEFL1 2.3 3.9E-02 NM_016339.2
PSD3 2.4 2.5E-04 NM_015310.3 B3GALTL 2.3 5.6E-04 NM_194318.3
PLK1 2.4 1.9E-02 NM_005030.3 ATP6V1E2 2.3 1.3E-03 NM_080653.3
PIK3CG 2.4 2.1E-04 NM_002649.2 CD300LF 2.3 8.5E-04 NM_139018.2
FMNL3 2.4 3.7E-02 NM_198900.2 TCEB2 2.3 2.8E-03 NM_007108.2
IL8RB 2.4 2.3E-03 NM_001557.2 LOC1001291692.3 2.9E-03 XM_001716328.1
SMAD7 2.4 1.1E-03 NM_005904.2 JUP 2.3 2.1E-03 NM_002230.1
MSI2 2.4 2.1E-02 NM_170721.1 MND1 2.3 3.0E-02 NM_032117.2
KIF23 2.4 1.1E-03 NM_004856.4 ST6GALNAC4 2.3 1.5E-03 NM_175039.3
NUSAP1 2.4 2.3E-03 NM_018454.5 NUP210 2.3 2.4E-02 NM_024923.2
RAPGEF3 2.4 4.2E-02 NM_006105.3 LIMK2 2.3 7.0E-03 NM_001031801.1
PPARG 2.4 7.6E-04 NM_138712.3 PPP2R1B 2.3 3.2E-03 NM_181699.2
LBR 2.4 3.8E-04 NM_002296.2 LOC93349 2.2 9.3E-03 NM_138402.3
FAM135B 2.4 3.7E-03 NM_015912.3 PLAUR 2.2 2.2E-03 NM_002659.2
P2RY12 2.4 2.3E-02 NM_022788.3 PLEKHG4 2.2 2.2E-03 NM_015432.2
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Gene FC p (Corr) Accession Gene FC p (Corr) Accession
TUT1 2.2 2.2E-03 NM_022830.1 AK1 2.1 5.6E-03 NM_000476.1
PFTK1 2.2 2.9E-03 NM_012395.2 CENPA 2.1 1.7E-02 NM_001042426.1
MYO1G 2.2 3.7E-02 NM_033054.1 HLA-DQB2 2.1 1.8E-03 NM_182549.1
LNPEP 2.2 2.2E-02 NM_175920.3 LOC1001313642.1 6.2E-03 XM_001725122.1
CTXN1 2.2 1.8E-03 NM_206833.2 DENND5A 2.1 6.5E-03 NM_015213.2
RTN2 2.2 4.5E-03 NM_206901.1 FAM89A 2.1 2.0E-02 XM_939093.1
SSBP3 2.2 5.4E-03 NM_018070.3 CENPK 2.1 3.8E-02 NM_022145.3
GSN 2.2 3.7E-02 NM_000177.3 CA11 2.1 1.1E-02 NM_001217.3
ABHD2 2.2 1.6E-03 NM_152924.3 RECK 2.1 3.1E-03 NM_021111.1
CD276 2.2 1.3E-02 NM_025240.2 KIAA0564 2.1 6.8E-04 NM_015058.1
CCNB1 2.2 1.6E-03 NM_031966.2 MPO 2.1 2.3E-02 NM_000250.1
ACOT1 2.2 9.7E-03 NM_001037161.1 IGSF8 2.1 1.9E-03 NM_052868.2
EFCAB4A 2.2 2.2E-02 NM_173584.3 RPS6KA1 2.1 2.5E-04 NM_002953.3
NDST1 2.2 2.0E-03 NM_001543.3 FCGR2B 2.1 6.9E-03 XM_938851.1
LY6E 2.2 1.0E-02 NM_002346.1 ITPKB 2.1 9.0E-04 NM_002221.2
BACE1 2.2 1.2E-02 NM_138971.2 TRAF3IP2 2.1 7.0E-03 NM_147686.1
MGC12538 2.2 7.1E-03 XR_040874.1 TBC1D10C 2.1 2.0E-02 NM_198517.2
NCF1 2.2 3.8E-02 NM_000265.4 C1ORF210 2.1 1.2E-02 NM_182517.1
KCNQ1 2.2 1.2E-02 NM_000218.2 LOC284757 2.1 1.1E-02 NM_001004305.1
SDCCAG8 2.2 1.7E-03 NM_006642.2 HELLS 2.1 1.4E-02 NM_018063.3
GK 2.2 1.1E-03 NM_203391.1 SLC25A40 2.1 1.6E-03 NM_018843.2
MYD88 2.2 3.7E-04 NM_002468.3 DOK2 2.1 1.6E-02 NM_003974.2
SLC27A3 2.2 7.3E-04 NM_024330.1 TRIP13 2.1 1.2E-02 NM_004237.2
EML4 2.2 5.4E-04 NM_019063.2 SEL1L3 2.1 7.5E-03 NM_015187.3
SPINK6 2.2 5.1E-03 NM_205841.2 FPR2 2.1 3.9E-02 NM_001005738.1
PTTG3P 2.2 9.2E-03 NR_002734.1 METTL9 2.0 1.5E-02 NM_016025.3
CSPG5 2.2 9.0E-04 NM_006574.3 LOC152586 2.0 1.8E-02 XM_929404.1
ACE 2.2 1.5E-02 NM_152830.1 KILLIN 2.0 3.9E-02 NM_001126049.1
VASH1 2.2 4.8E-04 NM_014909.3 ANKRD28 2.0 5.4E-03 NM_015199.2
ICAM2 2.2 4.5E-02 NM_001099786.1 HS.518527 2.0 1.3E-02 XM_374071
C13ORF3 2.2 2.9E-03 NM_145061.3 CSTA 2.0 7.6E-04 NM_005213.3
ABHD2 2.2 2.1E-03 NM_152924.3 CHAF1A 2.0 3.7E-02 NM_005483.2
KIAA0564 2.2 3.7E-03 NM_015058.1 HVCN1 2.0 1.7E-03 NM_001040107.1
LOC642456 2.2 1.1E-03 XM_925964.1 PTPN22 2.0 9.6E-04 NM_015967.3
PTPN22 2.2 1.9E-03 NM_012411.2 ACO1 2.0 4.7E-04 NM_002197.1
LIN7B 2.2 1.6E-03 NM_022165.2 PHLDA3 2.0 1.1E-02 NM_012396.3
S100A13 2.2 1.6E-03 NM_001024212.1 NT5C3L 2.0 2.0E-02 NM_052935.2
GK 2.2 2.7E-03 NM_000167.3 ABCG1 2.0 4.8E-02 NM_016818.2
TSGA14 2.2 2.0E-04 NM_018718.1 LOC652616 2.0 9.7E-03 XM_942152.1
C12ORF37 2.2 2.7E-03 XM_001134418.1 UFD1L 2.0 3.3E-02 NM_001035247.1
MYCBP 2.1 2.2E-03 NM_012333.3 MCM7 2.0 1.7E-02 NM_182776.1
HVCN1 2.1 1.7E-03 NM_032369.2 ITGA5 2.0 4.8E-03 NM_002205.2
C1S 2.1 2.7E-02 NM_001734.2 CD276 2.0 3.7E-03 NM_001024736.1
PLAUR 2.1 1.1E-03 NM_001005376.1 LOC1001334592.0 2.3E-03 XM_001720054.1
DENND3 2.1 7.3E-03 NM_014957.2 GAS1 2.0 5.5E-03 NM_002048.1
FAM100A 2.1 1.6E-03 NM_145253.2 CKLF 2.0 4.3E-04 NM_001040139.1
ZMYND15 2.1 1.2E-03 NM_032265.1 HS.191602 2.0 3.2E-02 AI821625
MPZL2 2.1 4.5E-03 NM_144765.1 EVL 2.0 4.7E-03 NM_016337.2
NEK6 2.1 5.4E-03 NM_014397.3 ST6GALNAC4 2.0 1.5E-03 NM_175039.3
SLC11A1 2.1 5.4E-03 NM_000578.2 DHCR24 2.0 2.4E-02 NM_014762.3
CTAGE6 2.1 3.7E-03 XM_936776.2 CCDC102B 2.0 1.5E-02 NM_001093729.1
PTPN22 2.1 3.7E-03 NM_015967.3 AKR1C3 2.0 3.9E-02 NM_003739.4
NEUROG2 2.1 8.9E-04 NM_024019.2 SLC9A1 2.0 1.6E-03 NM_003047.2
SLC25A29 2.1 1.2E-02 NM_001039355.1 LOC730254 2.0 2.2E-02 XM_001724977.1
LAPTM4B 2.1 6.8E-03 NM_018407.4 INSIG1 2.0 2.1E-02 NM_198336.1
FPR2 2.1 2.6E-02 NM_001462.3 PTCRA 2.0 3.4E-02 NM_138296.2
RASAL2 2.1 6.3E-03 NM_170692.1 KIF15 2.0 1.3E-02 NM_020242.1
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SEPP1 -89.9 1.1E-05 NM_005410.2 HPSE -6.9 3.3E-04 NM_006665.3
M160 -52.6 7.8E-06 NM_174941.3 GNG2 -6.9 3.9E-04 NM_053064.3
ADORA3 -45.3 4.5E-06 NM_001081976.1 ZNF467 -6.9 3.4E-04 NM_207336.1
LEP -34.1 7.8E-06 NM_000230.1 HPSE -6.9 1.0E-04 NM_006665.2
CACNA2D3 -34.0 3.9E-06 NM_018398.2 SRGAP3 -6.8 2.8E-04 NM_001033117.1
STAB1 -30.1 1.0E-05 NM_015136.2 DEPDC6 -6.7 4.6E-04 NM_022783.1
SERPINB2 -25.6 1.0E-05 NM_002575.1 EBI3 -6.7 1.4E-03 NM_005755.2
SERPINB2 -23.5 3.3E-05 NM_002575.1 ARL4C -6.6 1.1E-04 NM_005737.3
RNASE1 -22.2 1.7E-03 NM_198232.1 DEPDC6 -6.6 5.0E-05 NM_022783.1
CD163L1 -21.3 4.0E-05 NM_174941.4 RARRES1 -6.6 4.3E-05 NM_206963.1
SLC40A1 -19.7 5.3E-06 NM_014585.3 CUL9 -6.4 2.1E-05 NM_015089.2
IGF1 -19.0 6.8E-05 NM_000618.2 GAMT -6.4 3.3E-05 NM_000156.4
FLJ14213 -17.9 3.9E-06 NM_024841.3 NOV -6.3 2.3E-04 NM_002514.2
SERPINF1 -16.6 3.6E-05 NM_002615.4 TCF4 -6.1 3.4E-04 NM_003199.2
LGMN -16.2 3.4E-05 NM_001008530.1 ASIP -6.0 6.9E-05 NM_001672.2
CADM1 -15.7 3.1E-05 NM_014333.3 GATM -6.0 5.7E-04 NM_001482.2
ADORA3 -15.4 1.2E-04 NM_000677.3 HS.197143 -5.9 4.7E-05 AK126405
TMEM119 -15.4 4.2E-04 NM_181724.1 ADAM8 -5.8 9.7E-04 NM_001109.3
OLFML2B -15.2 8.6E-04 NM_015441.1 CCL2 -5.8 9.2E-03 NM_002982.3
SGPP2 -15.2 6.9E-04 XM_938742.1 SLC9A9 -5.6 4.7E-05 NM_173653.1
DLL1 -14.8 3.9E-06 NM_005618.3 BIRC3 -5.6 1.4E-03 NM_001165.3
SLC40A1 -14.7 6.2E-05 NM_014585.4 RASAL1 -5.6 1.7E-04 NM_004658.1
COL23A1 -14.2 2.1E-05 NM_173465.2 EDNRB -5.6 7.8E-06 NM_000115.1
BAALC -14.1 9.2E-06 NM_001024372.1 PTGDS -5.5 2.8E-04 NM_000954.5
RNASE1 -14.1 3.4E-03 NM_198235.1 MTSS1 -5.5 5.6E-05 NM_014751.4
HS3ST1 -13.4 2.6E-04 NM_005114.2 IL10 -5.5 5.4E-04 NM_000572.2
RBP1 -12.3 5.7E-04 NM_002899.2 TPST1 -5.5 2.0E-02 NM_003596.2
RAB3IL1 -12.1 8.6E-04 NM_013401.2 DHDH -5.5 3.3E-03 NM_014475.3
CD38 -11.9 1.0E-04 NM_001775.2 MARCKS -5.4 6.4E-05 NM_002356.5
TNFRSF9 -11.5 6.3E-04 NM_001561.4 LPAR5 -5.3 3.8E-03 NM_020400.4
FZD2 -11.5 1.7E-04 NM_001466.2 CXCL12 -5.3 6.0E-03 NM_199168.2
ADAMDEC1 -11.3 2.1E-05 NM_014479.2 MTSS1 -5.3 1.4E-05 NM_014751.2
TPSAB1 -11.3 3.4E-02 NM_003294.3 RGS20 -5.2 3.1E-03 NM_170587.1
CCL8 -11.0 6.5E-03 NM_005623.2 NCKAP1 -5.1 1.3E-03 NM_013436.3
BAALC -10.9 1.2E-04 NM_024812.2 PDK4 -5.1 3.2E-03 NM_002612.3
LILRB5 -10.2 3.1E-03 NM_006840.3 GSDMA -5.1 5.1E-03 NM_178171.4
EBI2 -9.4 7.3E-05 NM_004951.3 DYRK3 -5.1 1.5E-04 NM_003582.2
LGMN -9.3 1.1E-04 NM_001008530.1 VCAM1 -5.1 4.5E-03 NM_001078.2
CLEC10A -9.2 2.8E-03 NM_006344.2 ADA -5.0 1.2E-04 NM_000022.2
SCIN -9.1 1.3E-05 NM_033128.1 ATP8A1 -5.0 1.1E-05 NM_006095.1
FAM174B -8.9 5.3E-06 NM_207446.2 NT5DC2 -5.0 1.6E-05 NM_022908.1
IL18BP -8.3 2.1E-05 NM_173042.2 CD320 -5.0 4.3E-04 NM_016579.2
SLC35F2 -8.2 3.8E-03 NM_017515.3 TIFAB -5.0 7.3E-04 NM_001099221.1
EBI2 -8.2 3.8E-05 NM_004951.3 C1ORF128 -5.0 1.3E-05 NM_020362.3
C10ORF116 -8.2 8.6E-04 NM_006829.2 TTYH2 -5.0 1.4E-04 NM_032646.5
GPR183 -8.0 1.9E-05 NM_004951.4 TSPAN10 -5.0 1.1E-04 NM_031945.3
ADAMDEC1 -7.9 2.6E-05 NM_014479.2 MMP25 -5.0 1.3E-03 NM_022468.4
SDS -7.8 2.2E-04 NM_006843.2 COBLL1 -5.0 7.7E-04 NM_014900.3
CMKLR1 -7.8 6.8E-05 NM_004072.1 KCNJ5 -4.9 1.3E-02 NM_000890.3
TMEM37 -7.8 6.7E-03 NM_183240.2 HS.561679 -4.9 1.2E-04 DA830074
RARRES1 -7.4 3.6E-05 NM_002888.2 PNMA3 -4.9 3.4E-03 NM_013364.4
KITLG -7.4 5.4E-06 NM_000899.3 TPCN1 -4.9 8.6E-04 NM_017901.3
HTR2B -7.3 8.7E-04 NM_000867.3 CDH23 -4.8 8.9E-04 NM_052836.1
P2RY6 -7.3 3.4E-04 NM_176796.1 KLHL13 -4.7 3.3E-04 NM_033495.2
CCDC81 -7.2 4.0E-05 NM_021827.3 NCKAP1 -4.7 5.1E-04 NM_205842.1
CLEC10A -7.0 2.2E-03 NM_006344.2 LY9 -4.7 1.3E-03 NM_002348.2
KITLG -7.0 4.1E-05 NM_000899.3 PDPN -4.7 6.4E-03 NM_001006625.1
Appendix II
Gene FC p (Corr) Accession Gene FC p (Corr) Accession
PRDM1 -4.6 9.0E-05 NM_001198.2 ETV5 -3.6 1.0E-03 NM_004454.1
IGF1 -4.6 1.6E-03 NM_000618.2 LY9 -3.6 8.5E-03 NM_001033667.1
STARD13 -4.6 1.6E-03 NM_178006.1 FBN2 -3.6 4.7E-02 NM_001999.3
FARP1 -4.6 3.2E-04 NM_005766.2 FOXRED2 -3.6 2.1E-03 NM_024955.4
RARRES1 -4.5 6.9E-05 NM_002888.2 FOLR2 -3.6 1.4E-03 NM_000803.3
BIRC3 -4.5 6.8E-04 NM_001165.3 CXCL12 -3.5 2.8E-02 NM_000609.4
LINCR -4.5 5.4E-04 NM_001080535.1 CD200R1 -3.5 3.7E-03 NM_138806.3
RIMS3 -4.5 1.8E-03 NM_014747.2 ABCB6 -3.5 1.5E-03 NM_005689.1
PLTP -4.5 4.2E-04 NM_182676.1 NINL -3.5 3.1E-03 NM_025176.4
ASNS -4.4 4.5E-03 NM_133436.1 PTGIR -3.5 4.8E-04 NM_000960.3
LGI2 -4.4 3.9E-03 NM_018176.2 MS4A6A -3.5 2.3E-03 NM_152851.1
C6ORF192 -4.4 2.1E-03 NM_052831.2 IER3 -3.4 1.3E-02 NM_003897.3
OSGIN1 -4.4 1.6E-03 NM_182980.2 CXCL10 -3.4 1.4E-02 NM_001565.2
ABCC5 -4.3 5.2E-04 NM_001023587.1 FUCA1 -3.4 3.3E-04 NM_000147.3
HS.547277 -4.3 3.3E-04 W91949 ABCA3 -3.4 1.6E-03 NM_001089.1
PLTP -4.2 1.8E-03 NM_006227.2 FLJ77644 -3.4 6.8E-04 XM_001133074.2
HTRA1 -4.2 4.2E-03 NM_002775.3 SEMA4A -3.4 3.4E-04 NM_022367.2
CMTM8 -4.2 9.7E-04 NM_178868.3 SEPP1 -3.3 2.8E-03 NM_005410.2
SIGLEC15 -4.2 6.8E-04 NM_213602.1 C14ORF78 -3.3 5.8E-03 XM_001132404.1
HS3ST2 -4.2 1.1E-02 NM_006043.1 MPEG1 -3.3 3.4E-04 XM_166227.6
SNORD99 -4.2 2.8E-04 NR_003077.1 ABCC5 -3.3 4.0E-04 NM_001023587.1
PRDM1 -4.1 3.4E-04 NM_001198.2 NCF4 -3.3 3.4E-04 NM_013416.2
HES4 -4.1 3.3E-03 NM_021170.2 AHNAK2 -3.3 1.7E-03 NM_138420.2
ALOX15B -4.1 5.9E-03 NM_001141.2 RCN3 -3.3 6.3E-04 NM_020650.2
OAF -4.1 9.4E-04 NM_178507.2 BNIP3 -3.3 1.6E-03 NM_004052.2
QPRT -4.1 5.9E-05 NM_014298.3 CDK6 -3.3 5.1E-04 NM_001259.5
CLEC10A -4.1 1.3E-02 NM_182906.2 HSPA6 -3.3 3.9E-03 NM_002155.3
HGF -4.1 2.8E-04 NM_000601.4 SEZ6L2 -3.3 4.9E-02 NM_201575.1
PSAT1 -4.0 2.6E-02 NM_021154.3 CHST13 -3.3 5.5E-04 NM_152889.1
SNAPC1 -4.0 1.6E-04 NM_003082.2 EYA2 -3.3 6.0E-04 NM_172112.1
BNC2 -4.0 9.3E-03 NM_017637.5 NQO1 -3.2 3.6E-03 NM_000903.2
IL18BP -4.0 5.6E-05 NM_173042.2 BIRC3 -3.2 1.0E-03 NM_182962.1
MYO7A -4.0 8.9E-04 NM_000260.2 DPP4 -3.2 1.0E-03 NM_001935.3
ADM -4.0 1.7E-03 NM_001124.1 NIPAL4 -3.2 2.9E-02 NM_001099287.1
RN5S9 -3.9 2.0E-02 NR_023371.1 PPM1L -3.2 1.4E-03 NM_139245.2
MS4A6A -3.9 4.4E-03 NM_022349.2 HS.259679 -3.2 1.9E-02 AW956608
SEMA3A -3.9 7.4E-03 NM_006080.2 CCNA1 -3.2 4.6E-03 NM_003914.2
DDIT4L -3.9 2.5E-05 NM_145244.2 IL1R2 -3.2 3.0E-02 NM_173343.1
TMEM26 -3.9 4.5E-03 NM_178505.5 SULT1C2 -3.2 4.6E-02 NM_001056.3
RGL1 -3.9 2.8E-05 NM_015149.3 SLC2A5 -3.2 3.3E-03 NM_003039.1
MEF2C -3.9 2.8E-03 NM_002397.2 CDH23 -3.2 2.0E-03 NM_022124.3
GAL3ST4 -3.9 2.5E-03 NM_024637.4 FBLN5 -3.2 3.4E-04 NM_006329.2
ALOX15B -3.9 2.0E-02 NM_001141.2 HS.560357 -3.1 1.3E-02 AI539492
CCL5 -3.8 4.2E-03 NM_002985.2 ADAM28 -3.1 4.9E-04 NM_014265.4
ABCB4 -3.8 3.0E-03 NM_018850.2 ZBTB46 -3.1 3.4E-04 NM_025224.2
CHCHD6 -3.8 1.3E-03 NM_032343.1 CD200R1 -3.1 1.4E-03 NM_138940.2
MS4A6A -3.8 2.0E-03 NM_152851.1 ALOX15B -3.1 2.4E-02 NM_001039131.1
KCNJ5 -3.8 1.1E-02 NM_000890.3 ZSWIM4 -3.1 7.1E-03 NM_023072.1
KIR2DL4 -3.8 1.4E-03 NM_002255.3 LTC4S -3.1 3.3E-03 NM_145867.1
CDH23 -3.8 2.7E-03 NM_052836.1 LEP -3.1 5.1E-03 NM_000230.1
P2RY8 -3.8 1.9E-03 NM_178129.3 OKL38 -3.1 5.9E-04 NM_013370.2
DYRK3 -3.7 2.2E-03 NM_003582.2 ABP1 -3.1 1.8E-02 NM_001091.2
DNM3 -3.7 3.1E-03 NM_015569.2 ABHD12 -3.1 5.2E-04 NM_015600.3
TMEM163 -3.7 2.6E-03 NM_030923.3 ETV5 -3.1 8.3E-04 NM_004454.1
MEGF6 -3.7 2.8E-04 NM_001409.3 Feb-05 -3.1 1.6E-03 NM_138396.4
UBR4 -3.7 6.7E-04 NM_020765.2 C5ORF20 -3.1 2.1E-03 NM_130848.2
PCSK6 -3.7 5.1E-03 NM_138325.2 FOXRED2 -3.0 1.4E-03 NM_024955.4
Appendix II
Gene FC p (Corr) Accession Gene FC p (Corr) Accession
MGC16384 -3.0 1.1E-04 XM_001726755.1 IL4I1 -2.7 3.4E-04 NM_172374.1
LAT -3.0 2.3E-02 NM_001014987.1 CLIC2 -2.7 1.2E-03 NM_001289.4
CCDC28B -3.0 4.3E-03 NM_024296.2 SAMD4A -2.7 5.6E-03 NM_015589.3
PIP -3.0 8.2E-03 NM_002652.2 S100A12 -2.7 9.0E-03 NM_005621.1
C14ORF45 -3.0 1.1E-03 NM_025057.1 C9ORF98 -2.7 1.1E-02 NM_152572.2
C20ORF26 -3.0 1.9E-02 NM_015585.2 CMBL -2.7 4.5E-02 NM_138809.3
RHBDL2 -3.0 7.3E-04 NM_017821.3 FNDC5 -2.7 3.1E-03 NM_153756.1
REPS2 -3.0 1.5E-02 NM_004726.2 PKD2L1 -2.7 1.7E-02 NM_016112.2
RASSF2 -3.0 3.1E-05 NM_170774.1 USP46 -2.7 1.3E-04 NM_022832.2
HS.40061 -3.0 1.4E-04 BX112120 SEZ6L2 -2.7 1.3E-02 NM_201575.1
MYO10 -3.0 4.8E-04 NM_012334.1 SGTB -2.7 1.1E-02 NM_019072.2
NAV2 -3.0 8.4E-04 NM_145117.3 ZKSCAN1 -2.7 3.7E-03 NM_003439.1
MME -2.9 3.1E-02 NM_000902.3 LOC728499 -2.7 1.8E-04 XM_001127568.1
HS.579631 -2.9 1.6E-03 BU536065 ABCC5 -2.7 7.0E-04 NM_005688.2
OLFML3 -2.9 4.8E-04 NM_020190.2 GNGT2 -2.7 7.0E-04 NM_031498.1
SLC35F2 -2.9 5.9E-03 NM_017515.3 CXCL9 -2.7 3.5E-02 NM_002416.1
TSC22D3 -2.9 1.4E-03 NM_004089.3 H2AFY2 -2.7 1.5E-04 NM_018649.2
DDB1 -2.9 1.9E-03 XM_943551.1 SPATA7 -2.7 3.1E-03 NM_018418.2
LOC100170939 -2.9 9.6E-03 NR_024054.1 LOC100190986 -2.7 5.0E-03 NR_024456.1
SNORA33 -2.9 2.8E-04 NR_002436.1 LOC143666 -2.7 4.5E-03 XM_001127524.1
TSPAN33 -2.9 1.4E-03 NM_178562.2 SNORA61 -2.7 1.8E-04 NR_002987.1
TRAF3IP3 -2.9 2.6E-03 NM_025228.1 LOC100132564 -2.6 6.9E-03 XM_001713808.1
ENC1 -2.9 1.7E-03 NM_003633.1 MAP4K1 -2.6 2.0E-03 NM_001042600.1
FERMT2 -2.9 1.0E-02 NM_006832.1 ZNF774 -2.6 6.5E-03 NM_001004309.1
LOC653879 -2.8 7.4E-03 XM_936226.1 PTGFRN -2.6 4.3E-02 NM_020440.2
FAM125B -2.8 8.9E-04 NM_033446.1 FAM114A1 -2.6 3.9E-03 NM_138389.1
BASP1 -2.8 1.4E-03 NM_006317.3 ZNF296 -2.6 1.6E-04 NM_145288.1
MFSD2 -2.8 9.0E-03 NM_032793.2 TRAF5 -2.6 1.0E-02 NM_004619.3
SLMO1 -2.8 4.3E-03 NM_006553.2 UCHL1 -2.6 2.9E-02 NM_004181.3
TSPAN4 -2.8 6.0E-03 NM_001025234.1 KLF11 -2.6 1.3E-02 XM_001129527.1
LAT -2.8 2.6E-02 NM_001014987.1 PGBD5 -2.6 2.5E-02 NM_024554.2
REPS2 -2.8 9.4E-03 NM_004726.2 MCOLN2 -2.6 7.3E-03 NM_153259.2
DYSF -2.8 2.5E-02 NM_003494.2 PTK6 -2.6 1.8E-03 NM_005975.2
ZFP36L1 -2.8 1.3E-04 NM_004926.2 SNORA41 -2.6 6.5E-03 NR_002590.1
SPATA7 -2.8 4.4E-03 NM_001040428.2 LOC729779 -2.6 2.6E-02 XR_019592.2
HS.536451 -2.8 1.3E-03 BX105743 SLAMF7 -2.6 9.0E-03 NM_021181.3
TRAF1 -2.8 2.1E-02 NM_005658.3 CYP26B1 -2.6 4.3E-03 NM_019885.2
SLMO1 -2.8 3.5E-04 NM_006553.2 SMPDL3A -2.6 5.6E-03 NM_006714.2
CCL5 -2.8 1.4E-02 NM_002985.2 TMOD2 -2.6 9.1E-04 NM_014548.3
RASSF2 -2.8 5.0E-05 NM_170773.1 ACRBP -2.6 2.1E-04 NM_032489.2
BCL2 -2.8 9.6E-03 NM_000633.2 TOM1L2 -2.6 7.2E-03 NM_001082968.1
TMOD2 -2.8 1.5E-03 NM_001142885.1 LOC339843 -2.6 1.6E-03 XR_016598.2
OSBPL7 -2.8 2.6E-03 NM_145798.2 PPM1K -2.6 3.7E-03 NM_152542.2
C9ORF91 -2.8 2.6E-04 NM_153045.2 STARD13 -2.6 2.3E-04 NM_178008.1
HS.171481 -2.8 2.6E-03 CN484989 SLC46A1 -2.6 1.4E-03 NM_080669.3
SMPDL3A -2.8 3.9E-02 NM_006714.2 ABCC4 -2.6 5.8E-04 NM_005845.2
TRAF5 -2.8 7.9E-04 NM_004619.3 FCGR2A -2.6 3.3E-04 NM_021642.2
HS.562504 -2.8 8.2E-04 AW364673 RNU1-3 -2.5 2.6E-02 NR_004408.1
PAQR7 -2.8 7.6E-03 NM_178422.4 SLAIN1 -2.5 1.9E-03 NM_001040153.2
ITSN1 -2.8 8.5E-03 NM_003024.2 SAMSN1 -2.5 9.9E-05 NM_022136.3
KIR2DL3 -2.8 4.5E-02 NM_014511.3 NBPF11 -2.5 3.5E-03 NM_001101663.1
REPS2 -2.8 1.1E-02 NM_001080975.1 CD300A -2.5 2.4E-02 NM_007261.2
CFP -2.8 1.3E-02 NM_002621.1 NFKB2 -2.5 2.5E-03 NM_001077493.1
PLXNC1 -2.8 1.2E-03 NM_005761.1 ETS2 -2.5 1.2E-02 NM_005239.4
LAMA5 -2.7 1.8E-03 NM_005560.3 EPHB2 -2.5 9.1E-03 NM_004442.6
GCLM -2.7 1.1E-02 NM_002061.2 HS.434957 -2.5 4.1E-03 BC004287
GAMT -2.7 7.6E-04 NM_000156.4 KCNMB4 -2.5 2.9E-03 NM_014505.4
Appendix II
Gene FC p (Corr) Accession Gene FC p (Corr) Accession
TSHZ3 -2.5 1.1E-03 NM_020856.2 FCGR2A -2.3 2.0E-04 NM_021642.2
ABCC4 -2.5 3.3E-04 NM_005845.2 LOC728772 -2.3 1.9E-03 XM_001133074.1
CNRIP1 -2.5 5.7E-04 NM_001111101.1 GVIN1 -2.3 9.7E-04 XM_495863.3
PCDH10 -2.5 2.4E-03 NM_020815.1 ZDHHC14 -2.3 3.8E-03 NM_024630.2
SAMSN1 -2.5 9.8E-04 NM_022136.3 SULT1A3 -2.3 3.7E-03 NM_177552.2
RAB33A -2.5 3.5E-02 NM_004794.2 SULT1A4 -2.3 9.3E-04 NM_001017391.1
SNORA24 -2.5 1.9E-02 NR_002963.1 CTTN -2.3 2.3E-02 NM_005231.2
PORCN -2.5 2.3E-03 NM_022825.2 VNN1 -2.3 4.3E-03 NM_004666.1
CRHBP -2.5 2.5E-03 NM_001882.3 PHF16 -2.3 7.9E-04 NM_001077445.1
LOC153561 -2.5 1.7E-03 NM_207331.2 WWC3 -2.3 3.5E-03 NM_015691.2
CXCL13 -2.5 1.6E-02 NM_006419.1 LY9 -2.3 3.9E-03 NM_002348.2
AOAH -2.5 1.0E-03 NM_001637.1 EHD1 -2.3 1.0E-02 NM_006795.2
HLX -2.5 1.5E-03 NM_021958.2 TRIM47 -2.3 5.7E-04 NM_033452.2
LOC100134361 -2.5 2.6E-03 XM_001726827.1 CD163 -2.3 3.5E-02 NM_004244.4
CYGB -2.5 1.7E-02 NM_134268.3 GGA3 -2.3 3.9E-03 NM_138619.1
SCARNA9 -2.5 4.9E-03 NR_002569.1 ABHD12 -2.3 6.5E-04 NM_001042472.1
GAS7 -2.5 1.0E-03 NM_201433.1 GPR132 -2.3 3.0E-03 NM_013345.2
ZC4H2 -2.5 1.3E-03 NM_018684.1 IVNS1ABP -2.3 1.1E-04 NM_006469.4
KLRD1 -2.4 3.2E-02 NM_002262.2 AMDHD2 -2.3 9.3E-04 NM_015944.2
S1PR1 -2.4 1.6E-03 NM_001400.4 CCDC88C -2.3 2.1E-02 NM_001080414.2
SNORA16A -2.4 2.7E-03 NR_003035.1 TRPM2 -2.3 1.8E-02 NM_001001188.3
TRIM16 -2.4 1.0E-02 NM_006470.3 SDC3 -2.3 1.8E-03 NM_014654.2
ZC3H12C -2.4 1.5E-04 NM_033390.1 MAP3K14 -2.3 1.3E-03 NM_003954.2
AP1B1 -2.4 1.4E-03 NM_145730.1 LMOD3 -2.3 4.4E-02 NM_198271.2
LOC644150 -2.4 9.5E-03 XM_933686.1 TNFRSF8 -2.3 6.1E-03 NM_152942.2
KATNAL1 -2.4 1.0E-03 NM_001014380.1 PEG3 -2.3 1.3E-02 NM_006210.1
PTGFRN -2.4 3.8E-02 NM_020440.2 KIAA1328 -2.3 3.4E-04 NM_020776.1
HS.222909 -2.4 1.7E-03 AL117578 WDR74 -2.3 2.1E-02 NM_018093.1
PLIN2 -2.4 7.4E-03 NM_001122.2 SULT1C2 -2.3 3.0E-02 NM_001056.3
ARPM1 -2.4 2.8E-02 NM_032487.3 C17ORF91 -2.3 1.4E-03 NM_001001870.1
MAGED2 -2.4 3.7E-03 NM_177433.1 CPT1A -2.3 8.6E-04 NM_001031847.1
SNHG12 -2.4 4.6E-04 NR_024127.1 KLF6 -2.3 3.9E-04 NM_001008490.1
TSPAN4 -2.4 5.5E-03 NM_001025238.1 BCL2 -2.3 1.2E-02 NM_000633.2
NOL3 -2.4 5.3E-03 NM_003946.3 ELOVL6 -2.3 6.3E-03 NM_024090.1
ABLIM3 -2.4 1.9E-02 NM_014945.2 LOC606724 -2.3 3.1E-03 NR_002454.2
ZNF571 -2.4 1.3E-02 NM_016536.3 LOC100133840 -2.3 2.2E-02 XM_001714384.1
C6ORF85 -2.4 3.8E-03 NM_021945.4 HECTD2 -2.3 1.5E-03 NM_182765.2
PGM2L1 -2.4 8.6E-04 NM_173582.3 BCORL1 -2.3 1.2E-03 NM_021946.2
IL6R -2.4 2.1E-02 NM_000565.2 GDPD1 -2.3 2.5E-02 NM_182569.1
C13ORF31 -2.4 7.5E-04 NM_153218.1 ITSN1 -2.2 3.7E-03 NM_001001132.1
KIAA1147 -2.4 1.4E-03 XM_001130020.1 HS.569162 -2.2 3.3E-02 AV681673
CD180 -2.4 5.0E-03 NM_005582.1 IL6R -2.2 1.0E-02 NM_000565.2
SDCCAG3 -2.4 8.6E-04 NM_001039708.1 CYBASC3 -2.2 2.6E-03 NM_153611.3
PID1 -2.4 2.3E-03 NM_017933.3 AFF1 -2.2 2.9E-04 NM_005935.1
APPL2 -2.4 1.0E-03 NM_018171.3 MYL5 -2.2 4.1E-03 NM_002477.1
UBQLN3 -2.4 5.1E-03 NM_017481.2 GALIG -2.2 3.9E-04 NM_194327.1
SNCA -2.4 1.8E-03 NM_000345.2 MEI1 -2.2 3.0E-02 NM_152513.3
CACHD1 -2.4 1.9E-03 NM_020925.2 KRBA1 -2.2 3.7E-03 NM_032534.2
LRRC3 -2.4 1.0E-03 NM_030891.3 MAGED2 -2.2 2.2E-03 NM_201222.1
RNU1G2 -2.4 3.6E-02 NR_004426.1 EPB41 -2.2 5.1E-03 NM_203343.1
TRIM2 -2.4 3.6E-02 NM_015271.2 MESDC1 -2.2 1.5E-02 NM_022566.1
PPM1H -2.3 4.2E-04 NM_020700.1 ABHD12 -2.2 2.8E-04 NM_001042472.1
ARMCX1 -2.3 6.4E-03 NM_016608.1 FAM7A1 -2.2 5.8E-03 XM_931257.1
P2RY5 -2.3 1.3E-03 NM_005767.4 ACPP -2.2 1.7E-02 NM_001099.2
C17ORF38 -2.3 4.0E-03 NM_001010855.1 EPPB9 -2.2 1.1E-02 NM_015681.2
DLG4 -2.3 4.0E-03 NM_001365.2 LOC644860 -2.2 2.4E-02 XR_039515.1
ARL4A -2.3 1.0E-03 NM_001037164.1 LOC85389 -2.2 3.3E-03 NR_001453.1
Appendix II
Gene FC p (Corr) Accession Gene FC p (Corr) Accession
RRAS2 -2.2 7.8E-03 NM_012250.3 SNCA -2.1 9.2E-03 NM_007308.1
HS.311428 -2.2 2.2E-02 AK024261 WWP1 -2.1 4.8E-04 NM_007013.3
LILRB2 -2.2 1.3E-02 NM_001080978.1 SNORD104 -2.1 1.3E-02 NR_004380.1
LILRB5 -2.2 2.3E-03 NM_006840.3 GCNT1 -2.1 3.1E-02 NM_001097635.1
DACT3 -2.2 4.0E-03 NM_145056.1 HEBP2 -2.1 1.0E-02 NM_014320.2
ARRDC3 -2.2 1.5E-03 NM_020801.1 CKB -2.1 9.9E-03 NM_001823.3
SMCR5 -2.2 6.9E-03 NR_024007.1 GRIN3A -2.1 4.1E-03 NM_133445.1
ARMCX1 -2.2 6.1E-03 NM_016608.1 PON2 -2.1 5.6E-03 NM_000305.2
HABP4 -2.2 3.1E-03 NM_014282.1 HINT3 -2.1 1.4E-03 NM_138571.4
CCDC24 -2.2 3.0E-02 NM_152499.1 ANGPTL6 -2.1 3.6E-02 NM_031917.2
RHOB -2.2 1.1E-03 NM_004040.2 TSC22D3 -2.1 5.7E-04 NM_004089.3
ITGA4 -2.2 3.0E-03 NM_000885.4 SRGAP3 -2.1 9.9E-03 NM_001033117.1
C3ORF54 -2.2 6.5E-03 NM_203370.1 HS.527535 -2.1 2.2E-02 AK026716
FLJ33630 -2.2 6.6E-03 NR_015360.1 RB1 -2.1 1.1E-03 NM_000321.2
MTUS1 -2.2 4.8E-02 NM_001001924.1 CRYBB1 -2.1 2.2E-02 NM_001887.3
GAS6 -2.2 3.2E-02 NM_000820.1 C7ORF41 -2.1 2.6E-02 NM_152793.2
ARHGEF12 -2.2 5.1E-04 NM_015313.1 HS.561735 -2.1 2.8E-03 AL528570
GNB5 -2.2 4.6E-04 NM_006578.3 TOM1L2 -2.1 9.5E-03 NM_001082968.1
LOC729196 -2.2 1.0E-03 XM_001129638.1 HS.163752 -2.1 2.9E-02 AA204695
SGPP2 -2.2 5.1E-03 XM_001128702.1 HS.544637 -2.1 2.7E-02 AW276479
GPR175 -2.2 4.5E-04 NM_016372.1 C11ORF63 -2.1 3.1E-02 NM_199124.1
EMB -2.2 1.1E-02 NM_198449.1 SHROOM4 -2.1 4.7E-02 NM_020717.2
SULT1A3 -2.2 4.8E-04 NM_003166.3 ATP11C -2.1 2.4E-02 NM_173694.3
LOC100128309 -2.2 1.9E-03 XM_001717579.1 KLF6 -2.1 2.6E-03 NM_001008490.1
USE1 -2.2 5.6E-03 NM_018467.3 HSF4 -2.1 7.6E-03 NM_001040667.1
LILRB2 -2.2 6.8E-04 NM_001080978.1 SHMT1 -2.1 4.4E-02 NM_004169.3
OXER1 -2.2 7.1E-03 NM_148962.4 PRRG4 -2.1 4.1E-03 NM_024081.4
KIAA1147 -2.2 3.2E-04 NM_001080392.1 HS.575812 -2.1 3.1E-03 DB296040
HECTD2 -2.2 1.3E-02 NM_173497.1 INPP4B -2.1 1.8E-03 NM_003866.1
IL17RD -2.2 3.4E-02 NM_001080973.1 HEYL -2.1 8.8E-03 NM_014571.3
HS.542265 -2.2 3.4E-02 AI863214 TRIM32 -2.1 8.5E-03 NM_012210.3
KIAA1430 -2.2 5.8E-03 NM_020827.1 SDCCAG3 -2.1 1.0E-03 NM_001039708.1
TRIP10 -2.2 1.9E-02 NM_004240.2 TCF23 -2.1 3.8E-02 NM_175769.1
PLAU -2.2 5.5E-03 NM_002658.2 SNORA70 -2.1 7.9E-03 NR_000011.1
C5ORF30 -2.2 5.8E-03 NM_033211.2 SLAMF6 -2.1 1.3E-02 NM_052931.3
C14ORF145 -2.2 2.2E-02 NM_152446.2 LYSMD3 -2.1 3.3E-02 NM_198273.1
DHRS9 -2.1 1.0E-02 NM_005771.3 PCSK6 -2.1 2.6E-04 NM_138320.1
DDIT4 -2.1 1.8E-02 NM_019058.2 LOC647493 -2.1 9.9E-03 XM_942864.1
SNORD52 -2.1 3.3E-02 NR_002742.1 MFI2 -2.1 8.8E-03 NM_033316.2
AP2A2 -2.1 2.1E-03 NM_012305.2 ZSCAN12 -2.1 2.7E-03 NM_001039643.1
PPP2R2B -2.1 4.0E-02 NM_181676.1 SNX16 -2.1 1.7E-02 NM_152837.1
WAC -2.1 9.0E-03 NM_100264.1 WWOX -2.1 3.4E-02 NM_016373.1
TESC -2.1 2.7E-02 NM_017899.2 CXCL12 -2.1 2.0E-02 NM_000609.4
EPB41L5 -2.1 1.2E-03 NM_020909.2 GCDH -2.1 4.6E-03 NM_013976.2
ICOSLG -2.1 3.1E-02 NM_015259.4 LOC643757 -2.1 1.9E-03 XM_931780.1
ANGPTL4 -2.1 2.6E-02 NM_139314.1 ERCC6 -2.1 1.7E-02 NM_000124.1
LOC644474 -2.1 4.0E-02 XM_930098.1 BLOC1S2 -2.1 6.1E-03 NM_001001342.1
CNRIP1 -2.1 4.9E-03 NM_015463.2 SATB2 -2.1 1.4E-03 NM_015265.1
LSR -2.1 1.0E-02 NM_205835.2 LOC731789 -2.0 5.1E-04 XM_001722670.1
HLX -2.1 1.0E-02 NM_021958.2 IRAK2 -2.0 3.7E-02 NM_001570.3
AQP11 -2.1 1.0E-02 NM_173039.1 SLC45A4 -2.0 1.5E-02 XM_933796.2
HS.19339 -2.1 6.3E-04 BC035116 PCTK3 -2.0 3.2E-02 NM_212503.1
ST8SIA4 -2.1 3.5E-03 NM_005668.3 PTGS2 -2.0 3.3E-02 NM_000963.1
GCLM -2.1 3.0E-03 NM_002061.2 LOC100129269 -2.0 3.8E-02 XM_001719843.1
RAB3IP -2.1 3.8E-03 NM_001024647.2 ATP11C -2.0 4.9E-03 NM_173694.3
SAGE1 -2.1 2.7E-03 NM_018666.2 EEPD1 -2.0 1.1E-03 NM_030636.2
LOC727935 -2.1 2.2E-02 XM_001126418.1 SLC45A4 -2.0 1.5E-02 NM_001080431.1
Appendix II
Gene FC p (Corr) Accession
CHRNA5 -2.0 4.6E-02 NM_000745.2
SLC12A2 -2.0 5.1E-03 NM_001046.2
LOC647008 -2.0 6.5E-03 XM_929992.1
DTNA -2.0 7.4E-03 NM_032981.2
LOC644739 -2.0 2.0E-02 XM_933679.1
ATP8B4 -2.0 3.9E-03 NM_024837.2
TJP1 -2.0 3.0E-02 NM_003257.3
MYL5 -2.0 3.0E-03 NM_002477.1
CORO1A -2.0 6.5E-03 NM_007074.2
FXYD1 -2.0 2.5E-02 NM_005031.3
LRP8 -2.0 2.2E-02 NM_001018054.1
IGF2BP3 -2.0 1.8E-02 NM_006547.2
SQLE -2.0 8.9E-03 NM_003129.3
RAP2B -2.0 4.8E-02 NM_002886.2
PCDHGC4 -2.0 1.1E-02 NM_032406.1
TNFSF8 -2.0 3.6E-04 NM_001244.2
LOC100133923 -2.0 6.9E-04 XM_001714921.1
ASMTL -2.0 3.5E-02 NM_004192.2
RIMKLB -2.0 1.3E-02 NM_020734.2
DPRXP4 -2.0 9.9E-03 NR_002221.1
HS.552025 -2.0 1.4E-02 BM716742
IVNS1ABP -2.0 3.1E-04 NM_006469.4
Appendix III 
 
All genes regulated ≥ 2 fold change by 30 nM C5a on M-MΦ 
 
 
  
Appendix III
Gene 0.5 h 6 h 18 h Accession Gene 0.5 h 6 h 18 h Accession
EGR3 7.5 -1 1.1 NM_004430.2 LMNA 1.4 1.3 2.6 NM_005572.3
IL1B 6 -1.3 1.4 NM_000576.2 LMNA 1.4 1 2.5 NM_005572.3
FOSB 5.9 -1.3 -1.3 NM_006732.1 CCL7 1.3 -1 6.1 NM_006273.2
PHLDA1 5.7 -1.4 2.2 NM_007350.3 TUBB6 1.3 1.1 2.3 XM_940079.1
ATF3 5.3 -1.5 -1.3 NM_001040619.1 TPM4 1.3 1 2.5 NM_003290.1
EGR1 4.3 -1.5 1 NM_001964.2 MATK 1.2 1.1 2.2 NM_139355.2
EGR2 4.2 -1.9 -1.1 NM_000399.2 IL7R 1.2 1.2 2.2 XM_937367.1
PTGS2 3.3 1 1.2 NM_000963.1 FABP5L2 1.2 -1.3 2.1 XM_001721172.1
AXUD1 3.1 -1.1 1.1 NM_033027.2 YPEL3 1.2 -1 -2.6 NM_031477.4
CCL3L1 3 -1.4 1 NM_021006.4 TIMP3 1.2 -1.5 2.2 NM_000362.4
DUSP5 3 -1.1 1.4 NM_004419.3 IL1RN 1.1 -1.8 2.1 NM_173843.1
CCL3L1 3 -1.2 1.1 NM_021006.4 MGC4677 1.1 1.1 2.1 NM_052871.3
CCL3 2.9 -1.4 1 NM_002983.1 FAM129B 1.1 -1 3.7 NM_022833.2
BTG2 2.8 -1.5 -1.2 NM_006763.2 TPM4 1.1 1.1 2.2 NM_003290.1
CCL3L1 2.6 -1.1 -1.1 NM_021006.4 MATK 1.1 -1.1 2.1 NM_139354.2
TNF 2.6 -1 1.4 NM_000594.2 FABP5 1.1 -1.2 2.2 NM_001444.1
KLF6 2.5 -1.1 -1.1 NM_001008490.1 ALOX15B 1.1 -1.8 -2.1 NM_001141.2
CCL8 2.5 -1.1 1.3 NM_005623.2 ARID3A 1.1 -1.1 -2.1 NM_005224.2
MYADM 2.5 -1.2 1.7 NM_138373.3 ARMET 1.1 -1 2 NM_006010.2
HBEGF 2.5 -1.4 -1.1 NM_001945.1 IL1RN 1.1 -1.6 2 NM_173842.1
CCL4L2 2.5 -1.4 1.2 NM_207007.2 CD276 1.1 -1.2 2.5 NM_001024736.1
KLF6 2.4 -1.1 1 NM_001008490.1 CBX7 1.1 -1 -2.3 NM_175709.2
KLF4 2.4 -1.2 -1.5 NM_004235.3 HAMP 1.1 -1.6 -2 NM_021175.2
ZFP36 2.4 -1.3 -1.2 NM_003407.2 SLC7A5 1.1 -1.1 2.3 NM_003486.5
DUSP6 2.4 1.1 1.9 NM_001946.2 LOC387934 1.1 -1.3 2.1 XM_937508.2
CCL3L3 2.4 -1.3 -1 NM_001001437.3 FAM129B 1.1 1 3.2 NM_001035534.1
CD83 2.4 -1.4 1 NM_001040280.1 TRPM2 1.1 -1.1 -2.5 NM_001001188.3
NR4A2 2.3 1 -1.2 NM_006186.2 LOC642956 1.1 -1.4 2.1 XM_938166.3
PTGER2 2.3 -1 1 NM_000956.2 ZNF581 1 -1.2 -2.1 NM_016535.3
MCL1 2.3 -1.2 1 NM_021960.3 TMEM158 1 -1.3 2.4 NM_015444.2
KLF4 2.3 -1.3 -1.4 NM_004235.3 MARCKSL1 1 1.1 2.4 NM_023009.4
LOC728835 2.2 -1.3 1.2 XM_001133190.1 TUBB2A 1 -1 2 NM_001069.2
KLF2 2.2 -1.4 -1.7 NM_016270.2 DDX21 1 -1.2 2 NM_004728.2
CCL2 2.2 1.2 2.4 NM_002982.3 HS3ST1 1 1.1 2.4 NM_005114.2
KLF6 2.2 -1.1 -1.1 NM_001300.4 C5orf13 1 -1.1 -2.7 NM_004772.1
MCL1 2.2 -1 1.1 NM_021960.3 NDRG1 1 -1.2 -2 NM_006096.2
CD83 2.1 -1.5 -1.2 NM_004233.3 BOP1 1 1.1 2.2 NM_015201.3
IER2 2.1 -1.3 -1.1 NM_004907.2 ALOX15B 1 -1.7 -2.6 NM_001039131.1
DUSP6 2.1 1 1.5 NM_022652.2 PLAU 1 -1.2 -2.4 NM_002658.2
C13orf15 2.1 -1.4 -1.1 NM_014059.2 GFRA2 1 -1.1 4 NM_001495.4
SRF 2.1 -1.1 1.2 NM_003131.2 ZNF467 1 -1.2 -2.1 NM_207336.1
PPP1R15A 2 -1.2 -1.1 NM_014330.2 CTSL1 1 1.1 2.2 NM_001912.3
FILIP1L 2 -1.1 1.3 NM_014890.2 CTPS 1 1.1 2 NM_001905.1
GBP1 1.6 -1.1 2 NM_002053.1 UHRF1 -1 2.5 1.2 NM_001048201.1
MMP19 1.5 1.5 2.2 NM_001032360.1 GOLGA7B -1 -1.2 2.2 NM_001010917.1
Appendix III
Gene 0.5 h 6 h 18 h Accession Gene 0.5 h 6 h 18 h Accession
SLC29A1 -1 -1.3 -2.2 NM_001078174.1 TNFRSF21 -1.2 -1 2.6 NM_014452.3
LOC100133893 -1 -1.3 -2.3 XM_001724850.1 HTRA4 -1.2 -1.7 -2.6 NM_153692.2
LOC732415 -1 1.3 2.3 XM_001716577.1 SLC40A1 -1.2 -1.3 -2.1 NM_014585.4
PFKP -1 1.2 2 NM_002627.3 BCL11A -1.2 -1.5 -2.2 NM_022893.2
SLC40A1 -1 -1.2 -2.2 NM_014585.3 FLNB -1.2 -1.4 2.6 NM_001457.1
DBP -1 1.3 -2.4 NM_001352.2 PPAP2B -1.2 -1.4 -2.7 NM_177414.1
SRGAP3 -1 -1.3 -2.4 NM_001033117.1 FAIM3 -1.2 -2 -1.6 NM_005449.3
NRIP3 -1.1 -1.1 2.3 NM_020645.1 CXCR4 -1.2 -1.1 -2.1 NM_003467.2
PRKCA -1.1 1 2.2 NM_002737.2 BMF -1.3 -1.5 -3.1 NM_033503.3
AMICA1 -1.1 -1.6 -2.1 NM_153206.1 ABCC5 -1.3 -1.2 -2 NM_001023587.1
SLC7A1 -1.1 -1.1 2.5 NM_003045.3 CXCR4 -1.4 -1.5 -2.4 NM_001008540.1
TYMS -1.1 2.2 -1.1 NM_001071.1 MIR1914 -2.4 -1.8 -2.2 NR_031735.1
HPSE -1.1 -1.4 -4.7 NM_006665.2
PKD2L1 -1.1 -2.1 -2.1 NM_016112.2
LYPLAL1 -1.1 -1.1 -2.1 NM_138794.1
C6orf192 -1.1 -1.3 -2.1 NM_052831.2
BMF -1.1 -1.3 -2.4 NM_001003943.1
ANG -1.1 -1.2 -2.1 NM_001097577.1
ALPK1 -1.1 -1.1 -2 NM_025144.2
TLR7 -1.1 -1.2 -2.9 NM_016562.3
RPP40 -1.1 1 2.2 NM_006638.2
P8 -1.1 -1.3 -2.4 NM_012385.1
P2RY8 -1.1 -1.3 -2.9 NM_178129.3
PTRF -1.1 -1.2 2.4 NM_012232.3
SLC45A4 -1.1 -1.2 -2.5 XM_933796.2
TOR3A -1.1 -1.3 -2 NM_022371.3
C15orf52 -1.1 -1.4 -2.2 NM_207380.1
HVCN1 -1.1 -1.3 -2.1 NM_032369.2
IQCK -1.1 -1.3 -2.1 NM_153208.1
LOC100133866 -1.1 -1.3 -2.1 XM_001719715.1
SLC29A1 -1.1 -1.4 -2.4 NM_001078174.1
PPAP2B -1.1 -1.3 -2.5 NM_003713.3
KLHDC8B -1.1 -1.2 -3.2 NM_173546.1
TLR8 -1.1 -1 -2.2 NM_138636.2
LOC100129550 -1.1 -1.2 -2.4 NR_024618.1
TOM1 -1.1 -1.2 -2 NM_005488.1
LOC644496 -1.1 -1 2.1 XR_039005.1
DPEP2 -1.2 -1.3 -2 NM_022355.1
NUPR1 -1.2 -1.2 -2.3 NM_001042483.1
EPOR -1.2 1 -2 NM_000121.2
P2RY13 -1.2 -1.4 -2.1 NM_023914.2
PELI2 -1.2 -1.1 -2.2 NM_021255.2
HVCN1 -1.2 -1.1 -2.4 NM_001040107.1
LEP -1.2 -1.5 -2.2 NM_000230.1
NRP1 -1.2 1.1 2.3 NM_003873.4
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Inflammatory Responses Induced by Lipopolysaccharide Are
Amplified in Primary Human Monocytes but Suppressed in
Macrophages by Complement Protein C5a
Vernon Seow, Junxian Lim, Abishek Iyer, Jacky Y. Suen, Juliana K. Ariffin,
Daniel M. Hohenhaus, Matthew J. Sweet, and David P. Fairlie
Monocytes and macrophages are important innate immune cells equipped with danger-sensing receptors, including complement
and Toll-like receptors. Complement protein C5a, acting via C5aR, is shown in this study to differentially modulate LPS-induced
inflammatory responses in primary human monocytes versus macrophages. Whereas C5a enhanced secretion of LPS-induced IL-6
and TNF from primary human monocytes, C5a inhibited these responses while increasing IL-10 secretion in donor-matched
human monocyte-derived macrophages differentiated by GM-CSF or M-CSF. Gai/c-Raf/MEK/ERK signaling induced by C5a was
amplified in macrophages but not in monocytes by LPS. Accordingly, the Gai inhibitor pertussis toxin and MEK inhibitor U0126
blocked C5a inhibition of LPS-induced IL-6 and TNF production from macrophages. This synergy was independent of IL-10,
PI3K, p38, JNK, and the differentiating agent. Furthermore, C5a did not inhibit IL-6 production from macrophages induced by
other TLR agonists that are selective for Toll/IL-1R domain–containing adapter inducing IFN-b (polyinosinic-polycytidylic acid)
or MyD88 (imiquimod), demonstrating selectivity for C5a regulation of LPS responses. Finally, suppression of proinflammatory
cytokines IL-6 and TNF in macrophages did not compromise antimicrobial activity; instead, C5a enhanced clearance of the
Gram-negative bacterial pathogen Salmonella enterica serovar Typhimurium from macrophages. C5aR is thus a regulatory
switch that modulates TLR4 signaling via the Gai/c-Raf/MEK/ERK signaling axis in human macrophages but not monocytes.
The differential effects of C5a are consistent with amplifying monocyte proinflammatory responses to systemic danger signals, but
attenuating macrophage cytokine responses (without compromising microbicidal activity), thereby restraining inflammatory
responses to localized infections. The Journal of Immunology, 2013, 191: 4308–4316.
C
omplement is an important cascading network of .30
soluble plasma and insoluble membrane-bound proteins
that cooperate in innate immunity in the recognition,
opsonization, destruction, and removal of pathogens and infected
or damaged cells. Complement activation by classical, alternative,
and lectin pathways and other routes is tightly controlled, pro-
ducing the lytic membrane attack complex, as well as opsonins
such as C3b and proinflammatory anaphylatoxins C3a, C4a, and
C5a. Elevated plasma levels of C5a or its receptor are associated
with inflammatory diseases such as rheumatoid arthritis, inflam-
matory bowel diseases, respiratory distress syndrome, ischemia–
reperfusion injury, and sepsis (1). C5a binds to and signals through
the receptor C5aR (CD88), a class A G protein–coupled rhodopsin-
like receptor (2), and to a second receptor C5L2, which does not
couple G proteins and may be nonsignaling, but may also mod-
ulate C5aR (3, 4). C5aR couples to the pertussis toxin (PTX)–sen-
sitive Gai and in some cells such as monocytes to the PTX-insensitive
Ga16, and it recruits b-arrestins-1,2 to the plasma membrane (1, 5).
C5a activates several downstream signaling pathways, including
Akt, MEK, PI3K, phosphokinase A, phospholipase C (PLC), and
NF-kB (1).
The TLRs are an important family of type I transmembrane
proteins that respond to infectious organisms and danger signals by
initiating inflammatory responses, activating microbial killing and
clearance mechanisms, and priming the adaptive immune response
(6). Of 10 known human TLRs, TLR4 responds to LPS from
Gram-negative bacterial cell walls. TLR4 can signal through two
different pathways dependent on, and modulated by, separate
adaptor proteins MyD88 or Toll/IL-1R domain–containing adapter
inducing IFN-b (TRIF) (7). MyD88 activates IL-1R–associated
kinases (IRAKs) and TNFR-associated factor 6 (TRAF6), as well
as transcription factors NF-kB, AP-1, and IFN regulatory factor 5
(IRF5) further downstream. TRIF signals the induction of type I
IFNs by recruiting TRAF3 and receptor interacting protein 1 (RIP1)
to activate transcription factor IFN regulatory factor 3 (IRF3), NF-kB,
and AP-1. Both MyD88 and TRIF activate AP-1 via downstream
MAPK activation (8), although NF-kB and MAPK activation by
TRIF occurs later than for MyD88 (9).
In the present study, crosstalk between C5aR and TLR4 was
investigated in human monocytes and human monocyte–derived
macrophages (HMDMs) using the respective ligands C5a and
LPS. Crosstalk between different signaling pathways in mam-
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malian cells can result in unexpected and unique functional out-
comes (10). Some pathogens have evolved to evade or exploit host
microbial-killing by targeting C5aR and TLRs specifically. For
example, virulence proteins secreted by Staphylococcus aureus
bind to C5aR with potent antagonist activity, preventing recruit-
ment of phagocytes to sites of infection (11). Porphyromonas
gingivalis exploits the C5aR/TLR2 crosstalk by increasing cAMP
production in macrophages, which suppresses macrophage im-
mune function and enhances pathogen survival (12). Clearly, these
pathogens have evolutionarily adapted to exploit complement/
TLR crosstalk to their advantage. Although C5aR and TLR4
signaling have been separately investigated in many studies, there
is comparatively little reported about their interplay (13). Among
recent reports on C5aR/TLR4 crosstalk, C5a has been found to
downregulate TLR4-induced IL-12 production via PI3K-dependent
(14) and PI3K-independent (15) pathways in mouse macrophages;
to signal via the PI3K-Akt pathway to enhance LPS-induced IL-17F
cytokine production (16); and to suppress LPS-induced IL-17A and
IL-23 cytokine production in mouse macrophages (17). C5a-induced
suppression of the LPS-inducible IL-17A/IL-23 axis was reported
to occur via enhanced IL-10 production and ERK1/2 phosphoryla-
tion. However, most studies reporting C5a modulation of TLR4
signaling had been performed with murine rather than human cells
(18, 19). Some interpretations of human disease mechanisms have
been made based on extrapolating from observations of mouse
studies. However, there are important differences in LPS-induced
TLR4 signaling between humans and mice (20–22), necessitating
careful assessment of C5aR/TLR4 crosstalk in human cells.
Monocytes and macrophages are important cellular mediators
of innate immunity and are targets for C5a and LPS. Some features
of LPS signaling are also distinctly different between human mono-
cytes and macrophages (23). Monocytes act as danger sensors in the
circulation and typically generate a more rapid, heightened inflam-
matory response than do macrophages to danger signals. For exam-
ple, LPS alone can trigger inflammasome activation in monocytes,
whereas an additional activation signal such as ATP is required
in macrophages (24). The present study compares effects of C5a
on LPS responses in primary human monocytes versus donor-
matched macrophages derived through differentiating monocytes
with either GM-CSF or M-CSF. Surprisingly, we found that C5a
differentially modulated LPS responses depending upon the cell
type, that C5a activated the Gai/c-Raf/MEK/ERK axis to selec-
tively downregulate proinflammatory cytokine production from
macrophages but not monocytes, and that effects on macrophages
do not compromise but instead stimulate pathogen killing. Thus, it
is proposed that C5a has distinctly different regulatory effects on
myeloid cell functions during localized versus systemic inflam-
matory responses.
Materials and Methods
Reagents
Recombinant human GM-CSF, M-CSF, and IL-10 were purchased from
PeproTech. LPS from Salmonella enterica (serotype Minnesota RE 595),
U0126 monothanolate, wortmannin, and PTX were purchased from
Sigma-Aldrich. Imiquimod R837 (IMQ) and polyinosinic-polycytidylic
acid (poly(I:C)) were purchased from InvivoGen. Human C5a was pur-
chased from Sino Biological. Goat neutralizing Ab against human IL-10
(AB-217-NA) was purchased from R&D Systems. C5aR antagonist (3D53
also licensed as PMX53) (1, 25) was synthesized and characterized (an-
alytical HPLC, mass spectroscopy, and nuclear magnetic resonance spec-
troscopy) in-house as described (26). Abs against phosphorylated c-Raf
and total c-Raf were purchased from Cell Signaling Technology. All cell
culture reagents were purchased from Invitrogen, and all analytical-grade
chemical reagents were obtained from Sigma-Aldrich, unless otherwise
stated.
Isolation of human monocytes and macrophages
PBMCs were isolated from buffy coats of anonymous donors (Australian
Red Cross Blood Service, Kelvin Grove, QLD, Australia) by density
centrifugation using Ficoll-Paque Plus (GE Healthcare) following the
manufacturer’s instructions. Contaminating erythrocytes were removed by
repeated ice-cold sterile water. CD14+ MACS MicroBeads (Miltenyi
FIGURE 1. C5a acting via C5aR dose-de-
pendently modulates LPS-induced IL-6, TNF,
and IL-10 cytokine production in human mono-
cytes and macrophages (GM-Mf and M-Mf)
via C5aR. (A–C) Human CD14+ monocytes
(gray) and HMDMs (GM-Mf, black; M-Mf,
white) were serum-deprived for at least 8 h be-
fore treatment with LPS (5 ng/ml) in the ab-
sence or presence of various concentration of
C5a (0.03–300 nM) for 24 h. (D–F) For antag-
onism of C5aR, cells were pretreated with 3D53
(1 mM, 30 min) prior to C5a and LPS stimu-
lation. ELISA was used to detect levels of se-
creted (A, D) IL-6, (B, E) TNF, and (C, F) IL-10
in culture media. Error bars are means 6 SEM
of three independent experiments (n = 3). *p ,
0.05, **p , 0.01, ***p , 0.001 by Student t
test.
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Biotec) were used to positively select monocytes from isolated PBMCs
according to the manufacturer’s instructions. CD14+ monocytes were
seeded at 1 3 106 cells/ml in IMDM supplemented with 10% FBS, 100
U/ml penicillin, 100 mg/ml streptomycin, and 2 mM GlutaMAX at 37˚C
in presence of 5% CO2. To generate HMDMs, CD14
+ monocytes were
cultured in the presence of either 10 ng/ml GM-CSF (GM-Mf) or M-CSF
(M-Mf) for at least 6 d.
Quantitative cytokine ELISA
Cells were seeded at 1 3 106 cells/ml and serum-deprived overnight in the
incubator prior to treatment. LPS and C5a treatments were premixed prior
to 24 h stimulation. Cell culture supernatants were collected and cytokine
levels were determined using specific ELISA sets from BD Pharmingen,
according to the manufacturer’s instructions.
Isolation of mRNA and RT-PCR
Total RNA was extracted from cells using an RNeasy Mini Plus kit
(Qiagen), according to the manufacturer’s instructions. Total cellular RNA
(2–10 mg) was reverse transcribed to cDNA using oligo(dT) primer (1 mg)
and SuperScript III (Invitrogen), according to the manufacturer’s instruc-
tions. cDNA samples were stored at 220˚C until further use.
Gene expression analysis by real-time PCR
Gene-specific primers were designed using the free Web-based software
Primer-BLAST (National Center for Biotechnology Information). Quan-
titative real time-PCR was performed using an ABI Prism 7900 real-time
PCR system (Applied Biosystems), cDNA (50 ng), SYBR Green PCR
Master Mix (Applied Biosystems), and gene-specific primers. Relative gene
expression was normalized against 18S rRNA expression and then converted to
fold change against control samples. All samples were analyzed in duplicate.
Primer sequences used are: CD68, 59-TTTGGGTGAGGCGGTTCAG-39 and
39-CCAGTGCTCTCTGCCAGTA-59; 18S, 59-ACCACGGGTGACGGGGA-
ATC-39 and 39-CCGGGTCGGGAGTGGGTAAT-59.
Quantification of MEK1, ERK1/2, p38, and JNK
phosphorylation
Cells were seeded at 4000 cells/well in white ProxiPlate-384 (PerkinElmer)
overnight. On the following day, cells were serum-deprived for 2 h prior
to stimulation with C5a (30 nM), LPS (5 ng/ml), or both over a stated
time course. Alphascreen SureFire assays (PerkinElmer) were performed
according to the manufacturer’s instructions.
Western blot analysis
Equal amounts of total cell lysates (10 mg) were subjected to SDS-PAGE,
transferred to polyvinylidene difluoride membranes, and proteins were
detected using appropriate Abs according to the manufacturer’s instructions.
Bacterial clearance assay
Intracellular survival of Salmonella enterica serovar Typhimurium
(S. Typhimurium) strain SL1344 within HMDMs was monitored in gen-
tamicin exclusion assays (27). M-Mf were seeded at 200,000 cells/well in
penicillin/streptomycin-free media containing M-CSF (10 ng/ml). On the
following day, cells were infected with S. Typhimurium at a multiplicity of
infection (MOI) of 100. One hour after infection, cells were washed with
gentamicin (200 mg/ml) in penicillin/streptomycin-free media and further
incubated (1 h) to kill extracellular bacteria in the same media. Additional
incubations beyond this 2 h time point were carried out in media con-
taining 20 mg/ml gentamicin. At specific time points, cells were washed
twice and lysed with 0.01% Triton X-100 in PBS, after which lysates were
cultured overnight on Luria–Bertani agar. Colony counts were performed
to assess intracellular bacterial loads. The MOI was also confirmed by
plating out inoculum on Luria–Bertani agar plates and performing colony
counts. Treatments with C5a (30 nM) were conducted by cotreatment with
bacteria upon infection. For antagonism assays, cells were pretreated with
the C5a inhibitor 3D53 (1 mM) 30 min prior to infection. 3D53 was also
added back following the washing with gentamicin-containing media.
Statistical analysis
Data were plotted and analyzed using GraphPad Prism version 5.0c for
Mac OS X (GraphPad Software). Statistically significant differences were
assessed using a Student t test for paired comparison. All values of inde-
pendent parameters are shown as means6 SEM of at least three independent
experiments, unless otherwise stated. A p value , 0.05 was considered
statistically significant.
Results
C5a acting via C5aR differentially modulates LPS signaling in
human CD14+ monocytes versus macrophages
In light of recent discoveries linking crosstalk between TLRs and
the complement system as possible control points for regulation
of host defense (13), this study compared C5aR/TLR4 crosstalk
between human monocytes and macrophages, given their different
roles in responding to inflammatory stimuli. C5a decreased
LPS-induced secreted levels of IL-6 and TNF in both GM-Mf
and M-Mf, but it increased the levels of the same proinflammatory
cytokines in monocytes (Fig. 1A, 1B). Alternatively, C5a enhanced
LPS-induced IL-10 production from macrophages, but it had no
effect on this response in monocytes (Fig. 1C). This suggests that
the regulatory effects of C5aR on TLR4 depend on cellular context,
for example differentiation status. Although C5aR mediates C5a-
dependent responses, a second C5a receptor, C5L2, has also been
reported to exhibit anti-inflammatory functions (3, 28). However,
FIGURE 2. Temporal study of C5aR/TLR4 crosstalk in monocytes and
macrophages. Human CD14+ monocytes were differentiated to HMDMs
with either GM-CSF (10 ng/ml) (GM-Mf, black) or M-CSF (10 ng/ml)
(M-Mf, white) in 10% FBS/IMDM during a 6-d time course. Macrophage
marker (A) CD68 gene expression was monitored during differentiation in
the presence of GM-CSF (black) or in the presence of M-CSF (white) on
days 0, 2, 4, and 6. Genes were detected by quantitative RT-PCR, normalized
against 18S rRNA expression, and converted to fold change relative to day 0.
These cells were also treated with LPS (5 ng/ml) with and without C5a (30
nM) for 24 h in 10% FBS/IMDM on days 0, 2, 4, and 6 to monitor sup-
pression by C5a of LPS-induced IL-6 and TNF in HMDMs. ELISAwas used
to detect (B) IL-6, (C) TNF, and (D) IL-10 secreted in culture media. Error
bars are means6 SEM of three independent experiments (n = 3). *p, 0.05,
**p , 0.01, ***p , 0.001 by Student t test.
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the biological roles of C5L2 in inflammation are highly contro-
versial. Our group has previously developed 3D53, a potent, in-
surmountable, and selective antagonist of C5aR that does not bind
C5L2 (1, 29, 30). 3D53 blocked the immunomodulatory effects of
C5a on TLR4 signaling in both macrophages and monocytes (Fig.
1D–F), thus demonstrating that the observed responses of C5a
were mediated via C5aR rather than C5L2.
Temporal study of C5aR/TLR4 crosstalk in HMDMs
To further characterize the phenotypic switch in C5a responsive-
ness during monocyte to macrophage differentiation, time course
experiments were performed. As expected, mRNA levels of the
macrophage marker CD68 were increased after 4 d of differenti-
ation in the presence of either GM-CSF or M-CSF (Fig. 2A). The
suppressive effect of C5a on LPS-induced cytokine production
was apparent by day 4 for TNF, and by day 6 for IL-6 (Fig. 2B,
2C). Increased IL-10 production was also observed by day 4 (Fig.
2D). The suppressive effects of C5a on LPS-induced IL-6 and
TNF production in macrophages correlated with increased C5AR
and TLR4 expression during monocyte to macrophage differentia-
tion (Supplemental Fig. 1A, 1B). Levels of C5AR and TLR4 mRNA
were not affected by C5a treatment, but LPS decreased C5AR ex-
pression by ∼30% (Supplemental Fig. 1C, 1D), consistent with a
previous study (31).
C5a suppresses LPS-induced IL-6 and TNF via Gai- and
MEK-dependent signaling
C5a-dependent C5aR signaling involves coupling to Gai proteins
(5, 32). We used PTX, which specifically interferes with Gai
protein signaling, to investigate whether the blockade of Gai
signaling would reverse inhibition by C5a of TLR4 responses. As
expected, all modulatory effects of C5a on LPS-induced cytokine
production from monocytes and macrophages was sensitive to
PTX (Fig. 3). These results further confirmed involvement of
C5aR and not C5L2 signaling in this crosstalk, as C5aR, but not
C5L2, employs Gai signaling (1, 3). We also pharmacologically
targeted downstream signaling of C5aR signaling and found that
the MEK inhibitor U0126, a selective inhibitor of the ERK pathway
(33), prevented immunomodulation by C5a of LPS-induced IL-6
and TNF production in macrophages, but not monocytes (Fig. 3A,
3B). In monocytes, the enhancement of LPS-induced IL-6 pro-
duction by C5a was altered by the presence of MAPK p38 and
PLCb inhibitors SB203580 and U73122, respectively, whereas the
enhancement of LPS-induced TNF production was affected by
phosphokinase A inhibitor PKI 14-22 (Supplemental Fig. 2A, 2D).
Collectively, these data suggest that C5a-dependent ERK1/2 phos-
phorylation selectively suppresses LPS-induced IL-6 and TNF
production in macrophages. Interestingly, although the literature
suggests that ERK1/2 is involved in TLR-induced IL-10 production
from human macrophages (15, 34), we found in the present study
that C5a enhanced LPS-mediated IL-10 production in an ERK1/2-
independent, but Gai-dependent, manner (Fig. 3C). Similarly,
LPS-induced IL-10 production from monocytes, as well as from
GM-Mf and M-Mf, was ERK-independent (Fig. 3C).
C5a and LPS synergize for Raf/MEK/ERK phosphorylation in
macrophages
The data for PTX and U0126 inhibitors showed that C5a-modulated
suppression of LPS-mediated inflammatory responses was de-
pendent on Gai coupling and MAPK ERK1/2 phosphorylation.
Therefore, we further investigated additional checkpoints in the
signaling pathway between Gai signaling and upstream of ERK
phosphorylation (Gai/Raf/MEK/ERK) signaling cascade to fur-
ther map the crosstalk signaling mechanisms between C5aR and
TLR4. Interestingly, C5a phosphorylated c-Raf only in macro-
phages (both GM-Mf and M-Mf) but not in monocytes (Fig. 4A).
Co-treatment of GM-Mf or M-Mf with LPS and C5a synergis-
tically promoted c-Raf phosphorylation. This synergy was not
observed in monocytes. LPS triggered MEK1 phosphorylation in
macrophages (Fig. 4B). Although C5a and LPS each induced
MEK1 phosphorylation in monocytes and macrophages, the syn-
ergistic effect of LPS and C5a cotreatment was only observed in
FIGURE 3. C5a suppression of LPS-induced IL-6
and TNF in macrophages is sensitive to PTX and
MEKi (U0126) treatment. To inhibit Gai-dependent
interactions, cells were pretreated with PTX (200 ng/ml,
overnight) or, for MEK1/2 inhibition, U0126 (1 mM,
30 min) prior to LPS (5 ng/ml) with and without C5a
(30 nM) stimulation of monocytes (gray) and HMDMs
(GM-Mf, black; M-Mf, white). ELISA was used to
detect (A) IL-6, (B) TNF, and (C) IL-10 secreted cy-
tokines relative to the LPS response (100%) at 24 h
after stimulation. Error bars are means 6 SEM of three
independent experiments (n = 3). *p, 0.05, **p, 0.01,
***p , 0.001 by Student t test.
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macrophages. Consistent with this, cotreatment of GM-Mf or
M-Mf with LPS and C5a synergistically promoted ERK1/2
phosphorylation, whereas this synergy was not observed for
monocytes (Fig. 4C).
C5a and LPS synergize for phosphorylation of ERK1/2 but not
p38 or JNK in macrophages
Because C5a together with LPS potentiates ERK1/2 in macro-
phages, we next investigated the temporal profile of ERK1/2 ac-
tivation together with other MAPKs (p38 and JNK) in response to
C5a versus C5a plus LPS. C5a induced a transient peak in ERK1/2
phosphorylation within 5 min in monocytes (Fig. 5A) and mac-
rophages (Fig. 5B, 5C), but as we previously observed (Fig. 4C),
LPS amplified this response only in macrophages. C5a appeared
to have little or no effect on p38 and JNK phosphorylation (Fig.
5D–I) and did not amplify LPS-mediated activation of these sig-
naling responses. Although LPS at 5 ng/ml concentration induced
p38 and JNK phosphorylation, at the same concentration, LPS did
not stimulate ERK1/2 phosphorylation in HMDMs; however, at
a higher concentration (1 mg/ml), ERK1/2 phosphorylation was
detected after 20 min (Supplemental Fig. 2G). Although there was
no synergistic effect for p38 phosphorylation in monocytes, the
C5a-mediated amplification of LPS-induced IL-6 production
(Supplemental Fig. 2A), but not TNF production (Supplemental
Fig. 2B), from these cells was affected by the p38 inhibitor
SB203580. Furthermore, SB203580 did not block the suppression
by C5a of LPS-induced IL-6 and TNF production in macrophages
(Supplemental Fig. 2B, 2C, 2E, 2F).
C5a-mediated suppression of LPS-induced IL-6 and TNF is
IL-10 and PI3K independent
C5a has been previously reported to enhance LPS-induced IL-10
cytokine production from macrophages (15), and it has also
been reported to suppress IL-17A and IL-23 by enhancing IL-10
production (17). Consistent with such a mechanism, C5a upreg-
ulated LPS-induced IL-10 production from macrophages, but it
did not alter this response in monocytes (Fig. 1C). However, the
ability of the MEK inhibitor to block C5a-mediated suppression of
IL-6 and TNF production, without affecting enhancement of IL-10
production in macrophages, implied that the inhibitory effects on
IL-6 and TNF were IL-10–independent (Fig. 3C). We therefore
examined this hypothesis. LPS-induced IL-6 and TNF production
was suppressed with increasing concentrations of IL-10 (Supple-
mental Fig. 3A, 3B). This is consistent with literature indicating
that IL-10 attenuates IL-6 and TNF production from activated
macrophages (34, 35). A neutralizing Ab against human IL-10
(10 mg/ml) completely blocked the effect of exogenously added
IL-10 (2 ng/ml) in macrophages (Supplemental Fig. 3C, 3D), and
its addition prior to LPS stimulation resulted in increased TNF
production in GM-Mf and M-Mf (Fig. 6B). However, C5a still
suppressed IL-6 and TNF production in the presence of the neu-
tralizing Ab against human IL-10 (Fig. 6A, 6B), thus demon-
strating that the immunomodulation by C5a was independent of
IL-10. Therefore, C5a-enhanced LPS-induced IL-10 production
does not account for the inhibition of inducible IL-6 and TNF
production by C5a. Apart from IL-10, we also found that the
immunomodulation by C5a was also independent of LPS-induced
PI3K signaling in GM-Mf (Fig. 6C, 6D) and in M-Mf (Fig. 6E,
6F). The presence of the pan-PI3K inhibitor wortmannin at the
highest concentration (100 nM) did not abolish C5a-mediated
suppression of LPS-inducible IL-6 and TNF release, although
wortmannin on its own appears to enhance LPS-induced IL-6 and
TNF production from macrophages at 100 nM concentration.
C5a attenuation of LPS-induced IL-6 is selectively TLR4
mediated in macrophages
TLR4 signaling involves two major pathways, the Mal/MyD88-
and the TRAM/TRIF-dependent pathways (7). To determine
whether C5a affected responses through multiple TLRs in primary
human macrophages, poly(I:C) (TLR3 agonist signaling via TRIF)
and IMQ (TLR7 agonist signaling via MyD88) were used. In con-
trast to TLR4 activation by LPS, C5a amplified poly(I:C)-induced
(TRIF-dependent) IL-6 production from GM-Mf (Fig. 7B),
whereas it did not induce detectable levels of this cytokine in
monocytes and M-Mf (Fig. 7A, 7C). In the case of IMQ-induced
(MyD88-dependent) IL-6 production, C5a enhanced this response
in monocytes, as well as in both macrophage populations. C5a
also increased poly(I:C)-induced and IMQ-induced IL-10 pro-
duction in monocytes and M-Mf (Fig. 7D, 7F), but it did not
modulate this response in GM-Mf (Fig. 7E). These results sug-
gest that suppression of inducible IL-6 production by C5a in GM-
Mf and M-Mf is selective for TLR4 signaling.
C5a enhances clearance of S. Typhimurium from HMDMs
There is evidence in support of C5aR/TLR crosstalk being exploited
by some pathogens for host subversion (12, 35). Therefore, the
FIGURE 4. C5a induced Raf/MEK/ERK phosphorylation is amplified in
macrophages but not in monocytes by LPS. To quantify c-Raf, MEK1, and
ERK1/2 phosphorylation, monocytes (gray) GM-Mf (black), and M-Mf
(white) were treated with LPS (5 ng/ml) with and without C5a (30 nM) for
5 min, after which cells were lysed. (A) c-Raf phosphorylation was detected
by Western blot and probed with Abs against phosphorylated c-Raf and total
c-Raf. Bands were visualized by an ECL method and quantified by densi-
tometry measurements of phosphorylated c-Raf normalized with total c-Raf
against control. Levels of phosphorylated (B) MEK1 and (C) ERK1/2 were
measured by AlphaScreen SureFire assays. Error bars are means 6 SEM of
three independent experiments (n = 3). *p , 0.05, **p , 0.01, ***p ,
0.001 by Student t test.
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impact of C5a on the ability of HMDMs to clear S. Typhimurium
was examined. As expected, C5a alone did not have any bacte-
ricidal effect on S. Typhimurium (Fig. 8A). Instead, C5a promoted
the clearance of this bacterial pathogen from M-Mf, an effect that
was reversed by the C5aR antagonist 3D53 (Fig. 8B). In cytotoxicity
assays monitoring lactate dehydrogenase release, infection assay
FIGURE 5. C5a-induced ERK1/2 phosphory-
lation is amplified in macrophages but not mono-
cytes by LPS. To quantify (A–C) ERK1/2, (D–F)
p38, and (G–I) JNK phosphorylation, cells
(monocytes, GM-Mf, and M-Mf) were treated
with LPS (5 ng/ml) with and without C5a (30 nM)
for 10 min, after which cells were lysed. Phos-
phorylated ERK1/2, p38, and JNK were measured
by AlphaScreen SureFire assays. Treatments by
C5a, LPS, or both are represented by broken lines,
dotted lines, and solid lines, respectively. Error
bars are means 6 SEM of three independent
experiments (n = 3). **p , 0.01, ***p , 0.001
by student t test.
FIGURE 6. C5a suppression of LPS-induced IL-6
and TNF in macrophages is IL-10– and PI3K-inde-
pendent. To determine dependency of IL-10, GM-Mf
(black) and M-Mf (white) were pretreated with neu-
tralizing Ab against human IL-10 (10 mg/ml, 30 min),
or for dependency of PI3K signaling, wortmannin (1–
100 nM, pretreated for 1 h) prior to LPS (5 ng/ml) with
and without C5a (30 nM) stimulation, after which (A,
C, E) IL-6 and (B, D, F) TNF production were moni-
tored at 24 h after stimulation. Error bars are means 6
SEM of three independent experiments (n = 3). *p ,
0.05, **p , 0.01, ***p , 0.001 by Student t test.
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supernatants harvested 8 h after infection showed no differences
in macrophage viability irrespective of treatment (DMSO, SLI344,
hC5a, 3D53, or combinations), thereby indicating that reduced
bacterial loads upon C5a treatment were not a result of increased
macrophage death. Thus, C5a enhances human macrophage antimi-
crobial responses while reducing production of key proinflammatory
cytokines from these cells.
Discussion
Most pathogens trigger both complement and TLR activation,
and crosstalk between these two systems could potentially affect
inflammatory and antimicrobial responses in vivo in infectious
disease. However, studies on C5aR/TLR crosstalk have typically
focused on monocytes or macrophages separately. No previously
reported study has directly compared the impact of crosstalk on the
functional responses of primary human monocytes versus donor-
matched human macrophages. The present study has found that
the myeloid differentiation state is an important variable in de-
termining the impact of C5aR/TLR4 crosstalk on inflammatory
responses of human monocytes and macrophages. New findings in
this study suggest that C5a modulates TLR4 signaling in macro-
phages to favor pathogen clearance while simultaneously limiting
excessive inflammatory responses. This control may be important
during localized infections, whereas C5a detection by monocytes
likely acts as an alarm signal that triggers or amplifies inflammatory
responses during systemic infections.
The mechanisms of C5aR/TLR4 crosstalk are complex and
evidently species- and cell type–dependent. In human monocytes,
C5aR signaling has been reported to both downregulate (36) and
upregulate (37) TLR-induced IL-12 production. Although those
studies were performed on similar IFN-g–primed human blood
monocytes, the second signal used to stimulate the cells was
different. C5a suppressed LPS-induced IL-12 production but up-
regulated S. aureus Cowan I–induced IL-12 production. Although
not addressed in either study, the variations reported are likely due
to different TLRs being activated and differentially affected by
C5aR signaling. The present study emphasizes that C5a suppression
of IL-6 production is specific to LPS/TLR4 signaling in human
FIGURE 7. Suppression by C5a of inducible IL-6
production from macrophages is selective for LPS re-
sponses. Human CD14+ monocytes (gray) and HMDMs
(GM-Mf, black; M-Mf, white) were treated with 1)
LPS (TLR4 agonist, 5 ng/ml) with and without C5a
(30 nM) stimulation, 2) poly(I:C) (TLR3 agonist, 10
mg/ml) with and without C5a (30 nM) stimulation, or 3)
IMQ (TLR7 agonist, 10 mg/ml) with and without C5a
(30 nM) stimulation for 24 h in 10% FBS/IMDM.
ELISAwas used to detect (A–C) IL-6 and (D–F) IL-10
secreted in culture media. Error bars are means6 SEM
of three independent experiments (n = 3). *p , 0.05,
**p , 0.01, ***p , 0.001 by Student t test.
FIGURE 8. C5a decreases S. Typhimurium survival
in M-Mf. (A) Growth of S. Typhimurium was monitored
with and without C5a (100 nM) for 7 h. (B) M-Mf
were infected with S. Typhimurium (MOI of 100) with
and without C5a (30 nM). For antagonism of C5aR,
M-Mf were pretreated with 3D53 (1 mM) for 30 min
prior to C5a stimulation. Intramacrophage survival was
assayed at 2 and 8 h after infection. Graph shows a
representative of three independent experiments. Error
bars are means 6 SEM of experimental triplicates.
**p , 0.01, ***p , 0.001 by Student t test.
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macrophages, because IL-6 production is actually boosted by
C5aR crosstalk with other TLRs, such as TLR3 and TLR7. Similarly,
in mouse macrophages, C5a was reported to selectively crosstalk with
TLR4, but not TLR3, in suppressing IL-27 (p28) production (38).
C5a is thus not only a potent chemotactic agent, attracting immune
cells to site of infection or injury, but it also differentially modulates
host immune responses, possibly tailoring them to match a particular
type of infection.
The differentiating agents GM-CSF andM-CSF have differential
effects on macrophage lineage populations, which contribute to
their functional heterogeneity (39). GM-Mf are often considered
as “M1-like” macrophages, whereas M-Mf are classed as “M2-like”
macrophages, according to their cytokine and gene expression
profiles (40, 41). Whereas LPS-induced inflammatory cytokine
production was clearly enhanced in GM-Mf compared with M-Mf
in the present study, C5a exerted a similar suppressive effect on
inflammatory responses in both human macrophage populations.
Thus, the phenotypic switch in C5a responsiveness during monocyte
to macrophage differentiation occurred irrespective of the differ-
entiating agent. In the future, it will be of interest to determine
whether other macrophage-polarizing factors (e.g., IL-4, IgG)
influence the ability of C5a to suppress TLR4-inducible inflam-
matory mediator production. Although the basal levels of C5AR
and TLR4 increased during the course of differentiating mono-
cytes to macrophages, the differences in the expression levels are
unlikely to be the cause of the phenotypic switch in the crosstalk.
First, C5a treatments did not alter C5AR expression levels. Sec-
ond, C5a had opposing effects on inducible cytokine production
when the macrophages were challenged with poly(I:C) or IMQ,
instead of LPS.
The effects ofC5a onTLR4 responseswere PTX-sensitive in both
monocytes and macrophages, suggesting a Gai-sensitive mecha-
nism. C3a can also bind to a PTX-sensitive receptor, C3aR, that can
recruit GaI coupling when activated. Others have shown that C3a
acting on IFN-g–primed macrophages from C5aR2/2mice (14), as
well as other Gai-specific ligands acting on IFN-g–primed human
monocytes (42), can negatively regulate LPS-induced IL-12 pro-
duction. Also, PI3K signaling has been implicated in C5a regula-
tion of LPS signaling. The pan-PI3K inhibitor wortmannin was
reported by la Sala et al. (42) to block the suppression by C5a of
IL-12p70 production, but this was not the case in the study per-
formed by Hawlisch et al. (14). In our study, wortmannin treatment
had no impact on C5a-mediated suppression of LPS-induced IL-6
and TNF production in human macrophages under the conditions
examined. This suggests that the crosstalk is not only tightly reg-
ulated at multiple checkpoints in the signaling cascade, but that it is
also highly dependent on the activation status of the cells.
As shown previously in human neutrophils, C5a can activate the
Raf/MEK/ERK signaling cascade either directly via Gai activation
or indirectly via Gbϒ/PLCb/PKC pathways (32, 43). We found
that C5a-mediated suppression of LPS-induced IL-6 and TNF was
independent of PLCb signaling (Supplemental Fig. 2). Although
C5a rapidly phosphorylated ERK1/2 in both monocytes and mac-
rophages, consistent with the literature (14, 15), only in macrophages
did C5a increase c-Raf phosphorylation in the presence of LPS,
leading to a further downstream increase in phosphorylation of
MEK and ERK. Because LPS and C5a did not synergize to alter
other MAPKs (p38 and JNK) in monocytes and macrophages, we
attribute the differences in monocytes and macrophages to the
activation of the Gai/c-Raf/MEK/ERK pathway by C5a with LPS
in macrophages versus monocytes.
Low concentrations of LPS failed to stimulate ERK phospho-
rylation. However, only high concentrations of LPS triggered
delayed ERK1/2 activation (20 min after stimulation) by com-
parison with the C5a response, which occurs within 5 min. The
MAP3K tumor progression locus 2 is essential for activation of
ERK1/2 by multiple TLRs, including TLR4, in macrophages (44).
Consistent with this, we observed that LPS triggered MEK1 phos-
phorylation in macrophages independently of activation of another
MAP3K, c-Raf. ERK activation can produce different results,
depending on the stimulus and cell types, especially when com-
paring primary cells versus laboratory cultured cell lines (45). C5a
enhanced ERK1/2 activation in rat neutrophils, and this was as-
sociated with an increase in IL-6 production (46). This contrasts
with our present findings for human macrophages. Complement-
mediated ERK1/2 activation also inhibited IL-12 production in
human monocytes and mouse macrophages (14, 42), whereas the
opposite was observed in mouse dendritic cells (47). Such re-
ported variations in effects of C5a on LPS responses reinforce the
view that observations of complement-mediated effects on TLR
signaling are likely to not only be cell- and species-specific, but
also to vary with the inflammatory readout being monitored.
In summary, in this study we have identified C5aR as a regula-
tory switch that modulates LPS/TLR4 signaling via the Gai/c-Raf/
MEK/ERK signaling axis in primary human macrophages, but not
in monocytes. Extrapolating data from mice to humans, although
convenient, is often not appropriate (48). Regulatory mechanisms
involved in C5aR/TLR4 crosstalk that were previously reported
in mouse studies may not be conserved in humans. Differential
effects of C5a on monocytes versus macrophages have been dem-
onstrated in this study, consistent with a need to either amplify
monocyte proinflammatory responses during systemic danger
recognition or attenuate macrophage proinflammatory cytokine
responses (without compromising microbicidal activity) during
localized infections. Many therapies, including chemotherapy, ra-
diation, cancer vaccines, and small-molecule drugs, already use
immune cell–specific treatment strategies (49), but the rational
basis for targeting specific cell types frequently lacks a level of
understanding necessary to optimize such treatments. Studies such
as this one have the potential to unlock secrets relating to inter-
acting human immunoreceptors and control mechanisms that are
not obvious in studies targeting one particular receptor on a spe-
cific human immune cell type, let alone on immune cells from
other mammalian species.
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G  protein-coupled  receptors  (GPCRs)  are  among  the most  important  targets  in drug  discovery.  In  this
study,  we used  TaqMan  Low  Density  Arrays  to  profile  the full  GPCR  repertoire  of  primary  human
macrophages  differentiated  from  monocytes  using  either  colony  stimulating  factor-1  (CSF-1/M-CSF)
(CSF-1  M!) or granulocyte  macrophage  colony  stimulating  factor  (GM-CSF)  (GM-CSF  M!). The  over-
all  trend  was  a downregulation  of GPCRs  during  monocyte  to  macrophage  differentiation,  but  a core  set
of  10  genes  (e.g.  LGR4,  MRGPRF  and  GPR143)  encoding  seven  transmembrane  proteins  were  upregulated,
irrespective  of  the differentiating  agent  used.  Several  of  these  upregulated  GPCRs  have  not  previously
been  studied  in  the  context  of  macrophage  biology  and/or  inflammation.  As  expected,  CSF-1  M! and  GM-
CSF M!  exhibited  differential  inflammatory  cytokine  profiles  in response  to the Toll-like  Receptor  (TLR)4
agonist  lipopolysaccharide  (LPS).  Moreover,  15  GPCRs  were  differentially  expressed  between  these  cell
populations  in the basal  state.  For  example,  EDG1  was  expressed  at elevated  levels  in CSF-1  M!  versus
GM-CSF  M!,  whereas  the  reverse  was  true  for EDG6.  101  GPCRs  showed  differential  regulation  over  an
LPS  time  course,  with  65 of  these  profiles  being  impacted  by  the  basal  differentiation  state  (e.g.  GPRC5A,
GPRC5B).  Only  14 LPS-regulated  GPCRs  showed  asynchronous  behavior  (divergent  LPS  regulation)  with
respect  to  differentiation  status.  Thus,  the  differentiation  state  primarily  affects  the  magnitude  of  LPS-
regulated  expression,  rather  than  causing  major  reprogramming  of GPCR  gene  expression  profiles.  Several
GPCRs  showing  differential  profiles  between  CSF-1  M! and  GM-CSF  M!  (e.g.  P2RY8,  GPR92,  EMR3)  have
not  been  widely  investigated  in  macrophage  biology  and  inflammation.  Strikingly,  several  closely  related
GPCRs  displayed  completely  opposing  patterns  of  regulation  during  differentiation  and/or  activation  (e.g.
EDG1  versus  EDG6,  LGR4  versus  LGR7,  GPRC5A  versus  GPRC5B).  We  propose  that  selective  regulation  of
GPCR5A  and  GPCR5B  in  CSF-1  M! contributes  to  skewing  toward  the  M2  macrophage  phenotype.  Our
analysis  of the  GPCR  repertoire  expressed  during primary  human  monocyte  to macrophage  differenti-
ation  and TLR4-mediated  activation  provides  a valuable  new  platform  for conducting  future  functional
analyses  of  individual  GPCRs  in  human  macrophage  inflammatory  pathways.
© 2013 Elsevier GmbH. All rights reserved.
Abbreviations: CSF-1, colony stimulating factor-1; CSF-1 M!, monocytes differ-
entiated to HMDM with CSF-1; GM-CSF, granulocyte macrophage colony stimulating
factor; GM-CSF M!,  monocytes differentiated to HMDM with GM-CSF; GPCR, G
protein-coupled receptor; HMDM,  human monocyte-derived macrophage; HSC,
hematopoietic stem cell; IL, interleukin; LPS, lipopolysaccharide; TLDA, TaqMan low
density arrays; TLR, Toll-like receptor; TNF, tumor necrosis factor.
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Introduction
The human genome encodes more than 800 seven
transmembrane-containing proteins, of which more than 300
are non-olfactory receptors (Alexander et al., 2011). The major-
ity of these receptors transduce signals, at least in part, by
coupling to heterotrimeric G proteins. Thus, the term G protein-
coupled receptor (GPCR) is often used interchangeably with
seven transmembrane-containing receptor, although this is not
always the case. For simplicity, we hereafter refer to all seven
0171-2985/$ – see front matter ©  2013 Elsevier GmbH. All rights reserved.
http://dx.doi.org/10.1016/j.imbio.2013.07.001
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transmembrane-containing proteins as GPCRs. GPCRs have been
sub-divided according to the GRAFS classification system into the
glutamate, rhodopsin, adhesion, frizzled/taste2 and secretin GPCR
sub-families (Fredriksson et al., 2003). The International Union of
Basic and Clinical Pharmacology Committee on Receptor Nomen-
clature and Drug Classification alternatively classifies GPCRs into
class A (rhodopsin), class B (secretin), class C (glutamate), frizzled,
and other 7TM proteins. GPCRs are the most prevalent signal-
transducing proteins on the cell surface, and respond to a diverse
array of environmental cues to control numerous physiological and
pathological processes. They represent targets for approximately
one third of all pharmaceuticals (Overington et al., 2006). With
the recent emergence of solved three dimensional structures for
several class A GPCRs (Venkatakrishnan et al., 2013), this family
of cell surface proteins promises many new opportunities for
development of therapeutic agents.
Macrophages are key innate immune cells that occupy dis-
tinct anatomical locations within every tissue of the body, and are
recruited in further numbers to specific tissues when homeostasis
is dysregulated (Hume, 2008). As danger sentinels, macrophages
initiate inflammatory responses to enable a coordinated physio-
logical response to limit tissue damage and initiate and coordinate
repair processes. Macrophages recognize danger through several
families of pattern recognition receptors such as the Toll-like
receptors (TLRs) that detect both pathogen-associated molecular
patterns during infections, as well as host-derived damage-
associated molecular patterns that are indicative of cell stress
and/or damage during acute and chronic diseases. For example,
TLR4 recognizes lipopolysaccharide (LPS) from Gram-negative bac-
terial cell walls (Rossol et al., 2011), as well as several host-derived
factors including HMGB1 (Yang et al., 2010), oxidized LDL and beta-
amyloid peptide (Stewart et al., 2010). TLRs primarily act, though
not exclusively, by regulating the expression of a suite of genes that
control inflammation, antimicrobial responses and antigen presen-
tation.
Recent evidence suggests that tissue resident macrophage
populations can arise through both hematopoietic stem cell (HSC)-
dependent and -independent processes. The latter pathway occurs
independently of the c-Myb transcription factor and involves the
development of some tissue macrophage populations from embry-
onic macrophages in the yolk sac (Schulz et al., 2012). The former
pathway involves the cytokine-mediated differentiation of HSC
into circulating monocytes, and of these cells into tissue resi-
dent and inflammatory macrophages. Several cytokines, including
IL-3, GM-CSF, CSF-1 and IL-34, direct monocyte/macrophage dif-
ferentiation from HSC. CSF-1 and IL-34 are expressed widely, but
differentially, in adult mouse tissues (Wei  et al., 2010), and are
required for the differentiation of many tissue resident macrophage
populations (Wang et al., 2012; Yoshida et al., 1990). During acute
and chronic inflammation, several other cytokines including tumor
necrosis factor (TNF) (Sade-Feldman et al., 2013), interferon-"
(Schroder et al., 2004) and GM-CSF (Hamilton, 2008) can also
influence myeloid development. In terms of macrophage differ-
entiation, GM-CSF is probably the most widely studied of these
factors. Comparisons between GM-CSF- and CSF-1-differentiated
macrophages are often made in the context of classically activated
“M1” macrophages and alternatively activated “M2” macrophages,
respectively (Hamilton, 2008; Hamilton and Achuthan, 2013). M1
macrophages are associated with pro-inflammatory and micro-
bicidal responses, and are usually generated in vitro using IFN-"
plus LPS. In contrast, M2  macrophages are associated with anti-
inflammatory responses, tissue remodeling and immunoregulation
and are typically generated in vitro using IL-4 or IL-13 (Biswas
et al., 2012). The extensive phenotypic diversity and plasticity
of macrophages means that this classification system is probably
overly simplistic, but it is certainly the case that GM-CSF is typically
present at elevated levels during inflammatory responses, and that
GM-CSF-differentiated macrophages have a hyper-inflammatory
phenotype. For example, in in vitro experiments, mouse bone
marrow-derived macrophages differentiated with GM-CSF display
elevated LPS-triggered inflammatory responses, as compared to
those differentiated with CSF-1 (Fleetwood et al., 2007). Increased
pro-inflammatory responses have also been reported with primary
human monocytes differentiated into macrophages with GM-CSF
versus CSF-1 (Lacey et al., 2012; Sierra-Filardi et al., 2010; Verreck
et al., 2004). Furthermore, many studies have demonstrated patho-
logical roles for this cytokine in inflammatory diseases (Hamilton,
2008; Hamilton and Anderson, 2004), and in acute inflamma-
tory models such as LPS-induced lung inflammation (Bozinovski
et al., 2002). Thus, GM-CSF M! can be considered as representative
of inflammatory macrophages. In contrast, CSF-1 M! are proba-
bly reasonable cellular surrogates of tissue resident macrophages
under homeostatic conditions, since CSF-1 is constitutively present
in vivo during homeostasis.
We  previously documented the constitutive and LPS-regulated
GPCR repertoire of mouse macrophages (Lattin et al., 2008). This
analysis identified several members of the P2RY family of GPCRs
that were enriched in macrophages and/or regulated by LPS. More
recently however, we  identified widespread divergence in LPS-
regulated gene expression between primary human and mouse
macrophages (Schroder et al., 2012). Others have also reported
human versus mouse differences in the basal gene expression
programs of monocyte subsets (Ingersoll et al., 2010), and in CSF-
1 and GM-CSF differentiated macrophages (Lacey et al., 2012).
Such differences may  contribute to the very different transcrip-
tomic responses in mouse models versus human inflammatory
diseases (Seok et al., 2013). In light of such species differences and
the need to understand GPCR expression profiles and functions
in normal and pathological immune responses, we  conducted a
detailed expression analysis of the non-sensory GPCR repertoire
expressed during primary human monocyte to macrophage dif-
ferentiation and their activation by the TLR4 agonist, LPS. Our
analysis has identified a small set of GPCRs that are upregulated
during monocyte to macrophage differentiation, as well as numer-
ous GPCRs showing differential expression patterns between CSF-1
M! and GM-CSF M!.  Our data provide insights into the differential
inflammatory profiles of these macrophage populations, and iden-
tifies several GPCRs not previously associated with inflammation
and/or macrophage biology (e.g. LGR4, MRGPRF). This information
is expected to be a valuable resource for future functional analysis
of human macrophage-expressed GPCRs.
Materials and methods
Cell culture and reagents
All studies using primary human cells were approved by the
University of Queensland Medical Research Ethics Committee.
Human CD14+ monocytes were isolated from buffy coat provided
by the Australian Red Cross Blood Service using MACS CD14+
positive selection kits (Miltenyi Biotech), according to the manu-
facturer’s instructions. CD14+ monocytes were cultured overnight
on 10 cm TC plates (Nunc) prior to RNA extraction. Human
monocyte-derived macrophages (HMDM) were generated by 7-
day in vitro culture of CD14+ monocytes in the presence of either
1 × 104 U/mL recombinant human CSF-1 (Chiron) (CSF-1 M!)  or
10 ng/mL recombinant human GM-CSF (Peprotech) (GM-CSF M!).
Both CD14+ monocytes and HMDMs  were maintained in Iscove’s
modified Dulbecco’s medium (Life Technologies), supplemented
with 10% heat-inactivated fetal calf serum (Life Technologies),
20 U/mL penicillin (Life Technologies), 20 #g/mL streptomycin (Life
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Technologies) and 2 mM l-glutamine (Life Technologies). On day 6,
CSF-1 M! and GM-CSF M! were replated on 10 cm TC plates in the
presence of fresh CSF-1 or GM-CSF (10 × 106 cells per plate in 10 mL
complete media). On day 7, these cells were treated with 10 ng/mL
Salmonella enterica serovar minnesota LPS (Sigma, L9764) for 1, 4,
8 or 24 h, or were left untreated, after which RNA was extracted.
Culture supernatants were prepared from the same samples.
cDNA generation and TaqMan low density arrays
RNA extraction was performed using RNeasy mini kits (Qiagen),
as per the manufacturer’s instructions. Genomic DNA contami-
nation of purified RNA was removed by treatment with DNaseI
(Life Technologies). cDNA was generated from 2 #g of extracted
RNA using Superscript III (Life Technologies). Samples were ana-
lyzed on pre-designed 384-well Human GPCR TaqMan Low Density
Arrays (TLDA) (Life Technologies, Cat No. 4367785). These arrays
contained validated primer/probe sets for 367 GPCRs and 14
endogenous controls (18S, ACTB, B2M, GAPDH, GUSB, HMBS,
HPRT1, IPOB, PGK1, POLR2A, PPIA, RPLPO, TBP and TFRC). 250 ng of
cDNA was loaded per port on each TLDA card. TLDA were run on a
Life Technologies 7900HT fast real-time PCR instrument, according
to the manufacturer’s instruction.
TLDA data analysis
Data were analyzed using RQ manager version 1.2 (Life Tech-
nologies) and Integromics StatMiner software suite version 4.2
(Integromics). CT thresholds were set in the linear phase of each
genes amplification plot using RQ manager version 1.2 and were
kept consistent across samples. The Genorm algorithm, built into
the StatMiner software, was applied to determine the most sta-
ble endogenous controls, with 18S, ACTB, GAPDH, HPRT1, PGK1
and PPIA selected for data normalization. Only genes with a mean
CT ≤ 32 for at least one sample were included in StatMiner analyses.
HDAC3 and MATK,  which were included on the commercially avail-
able arrays and were not annotated as control genes, were excluded
from further analysis, since they do not encode seven transmem-
brane receptors. Subsequent statistical analysis was  performed
using the R statistical software. Principal component analysis and
hierarchical clustering were used as unsupervised approaches to
cluster the data. In both cases, a multilevel approach was applied to
take into account repeated measures for individual donors (Liquet
et al., 2012). To identify GPCRs showing statistically significant dif-
ferential expression between monocytes and either CSF-1 M! or
GM-CSF M!,  a linear mixed model, followed by Benjamini and
Hochberg multiple correction, was employed. Genes showing ≥5
fold differences between these populations were also captured to
identify genes of likely biological significance, even though some
may  not have shown statistically significant differences for the
sample size analyzed. To identify GPCRs showing statistically sig-
nificant changes in gene expression in response to LPS, one-way
Welch t-tests followed by Benjamini and Hochberg multiple cor-
rection were applied for each time point (Benjamini and Hochberg,
1995). As above, genes showing ≥5 fold differences in LPS-regulated
gene expression at any single time point were also captured. In
addition, a statistical analysis was performed using repeated meas-
ures ANOVA to include time (h LPS stimulation), differentiation
status (CSF-1 M! or GM-CSF M!)  and the interaction between
time and differentiation status as fixed effects, and the individ-
ual donors as a random effect. This analysis enabled us to capture
genes showing statistically significant LPS-regulated profiles, and
the impact of differentiation status on these profiles. Genes iden-
tified as having a significant interaction were further described as
having an “asychronous behavior” across time and differentiation
status. All heatmaps were displayed with Euclidian distance and
Ward linkage.
SYBR Green qPCR
RNA was prepared using Qiagen Rneasy mini-kits (Qiagen).
cDNA was  generated with Superscript III reverse transcriptase
(Life Technologies). Levels of mRNA for individual genes were
determined by quantitative real-time PCR using SYBR Green (Life
Technologies), gene specific primers, and an ABI Prism 7900 HT
sequence detection system (Life Technologies). CT values were
calculated from amplification plots and gene expression was
expressed relative to the internal control, hypoxanthine phospho-
ribosyltransferase 1 (HPRT1), using the !CT method. Statistical
analysis was performed using GraphPad Prism 5© software. Sig-
nificance was  calculated by one-way ANOVA, with a Bonferroni
correction applied for multiple comparisons. Primer sequences are
contained within Supplementary data.
ELISAs
Levels of specific cytokines (IL-6, IL-10 and TNF) in HMDM
cell culture supernatants at 24 h post-stimulation were measured
using sandwich ELISAs (Becton Dickinson), according to the man-
ufacturer’s instructions. Statistical analysis was performed using
GraphPad Prism 5© software. Significance was calculated by one-
way ANOVA, with a Bonferroni correction applied for multiple
comparisons.
Immunoblotting
Day 6 CSF-1 M! and GM-CSF M! were plated overnight in 6-
well plates (1 × 106 cells/well in 2 mL  complete media). On day 7,
these cells were treated with 10 ng/mL S. enterica serovar min-
nesota LPS (Sigma, L9764) for 1, 4, 8, 24 or 48 h, or were left
untreated. Cells were lysed with 66 mM Tris–HCl (pH 7.4)/2%
SDS, containing 1 mM sodium vanadate (Sigma), 1 mM sodium
pyrophosphate (Sigma), 1 mM  sodium molybdite (Sigma), 10 mM
sodium fluoride (Sigma) and 1× Complete EDTA-free protease
inhibitor cocktail (Roche). Proteins were resolved by SDS-PAGE
using pre-cast NuPAGE Bis-Tris 4–12% gels (Life Technologies) and
transferred to methanol-activated Immobilon-P PDVF membranes
(Millipore). Membranes were blocked and probed with rabbit
anti-EDNRB (1:1000) (Abcam) and rabbit anti-GAPDH (1:10,000)
(Trevigen). Membranes were probed with Goat HRP-linked anti-
rabbit IgG secondary antibody (1:2500) (Cell Signaling). HRP was
detected using the ECL Plus system (GE Healthcare) and Fuji film.
Results
The GPCR repertoire during primary human macrophage
differentiation and activation
To generate an atlas of the non-olfactory GPCR repertoire dur-
ing human macrophage differentiation and activation, we used
Human GPCR TLDA (Life Technologies) to analyze donor-matched
CD14+ monocytes, macrophages differentiated from CD14+ mono-
cytes with either CSF-1 (CSF-1 M!)  or GM-CSF (GM-CSF M!), and
CSF-1 M! and GM-CSF M! activated with LPS for 1, 4 or 24 h. Of
the 367 GPCRs on the TLDA, 123 GPCRs were expressed in at least
one of the above conditions at a level above the selected threshold
(CT ≤ 32) (Supplementary data). Consistent with prior expectation,
principal component analysis demonstrated that individual treat-
ments from the 3 different donors (biological replicates) clustered
together, that the monocyte profile diverged substantially from the
various macrophage profiles, and that the 4 and 24 h LPS-treated
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Fig. 1. Unsupervised clustering of the GPCR expression repertoire. Principal component analysis (A) and hierarchical clustering analysis (B) of all filtered data (at least one
condition showing a mean CT ≤ 32).
macrophage populations were clearly differentiated from the cor-
responding control and 1 h LPS-treated macrophage populations
(Fig. 1A). These conclusions were also supported by unsupervised
hierarchical clustering analysis (Fig. 1B). Fig. S1 again shows that
monocytes diverge substantially from the macrophage populations
in terms of their GPCR profile. Collectively, the above findings indi-
cate that inherent donor variability does not confound analysis of
this data set, and provide confidence in the robustness of the data
as a whole.
GPCR expression patterns during human monocyte to
macrophage differentiation
We  next identified GPCRs differentially expressed during
human monocyte to macrophage differentiation. Of the 60 GPCRs
showing statistically significant differential expression patterns
between monocytes and HMDM,  38 were different between mono-
cytes and HMDM irrespective of the differentiation stimulus, 6
differed only between monocytes and CSF-1 M!,  and 16 differed
only between monocytes and GM-CSF M! (Fig. 2A). Thus, the
majority of changes in GPCR expression during macrophage differ-
entiation occur irrespective of the differentiation stimulus. Fig. 2B
illustrates those GPCRs showing ≥5 fold difference between mono-
cytes and CSF-1 M!,  whilst Fig. 2C highlights those GPCRs with a
≥5 fold difference between monocytes and GM-CSF M!.  For GPCRs
that were regulated during monocyte to macrophage differentia-
tion irrespective of the differentiating agent, there was  broadly a
trend for downregulation of expression. That is, 28 of 38 GPCRs
were downregulated during differentiation to both CSF-1 M! and
GM-CSF M!,  while only 10 GPCRs were upregulated (Supplemen-
tary data). We used SYBR Green qPCR, incorporating additional
donor samples, to further confirm that LGR4 (Fig. 2D), novel in the
context of macrophage biology and inflammation, was upregulated
during macrophage differentiation.
GM-CSF M"  display enhanced pro-inflammatory responses as
compared to CSF-1 M"
Other groups have reported that GM-CSF M! display enhanced
inflammatory cytokine profiles by comparison to CSF-1 M! (Lacey
et al., 2012; Sierra-Filardi et al., 2010; Verreck et al., 2004). We  first
confirmed these previous observations for the specific macrophage
populations used in the TLDA analysis. GM-CSF M! displayed
enhanced LPS-induced levels of secreted IL-6 (Fig. 3A) and TNF
(Fig. 3B), as well as reduced levels of secreted IL-10 (Fig. 3C), by
comparison to CSF-1 M!.  Similarly, LPS-induced mRNA levels of IL-
6 and IL-12p40 were increased in GM-CSF M! (Fig. 3D, E), although
interestingly, TNF was  not (Fig. 3F). As expected, LPS-induced IL-10
and CCL2 mRNA levels were reduced in GM-CSF M! in comparison
to CSF-1 M! (Fig. 3G, H). These findings thus validate our approach
for examining GPCR expression profiles in CSF-1 M! versus GM-CSF
M! for the specific samples used in the TLDA profiling.
We  next asked which GPCRs were differentially expressed in
unstimulated CSF-1 M! versus GM-CSF M!.  15 GPCRs showed
differential expression profiles for CSF-1 M! versus GM-CSF M!
(Fig. 2A, Supplementary data). Fig. 4A shows those GPCRs with
≥5 fold difference between unstimulated CSF-1 M!  and GM-CSF
M!,  some of which are not statistically significant for the sam-
ple size, but are likely to be biologically significant. We again used
independent SYBR Green PCR on additional donors to confirm ele-
vated EDNRB and EDG1 mRNAs in CSF-1 M! versus GM-CSF M!
(Fig. 4B, C), as well as increased HRH4 and EDG6 expression in
GM-CSF M! versus CSF-1 M! (Fig. 4D, E). Such GPCRs could con-
ceivably contribute to the differing inflammatory profiles of these
two macrophage populations.
GPCR profiling of primary human macrophage LPS-mediated
activation
Our initial unsupervised clustering approaches demonstrated
that LPS had little effect on GPCR expression at 1 h post-LPS stim-
ulation, but had profound effects at 4 and 24 h post-stimulation
(Fig. 1A, B). We  next used two distinct approaches to capture
individual LPS-regulated GPCRs. Firstly, we  performed statistical
analysis at individual time points (Supplementary data). Secondly,
we used a repeated measures analysis to capture genes showing
divergent profiles over the LPS time course (Supplementary data).
The latter analysis identified 101 GPCRs that were significantly
regulated by LPS, of which 65 showed differing LPS profiles for
CSF-1 M! versus GM-CSF M! (Fig. 5A). However, only 16 genes
displayed asynchronous behavior (i.e. a significant interaction in
the repeated measures ANOVA) when comparing differentiation
status (CSF-1 versus GM-CSF-1) versus LPS regulation (Fig. 5A),
thus indicating that the major effect of different differentiation
conditions was  to alter the magnitude of the LPS response, rather
than to cause a divergence in the LPS profile. Fig. 5B highlights
all LPS-regulated genes affected by differentiation status, whilst
Fig. 5C shows the 16 genes displaying asynchronous behavior. We
incorporated additional donor samples and LPS time points to inde-
pendently validate LPS-regulated expression of individual GPCRs
(P2RY5, LGR4) (Fig. 5D, E), including examples of LPS-regulated
genes that were substantially affected by differentiation status
(EDNRB, GPRC5A) (Fig. 5F, G). The latter are likely to contribute to
differential inflammatory profiles of CSF-1 M! versus GM-CSF M!.
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Fig. 2. GPCR mRNA regulation during macrophage differentiation. (A) Venn diagram showing statistically significant differential expression of GPCR-encoding genes during
human  monocyte to macrophage differentiation (for both CSF-1 M! and GM-CSF M!, as well as CSF-1 M! versus GM-CSF M!). GPCRs showing ≥5 fold difference in gene
expression for CSF-1 M!  versus donor matched monocytes (B) and GM-CSF M! versus donor matched monocytes (C) (log10 scale). (D) Independent qPCR validation (SYBR
Green) of upregulated LGR4 mRNA expression during human monocyte to macrophage differentiation (mean of 5 independent donors + SEM).
The elevated expression of EDNRB in CSF-1 M!,  as well as downreg-
ulation by LPS in both macrophage populations, was also confirmed
at the protein level (Fig. 5H).
Discussion
Previous studies have used microarray expression profiling to
provide important insights into gene regulation and biological
responses during differentiation of primary human monocytes to
macrophages and/or macrophage polarization (Biswas et al., 2006;
Irvine et al., 2009; Lacey et al., 2012; Li et al., 2007; Liu et al.,
2008; Martinez et al., 2006; Sierra-Filardi et al., 2010). Nonetheless,
issues such as sensitivity for weakly expressed genes, incomplete
transcriptome coverage and probe failure have limited the capac-
ity of microarrays to capture truly global gene expression data. RNA
sequencing can potentially overcome such issues, as can TLDA for
analysis of individual gene families. Martinez et al. (2006) used
microarrays to identify 53 GPCRs differentially expressed between
monocytes, differentiated cells (3 day, 7 day) and/or polarized
macrophages (M1: IFN-" plus LPS; M2:  IL-4). Although these con-
ditions were not directly comparable to our own, using TLDA we
identified 119 GPCRs that were differentially expressed during
human macrophage differentiation and/or activation. Several of
these GPCRs (e.g. MRGPRF, LGR4, GPR143) were not identified in
the former study. More recently, Lacey et al. (2012) used microar-
rays to identify differential gene expression programs in human
and mouse CSF-1 M! versus GM-CSF M!.  As with our recent anal-
ysis of LPS-regulated gene expression (Schroder et al., 2012), this
study found substantial divergence at the individual gene level
when comparing mouse versus human macrophage populations.
Although Lacey et al. (2012) did not analyze LPS-regulated gene
expression in their microarray analysis, they did identify several
GPCRs differentially expressed between CSF-1 M! and GM-CSF
M!. The data on these GPCRs were generally consistent with our
own. Our study also complements a very recent study that used
TLDA to analyze ion channel and GPCR expression in human alve-
olar macrophages versus various other macrophage populations
(Groot-Kormelink et al., 2012). The primary aim of that study was
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Fig. 3. Inflammatory responses are elevated in GM-CSF M! versus CSF-1 M!. (A–C) Secreted LPS-induced cytokine production (A: IL-6; B: TNF; C: IL-10) from CSF-1 M! and
GM-CSF M! used in TLDA analysis (mean of 3 independent donors + SEM; *P < 0.05, **P < 0.01). (D–H) LPS-regulated mRNA expression for genes encoding cytokines in CSF-1
M!  and GM-CSF M! used in TLDA analysis (D: IL6; E: IL12p40; F: TNF; G: IL10; H: CCL2) (mean of 3 independent donors + SEM; *P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 4. GPCR mRNA regulation during macrophage polarization. (A) GPCRs showing ≥5 fold difference in gene expression for CSF-1 M! versus donor matched GM-CSF M!
(log10  scale). (B–E) Independent qPCR validation (SYBR Green) of differential EDNRB (B), EDG1 (C), HRH4 (D) and EDG6 (E) mRNA expression between CSF-1 M! and GM-CSF
M!  (mean of 5 independent donors + SEM).
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Fig. 5. The influence of differentiating agent on LPS-regulated GPCR mRNA
expression. (A) Venn diagram showing statistically significant LPS-regulated
GPCR-encoding genes in CSF-1 M! and/or GM-CSF M!,  including a comparison
of  differentiation status versus LPS regulation. All genes indicated are statistically
significant when considering the entire profile (con, 1 h LPS, 4 h LPS, 24 h LPS).
Semi-supervised hierarchical clustering of all statistically significant LPS-regulated
GPCR-encoding genes affected by differentiation status (B) and all statistically
significant genes showing asynchronous behavior when comparing differentiation
status versus LPS regulation (C). (D–G) Independent qPCR validation (SYBR Green)
to determine the validity of various cellular models as surrogates for
alveolar macrophages, so it did not compare profiles of CSF-1 M!
versus GM-CSF M!,  nor did it examine LPS-regulated GPCR expres-
sion. Thus, our data provide a new resource of GPCR expression
patterns during human macrophage differentiation and activation.
In addition to identifying broad trends such as downregulation of a
substantial set of GPCRs during differentiation from monocytes to
macrophages, our approach has identified sets of GPCRs that were
(1) upregulated during macrophage differentiation; (2) differen-
tially expressed between unstimulated CSF-1 M! and GM-CSF M!;
(3) LPS-regulated; and (4) LPS-regulated and impacted upon by the
differentiating agent.
Although the regulation and function of individual GPCRs, par-
ticularly chemokine receptors, during monocyte to macrophage
differentiation has been widely studied, our analysis captured sev-
eral others that have not been extensively studied in the context
of macrophage biology or inflammation. For example, LGR4 mRNA
was upregulated in both CSF-1 M! and GM-CSF M!,  as com-
pared to monocytes (Fig. 2D). The secreted R-spondin proteins
are LGR4 ligands that potentiate Wnt/$-catenin signaling (Carmon
et al., 2011; Glinka et al., 2011; Ruffner et al., 2012). Some stud-
ies have shown that Wnt  signaling, acting via Frizzled receptors,
regulates macrophage inflammatory responses (Blumenthal et al.,
2006; Schaale et al., 2011). However, to our knowledge, no previ-
ous studies have examined LGR4 functions in this cell type. LGR4
is essential for several developmental processes, including epithe-
lial cell proliferation and paneth cell differentiation in the intestine
(Mustata et al., 2011). This requirement is likely to underpin the
increased susceptibility and severity of Lgr4−/−mice to dextran sul-
fate sodium-induced inflammatory bowel disease (Liu et al., 2013).
Our data suggest that LGR4 expression in macrophages may also
act to modulate inflammatory pathways. As with LGR4, MRGPRF
was strongly upregulated in CSF-1 M! and GM-CSF M! versus
monocytes (115.7 fold and 422.4 fold, respectively; Fig. 2B, C, Sup-
plementary data). This gene belongs to the MAS-related GPCRs that
are expressed in sensory neurons (Dong et al., 2001) and have been
linked to inhibition of pathological pain (Guan et al., 2010). MRG-
PRF has yet to be deorphanized, and very little is known about
the regulation or function of this specific family member. One
study showed that its expression was significantly downregulated
in a mouse model of intestinal inflammation (Avula et al., 2011).
Similarly, we observed that in addition to its robust upregulation
during monocyte to macrophage differentiation, LPS downregu-
lated its expression in macrophages (Supplementary data). We are
not aware of any studies examining MRGPRF expression and/or
function in macrophages. Other genes encoding GPCRs that were
upregulated during macrophage differentiation and have not been
studied in this context include GPR143, GPR125 and GPR85,  amongst
others (Fig. 2B, C).
Given the differing inflammatory cytokine profiles of CSF-
1 M! and GM-CSF M!,  GPCRs showing differential expression
between these two  cell populations have the potential to mod-
ulate inflammatory pathways. We  identified 15 such GPCRs in
the basal state (Fig. 2A), as well as many others when comparing
across an LPS time course (Fig. 5A). The set of GPCRs associated
with elevated expression in unstimulated CSF-1 M! versus GM-CSF
M! generally reflects downregulated expression during GM-CSF-
mediated differentiation of monocytes into macrophages. One
striking exception to this was  HTR2B that was  weakly expressed
by both monocytes and GM-CSF M!,  but was upregulated during
of LPS-regulated genes, including those affected by differentiation status (D: LGR4; E:
P2RY5;  F: EDNRB; G: GPRC5a) (mean of 5 independent donors + SEM). (H) EDNRB pro-
tein expression levels, as assessed by immunoblotting, over a 48 h LPS time course
in CSF-1 M! and GM-CSF M!.  GAPDH protein levels are shown as a loading control.
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differentiation with CSF-1 (Supplementary data). This GPCR, a
receptor for serotonin, was recently shown to be selectively
expressed by M2  macrophages and to skew macrophage polar-
ization toward this phenotype (de las Casas-Engel et al., 2013).
Conversely, HRH4, which encodes a histamine receptor, was essen-
tially undetectable in monocytes and CSF-1 M!,  but was  robustly
upregulated during differentiation with GM-CSF (Fig. 4D, Supple-
mentary data). Consistent with this, Simon et al. (2012) reported
that CD1a+ dendritic cells, differentiated from human monocytes
with GM-CSF plus IL-4, expressed this receptor. There has been
intense interest in HRH4 as an inflammation target (Walter et al.,
2011), and a recent study linked this receptor to LPS-induced
TNF production from macrophages in vivo (Cowden et al., 2013).
Several other GPCRs that were selectively enriched in CSF-1 M!
(e.g. P2RY8,  GPR92)  or GM-CSF M! (e.g. EMR3) have not previ-
ously been linked to polarized macrophage phenotypes (unlike
HTR2B and HRH4),  and clearly warrant further investigation in this
context.
Not surprisingly, LPS regulated the expression of a substantial
number of genes encoding GPCRs over a 24 h time course (101
genes). Many of these were also regulated during differentiation
or polarization of macrophages. For example, LGR4 and MRGPRF
were upregulated during monocyte to macrophage differentia-
tion (Fig. 2B–D), and were also downregulated by LPS in HMDM
(Fig. 5D, Supplementary data). Similarly, EDNRB was expressed at
elevated levels in unstimulated CSF-1 M! as compared to GM-
CSF M!  (Fig. 4B), and was also downregulated by LPS in both cell
populations (Fig. 5F, H). Again, numerous GPCR-encoding genes
upregulated by LPS (e.g. GPR31,  GPR64) or downregulated by LPS
(e.g. GPR126, GPR143) are yet to be studied in macrophage biology
and/or TLR signaling. These represent obvious candidates for future
functional analysis.
One clear signature arising from our profiling data was  that
divergent regulation of closely related family members was com-
mon. For example, EDG1 and EDG6, which both encode GPCRs
that sense sphingosine-1-phosphate, showed opposing regula-
tion in CSF-1 M! versus GM-CSF M! (Fig. 4C, E). Similarly, LGR4
and LGR7 were downregulated and upregulated by LPS, respec-
tively (Fig. 5D, Supplementary data), and divergent LPS profiles
were also apparent for ADORA2A versus ADORA2B (Supplemen-
tary data), and GPCR5A versus GPCR5B (Fig. 5G, Supplementary
data). The functional significance of such opposing regulation is
not always clear, but it is tempting to speculate that coordinated
changes in expression of related GPCRs may  provide a molecu-
lar switch to control macrophage inflammatory pathways. At least
in the case of GPRC5A and GPRC5B, emerging evidence supports
this possibility. Gprc5a−/− mice develop exacerbated lung inflam-
mation that is accompanied by amplified NF-%B activation and
pro-inflammatory cytokine production (Barta et al., 2012; Deng
et al., 2010), whereas Gprc5b−/− mice were protected from diet-
induced obesity, and displayed reduced inflammatory cytokine
production and NF-%B activation (Kim et al., 2012). For this gene
pair, LPS regulation was much more striking in CSF-1 M! as com-
pared to GM-CSF M!,  with GPRC5A being induced and GPRC5B
repressed in CSF-1 M! (Fig. 5G, Supplementary data). On the
basis of the above knock-out mouse studies, this regulation would
be predicted to constrain LPS-induced inflammatory responses in
CSF-1 M!,  whereas this control mechanism would not exist in
GM-CSF M!.  Hence, selective GPRC5A and GPRC5B regulation in
CSF-1 M! hints that these receptors may  contribute to skewing
of M2  M! polarization. This possibility warrants further investi-
gation. In summary, our detailed expression analysis of the GPCR
repertoire during monocyte to macrophage differentiation and
LPS-mediated activation provides a wealth of candidate GPCRs as
uncharacterized, but potentially targetable, regulators of inflam-
mation.
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ABSTRACT Mammalian survival depends on metab-
olizing nutrients, storing energy, and combating infec-
tion. Complement activation in blood triggers energy-
depleting immune responses to fight infections. Here
we identify surprising energy-conserving roles for com-
plement proteins C5a and C3a and their receptors,
C5aR and C3aR, roles that are contraindicated in
complement biology. Rats fed a high-carbohydrate
high-fat diet developed obesity, visceral adiposity, adi-
pose inflammation, glucose/insulin intolerance, and
cardiovascular dysfunction that correlated with in-
creased plasma C3a, adipose C5aR, and C3aR. These in
vivo changes were dramatically attenuated by receptor-
selective antagonists of either C5aR (5 mg/kg/d p.o.)
or C3aR (30 mg/kg/d p.o.), which both reduced pro-
inflammatory adipokines and altered expression of
inflammatory genes in adipose tissue. In vitro C5a and
C3a (100 nM) exhibited novel insulin-like effects on
3T3-L1 adipocytes, promoting energy conservation by
increasing glucose and fatty acid uptake while inhibit-
ing cAMP signaling and lipolysis, and induced PGE2
release from macrophages, effects all blocked by each
respective antagonist (10 !M). These studies reveal
important new links between complement signaling
and metabolism, highlight new complement func-
tions on adipocytes and in adipose tissue, demon-
strate how aberrant immune responses may exacer-
bate obesity and metabolic dysfunction, and show
that targeting C3aR or C5aR with antagonists is a new
strategy for treating metabolic dysfunction.—Lim, J.,
Iyer, A., Suen, J. Y., Seow, V., Reid, R. C., Brown, L.,
Fairlie, D. P. C5aR and C3aR antagonists each inhibit
diet-induced obesity, metabolic dysfunction, and adi-
pocyte and macrophage signaling. FASEB J. 27,
822–831 (2013). www.fasebj.org
Key Words: adipose inflammation ! complement ! GPCR ! meta-
bolism ! immunity
Modern diets high in carbohydrates and saturated
fats are producing a global epidemic in obesity, type
II diabetes, and cardiovascular disease. Metabolic
dysfunction predisposes people to these conditions
and is characterized by abdominal obesity, glucose
and insulin intolerance, elevated plasma triglycerides
and cholesterol, and liver and cardiovascular abnor-
malities (1, 2). Obesity and metabolic dysfunction
are now associated with a state of chronic low-grade
inflammation, but the nature and importance of this
association remain unclear (3–5). Energy deficiency
through malnutrition or starvation impairs immune
responses in mammals, while nutrient overload in-
duces inflammatory responses through cellular stress
in mitochondria, endoplasmic reticulum, and other
organelles, with chronic inflammatory diseases often
associated with premature or more severe metabolic
dysfunction (6). Metabolic defects, such as insulin
resistance in muscle and lipid accumulation in liver,
can occur even in preobese states without obvious
systemic inflammation (7); whereas a single high-
carbohydrate, high-fat meal induces oxidative and
inflammatory responses in healthy lean people (8).
Obesity and metabolic dysfunction are also induced
by altered nutrient sensing, gut microbiota, immune
networks, and metabolism of fatty acids in adipose
tissue (9, 10). These observations suggest that energy
homeostasis may be regulated and coordinated by
signaling molecules and pathways that are common
to those in inflammatory networks. Inflammatory
mediators that make important contributions to in-
nate and adaptive immunity are the complement
proteins, an ancient network of plasma proteins that
effect recognition, opsonization, destruction, and
removal of pathogens and infected or damaged cells.
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Activating the complement network triggers immune
responses that use substantial amounts of energy to
fight infection.
Among products of complement activation are the
proteins C3a and C5a that bind to specific G-protein-
coupled receptors (GPCRs; C3aR and C5aR) on
surfaces of immune cells and induce chemotaxis,
inflammatory signaling, and immunological defense
against infection and injury (11). These plasma pro-
teins have also recently been found to have nonim-
munological roles, such as in hematopoiesis, tissue
regeneration, angiogenesis, and lipid metabolism
(12). Complement factors B, H, and C3 are also
secreted by adipose tissue (13, 14), and plasma C3
concentrations have been reported to correlate with
obesity, type II diabetes, cardiovascular disease, and
postprandial serum triglycerides (15–17). C3 is pro-
teolytically cleaved to the chemotactic proinflamma-
tory protein C3a and then to a derivative C3a-desArg,
which has been controversially linked to adipose
stimulation and C5L2 binding (18, 19). Neither C3a
nor C5a has been reported to regulate adipocytes,
adipose function, lipid homeostasis, or metabolic
dysfunction, and no C3aR or C5aR antagonists have
been examined in metabolic syndrome.
Here we report novel discoveries for receptor-
selective antagonists of C3aR and C5aR, using these
compounds to identify and characterize important
previously unknown roles for C3a and C5a in lipid/
carbohydrate metabolism and energy homeostasis,
attenuate diet-induced obesity and metabolic dys-
function in rats, and dissect mechanisms by which
these complement proteins modulate adipocyte and
adipose function. Obesity, visceral adiposity, and
metabolic dysfunction were induced in rats fed for 16
wk on a diet high in carbohydrates and saturated fats.
Those rats given a selective antagonist of C3aR or
C5aR during the last 8 wk of the diet had substantially
reduced adiposity and body weight and significantly
altered adipose and liver metabolism. Mechanisms
were studied in vivo, ex vivo, and in vitro to reveal for
the first time that C3a and C5a act directly on
adipocytes and indirectly, via macrophages, to pro-
mote obesity, adiposity, and energy conservation.
C3a and C5a were found to exert insulin-like func-
tions on adipocytes by stimulating their uptake of
fatty acid and glucose, while inhibiting cyclic adeno-
sine monophosphate (cAMP) stimulation and lipoly-
sis. These new metabolic roles for C3a and C5a in
regulating energy storage and utilization in adipose
and liver contrast starkly with the intensive energy
consuming roles of other complement components
that fight infection. Since the compounds used here
are potent and selective antagonists of human C3aR
and C5aR, such antagonism may also be therapeuti-
cally useful for the prevention and treatment of
diet-induced obesity, metabolic dysfunction, and car-
diovascular diseases in humans. This is the first
report of an antagonist for either of these receptors
exerting an influence on obesity and adiposity.
MATERIALS AND METHODS
Animal studies
Male Wistar rats were bred at The University of Queensland
Biological Resources Facility. All experimental procedures
were approved by the Animal Experimental Ethics Commit-
tee of The University of Queensland, under the guidelines of
the National Health and Medical Council of Australia. The
8–9 wk old male Wistar rats were provided ad libitum access to
either a cornstarch (CS) or a high-carbohydrate, high-fat
(HCHF) diet for 16 wk. The CS and HCHF diets were
described previously (20). HCHF-group rats further received
drinking water supplemented with 25% fructose, while the CS
group received normal drinking water for the 16 wk (20).
C5aR antagonist (C5aRa; 5 mg/kg/d dissolved in 10% etha-
nol/distilled water), also known as Ac-(cyclo-2,6)-Phe-[Orn-
Pro-dCha-Trp-Arg] or 3D53 (21, 22), and C3aR antagonist
(C3aRa; 30 mg/kg/d dissolved in 10% ethanol/distilled
water), also known as N2-[(2,2-diphenylethoxy)acetyl]-l-argi-
nine or SB290157 (23) were administered daily by oral gavage
to HCHF-treated male Wistar rats, starting after wk 8 of the
study protocol. Control HCHF-fed rats received equal
amounts of 10% ethanol/distilled water as oral gavage vehi-
cle. Dual energy X-ray absorptiometric measurements were
performed as described previously (20). Oral glucose toler-
ance (2 g/kg body weight) and insulin tolerance tests (0.3
IU/kg body weight) were performed as described previously
(20). Plasma lipids and enzymes concentrations were mea-
sured by the Veterinary Pathology Service of The University of
Queensland. Systolic blood pressure (24) and changes in
cardiovascular structure and function (20, 24) were made as
described after 16 wk. Collagen analysis was performed in
excised perfused hearts using picrosirius red staining as
described previously (20, 24).
Cell studies
The 3T3-L1 [European Collection of Cell Cultures (ECACC);
Sigma-Aldrich, Castle Hill, NSW, Australia] preadipocytes
were maintained in DMEM supplemented with 10% fetal
bovine serum (FBS), 10 U/ml penicillin, 10 U/ml streptomy-
cin, and 10 mM glutamine. Differentiation was induced 2 d
after confluence in DMEM/10% FBS supplemented with 0.35
!M insulin, 0.5 mM 3-isobutyl-1-methylxanthine, and 0.25 !M
dexamethasone. After 3 d, the differentiating medium was
replaced with postdifferential medium consisting of DMEM/
10% FBS with 0.35 !M insulin. Fully differentiated 3T3-L1
adipocytes (!90% of which showed phenotypic appearance
by accumulation of multiple lipid droplets) were then refed
every 2 d with DMEM/10% FBS. Primary human monocyte-
derived macrophages were purified from buffy coat using
Ficoll-Paque Plus (GE Healthcare, Castle Hill, NSW, Austra-
lia) density centrifugation, and CD14" monocytes were pos-
itively selected using CD14" MACS magnetic beads (Miltenyi
Biotech, Auburn, CA, USA). CD14" cells were then differen-
tiated with 10 ng/ml of macrophage-colony stimulating factor
for 7 d. RAW264.7 cells [American Type Culture Collection
(ATCC), Manassas, VA, USA] were maintained in DMEM
supplemented with 10% FBS, 10 U/ml penicillin, 10 U/ml
streptomycin, and 10 mM glutamine.
Real-time PCR
All samples were homogenized in Qiazol (Qiagen, Doncaster,
VIC, Australia). RNA was extracted from the homogenate
according to the RNeasy mini kit (Qiagen) manufacturer’s
instructions. Primers (Supplemental Table S1) were designed
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using the Primer-Blast online-based software (www.ncbi.nlm.
nih.gov/tools/primer-blast/). PCR was run on an ABI PRISM
7500 (Applied Biosystems, Melbourne, VIC, Australia) as
described previously (25).
Immunoblot analysis
For serum samples, equal loading volumes were concentrated
using Amicon 30-kDa Ultra 0.5 ml centrifugal filter devices
(Millipore, Billerica, MA, USA) before being subjected to
SDS-PAGE. Retroperitoneal adipose tissue and 3T3-L1 adi-
pocytes were homogenized on ice. Equal amounts of proteins
were loaded and separated on denaturing SDS-PAGE, trans-
ferred, and detected using appropriate antibodies. Densito-
metric measurements of the immunoblot were analyzed using
ImageJ 1.40e software (U.S. National Institutes of Health,
Bethesda, MD, USA).
Enzyme-linked immunosorbent assay (ELISA)
Retroperitoneal adipose tissue (150 mg) was incubated in
KRBH for 24 h at 37°C. Explants were collected, and adipo-
kine levels were determined using specific ELISA sets from
BD Pharmingen (San Jose, CA, USA). RAW264.7 cells were
seeded at a density of 1 # 106 cells/ml and treated with
various agents for 24 h, and culture supernatant was collected
for prostaglandin E2 (PGE2) analysis using monoclonal kits
from Sapphire Bioscience (Sydney, NSW, Australia).
cAMP analysis
cAMP concentrations were determined using a cAMP-Glo
assay (Promega, Madison, WI, USA) according to the manu-
facturers’ instructions. Briefly, 3T3-L1 adipocytes were seeded
at a density of 5 # 105 cells/ml and allowed to adhere
overnight in DMEM/10% FBS. Culture media were then
removed, and cells were washed with PBS supplemented with
2 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich) and 200
!M 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-
1724; Sigma-Aldrich). Compounds were added at specified
concentration and incubated at room temperature for 10 min
and then lysed.
Fatty acid and glucose uptake
Fatty acid uptake was measured using the QBT Fatty Acid
Uptake Assay Kit (Molecular Devices, Sunnyvale, CA, USA).
The 3T3-L1 adipocytes were seeded at 5 # 105 cells and
serum-starved for 1 h. Cells were exposed to various agents for
30 min at 37°C. For the inhibition assay, cells were pretreated
with C3aRa or C5aRa for 30 min prior to addition of
compounds. Glucose uptake was performed using a nonra-
dioisotope enzymatic assay as described previously (26).
Briefly, cells were serum-starved for 2 h and pretreated with
C3aRa or C5aRa for 30 min, followed by stimulation with
various agents for 1 h. After incubation, 2-deoxyglucose (0.5
mM) was added and incubated for 30 min.
Lipolysis
3T3-L1 adipocytes were incubated in KRBH supplemented
with 0.1% glucose and 2.5% fatty acid-free BSA. Glycerol
released was quantified using coupled enzyme reactions from
Free Glycerol Reagent (Sigma-Aldrich).
Competitive receptor binding
Radioligand receptor binding was performed as described
previously (27). Briefly, human monocyte-derived macro-
phages were incubated with 125I-C3a or 125I-C5a and various
concentrations of C3a, C5a, C3aRa, and C5aRa for 1 h at
room temperature. Radioactivity uptake was determined by
scintillation counting on a $-counter.
Compounds and materials
C5aRa (3D53) and C3aRa (SB290157) were synthesized and
characterized in-house. Human recombinant C5a, PGE2, and
$-actin antibody were purchased from Sigma-Aldrich. Human
serum C3a was purchased from Calbiochem (San Diego, CA,
USA). Anti-C3a and HRP-linked rabbit anti-chicken antibod-
ies were purchased from Abcam (Cambridge, MA, USA).
Anti-C3aR and anti-C5aR antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Statistical analysis
Data were analyzed using GraphPad Prism 5.0 (GraphPad,
San Diego, CA, USA). Pairwise comparisons between treat-
ments were assessed by 2-tailed Student’s t test, and changes
in body weight differences were analyzed by 2-way ANOVA
with Bonferroni posttests. All data and error bars are ex-
pressed as means % se. Values of P & 0.05 were considered
statistically significant.
RESULTS
C3aRa and C5aRa prevent and treat diet-induced
obesity in rats
Since C3 may be a biomarker for obesity (15–17), we
hypothesized that antagonists of C3aR or C5aR that
prevent proinflammatory actions of two downstream
products (C3a and C5a) of complement activation
might attenuate diet-induced metabolic dysfunction in
rats. Notably, C3a and C5a are not required to generate
the membrane attack complex that enables comple-
ment-mediated lysis of bacteria or damaged cells, and
so blocking the action of C3a and C5a does not block a
key feature of host immunity.
Here we study a C3aRa, SB290157 (23), that binds on
immune cells specifically to C3aR (but not C5aR or
C5L2; ref. 27 and Supplemental Fig. S1A), and a
C5aRa, 3D53 (21, 22), that binds on immune cells
specifically to C5aR (not C5L2 or C3aR; refs. 28, 29 and
Supplemental Fig. S1B). The two antagonists were used
to elucidate regulation of adiposity and metabolic
function in rats fed a HCHF diet. Relative to rats fed a
low-fat CS diet, those receiving the HCHF diet for 16 wk
become obese, gaining body weight and total fat mass,
especially abdominal or visceral fat (Fig. 1) together
with classic signs of metabolic syndrome (20). The con-
centrations of plasma C3a and expression of C3aR and
C5aR in adipose tissue were also elevated by HCHF
feeding, positively correlating with increased adiposity as
well as symptoms of metabolic dysfunction (Figs. 1 and 2)
and local adipose tissue inflammation (Fig. 3). After 16
wk of HCHF feeding, many of the metabolic indicators
(Figs. 1 and 2) were attenuated or reversed by daily oral
administration from wk 8–16 with the C3aRa (30
mg/kg/d) or the C5aRa (5 mg/kg/d), with marked
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prevention in total fat mass, body weight gain (wk 8–16
HCHF, 21%1%; "C3aRa, 12%2%; "C5aRa, 13%3%),
visceral fat deposition, plasma C3a, and adipose C3aR
and C5aR (Fig. 1). Antagonist treatment did not result
in appetite suppression (Supplemental Fig. S2). This is
the first report of an antagonist for either of these
receptors influencing obesity and adiposity.
C3aRa and C5aRa inhibit metabolic dysfunction in rats
The increase in plasma C3a concentration induced by
HCHF feeding over 16 wk was prevented by C3aRa
treatment from wk 8-16, with plasma C3a being com-
parable to that in CS-fed rats (Fig. 1D). Despite not
detecting plasma C5a (below detection limits) in
HCHF-fed rats, comparable metabolic improvements
were observed in rats treated with C5aRa or C3aRa
(Figs. 1 and 2). We note that C5a is not normally
detectable in human plasma because it is readily con-
verted to C5adesArg by carboxypeptidases. Metabolic
parameters that were elevated in rats fed the HCHF vs.
the CS diet include impaired glucose and insulin
tolerance (Fig. 2B, C), elevated plasma lipids and liver
enzymes (Fig. 2D, E), increased systolic blood pressure
Figure 1. Antagonists C3aRa and C5aRa modulate diet-induced obesity and adiposity in rats. A) Cumulative percentage weight
gain for HCHF-fed rats (n'10) with or without daily oral treatment from wk 8–16 with C3aRa (n'8) or C5aRa (n'8). B) Body
mass composition for CS- vs. HCHF-fed rats with or without C3aRa or C5aRa treatment, assessed by dual X-ray emission
spectroscopy (n'5). C) Visceral adiposity index for rats from different treatment groups (n'6). D) Plasma C3a concentrations
from rats, determined by immunoblot analysis; each lane represents serum from one individual animal (n'4). E, F) Protein and
mRNA level of C3aR (E) and C5aR (F) in adipose tissue from different treatment groups (n'4). Optical density of bands was
measured using ImageJ software. Error bars are means % se. *P & 0.05, **P & 0.01, ***P & 0.001.
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(Supplemental Fig. S2C), and abnormalities in cardiac
structure (e.g., increased collagen deposition in the left
ventricle of the heart) and function (Fig. 2F–H and
Supplemental Fig. S2D). All these parameters, except
elevated triglycerides and systolic blood pressure, were
attenuated by treatment with C3aRa or C5aRa (Fig.
2D), including cardiac fibrosis as measured by collagen
deposition (Supplemental Fig. S2D). Treatment with
C3aRa also displayed a modest increase in fasting blood
glucose concentration in these rats (Fig. 2A).
Figure 2. In vivo responses of antagonists C3aRa and C5aRa on the regulation of metabolic parameters elevated in HCHF- vs.
CS-fed rats. A) Fasting blood glucose concentrations in rats of different groups (n'6). B) Oral glucose tolerance test (OGTT)
in rats of different groups (n'6). C) Insulin tolerance test (ITT) in rats of different groups (n'6). D) Plasma concentrations
for nonesterified fatty acids (NEFA), triglycerides, and total cholesterol in rats of different groups (n'5–10). E) Plasma liver
enzymes for alanine transaminase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), and alkaline phospha-
tase (ALP) in rats of different groups (n'5–10). F–H) Echocardiographic and histological characterization of cardiac structure
(F) and function (G, H) of rats in different groups (n'6–10). Error bars are means % se. *P & 0.05, **P & 0.01, ***P & 0.001.
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C3aRa and C5aRa inhibit adipose inflammation
Obesity is usually accompanied by dysregulation of
genes involved in metabolism, inflammation, and cel-
lular stress in adipose tissue (30–32). We investigated
several genes that may be influenced by HCHF feeding
and modulated by C3aRa and C5aRa in rats. In retro-
peritoneal adipose tissue, the expression of leptin (Lep)
and macrophage-specific gene (Emr1) was altered in
HCHF rats. Treatment with either C3aRa or C5aRa
attenuated these changes. Similarly, expression of pro-
inflammatory adipokines, such as interleukin-6 (Il6), tu-
mor necrosis factor ( (Tnfa), and prostaglandin-endoper-
oxide synthase 2 (Ptgs2), in retroperitoneal adipose tissue
was increased by HCHF feeding and attenuated by the
antagonists (Fig. 3A). Given that adipokine-mediated
inflammatory responses are mechanistically linked to
insulin resistance and metabolic dysfunction (33–35),
we also examined the secretory profile of obesity-
related inflammatory adipokines such as monocyte
chemotactic protein-1 (MCP-1), IL-6, and TNF-(. Ex
vivo analysis of retroperitoneal adipose tissue explants
from HCHF rats showed elevated secretion of these
proinflammatory adipokines, which were attenuated by
in vivo treatment over wk 8–16 with either C3aRa or
C5aRa (Fig. 3B). These results clearly demonstrate
decreased adiposity and improved metabolic and in-
flammatory status through antagonist blockade of C3aR
and C5aR in vivo.
C3aRa and C5aRa ameliorate inflammatory responses
in murine macrophages
Since C3a and C5a act directly on immune cells, we
investigated whether these proteins might also exert
paracrine control over adipocytes viamacrophages that
are particularly associated with phagocytosing excess
lipids and possibly secreting antilipolytic factors to
curtail the increase in free fatty acids during lipolysis in
obesity (36). We stimulated RAW264.7 murine macro-
phages with C3a or C5a, and found particularly en-
hanced secretion of PGE2 from these macrophages.
Pretreatment with C3aRa and C5aRa abolished this
stimulatory effect (Fig. 4A, B). Due to limitations on
examining rat adipocytes, we investigated whether
PGE2 could alter C3aR and C5aR expression in 3T3-L1
murine adipocytes. We found that stimulating adi-
pocytes with PGE2 also led to increased gene and
protein expression of C3aR and C5aR (Fig. 4C, D).
PGE2 has been implicated as having a paracrine influ-
ence on adipocytes through inhibition of lipolysis (37).
Our findings demonstrate that C3a and C5a may per-
petuate the underlying immune response in obesity by
stimulating macrophages to secrete inflammatory and
antilipolytic mediators, such as PGE2, that increase
responsiveness to C3a and C5a, and may also control
influx/efflux of macrophages into adipose tissue dur-
ing weight loss.
C3aRa and C5aRa modulate lipid homeostasis in
3T3-L1 adipocytes
To investigate whether adipogenesis can alter the in-
volvement of C3a/C3aR and C5a/C5aR, we induced
3T3-L1 preadipocytes to undergo adipogenesis. We
found that C3ar and C5armRNA levels became elevated
on differentiation of 3T3-L1 preadipocytes to mature
adipocytes, although only C5aR protein expression
increased on maturation while C3aR protein expres-
sion remained unchanged (Supplemental Fig. S3). This
suggests that C5a, if not both C3a and C5a, might be
important for regulating adipogenesis by recruiting
preadipocytes.
Since development of adipogenesis and adipocyte
hypertrophy involves the uptake of excess nutrients,
such as glucose and fatty acids, we investigated whether
C3a and C5a can modulate lipid homeostasis. We
found that C3a and C5a were able to stimulate uptake
of 2-deoxyglucose (Fig. 5A) and BODIPY fatty acid (Fig.
5B) by 3T3-L1 adipocytes. Notably, pretreatment with
C3aRa and C5aRa blocked the uptake of 2-deoxyglu-
cose and BODIPY fatty acid, returning them to basal
levels suggestive of selective actions through their re-
spective receptors (Fig. 5A, B). C3aR and C5aR are
Figure 3. Ex vivo analysis of inflammatory pro-
files in rat adipose tissue. A) Real-time PCR
gene expression of adipokines in adipose tissue
in rats of different groups. B) Protein expres-
sion of obesity-related proinflammatory adipo-
kines from explants of adipose tissue. Error
bars are means % se. *P & 0.05, **P & 0.01,
***P & 0.001.
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primarily Gi-coupled receptors in immune cells, and,
since cyclic AMP (cAMP) is vital for dictating lipolysis
(38), we examined the capacity of C3a and C5a to
decrease cAMP concentrations in adipocytes (Fig. 5C).
Both C3a and C5a reduced cAMP concentrations, and
pretreatment with pertussis toxin attenuated both C3a-
and C5a-mediated inhibition of cAMP (Supplemental
Fig. S4), establishing that both C3aR and C5aR are
Gi-coupled receptors in adipocytes. Further, we demon-
strated that both C3a and C5a suppressed isoprotere-
nol-induced lipolysis measured as glycerol release (Fig.
5D). Consistent with the above findings, treatment with
either C3aRa or C5aRa restored both cAMP concentra-
tions and lipolysis in adipocytes. Taken together, these
results suggest that both C3a and C5a are important
promoters of energy conservation in adipose tissue,
both promoting energy storage through uptake of
2-deoxyglucose and fatty acids into adipocytes, while at
the same time retarding energy utilization by inhibiting
cAMP stimulation and lipolysis. The antagonists were
able to inhibit these effects that contribute to adiposity
in vitro, and thus to inhibit diet-induced obesity in vivo.
DISCUSSION
This study reveals important new findings indicating
involvement of complement anaphylatoxins C3a and
C5a and their receptors in adipocyte biology, energy
conservation, diet-induced adiposity, and metabolic
dysfunction. Oral administration over 8 wk with selec-
tive antagonists C3aRa and C5aRa (Supplemental Fig.
S1) ameliorated classic symptoms of metabolic syn-
drome in diet-induced obese rats, with marked reduc-
tion in body weight, visceral fat, and adiposity, and
improvements in glucose and insulin intolerance, adipose
tissue inflammation, obesity-associated adipokines, and
certain lipid and cardiovascular abnormalities (Figs. 1–3
and Supplemental Fig. S2). The mechanism for these in
vivo effects was traced to previously unknown signaling
roles for C3a and C5a in promoting energy conservation
and regulating energy homeostasis in adipose tissue
(Fig. 3). Receptor-selective antagonists were used here
to identify two conceptually new mechanisms for in-
volvement of C3a and C5a in metabolic function,
namely stimulating uptake of fatty acid and glucose by
adipocytes, while at the same time inhibiting fat burn-
off by inhibiting cAMP stimulation and lipolysis in
adipocytes (Fig. 5). It is known that activating comple-
ment proteins in blood triggers immune responses that
require energy to fight infection, but here we identify
for the first time new energy-conserving roles for com-
plement proteins, C3a and C5a, and their receptors,
C3aR and C5aR, that are contraindicated in known
complement biology.
Figure 4. C3aRa and C5aRa modulate inflammatory responses in RAW264.7 macrophages. A, B) PGE2 secretion is enhanced by
C3a (A) and C5a (B), but inhibited by pretreatment with C3aRa (A) or C5aRa (B). C, D) Up-regulation of protein and mRNA
expression levels of C3aR (C) and C5aRa (D) in 3T3-L1 adipocytes in the presence of PGE2. Error bars are means % se. *P &
0.05, **P & 0.01, ***P & 0.001.
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Notably, C3a and C5a are not directly required
during host immunity to generate the membrane attack
complex that enables complement-mediated lysis of
bacteria or damaged cells, and so blocking the action of
C3a and C5a on their respective cell surface GPCRs
does not block host immunity. Complement signaling
through these proteins clearly plays previously un-
known and important roles in regulating metabolism
and energy homeostasis through direct action on adi-
pocytes and indirect action through other nonadipose
cells (e.g., macrophages) on adipocytes.
Both C3a and C5a were shown herein to act in vitro
directly on adipocytes, altering carbohydrate and lipid
storage, transport, and utilization, including adipogen-
esis, lipogenesis, glucose uptake, and lipolysis (Fig. 5).
Our conclusions are offered partial support from a
recent gene expression study demonstrating that C3aR
may be a candidate gene for predicting obesity and
transcriptional networking related to diabetes and ath-
erosclerosis in mice (39). Furthermore, mice with diet-
induced obesity exhibited increased expression of adi-
pose tissue C3aR, while C3aR)/) knockout mice have
reduced macrophage infiltration in adipose tissue with
improved insulin responsiveness (40). However, mech-
anisms associating the C3aR)/) phenotype with im-
proved adiposity and insulin responsiveness were in-
conclusive and attributed to macrophage responses
(40), rather than to adipocytes and immune cells in
combination in adipose tissue as described herein.
Although adipocytes have evolved to specifically reg-
ulate energy storage and utilization, their functions are
compromised by excessive fat uptake or by paracrine
influences from immune cells that infiltrate adipose
tissue and secrete proinflammatory agents. Adipocytes
and immune cells in adipose tissue release many bioac-
tive mediators, including adipokines and inflammatory
cytokines that, when aberrantly expressed, result in
metabolic dysfunction (4). Paracrine signaling through
PGE2 secreted by macrophages (Fig. 4) constitutes a
paracrine loop by which these complement mediators
aid further recruitment of immune cells into adipose
tissue, thereby perpetuating local adipose inflamma-
tion and proliferative adipocyte precursor cells that
induce adipogenesis in response to increased demands
for energy storage in obesity. While the C3aRa and
C5aRa used here have certain anti-inflammatory prop-
erties in animal models of inflammatory diseases (11,
27, 41), other anti-inflammatory agents, such as salicy-
lates, have shown negligible or only very minor benefits
in vivo in metabolic syndrome (42).
Although complement proteins are formed in re-
sponse to infection through energy-depleting immune
defense mechanisms, certain byproducts of the activa-
tion of the complement protein network, such as C3a
and C5a, play roles in metabolism and evidently pro-
mote energy conservation. This occurs directly through
adipocytes by promoting fatty acid and glucose uptake
while at the same time inhibiting lipolysis, and indi-
rectly through macrophages by stimulating release of
PGE2, which is also known to regulate cAMP stimula-
tion in adipocytes. Metabolic homeostasis is important
for an optimally functioning immune system, since
Figure 5. C3aRa and C5aRa modulate glucose or lipid homeostasis in 3T3-L1 adipocytes. A) Like insulin (3 nM), C3a stimulates
uptake of 2-deoxyglucose (2-DG) in 3T3-L1 adipocytes but was inhibited by pretreatment with C3aRa (10 !M). C5a (100 nM)
had no effect (not shown). B) Like insulin (50 nM), C5a stimulates uptake of fatty acids by 3T3-L1 adipocytes, which was
inhibited by pretreatment with C5aRa (10 !M). C3a (100 nM) had no effect (not shown). C) C3a and C5a (100 nM) inhibit
cAMP stimulated by forskolin in 3T3-L1 adipocytes, while pretreatment with C3aRa or C5aRa (10 !M) normalizes cAMP
concentrations to levels induced by forskolin. D) C3a and C5a (100 nM) inhibit isoproterenol-induced glycerol release from
3T3-L1 adipocytes, while pretreatment with C3aRa or C5aRa (10 !M) normalizes glycerol release to isoproterenol-levels.
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initiation and maintenance of immunity is metaboli-
cally expensive and is impaired during both energy
deficiency and surplus (5). Energy regulation through
storage, transport, and metabolism may be intimately
coordinated with immune defense and pathogen-sens-
ing mechanisms in an organism. Recent evidence sug-
gests that nutrient and pathogen sensing systems in
humans may have evolved together, possibly to coordi-
nate efficient management of energy homeostasis, met-
abolic function, and immune defense (6). Taken to-
gether, our results indicate an important link between
energy homeostasis and innate immunity, raising the
specter of aberrant immune responses (producing C3a
and C5a and overexpressing C3aR and C5aR) exacer-
bating metabolic dysfunction and vice versa. The results
suggest that targeting key signaling components of the
complement system, and by implication perhaps other
immune components, may be of therapeutic benefit for
treating diet-induced obesity, metabolic dysfunction,
and cardiovascular disease.
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